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Abstract 
Unraveling the molecular mechanism underlying ALS-linked astrocyte 
toxicity for motor neurons 
Burcin Ikiz 
Mutations in superoxide dismutase-1 (SOD1) cause a familial form of amyotrophic lateral 
sclerosis (ALS), a fatal paralytic disorder. Transgenic mutant SOD1 rodents capture the 
hallmarks of this disease, which is characterized by a progressive loss of motor neurons. Studies 
in chimeric and conditional transgenic mutant SOD1 mice indicate that non-neuronal cells, such 
as astrocytes, play an important role in motor neuron degeneration. Consistent with this non-cell 
autonomous scenario are the demonstrations that wild-type primary and embryonic stem cell-
derived motor neurons selectively degenerate when cultured in the presence of either mutant 
SOD1-expressing astrocytes or medium conditioned with such mutant astrocytes. The work in 
this thesis rests on the use of an unbiased genomic strategy that combines RNA-Seq and “reverse 
gene engineering” algorithms in an attempt to decipher the molecular underpinnings of motor 
neuron degeneration caused by mutant astrocytes. To allow such analyses, first, mutant SOD1-
induced toxicity on purified embryonic stem cell-derived motor neurons was validated and 
characterized. This was followed by the validation of signaling pathways identified by 
bioinformatics in purified embryonic stem cell-derived motor neurons, using both 
pharmacological and genetic techniques, leading to the discovery that nuclear factor kappa B 
(NF-κB) is instrumental in the demise of motor neurons exposed to mutant astrocytes in vitro. 
These findings demonstrate the usefulness of this novel genomic approach to study 
neurodegeneration and to point to NF-κB as a potential valuable therapeutic target for ALS. 
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Chapter 1: Introduction 
1.1. Amyotrophic Lateral Sclerosis 
1.1.1. General definition 
Amyotrophic lateral sclerosis (ALS), also known as “Lou Gehrig’s disease” in the USA, is the 
most frequent adult-onset paralytic disorder. As reviewed by Rowland and collaborators (2010), 
the disease is found worldwide, with a prevalence of roughly 3-5 per 100,000 individuals. Onset 
of symptoms is usually in the fourth or fifth decade of life with about 10% of the cases beginning 
before the age of 40 and less than 5% before the age of 30. Common clinical features of ALS 
include muscle weakness and wasting followed by paralysis. The disease progresses rapidly with 
a mean survival of three years after diagnosis. Respiratory failure, due to respiratory muscle 
paralysis, is the primary cause of patient death (Mizutani et al., 1992). As discussed in more 
detail below, pathologically, ALS is characterized mainly by a loss of both upper and lower 
motor neurons (Hirano, 1996). To date, only a few approved treatments, such as mechanical 
ventilation and the drug riluzole, prolong survival to some extent in ALS patients. Therefore, not 
only is it absolutely necessary to develop more effective neuroprotective therapies, but it is also 
important that we find the mechanism by which motor neurons die in ALS and how the disease 
propagates and progresses. 
 
1.1.2. Clinical presentation of the disease 
1.1.2.1. Sporadic versus familial 
ALS is essentially a sporadic disease, in that it occurs in absence of any apparent genetic linkage 
(Pasinelli and Brown, 2006). However, in roughly 10% of the cases, ALS is inherited, and in 
these rare cases, the phenotype can be transmitted either as an autosomal dominant or recessive 
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trait (Pasinelli and Brown, 2006). Of note, patients with familial ALS (fALS) are almost 
indistinguishable from sporadic ALS (sALS) patients, albeit typically, the former presents with a 
younger onset, a faster course of the disease, and a shorter survival after diagnosis (Rowland, 
2010). Additionally, similar superoxide dismutase-1 (SOD1)- and TAR DNA binding protein-43 
(TDP-43)-positive inclusions have been found in tissues from sALS and fALS patients (Arai et 
al., 2006; Bosco et al., 2010; Forsberg et al., 2010; Kato et al., 2000; Shibata et al., 1994). A 
multi-targeted drug named riluzole has been shown to have similar neuroprotective effects in 
sALS and fALS patients (Sojka et al., 1997). Moreover, cerebrospinal fluid samples from sALS 
and fALS cases have been shown to have comparable toxic effects on rat spinal cord neurons in 
vitro (Tikka et al., 2002). Collectively, these observations emphasize the striking similarities 
between sALS and fALS, and suggest that, while classification of sALS versus fALS might be 
important for genetic counseling, the mechanisms of neurodegeneration in both fALS and sALS 
may intersect. Thus, unraveling the molecular basis by which mutant gene products of fALS 
cause motor neuron degeneration may provide important insights into the pathogenesis of sALS.  
 
1.1.2.2. Clinical forms of ALS 
As mentioned above, in ALS, both the upper motor neurons [Figure 1.1; red] and the lower 
motor neurons [Figure 1.1; green] may be affected. However, the clinical presentation of ALS 
may differ depending on the extent of involvement of each type of motor neuron. The classical 
form of ALS involves primarily the upper motor neurons and the lower motor neurons that 
innervate the limbs. ALS is characterized by muscle weakness, muscle wasting, and fasciculation 
(which often predominate in the lower limbs), as well as by hyperactive tendon reflexes, 
spasticity, and Hoffman and Babinski signs (which often predominate in the upper limbs) 
(Przedborski et al., 2003; Rowland, 1998). In addition, as the disease advances, patients often 
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develop signs of bulbar involvement (i.e. 
involvement of the IX-XII cranial nerves 
leading to problems with speech, 
swallowing, tongue atrophy and 
twitching). Other cranial nerves are much 
less affected, especially those innervating 
the extrinsic muscles of the eyes (i.e. 
cranial nerves III, IV, and VI, which are 
typically spared in most patients, unless 
they are maintained alive for a long time 
by mechanical ventilation).  
In addition to the classical form 
of ALS, there are three clinical variants 
that are labeled according to the major muscle regions affected during the disease process. These 
are: 
 The bulbar form of ALS: where bulbar manifestations arise before the legs and 
arms are affected; 
 Progressive muscle atrophy: patients with overt signs of lower motor neuron 
involvement, but no clear sign of upper motor neuron involvement; 
 Primary lateral sclerosis: patients with marked upper motor neuron signs, but with 
very few or no signs of lower motor neuron involvement nor atrophy.  
 
 
Figure 1.1: Schematic representation of upper 
(red) and lower motor neurons (green) that 








1.1.3. Neuropathology of ALS 
The major pathological feature of ALS is the degeneration of upper and lower motor neurons. 
However, the neuropathology of ALS also includes degeneration of at least 30% of the small 
interneurons in the motor cortex and spinal cord, in addition to reactive gliosis (Ekblom et al., 
1994; Kawamata et al., 1992; Murayama et al., 1991; Schiffer et al., 1996). 
An established hallmark of ALS is the presence of various inclusion bodies in 
degenerating neurons and surrounding reactive astrocytes [Figure 1.2a] (Barbeito et al., 2004). 
Ubiquitinated inclusions [Figure 1.2b] 
are the most specific and the most 
common type of inclusions in ALS and 
are found in lower motor neurons of the 
brainstem and the spinal cord 
(Matsumoto et al., 1993) and in 
corticospinal upper motor neurons 
(Sasaki and Maruyama, 1994). These 
inclusions are classified as ‘Lewy body-
like’ [Figure 1.2c] and ‘Skein-like’ 
[Figure 1.2d] (He and Hays, 2004; 
Kawashima et al., 1998).  
While the exact composition of 
these inclusions is not known, proteins identified so far include ubiquitin (Leigh et al., 1991) and 
SOD1 (Shibata et al., 1994). Moreover, accumulations of intermediate filament proteins are 
found in hyaline conglomerate inclusions and in axonal ‘spheroids’ in spinal cord motor neurons 




(A) Gliosis demonstrated in the spinal ventral horn using 
glial fibrillary acid protein (GFAP) antibody; (B) Lower 
motor neurons in ALS showing both compact (filled arrow) 
and skein-type (arrow) neuronal cytoplasmic inclusions 
stained for ubiquitin; (C) “Lewy-like hyaline inclusion” body 
in a spinal motor neuron; (D) p62 staining of a skein type 





(Corbo and Hays, 1992) as well as in pyramidal cells of the motor cortex (Troost et al., 1992) in 
ALS postmortem tissue.  
Additionally, Bunina bodies, which are cystatin C-containing inclusions, are found in the 
cell bodies of motor neurons in ALS (Okamoto et al., 1993; Sasaki and Maruyama, 1994). These 
are now thought to be less specific for ALS than the ubiquitinated and neurofilamentous 
inclusions, as they are similar to structures found in neurons of aged rats and humans (Kusaka, 
1999). Other neuropathological features of ALS include fragmentation of the Golgi apparatus 
(Gonatas et al., 1998), mitochondrial vacuolization (Okamoto et al., 1990) and ultrastructural 
abnormalities at synaptic terminals (Sasaki and Iwata, 1996). 
 
1.2. Familial ALS and SOD1 mutations 
1.2.1. Heterogeneity of fALS 
As indicated above, fALS, which makes up about 10% of all ALS cases, is often inherited in an 
autosomal dominant manner, though rarer cases of autosomal recessive and X-linked disease do 
exist (Ince et al., 2011). fALS is genetically heterogeneous including 15 mapped loci and more 
than 10 identified causative genes. These genes are represented in Table 1.1 and include SOD1, 
TAR DNA binding protein (TARDBP) and ‘fused in sarcoma’ (FUS).  
Table 1.1: ALS-associated genes 
 
Gene Locus Chromosomal 
locus 
Gene Onset/Inheritance References 




ALS2 2q33.2 Alsin Juvenile/AR (Hadano et al., 
2001) 
ALS3 18q21 Not identified Adult/AD (Hand and 
Rouleau, 2002) 
ALS4 9q34 SETX Juvenile/AD (Chen et al., 
2004) 
ALS5 15q21.1 SPG11 Juvenile/AR (Orlacchio et al., 
2010) 
ALS6 16p11.2 FUS Adult/AD (Kwiatkowski et 
al., 2009; Vance 
et al., 2009) 
ALS7 20p13 Not identified Adult/AD (Sapp et al., 
2003) 
ALS8 20q13.3 VAPB Adult/AD (Nishimura et 
al., 2004) 
ALS9 14q11.2 ANG Adult/AD (Greenway et al., 
2006) 
ALS10 1p36.2 TARDBP Adult/AD (Sreedharan et 
al., 2008) 
ALS11 6q21 FIG4 Adult/AD (Chow et al., 
2009) 
ALS12 10p15-p14 OPTN Adult/AD & AR (Maruyama et 
al., 2010) 
ALS13 12q24 ATXN2 Adult/AD (Elden et al., 
2010) 
ALSX Xp11-q12 UBQLN2  Adult/X-linked (Deng et al., 
2011) 





However, all of these ALS-associated genes identified to date can account for, at most, 25-30% 
of all cases of fALS keeping the doors open for a lot more discoveries in the genetics of the 
disease (Andersen and Al-Chalabi, 2011). Below is a selection of the most important genes 
followed by a review of mutations in SOD1.  
 
1.2.1.1. Alsin (ALS2) 
Alsin is a GTPase regulator, whose recessive mutations cause a slowly progressive, juvenile-
onset, upper motor neuron-phenotype disease (Hadano et al., 2001). 
 
1.2.1.2. Senataxin (SETX) 
SETX is presumed to be involved in RNA processing. While the dominantly inherited missense 
mutations cause a young onset, very slow evolving form of ALS (Chen et al., 2004), recessive 
ALS + FTD 9p13.2-p21.3 C9ORF72 Adult/AD (DeJesus-
Hernandez et al., 
2011; Renton et 
al., 2011; Vance 
et al., 2009) 
FTD + FTD 9p13 SIGMAR1 Adult/AD (Luty et al., 
2010) 
ALS + 
Dementia + PD 
17q21 MAPT Adult/AD (Hutton et al., 
1998) 
 
All of the ALS and ALS-FTD associated genes identified to date, which account for, at most, 25-30% of all fALS 
cases (Andersen and Al-Chalabi, 2011; Ince et al., 2011). Please see the text for the extension of the gene names, as 
well as their function and types of mutations. AD, autosomal dominant; AR, autosomal recessive; FTD, 
frontotemporal dementia; PD, Parkinson’s disease. 
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mutations of SETX can result in ataxia, oculomotor apraxia type 2, axonal sensorimotor 
neuropathy, or a hereditary motor neuropathy (Moreira et al., 2004).  
 
1.2.1.3. TAR DNA binding protein (TARDBP) 
The discovery of neuronal cytoplasmic inclusions containing TDP-43 in patients with ALS or 
frontotemporal dementia prompted the analysis of TARDBP, the gene that encodes the TDP-43 
protein, in fALS families. TARDBP mutations have been reported in 4-6% of fALS cases 
without SOD1 mutations and in 0-2% of diagnosed sALS cases (Andersen and Al-Chalabi, 
2011). 
Under normal circumstances, TDP-43 is involved in RNA processing, gene splicing, 
transcription regulation, and mRNA modulation (Van Deerlin et al., 2008). The mutations in 
TARDBP are found to result in redistribution of TDP-43 from the nucleus to the cytoplasm in 
neurons and glia in the spinal cord. Masu et al. (2009) and Nishimura et al. (2010) argue that the 
mislocalization of TDP-43 and impaired TDP-43 trafficking, due to mutations in TARDBP, 
might be the cause of the motor neuron toxicity. To test this hypothesis, Wegorzewska et al. 
(2011) created transgenic mice expressing a mutated human TDP-43 that causes fALS. These 
mutant mice develop a clinical syndrome similar to human ALS, including ubiquitinated 
aggregate pathology with selective vulnerability of cortical upper motor neurons and spinal 
motor neurons, increase in astrocyte and microglia activation in cortical layer 5, and loss of 
spinal motor neurons, axons and muscle fibers at end-stage (Wegorzewska et al., 2009). 
However, this animal model does not mimic the disease as well as the SOD1 models do. The 
differences between these models include the lack of cytoplasmic aggregates of TDP-43, the loss 
of approximately 20% versus 50% spinal motor neurons at end-stage, and the appearance of 
9 
 
cortical and descending corticospinal tract pathology before developing lower motor neuron 
degeneration in mutant TDP-43 mice versus mutant SOD1 mice (Wegorzewska et al., 2009). 
Due to these differences, the TDP-43 model is not as well studied as the SOD1 model, which 
will be discussed in more detail later in the chapter. 
 
1.2.1.4. ‘Fused in Sarcoma’ (FUS) 
The FUS protein resembles TDP-43 with functions involved in alternative splicing, genomic 
maintenance, and transcription factor regulation. FUS mutations are found in 4-6% of fALS and 
0.7-1.8 of sALS cases (Kwiatkowski et al., 2009; Vance et al., 2009). Pathological findings of 
neuronal cytoplasmic accumulation of FUS protein, in the absence of TDP-43 staining, have 
been found in patients with FUS mutations. However, it is unclear whether the toxicity in mutant 
FUS cases is mediated through abnormal RNA modulation and metabolism, or by 
mislocalization of protein in the cell. Together, the discovery of mutations in TDP-43 and FUS 
has directed the focus of ALS research towards the roles played by RNA metabolism and 
processing in this disease.  
 
1.2.1.5. VAMP-associated protein type B (VAPB) 
VAPB is involved in intracellular membrane transportation and is primarily located in the 
endoplasmic reticulum (ER). A mutation of this gene induces the formation of insoluble 






1.2.1.6. Angiogenin (ANG) 
ANG shares a metabolic pathway with vascular endothelial growth factor (VEGF), which is 
implicated in ALS (Greenway et al., 2006). So far, 17 ANG missense mutations have been found 
as rare causes of ALS.  
 
1.2.1.7. Optineurin (OPTN) 
While mutations in OPTN were initially reported in primary open angle glaucoma and ataxia 
patients, Maruyama et al. (2010) identified three mutations in patients with fALS or sALS, 
including both autosomal dominant and autosomal recessive mutations. One of these mutations 
was associated with OPTN cytoplasmic inclusions, where the authors found that TDP-43 and 
SOD1 inclusions of sALS and SOD1-associated ALS were also immunolabeled by OPTN 
antibodies. This implied the possibility of a shared pathogenesis between sALS and fALS. 
Additionally, the authors demonstrated that the nonsense and missense mutations of OPTN 
eliminated the inhibitory role of nuclear factor kappa B (NF-B), which is an oxidative stress 
transcription factor involved in regulating neuronal cell death and inflammation. These results 
suggested that NF-B might be a therapeutic target for ALS. This will be discussed further in the 
later stages of this thesis.  
 
1.2.1.8. Ataxin-2 (ATXN2) 
While CAG-trinucleotide repeat expansion in the ATXN2 gene to 34 or more repeats is 
associated with spinocerebellar ataxia type 2, intermediate-length polyQ expansion (27-33 
repeats) on one allele of ATXN2 has been found to be a significant risk factor for ALS in North 




1.2.1.9. The 9p21 locus (C9ORF72) 
Most recently, (GGGGCC)n, a massive hexanucleotide-repeat expansion in the intron between 
noncoding exons 1a and 1b of the uncharacterized gene C9ORF72, has been found to be an ALS 
causative gene (DeJesus-Hernandez et al., 2011; Renton et al., 2011). While normal individuals 
have, at most, 23 repeats, individuals with ALS or frontotemporal dementia can have up to 1,600 
repeats. Moreover, this expansion seems to account for a significant portion of fALS and sALS 
cases, about 40% of fALS and 7-10% of sALS cases (Morris et al., 2012), and thus far, is more 
represented than any of the other identified genes, which makes this gene a very promising one 
for further study. 
 
1.2.2. SOD1 mutations 
SOD1 is a 153-amino acid, abundant, ubiquitously expressed homodimeric cytosolic enzyme 
whose only known activity is to dismutate superoxide to hydrogen peroxide (Longo et al., 1996). 
Catalysis by SOD1 is mediated in two asymmetric steps by an essential copper atom, which is 
alternately reduced and oxidized by superoxide. Two other types of superoxide, mitochondrial 
SOD2 and extracellular SOD3, exist, but thus far, no mutations in these isoforms have been 
described (Cleveland and Rothstein, 2001).  
Mutations in SOD1 are the most common in fALS, accounting for about 20% of the cases 
(Rosen et al., 1993). So far, more than 150 mutations have been found in SOD1 along the 
peptide sequence causing the mutant protein to misfold and accumulate [Figure 1.3] 
(http://alsod.iop.kcl.ac.uk/). All of these mutations give rise to a very similar disease phenotype 
in humans, even though the disease duration and age at onset may vary among patients with 
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different SOD1 mutations (Cudkowicz et al., 1997). Moreover, these SOD1 mutations, which are 
present at birth and are ubiquitously expressed in all tissues, produce a rapidly progressive adult-
onset degenerative disease in which motor neurons are the primary cell types affected.  
 
1.2.2.1. Causative hypotheses 
Several hypotheses have been proposed to provide an explanation of how a multitude of 




Figure 1.3: ALS-causing mutations lie throughout the SOD1 polypeptide 
 
 
(A) Well-known mutations in the 153-amino-acid SOD1 polypeptide that cause ALS; and (B) their positions in the 
three-dimensional structure of crystallized human SOD1. (Cleveland and Rothstein, 2001)  
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1.2.2.1.1. Conformational changes 
The first hypothesis is that most, if not all, of the known SOD1 mutations lead to a relaxed 
conformation of the protein. These less-tightly folded enzymes thus catalyze aberrant copper-
mediated chemistry either by allowing oxidation of aberrant substrates (i.e. substrates that 
normally will never gain access to the catalytic site) or by handling the copper clumsily and 
frequently releasing it. The latter might allow free copper to catalyze unwanted oxidative 
reactions, which might result in oxidative stress-linked toxicity. Although in vitro findings 
supporting the oxidative stress hypothesis exist in the literature (Goto et al., 2000), three lines of 
evidence continue to offer strong evidence against the primary toxicity of SOD1 mutants arising 
from aberrant oxidative chemistry: (a) the insensitivity of toxicity to the level of SOD1 activity 
(Bruijn et al., 1998); (b) the undiminished toxicity despite lower copper loading in vivo in mice 
(Subramaniam et al., 2002); and (c) the paucity of evidence for increased markers of oxidative 
damage in SOD1-mediated human disease (Bowling et al., 1993; Ferrante et al., 1997) and in 
mutant SOD1 mouse models (Williamson et al., 2000). 
 
1.2.2.1.1. Loose zinc binding 
A second hypothesis is that mutant SOD1 binds to structural zinc less effectively than wild-type 
SOD1. Mutant SOD1 depletion of zinc in primary motor neurons was found to provoke rapid 
neuronal death in a manner that is dependent on neuronal nitric oxide synthase, accompanied by 
elevated levels of protein-bound nitrotyrosine (Estevez et al., 1999). However, this view remains 
controversial as it is unclear how all of the 150 different mutations can affect the binding of zinc. 
Moreover, in vivo studies have shown that limiting nitric oxide production either by ablating or 
inhibiting neuronal nitric oxide synthase provides marginal benefit to transgenic mice expressing 
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mutant SOD1 (Facchinetti et al., 1999), suggesting that the disease pathology observed in these 
mice is not caused by the mutant SOD1 depletion of zinc in motor neurons. Additionally, 




 mutant mice (Bruijn 
et al., 1997; Williamson et al., 2000).  
 
1.2.2.1.3. Propensity to aggregate 
Mutant SOD1 misfolding results in cytoplasmic ubiquitin-positive protein aggregates that are 
potentially toxic for motor neurons. This pathological characteristic is also visible in sALS cases. 
One study has shown that forced expression of SOD1 mutants by microinjection provokes 
mutant-dependent aggregates selectively in motor neurons, but not in sensory or hippocampal 
neurons, followed by cell death (Bruening et al., 1999; Durham et al., 1997). Moreover, 
aggregates as well as acute toxicity can be ameliorated by elevating the level of the protein-
folding chaperone HSP70 (Bruening et al., 1999). These in vitro findings highly support the 
hypothesis of toxicity arising from mutant-mediated protein misfolding.  
 
Regardless of which of the above hypotheses may be correct, it seems certain that the 
changes that occur in SOD1 caused by mutations provoke the demise of motor neurons, not 
through a loss-of-function, but rather through a gain-of-function effect. The most salient 
arguments in favor of this assertion are the following. Although SOD1 is thought to be essential 
for living organisms (Halliwell and Gutteridge, 1991), mutant mice deficient in this enzyme 
thrive and do not develop an ALS phenotype (Reaume et al., 1996). In contrast, transgenic 
rodents expressing either catalytically active SOD1 mutations (Gurney et al., 1994; Wong et al., 
1995) or catalytically inactive SOD1 mutations (Bruijn et al., 1997; Wang et al., 2003) mimic the 
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clinical and neuropathological hallmarks of ALS. Furthermore, transgenic mice expressing high 
levels of wild-type human SOD1 are healthy (Gurney et al., 1994) and co-overexpression of 
mutant SOD1 with wild-type human SOD1 does not lead to the rescue of the paralytic phenotype 
(Bruijn et al., 1998).  
 
1.2.3. Mode of action of mutant SOD1 and current in vitro models of ALS: 
To date, it has been proposed that mutant SOD1 cytotoxity involves a number of different 
mechanisms, such as oxidative stress (Wiedau-Pazos et al., 1996; Yim et al., 1996), protein 
aggregation (Durham et al., 1997), aberrant protein-protein interactions (Kunst et al., 1997), 
decreased binding affinity of zinc (Estevez et al., 1999), mitochondrial dysfunction (Liu et al., 
2004), excitotoxicity (Plaitakis and Caroscio, 1987), glutamate transporter failure (Rothstein et 
al., 1992), endoplasmic reticulum stress (Kikuchi et al., 2006; Saxena et al., 2009), and apoptosis 
(Kostic et al., 1997) none of which are mutually exclusive. Some of these proposed mechanisms 
are described, in more detail, below: 
 
1.2.3.1. Oxidative stress  
The proposed mechanism on how mutant SOD1 can result in oxidative stress is already 
explained in the section above. Moreover, it has been found that extracellular mutant SOD1 
causes injury to and death of motor neurons in the presence of microglia (Zhao et al., 2010). In 
tbe light of the existing data collected so far, it can be concluded that while oxidative stress is 
one of the major characteristics of ALS pathogenesis, it may not be the primary cause of mutant 






1.2.3.2. Mitochondrial dysfunction 
Another proposed mechanism is that misfolded SOD1 damages mitochondria by being deposited 
onto the cytoplasmic face of the outer membrane of the mitochondria in spinal cord (Israelson et 
al., 2010; Liu et al., 2004). ATP levels have also been reported to be decreased in spinal cords of 
presymptomatic and symptomatic transgenic mutant SOD1 mice (Browne et al., 2006; Mattiazzi 
et al., 2002). It has also been shown that ALS mitochondria are degenerated with an altered 
ultrastructure and impaired dynamics (Magrane et al., 2009). More recently, Magrane et al. 
(2012) followed mitochondria in mutant SOD1-expressing motor neurons using a mitochondria-
targeted fluorescent probe and found that mitochondrial dynamics alterations and bioenergetics 
dysfunctions work together in triggering synaptic alterations in mutant SOD1-expressing motor 
neurons. Moreover, mitochondrial dysfunction seems not to be limited to neurons as this has also 
been observed in mutant SOD1 astrocytes (Cassina et al., 2008). These findings suggest that not 
only mitochondrial dysfunction is a key feature of mutant SOD1 disease pathogenesis, but might 
also have a contributory role in motor neuron degeneration during the disease process.  
 
1.2.3.3. Glutamate Excitotoxicity 
Glutamate excitotoxicity, the excessive firing of motor neurons due to failure to remove synaptic 
glutamate, is observed both in transgenic mutant SOD1 mouse models, and in fALS and sALS 
patient samples (Ilieva et al., 2009). The first evidence of abnormalities in glutamate handling in 
ALS came from the discovery of large increases in the levels of glutamate in the cerebrospinal 
fluid of ALS patients (Rothstein et al., 1990; Shaw et al., 1995), which is now reported in about 
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40% of sALS patients (Spreux-Varoquaux et al., 2002). These findings were followed by a 
significant elevation of extracellular central nervous system glutamate levels in transgenic ALS 
mice (Alexander et al., 2000).  
Furthermore, mutant SOD1 expression correlates well with disturbances in glutamate 
transmission in transgenic ALS mice, where loss of excitatory amino acid transporter 2 (EAAT2) 
protein expression, the main glutamate transporter in astrocytes responsible for 90% of the total 
glutamate uptake, was found in spinal cords from SOD1
G85R
 mice (Bruijn et al., 1997). This 
study led to the proposal that impaired glutamate uptake in transgenic ALS mice might cause 
excitotoxic killing of motor neurons. However, it was not clear in the study whether the loss of 
expression of EAAT2 was due to the loss of the protein or to the lack of recognition by its 
antibodies. In favor of the loss of EAAT2 protein expression hypothesis, aberrant editing of 
mRNA was observed, which was suggested to lead to aberrant EAAT2 synthesis. Moreover, the 
astrocytic overexpression of EAAT2 was found to rescue motor defects and neurodegeneration, 
but not lifespan in transgenic mutant SOD1 mice (Guo et al., 2003). In contrast, the Shaw group 
found that the two splice forms of EAAT2 RNA that have been reported to account for the 
EAAT2 protein loss are not expressed significantly more in ALS patients than in controls, 
indicating that the involvement of EAAT2 transcripts in ALS is not primary (Meyer et al., 1999). 
Finally, it was found that the partial disruption of endogenous EAAT2 in transgenic mutant 
SOD1 mice potentiated neuronal loss and slightly worsened mortality (Pardo et al., 2006). All of 
these outcomes support a secondary and modifying role for EAAT2 in motor neuron 
degeneration through its loss in mutant SOD1-expressing astrocytes.  
 Another hypothesis about the role of glutamate transporters in the ALS disease process 
comes from the Trotti group, where the group argues that glutamate transporters might be 
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present, but hypofunctional due to post-translational damage (Trotti et al., 2001). While different 
studies point to a defect in EAAT2 in ALS, it remains unclear whether this alteration is a cause 
or a consequence of the disease, and whether the EAAT2 defect may have any pathogenic 
significance. This is because other glutamate transporters that are presumably not affected in 
ALS are also expressed by both astrocytes and neurons. 
 
1.2.3.4. Endoplasmic reticulum stress 
It is also believed that some misfolded proteins, such as mutant SOD1, are sent to the 
endoplasmic reticulum (ER), even though they lack the proper signal peptide for the 
translocation. The excess of misfolded proteins in the ER may cause an ER-associated protein 
degradation response, which leads to ER-stress. This stress, in turn, may activate ER stress-
related cell death signaling pathways, including apoptosis (Kikuchi et al., 2006).  Consistent with 
these findings, the Caroni group (this study will be discussed, in more detail, in “Selective 
degeneration of motor neurons in ALS” section of this chapter) has found an up-regulation of ER 
stress-related genes in vulnerable motor neurons of presymptomatic transgenic mutant SOD1 
mice (Saxena et al., 2009). 
 
1.2.3.5. Apoptosis 
Despite considerable efforts, the initial noxious signal linking mutant SOD1 to known 
downstream death-related molecular pathways, such as apoptosis, remains mysterious. Over the 
years, various attempts have been made to unravel such initial signals using in vitro models of 
motor neuron degeneration for SOD1-linked ALS. However, under basal culture conditions, the 
expression of mutant SOD1 did not induce, by itself, any detectable cell death in primary motor 
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neurons isolated from transgenic mutant SOD1 animals (Kuo et al., 2004; Raoul et al., 2002). It 
only triggered some morphological and electrophysiological abnormalities and minimal cell 
death in models of stably transfected motor neuron cell lines (Maxwell et al., 2004; Pasinelli et 
al., 1998; Sathasivam and Shaw, 2005). To circumvent this problem, different strategies have 
been tried to challenge motor neuron survival with stressors that presumably mimic aspects of 
the disease. For instance, mutant SOD1-expressing cell lines were challenged by serum 
starvation (Sathasivam and Shaw, 2005), enzymatically-induced oxidative stress (Pasinelli et al., 
1998), or toxins, such as cyclosporin A (Maxwell et al., 2004). Similarly, mutant SOD1-
expressing primary motor neurons were challenged by Fas, nitric oxide (Raoul et al., 2002) or 
excitotoxins like kainate (Spalloni et al., 2004). In all of these studies, the challenged mutant 
cells showed an increased vulnerability compared to the cells expressing human wild-type or 
endogenous forms of SOD1. In addition to these interventions, there has been a significant 
amount of interest in the field to find models that are pathogenically and pathologically similar to 
ALS and specific to motor neurons. 
 
1.2.4. Transgenic mutant SOD1 animal models 
So far, the majority of ALS research has focused on transgenic rodents expressing mutant SOD1, 
since sALS and fALS are clinically and pathologically almost indistinguishable from each other. 
At present, there are 12 different human SOD1 mutations expressed in mice [Table 1.2] (Turner 
and Talbot, 2008). These include 9 missense and 3 C-terminal truncated variants. Among these, 
transgenic SOD1
G93A 











rodents. These mutants either are abundantly expressed, 
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) or marginally expressed, and unstable 
with negligible activity (such as in SOD1
G85R
) in the central nervous system.  
Table 1.2: Transgenic mutant SOD1 mouse models 
























































The information about all of the existing transgenic mutant SOD1 mouse models; taken from the review of Turner 
and Talbot (2008). Please see text for more information on the clinical and neuropathological characteristics of these 
mice. nd, not described. 
 
The time course of clinical and neuropathological features of transgenic SOD1
G93A 
mice 
is summarized in Figure 1.4. These mice develop hindlimb tremors and muscle weakness around 
90 days detected by locomotor deficits, progressing to paralysis and premature death at around 
120-140 days (Gurney et al., 1994). Pathologically, neuromuscular junctions degenerate at 
around 47 days of age, in a manner that is selective for fast-fatigable motor units (Fischer et al., 
2004; Pun et al., 2006). Moreover, proximal axonal loss is prominent after 80 days of age, 
coinciding with motor impairment. This is followed by about 50% loss of lower motor neurons 
after 100 days of age (Fischer et al., 2004). Pathological features of spinal motor neurons include 
mitochondrial vacuolization (Dal Canto and Gurney, 1995), Golgi apparatus fragmentation 
(Mourelatos et al., 1996), neurofilament-positive inclusions (Tu et al., 1996), and cytoplasmic 
SOD-immunoreactive aggregates (Johnston et al., 2000). Spinal cords are also characterized by 
astrocytosis and microgliosis around symptom onset (Hall et al., 1998). Similar features are 
observed in transgenic SOD1
G37R 
mice and in transgenic SOD1
G85R 













(Wang et al., 
2005a) 












disease onset and much shorter disease duration for SOD1
G85R 
mice. [Table 1.2] (Bruijn et al., 
1997). 
Despite the close similarities between the phenotype of transgenic mice expressing 
mutant SOD1 and human ALS patients, including the early and specific neurodegeneration of 
corticospinal motor neurons and related subcerebral projection neurons (Ozdinler et al., 2011), 
the animal model differs from the human disease in few ways: First, vacuolar degeneration, 
which is seen in transgenic mice, has not been a well-established pathology of motor neurons 
from ALS patients. And second, neurofilamentous accumulation in cell bodies and proximal 
axons is infrequent in transgenic rodents, but is more prominent in ALS patients. Regardless of 





Mice develop hindlimb tremor, weakness, and locomotor deficits at about 90 days, which is preceded by 
distal synaptic and axonal degeneration. These symptoms are followed by fatal paralysis about 1 month later 
concomitant with spinal motor neuron loss and reactive gliosis. IPC: insoluble protein complexes; NMJ: 
neuromuscular junction; UPS: ubiquitin-proteasome system. (Guégan et al., 2001; Turner and Talbot, 2008) 
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these limitations, however, transgenic mutant SOD1 rodents are excellent experimental models 
of ALS, which have been used in most of the ALS research so far in understanding the biology 
and pathogenesis of the disease. 
 
1.3. Motor neuron death in ALS 
1.3.1. Death mechanism in transgenic mutant SOD1 animals 
One of the main features of ALS that have been studied in transgenic mutant SOD1 mouse 
models has been the mechanism by which motor neurons die. Whether motor neurons die by 
apoptosis, which is a form of programmed cell death – whose morphological hallmarks include 
cytoplasmic and nuclear condensation, compaction of nuclear chromatin into circumscribed 
masses along the inside of the nuclear membrane, and structural preservation of organelles 
(Guégan and Przedborski, 2003) – has been an important question in the field. In transgenic 
mutant SOD1 animals, dying neurons were found to be atrophic with large vacuoles in the 
cytoplasm due to dilated rough ER, Golgi apparatus, and mitochondria (Dal Canto and Gurney, 
1995). 
Ultrastructural studies from our laboratory have shown that sick neurons in transgenic 
mutant SOD1 mice have diffusely condensed cytoplasm and nuclei with irregular shapes 
(Guégan and Przedborski, 2003). While apoptotic cells are observed in the anterior horn of end-
stage transgenic SOD1
G93A 
mice [Figure 1.5a], they are rare in number. These results suggest that 
neuronal cells die by apoptosis in transgenic mutant SOD1 animals. However, apoptosis, since it 
is observed as being rare in number, may not be the only form of cell death observed in motor 
neurons. Also, apoptotic markers are known to be short-lived, and thus, might not be sufficient to 
tell which form of death motor neurons go through.  
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 Besides exhibiting certain morphological features, apoptotic cells also activate various 
molecular pathways, including the Bcl-2 family and the caspases. In human ALS cases and 
transgenic SOD1
G93A 
mice, anti-apoptotic Bcl-2 mRNA expression is significantly decreased and 
pro-apoptotic Bax mRNA is increased in the lumbar spinal cord compared to controls (Mu et al., 
1996; Vukosavic et al., 1999). In addition, our group has observed an increase in the expression 
of the active form of Bax (i.e. translocation of Bax from cytosol to mitochondria) over the course 
of the disease process (Guégan and Przedborski, 2003) [Figure 1.5b]. Moreover, overexpression 
of Bcl-2 has been found to mitigate neurodegeneration and to prolong survival in transgenic 
SOD1
G93A 
mice (Kostic et al., 1997). Interestingly, a study crossing Bax-deficient mice with 
transgenic SOD1
G93A 
mice found that Bax deletion does not prevent neuromuscular denervation 
or mitochondrial vacuolization. However, it completely rescues motor neurons from death, 




(A) Apoptotic cells found in the anterior horn of an end-stage transgenic mutant SOD1
G93A 
mouse; (B) Western 
blot analysis of spinal cord extracts shows the relocation of Bax from the cytosol to the mitochondria over the 
course of the disease, suggesting an increase in the active form of pro-apoptotic Bax; (C) Coincidental changes of 
cytochrome c in the opposite direction; (D) Effector caspases, such as caspase-7, are activated later in the disease 
process. 1M (AS): 1 month, asymptomatic stage; 2M (AS): 2 months, asymptomatic stage; 3M (BS): 3 months, 
beginning of symptoms; 5M (ES): 5 months, end stage; Non-TG: non-transgenic littermates. Taken from Guegan 




mildly extends lifespan (mean = 157 ± 9 days versus 137 ± 7 days) and delays motor dysfunction 
(136 ± 13 days versus 119 ± 11 days) in Bax-deficient/mutant SOD1 mice (Gould et al., 2006). 
This study suggested a complete dissociation between motor neuron death and motor dysfunction 
in ALS. In a subsequent study, Reyes et al. (2010) bred conditionally-deficient, in the central 
nervous system, Bax and Bak mice with transgenic SOD1
G93A
 mice, and found that the neuronal 
deletion of Bax and Bak prevented motor neuronal loss and axonal degeneration, delayed onset 
of motor manifestations (167 ± 8 days versus 139 ± 4 days), and extended survival (136 ± 5 days 
versus 111 ± 4 days). Collectively, the above data support the idea that the apoptotic machinery 
contributes to the natural course of the ALS-like phenotype in transgenic mutant SOD1 mice.  
 Similarly, our group has found increased content of pro-apoptotic cytosolic cytochrome c 
and active caspase 7 in transgenic SOD1
G93A 
mice over the course of the disease, but only after 
the onset of paralysis (Guégan and Przedborski, 2003) [Figure 1.5c-d respectively]. Consistent 
with these results has been the finding showing that the prevention of mitochondrial cytochrome 
c release lengthens the lifespan of transgenic SOD1
G93A 
mice (Zhu et al., 2002).  
 
1.3.2. Differential susceptibility of spinal motor neurons in ALS 
While studying transgenic mutant SOD1 animal models as a whole provides clues about the 
death mechanism motor neurons go through in ALS, it was only when motor neuron subtypes 
and pools were studied separately that the field began to learn about the different levels of 
susceptibility/resistance of spinal motor neurons. Spinal motor neurons segregate into three 
subtypes: alpha, beta, and gamma. Of these, the most abundant subtype, alpha-motor neurons, 
innervate contractile skeletal fibers and are classified according to the function of the fiber type 
that they innervate: fast-twitch fatigable (FF), fast-twitch fatigue-resistant (FR), and slow-twitch 
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fatigue-resistant (S) (Burke et al., 1973). In ALS, axons of FF motor neurons followed by FR 
motor neurons are far more likely to show degeneration than those of S motor neurons, many of 
which survive until the later stages of the disease (Fischer et al., 2004; Frey et al., 2000; Hegedus 
et al., 2007; Pun et al., 2006).  
Following the different susceptibilities of spinal motor neuron subtypes, the Caroni group 
performed an in vivo longitudinal gene array study on lumbar motor neurons that are selectively 
vulnerable (VUL, i.e. the FF motor neurons) or resistant (RES, i.e. the FR and S motor neurons) 
(Saxena et al., 2009). This study revealed that the subtype-selective ER stress responses 
influence disease manifestations (Saxena et al., 2009). Indeed, in this study, it was shown that 
VUL motor neurons are selectively prone to ER stress and, in the gene array analyses, these 
motor neurons gradually up-regulate ER stress markers in mouse models of fALS. Moreover, the 
group showed that ubiquitin signals increase in both VUL and RES motor neurons 25-30 days 
before the earliest denervations, while an unfolded protein response (UPR) coupled with early 
stress management pathways is initiated only in VUL motor neurons followed by an abrupt 
down-regulation at age P30 [Figure 1.6]. Saxena et al. showed that this transition is followed by 
selective axonal degeneration and spreading of stress.  
Moreover, salubrinal, a known inhibitor of eIF2α phosphatase enzymes, provided clear 
protection against axon pathology and neuromuscular denervation and delayed disease 
progression. In contrast, when the ER stress was increased chronically, a hastening of disease 
manifestations was noted. These results suggested that cell-type-selective ER stress responses 
influence the clinical manifestations and progression of the disease in fALS mouse models. 
Thus, these results support the subtype-selective vulnerability of motor neurons in ALS and the 
consensus that ER stress plays a role in the ALS disease process. 
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Another example of degeneration occurring in a subset of motor neurons has been found 
by Raoul et al., where the group demonstrated that about 50% death occurs in cultured primary 
spinal motor neurons through the activation of the Fas death receptor-mediated pathway 
involving two parallel death cascades [Figure 1.7a] (Raoul et al., 2002). This pathway includes 
the activation of the kinases ASK1 and p38, the transcription of neuronal nitric oxide synthase, 
and the up-regulation of Fas ligand [Figure 1.7b] (Raoul et al., 2006; Raoul et al., 2002). This 
group, along with others, suggested a role for this specific pathway in the cell-autonomous motor 
neuron degeneration in transgenic mutant SOD1 models due to the following findings: (1) Motor 
Figure 1.6: Early increase in stress and UPR pathways in vulnerable motor neurons in 




(A) Vulnerable (VUL) motor neurons exhibit an early up-regulation of stress management pathways, followed by 
their abrupt down-regulation at P30; (B) VUL motor neurons show an up-regulation of UPR- and stress-related 




neurons purified from mutant SOD1 embryos are 100-fold more sensitive to Fas activation than 
their control counterparts (Raoul et al., 2002); (2) Fas/nitric oxide pathway is up-regulated in 
vivo months before the onset of symptoms 
(Raoul et al., 2006; Veglianese et al., 2006; 
Wengenack et al., 2004); and (3) the 
administration of siRNA to Fas in transgenic 
mutant SOD1 mice extended lifespan in these 
mice (Locatelli et al., 2007).  
 
1.3.3. Non-cell autonomous contribution to 
motor neuron death 
Once the field discovered the selective 
susceptibility of motor neuron subtypes, one of 
the main questions became whether motor 
neurons die in a cell autonomous, i.e. damage 
within a selective population of cells alone is 
enough to produce disease (Ilieva et al., 2009), 
or non-cell autonomous manner. The Caroni 
group was the first to address this question. 
Here, this group utilized a Thy1 expression 
cassette to drive high constitutive expression of 
mutant SOD1 in postnatal motor neurons, 
including upper and lower motor neurons (Lino 





(A) When treated with Fas ligand (sFasL), EGFP 
positive motor neurons show about 50% loss after 48 
hours in culture. Motor neurons are transfected with an 
expression vector coding for the EGFP (pEGFP) in 
combination with vectors coding for either an empty 
vector, wild-type HA-tagged ASK1 (pHA-ASK1), or 
the dominant-negative form of ASK1 (ASK1-K709R). 
Motor neurons that are treated with sFasL and 
transfected with dominant-negative vector showed a 
rescue of loss, suggesting that ASK1 is required for 
Fas-induced motor neuron death; (B) The schematic of 
the Fas-mediated death pathway that can be triggered 




et al., 2002). In this study, the group showed that restricted expression of mutant SOD1 in 
postnatal motor neurons did not cause motor neuron pathology or disease. Furthermore, the 
group produced double transgenic mice by crossing human SOD1 minigene G93A mice with 
Thy1-SOD1 G93A mice, which had about 2-fold higher SOD1 G93A expression in spinal cord 
than single transgenic mice. These double transgenic mice, however, did not exhibit any 
significant difference in the onset or progression of the disease (Lino et al., 2002). Assuming that 
the level of overexpression of mutant SOD1 was sufficient to bring about the ALS phenotype, 
this study suggests that the accumulation of mutant SOD1 primarily in postnatal motor neurons 
is necessary but not sufficient to induce motor neuron degeneration.  
This study was followed a year later by that of a consortium of three laboratories, who 
generated different chimeric mice that were mixtures of normal and mutant SOD1-expressing 
cells (Clement et al., 2003). To assess whether mutant SOD1-expressing non-neuronal cells can 
influence neighboring wild-type neurons, these investigators analyzed spinal cord sections from 
the chimeric animals at end-stage and found ubiquitin-positive protein aggregates, which are an 
early sign of neuronal damage, in neuronal processes and, to a lesser extent, in cell bodies 
[Figure 1.8]. These ubiquitin-positive aggregates were not detected in neurons of wild-type mice. 
In the same study, the group also found that wild-type non-neuronal cells can mitigate the demise 
of mutant SOD1-expressing motor neurons compared to those in parental transgenic mutant 
SOD1 mice (Clement et al., 2003). This study was the first to show the non-cell autonomous 
contribution to motor neuron death in ALS. Subsequently, Yamanaka et al. (2008a) generated 
chimeric mice in which all motor neurons and oligodendrocytes expressed mutant SOD1 in a 
cellular environment containing variable numbers of wild-type non-motor neurons. In most of 
these chimeras, the presence of wild-type non-motor neurons significantly delayed the onset of 
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motor neuron degeneration, 
suggesting that symptom onset in 
ALS is a non-cell autonomous 
phenomenon.  
 
1.3.4. ALS-linked astrocyte 
toxicity for motor neurons: 
1.3.4.1. In vitro: 
The studies discussed above were a 
breakthrough in the understanding 
of the ALS disease process because 
these investigators discovered the 
non-cell autonomous role of 
neighboring cells in ALS.  However, 
none of these studies identified 
which of the neighboring cells are precisely responsible for the demise of motor neurons. The 
first group to address this question was the Barbeito group in 2005, who suggested that FGF-1, 
released by oxidative stress from motor neurons, might have a role in activating neighboring 
astrocytes, which could, in turn, initiate motor neuron apoptosis in ALS through a p75 low 
affinity neurotrophin receptor (P75
NTR
)-dependent mechanism (Cassina et al., 2005). This study 
was the first one to suggest a non-cell autonomous role for astrocytes, the most abundant type of 
glia cells which, under healthy conditions, provide nutritional and structural support to motor 
neurons. 
Figure 1.8: Non-cell autonomous damage caused by 
mutant SOD1 neighboring non-neuronal cells to 
motor neurons 
 
Confocal images of (A) wild-type; (B) SOD1
G85R
; and (C) 
SOD1
G37R
 mice spinal cord cross section lumbar regions are 
stained with neurofilament SMI32 (red), and ubiquitin (blue) 
antibodies. Ubiquitin-positive aggregates (arrows) are present in 
the cell bodies of mutant animals. (D-I) Arrows point to a wild-
type axon or cell body (green) with elevated levels of ubiquitin 




Expanding this study, the Przedborski group showed that mutant SOD1-expressing 
astrocytes release a factor that is selectively toxic to primary motor neurons using an in vitro co-
culture model of motor neurons and glia (Nagai et al., 2007). Worth noting is the fact that, the 
group found that the expression of mutant SOD1 in primary mouse spinal motor neurons did not 
cause the demise of these cells up to 14 days in culture, but  rather resulted in mild morphometric 
alterations [Figure 1.9a] (Nagai et al., 2007). Conversely, Di Giorgio et al. (2007), who used a 
very similar co-culture 
strategy as the Przedborski 
group, with the exception that 
their  embryonic stem cell-
derived motor neurons were 
kept in vitro for much longer 
period of time, found that the 
expression of mutant SOD1 
in motor neurons was 
associated with a progressive 
loss of motor neurons [Figure 1.9b] (Di Giorgio et al., 2007). Regardless of the reasons for this 
apparent discrepancy, both studies agree on the fact that some non-cell autonomous mechanisms 
contribute to the demise of motor neurons in this in vitro model of ALS. Furthermore, the 
Przedborski group has shown that the toxicity of mutant astrocytes is specific for motor neurons 
[Figure 1.10a-b] and that not every type of cell expressing mutant SOD1, such as fibroblasts, can 
kill motor neurons [Figure1.10e]. Moreover, the group has found that medium conditioned 




(A) The non-transgenic (NTg), transgenic wild-type SOD1 (WT), and 
transgenic mutant SOD1
G37R 
(G37R) primary motor neurons (PMNs) 
show no difference in number after 1, 7, and 14 days in vitro (Nagai et 
al., 2007). (B) GFP+ motor neurons that derived from 
Hb9::GFP:SOD1G93A cells showed more loss over time than the 
neurons that derived from Hb9::GFP cells, suggesting a cell-autonomous 
contribution (Di Giorgio et al., 2007). 
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specifically with mutant SOD1-expressing astrocytes selectively kills motor neurons [Figure 
1.10c-e]. 
Following these studies, Xiao et al. 
(2007) tested the toxic effect of mutant 
SOD1-expressing microglia in co-culture 
with motor neurons. This group found that, 
following the activation with 
lipopolysaccharide, mutant microglia 
released more nitric oxide, more 
superoxide, and less insulin-like growth 
factor-1 than wild-type microglia. 
Moreover, the group showed that in co-
culture, mutant microglia induced more 
motor neuron death, as well as decrease in 
neurite numbers and length, than do wild-
type microglia. The group also observed, 
however, less than 20% motor neuron 
death, which was much less than the effect 
shown by our group with mutant SOD1-
expressing astrocytes.  
Advancing the investigation of the non-cell autonomous contribution of astrocytes in 
ALS, the Kaspar group generated astrocytes from postmortem tissue from both fALS and sALS 
patients. They showed, in co-culture and conditioned medium, that these astrocytes from both 
Figure 1.10: Medium conditioned specifically 
with mutant SOD1-expressing astrocytes 
selectively kills motor neurons 
e
 
(A) Primary motor neurons (PMNs) on an astrocyte 
monolayers immunostained for eGFP and GABA at 7 
days; (B) The percentage of surviving PMNs on mutant 
monolayers at 7 days is lower than that of GABAergic 
neurons; (C-D) The percentages of surviving Map2-
positive DRG neurons exposed to conditioned medium 
(CMd) from mutant astrocytes at 2 versus 7 days are 
identical; (E) In comparison to CMd from mutant 
astrocytes, CMd from other mutant cells have no effect on 
PMN survival. (Nagai et al., 2007)  
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patient groups were similarly toxic for motor neurons [Figure 1.11] (Haidet-Phillips et al., 2011). 
The group also demonstrated that the knock-down of SOD1 expression significantly attenuated 
astrocyte-derived motor neuron toxicity. This 
study was the first to indicate the role of 
astrocytes as a non-cell autonomous component 
in sALS.  
 
1.3.4.2. In vivo: 
The first study that investigated the non-cell 
autonomous contribution of mutant SOD1-
expressing astrocytes in vivo came from 
Yamanaka et al., where the group mated 
loxSOD1
G37R 
mice with mice carrying Cre 
recombinase driven by the GFAP promoter 
(Yamanaka et al., 2008b). The group found that 
the diminished mutant SOD1 expression in 
GFAP
+
 cells did not alter the age at onset of the 
motor manifestations, but did delay microglial 
activation and significantly slowed disease 
progression (Yamanaka et al., 2008b). While this 
study was a helpful first study to understand the effects of mutant astrocytes on the ALS disease 
process, it had one major pitfall: GFAP is a marker of reactive astrocytes that is known not to be 
robustly expressed in vivo before activation. In fact, in an in vivo gene array study performed by 
Figure 1.11: Astrocytes derived from 
sALS and fALS patients cause motor 
neuron death in vitro 
 
 
Motor neurons 24 or 120 hours after being 
exposed to medium conditioned with either non-
ALS control, fALS or sALS astrocytes (Haidet-
Phillips et al., 2011). Quantification of motor 
neurons shows that astrocytes derived from sALS 
or fALS patients are toxic for motor neurons. 
1800, SCP-27 & 63358 are non-ALS control cell 
lines. (Scale bar, 100 µm) 
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the Barres group at Stanford University, GFAP has been found to be expressed rather weakly in 
the mouse brain (Cahoy et al., 2008). Aldh1l1, in the same study, on the other hand, was found to 
be the main marker for astrocytes. Thus, GFAP might not have been the best promoter to study 
the role of mutant SOD1 in astrocytes in this mouse model of ALS. 
Additionally, in a focal 
transplantation-based astrocyte 
replacement study, Lepore et al. (2008) 
transplanted lineage-restricted astrocyte 
precursors, glial-restricted precursors 
(GRPs), around cervical spinal cord 
respiratory motor neurons in transgenic 
SOD1
G93A 
rats. These transplanted GRPs 
survived in diseased tissue, 
differentiated efficiently into astrocytes 
[Figure 1.12a], and reduced 
microgliosis. They also extended 
survival [Figure 1.12b] and disease 
duration [Figure 1.12c], attenuated 
motor neuron loss [Figure 1.12d], and 
slowed declines in forelimb motor and 
respiratory physiological function 
(Lepore et al., 2008). Moreover, in a 
later study, the same group managed to transplant human GRPs into cervical spinal cord of 
Figure 1.12: Focally-transplanted astrocytes 
are neuroprotective in mutant SOD1 rats 
 
(A) GFP positive GRPs efficiently differentiated into 
GFAP
+
 astrocytes following transplantation; (B) 
Transplanted GRPs significantly increased overall animal 
survival; (C) and prolonged disease duration. (D) 
Transgenic mutant SOD1 rats had significantly reduced 







mice. However, these transplants neither accelerated nor slowed 
progression of disease in mutant SOD1 mice, including the unchanged outcome measures for 
weight loss, survival, declines in hindlimb and forelimb grip strength, disease onset, and disease 
duration (Lepore et al., 2011).  
 
1.3.5. Unraveling the molecular mechanism underlying the ALS-linked astrocyte toxicity 
for motor neurons 
After the discovery of the mutant SOD1-expressing astrocyte toxicity for motor neurons in vitro 
and in vivo, we wanted to elucidate the molecular mechanism underlying this toxicity. To do this, 
we initially followed a candidate-based approach where we investigated the relevance of 
molecules, previously found by other groups, in our in vitro model system. Below is a review of 
some of these investigations. 
First, Van Damme et al. (2007) found that, in co-culture, wild-type but not mutant SOD1-
expressing astrocytes up-regulate the glutamate receptor subunit, GluR2, in motor neurons 
through an unidentified soluble factor. Under healthy conditions, GluR2 protects motor neurons 
from excitotoxicity by producing receptors impermeable to Ca
2+
. The group showed that mutant 
SOD1-expressing astrocytes have reduced GluR2-regulating capacity rendering motor neurons 
vulnerable to excitotoxicity (Van Damme et al., 2007). Addressing this proposed mechanism, our 
group compared glutamate levels in medium conditioned with mutant versus wild-type 
astrocytes and found no significant difference between these two types of medium (data not 
shown). Furthermore, the Przedborski group also found that the application of CNQX, a potent 
AMPA/kainate receptor antagonist that was shown to prevent the phenotype observed by Van 
Damme et al., did not mitigate the toxic actions of mutant astrocytes on motor neurons (Nagai et 
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al., 2007). Thus, we inferred that this mechanism is not relevant to what we are observing in our 
system. 
Secondly, following the oxidative stress theory, Vargas et al. thought that the activation 
of redox-sensitive nuclear factor erythroid-2-related transcription factor 2 (Nrf2) is coordinated 
with the up-regulation of antioxidant defenses. The group found that the astrocyte-selective up-
regulation of Nrf2 produced a significant delay in symptom onset in transgenic mutant SOD1 
mice (Vargas et al., 2008a). Following this finding, we looked at the differential activity of Nrf2, 
using Western blot, and found Nrf2 to be localized more in the nuclei of motor neurons after 48 
hours of exposure to medium conditioned with mutant astrocytes than in the nuclei of motor 
neurons exposed to medium conditioned with wild-type astrocytes (data not shown), suggesting 
an increase in Nrf2 activity. Moreover, in our model system, we found that the addition of tBHQ, 
shown to increase Nrf2 activity (Li et al., 2005), resulted in a moderate increase (15 ± 2%) in 
motor neuron survival (data not shown). While very preliminary, these data were consistent with 
those of Vargas et al. 
Then, Di Giorgio and collaborators performed a gene array comparing mutant SOD1-
expressing glia to wild-type glia and found prostaglandin D2 (PGD2) receptor to be up-
regulated by more than 14-fold in mutant glia, along with several cytokines, such as Mcp2, 
Cxcl7, and Rantes at smaller fold changes (Di Giorgio et al., 2008). While they showed a partial 
rescue of motor neuron loss with a specific antagonist to the PGD2 receptor, these researchers 
never validated their gene array results using qRT-PCR or Western blot. Furthermore, our group 
tested a series of PGD2 antagonists, including the one used by Di Giorgio et al., but did not 
observe any neuroprotection (data not shown). Our group also failed to detect any increase in 
PGD2 receptor levels in mutant SOD1-expressing astrocytes compared to wild-type astrocytes 
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using Western blot (data not shown). Thus, while the study was interesting in showing relevance 
to non-cell autonomous contribution to human motor neurons, some of the molecular results 
reported in this work could not be reproduced by our group. This may be due to the variability 
and the differences between the purity of the astrocyte cultures of the groups.  
A gene expression profiling study of spinal cord astrocytes from presymptomatic 
transgenic SOD1
G93A 
mice, performed by the Shaw group, revealed impairment of the astrocyte 
lactate efflux transporter, which resulted in a significant decrease in spinal cord lactate levels 
(Ferraiuolo et al., 2011a). Similarly, the Rothstein group has shown that the most abundant 
lactate transporter in the central nervous system, monocarboxylate transporter 1, is reduced in 
patients and mouse models of ALS and might be contributory to how oligodendroglia produce 
neurotoxicity during the disease process (Lee et al., 2012). Additionally, the Shaw group’s study 
also showed an increase in nerve growth factor (NGF) production, which resulted in the 
activation of the p75
NTR 
receptor in neighboring motor neurons (Ferraiuolo et al., 2011a). The 
investigators have also found increased levels of pro-NGF in cerebrospinal fluid of ALS patients. 
Similarly, the Barbeito group found that p75
NTR
, triggered by NGF, is implicated in the selective 
loss of motor neurons from transgenic mutant SOD1 mice (Cassina et al., 2005). Following these 
results, our group tested several blocking antibodies for the p75
NTR 
receptor in our co-culture 
model system, but found no beneficial effect on motor neuron survival (data not shown). 
Therefore, it is unlikely that the p75
NTR 
pathway is involved in the mechanism of mutant SOD1 
astrocyte-derived motor neuron toxicity that we are studying. 
Another mutant SOD1 astrocyte-derived motor neuron toxicity mechanism proposal 
came from the Raoul group, where the group showed that mutant SOD1-expressing astrocytes 
kill motor neurons through an interferon-gamma (IFN-γ)/LIGHT-mediated pathway [Figure 
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1.13] (Aebischer et al., 2011). The group further demonstrated that IFN-γ is up-regulated in 
spinal cords of mutant SOD1
G93A 
mice and that targeted deletion of Light in transgenic mice 
delays the progression but not the onset of symptoms (Aebischer et al., 2011).  
In their next study, the group observed significantly increased levels of IFN-γ in human 
sALS spinal cords compared to control cases. They 
also observed that LIGHT and its receptor, LT-R, 
are expressed mostly in motor neurons, but both in 
ALS and control cases. They also found that the 
LIGHT levels are increased in human ALS spinal 
cords (Aebischer et al., 2012). These results 
suggested that the IFN-γ-triggered LIGHT pathway 
might contribute to human ALS pathogenesis. Our 
group is currently examining the involvement of 
IFN-γ in our co-culture model using motor neurons 
from IFN-γ knockout animals and assessing the 
survival of these motor neurons. Our group has also 
tested a LT-R antagonist (Alexis Biochemicals) 
and an IFN-γ neutralizing antibody (Sigma) in our 
co-culture model and did not observe any 
improvement on the survival of motor neurons. 
Both of these compounds were used by the Raoul 
group (Aebischer et al., 2011).  
Figure 1.13: An alternative IFN-
γ/LIGHT pathway-mediated mutant 
astroctye-derived motor neuron 
toxicity mechanism 
 
(A) IFN-γ was added to motor neuron cultures 
from wild-type or mutant embryos 24 hours 
after plating at indicated concentrations. Motor 
neuron survival was determined 48 hours later. 
(B) Mutant and wild-type motor neurons were 
treated 24 hours after being plated, with 
sLIGHT and with or without IFN-γ (10 ng/ml). 




As one can deduce from all of the above, thus far, all of the candidate-based 
investigations we have performed have been unsuccessful. That is why, for this thesis project, 
it was decided to use an unbiased RNA-Seq method to elucidate the molecular basis of the 
ALS-linked mutant astrocyte toxicity for motor neurons. Moreover, most of the above-
mentioned studies have focused on identifying the toxic factor released from mutant SOD1-
expressing astrocytes and the receptors that are subsequently activated in motor neurons, but not 
on the death signaling pathways that are activated in motor neurons in response to mutant 
astrocytes.  
While these are interesting questions to investigate and these studies have added 
substantial insights into answering some of the questions that were asked, the results from the 
above-mentioned studies have been hard to interpret when taken together, because the 
mechanisms, which have been suggested by the different cited groups, were looking from the 
astrocyte point-of-view and were all different. This difference can be overcome when the 
mechanism is studied from the motor neuron point of view, since the selective loss of motor 
neurons has been consistent across all of these non-cell autonomous disease models. As a result, 
for this thesis, it was decided to focus, not on astrocytes, but on wild-type motor neurons upon 
exposure to mutant SOD1-expressing astrocytes.  
It was also decided to specifically focus on the molecular mechanism that occurs in 
these motor neurons before they become committed to die. Indeed, a significant number of 
studies seem to investigate motor neuron degeneration by looking at late-stage events, when 
many of the motor neurons are already committed to die. It was believed that searching for 
neuroprotective targets at such a stage may thus not be very fruitful. Consequently, this thesis 
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work was set on the premise that unraveling early molecular alterations in motor neurons may be 
more promising in terms of finding effective therapeutic avenues for ALS.  
Accordingly, this thesis work first focused on characterizing a well-controlled in vitro 
model of non-cell autonomous motor neuron degeneration, where the timing of the toxicity and 
the point of no return for motor neurons were identified. Moreover, in this model system, 
cultured motor neurons needed to be purified and be in large enough quantities so that sufficient 
amounts of RNA could be extracted for genomic studies. Thus, the first goal was to address these 
prerequisites and the results of these first set of investigations are presented and discussed in 
Chapter 2 of this thesis.  
In Chapter 2, an in vitro model of ALS composed of purified wild-type embryonic stem 
cell-derived motor neurons was characterized in which, following 7 days of exposure to mutant 
astrocyte-conditioned medium, about half of the motor neurons are lost. This finding is identical 
to what the Przedborski group has previously observed with primary spinal motor neurons and 
mutant astrocytes (Nagai et al., 2007). Capitalizing on this cell model system characterized in 
Chapter 2, an RNA-Seq assay was used to identify gene alterations germane to the toxicity of the 
mutant astrocytes by elucidating relevant molecular pathways that are dysregulated in motor 
neurons. To analyze the results of this assay, a reverse gene engineering algorithm generated by 
the Califano group (Carro et al., 2010) was utilized to infer transcription factors whose activities 
are altered in this model system. The findings from this analysis are presented and discussed in 
Chapter 3 of this thesis. Finally, as described in Chapter 4, NF-B was discovered to be one of 
the most dysregulated transcription factors in the model system studied. Using Western blot and 
a specialized ELISA kit, an increase in the transcriptional activity of NF-B was demonstrated in 
motor neurons exposed to mutant astrocyte-conditioned medium. In addition, both the 
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pharmacological and genetic inhibition of NF-B in motor neurons was shown to result in the 
full rescue of these neurons in vitro.  
The main conclusions of this thesis work are the following. This is the first time that the 
reverse gene engineering algorithm is used in a model of neurodegeneration and the results from 
this thesis work demonstrate that such new approaches may be quite powerful for identifying 
pathogenic mechanisms. Furthermore, NF-B has been found to be instrumental in mediating the 
demise of motor neurons in response to mutant astrocytes in our in vitro model of ALS. If this 
finding faithfully reflects a key pathogenic event in ALS, then drug development projects aimed 
at identifying and testing (pre-clinically, first, and then clinically) NF-B antagonists may have 




Chapter 2: Validation of a non-cell autonomous model of ALS using 
purified embryonic stem cell-derived motor neurons exposed 
to mutant astrocyte-conditioned medium 
 
2.1. Introduction 
2.1.1. Primary versus embryonic stem cell-derived motor neurons 
Following the publication from our laboratory on the toxic effect of mutant SOD1-expressing 
astrocytes on the survival of motor neurons (Nagai et al., 2007), our aim was to elucidate the 
molecular mechanism underlying this non-cell autonomous neurodegenerative model. To 
achieve this stated goal, we initially performed a number of candidate-based investigations, 
which failed to provide us with enough insights into the molecular signaling driving the demise 
of motor neurons in this in vitro ALS model. Consequently, we thought to change the strategy 
and search for the molecular underpinning of this motor neuron death phenotype from a 
candidate-based to an unbiased genomic approach using an RNA-Seq assay; this assay is 
discussed in more detail in the next chapter.  
As a prerequisite to performing the proposed genomic assay, it was necessary to obtain 
purified motor neurons in large quantities. In the initial studies by Nagai and collaborators 
(2007), which revealed the non-cell autonomous role of astrocytes in ALS, primary spinal motor 
neurons were mainly used. Several investigators have shown such neuronal preparations to be 
suitable for probing the molecular basis of selective motor neuron degeneration caused by 
mutant SOD1 (Raoul et al., 2002). However, for this thesis work, obtaining sufficient numbers of 
purified primary motor neurons from embryonic day 12.5 mouse spinal cords would be quite 
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challenging. Furthermore, using immortalized cell lines, such as neuroblastoma, was not 
desirable, since the goal of this work was to explore the molecular mechanism of neuronal death. 
Therefore, it was decided to use a readily-expandable source of motor neurons that is provided 
by embryonic stem cells subjected to the differentiation protocol published by Wichterle et al. 
(2002). 
Indeed, based on the knowledge gained from developmental studies of motor neuron 
identity specifications [Figure 2.1a], Wichterle and collaborators (2002) developed a method to 
differentiate mouse embryonic stem cells into motor neurons with an efficacy of about 30% in 
vitro. Embryonic stem cells were obtained from a transgenic mouse line in which the gene for 
Figure 2.1: Differentiation of embryonic stem cell-derived motor neurons 
 
(A) This schematic shows the progressive steps in motor neuron specification, where neural inductive signals 
convert primitive ectodermal cells to a rostral neural fate, followed by a more caudal identity with the addition 
of retinoic acid (RA). Spinal progenitors, then, are converted to motor neurons by sonic hedgehog (Shh) 
signaling. (B) Bright-field and fluorescence images show eGFP expression in embryoid bodies grown for 5 
days with retinoic acid and sonic hedgehog. These embryonic stem cell-derived motor neurons extend beautiful 




enhanced green fluorescent protein (eGFP) is expressed under the control of the motor neuron 
specific homeobox gene Hb9 promoter. In this method, mouse embryonic stem cells are first 
grown in aggregate cultures for 2 days to form embryoid bodies. Then, embryoid bodies are 
grown for 2 to 3 days and treated with retinoic acid and sonic hedgehog for caudalization and 
ventralization, respectively. At this point, the embryoid bodies take the identity of motor neuron 
progenitor cells. Upon being plated for 2 days on matrigel, which is a gelatinous protein mixture 
that resembles the complex extracellular environment found in many tissues, these cells 
morphologically resemble to primary spinal motor neurons [Figure 2.1b] (Wichterle et al., 2002).  
At the end of the differentiation process, these embryonic stem cell-derived motor 
neurons not only express specific motor neuron markers such as Hb9 and Islet1 (Wichterle et al., 
2002) but also exhibit a special spinal motor neuron identity belonging to the brachial lateral 
motor column (Peljto et al., 2010). During development, in vivo, motor neurons acquire 
columnar identities: medial, hypaxial, or lateral, which determine their settling positions in the 
ventral spinal cord as well as the selection of the muscles that they innervate (Jessell, 2000). 
In addition, embryonic stem cell-derived motor neurons display an interesting change in 
identity depending on the medium they are treated with during differentiation. Peljto et al. (2010) 
has shown that embryonic stem cell-derived motor neurons that are treated only with retinoic 
acid and sonic hedgehog show a rostral and cervical medial motor column-like identity. On the 
other hand, the neurons that are treated with a caudalizing/ventralizing (CV) medium that 
contains Advanced DMEM/F12/Neurobasal medium supplemented with 10% KnockOut Serum 
Replacement result in the generation of spinal motor neurons with brachial and lateral motor 
column characteristics [Figure 2.2a]. Motor neurons that are treated with CV medium also show 
a higher expression of FoxP1, a member of the winged-helix/forkhead transcription factors, than 
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LIM/homeobox protein Lhx3 (Peljto et al., 2010) [Figure 2.2b], suggesting that the generated 
motor neurons are lateral motor column neurons.   
In addition to similarities on the basis of molecular markers and morphology, embryonic 
stem cell-derived motor neurons have also been shown to be functionally comparable to spinal 
motor neurons. For example, when grafted in ovo, embryonic stem cell-derived motor neurons 
also migrate to the ventral spinal cord and send out axons along motor nerve tracts (Wichterle et 
al., 2009). Furthermore, embryonic stem cell-derived motor neurons have been shown to 
innervate muscle fibers both in vitro and in vivo (Miles et al., 2004; Soundararajan et al., 2006; 
Figure 2.2: Brachial and lateral motor column identity of embryonic stem cell-derived 
motor neurons 
 
(A) Upon exposure to CV medium vs. retinoic acid and sonic hedgehog only (RA/Hh), embryonic stem cell 
derived motor neurons display a change in identity from rostral and cervical, expressing Hox5 gene, to brachial 
and thoracic, expressing Hox6, Hox8, Hox9 developmental genes. (B) Similarly, there is an increase in the 
expression of FoxP1 over Lhx3 in the embryonic stem cell-derived motor neurons that are treated with CV 
medium vs. RA/Hh, where Foxp1 is a marker of lateral motor column (LMC) and Lhx3 a marker of median 
motor column (MMC). HMC: hypaxial motor column; a5: Hoxa5; c6: Hoxc6; c8: Hoxc8; c9: Hoxc9 genes. 
Taken from Peljto et al. (2010) 
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Yohn et al., 2008). They also develop many functional properties, such as expressing receptors 
for excitatory and inhibitory transmitter systems, developing electrophysiological properties 
necessary to produce appropriate patterns 
of action potential firing, and forming 
cholinergic synapses with muscle cells in 
culture (Miles et al., 2004). All of these 
features of embryonic stem cell-derived 
motor neurons demonstrate how 
structurally and functionally similar these 
neurons are to primary motor neurons. 
Hence, using the method generated 
by Wichterle et al. (2002), our group 
produced embryonic stem cell-derived 
motor neurons. Some of these common 
features were immunopositivity for the 
pan-neuronal marker, microtubule-
associated protein 2 (Map2), and for 
motor neuron markers, cholinergic 
transmitter synthetic enzyme choline 
acetyltransferase (ChAT) and Islet1/2 
[Figure 2.3] (Nagai et al., 2007). In 
addition, embryonic stem cell-derived 
motor neurons co-cultured on mutant SOD1-expressing astrocyte monolayers showed the same 
Figure 2.3: Visualization of primary and 
embryonic stem cell-derived motor neurons 
 









 large primary motor 
neurons (PMNs) derived from non-transgenic mouse 
embryos. Double immunostaining of primary neuronal 








PMNs derived from a transgenic Hlxb9-GFP1Tmj embryo. 
Embryonic stem cell-derived motor neurons (ESMNs) 
expressing eGFP under the Hb9 promoter are 
immunopositive for (E-F) Map2; (G) ChAT; and (H) Islet 1/ 
2. (Scale bars, 50 m [A-D, F-H], 100 m [E]) Taken from 
Nagai et al. (2007)  
 





magnitude of loss as primary motor 
neurons co-cultured on mutant 
astrocyte monolayers [Figure 2.4a-b] 
(Nagai et al., 2007). Similarly, 
embryonic stem cell-derived motor 
neurons and primary motor neurons 
were found to be identically 
susceptible to medium conditioned 
with mutant SOD1-expressing 
astrocytes [Figure 2.4c] (Nagai et al., 
2007). These results illustrate how 
similar the sensitivities of primary and 
embryonic stem cell-derived motor 
neurons are with respect to the 
toxicity mediated by mutant SOD1-
expressing astrocytes and how 
suitable embryonic stem cell-derived 
motor neurons appear to be to study 
the molecular mechanism underlying 
this toxic phenotype.  
 
2.1.2. Involvement of Bax 
Nagai et al. first used wild-type 
Figure 2.4: Sensitivity of embryonic stem cell-
derived motor neurons to mutant astrocyte-
released toxicity 
 
(A) 7 days after plating, there are about 40-50% less primary 
motor neurons (PMNs) in co-culture with mutant SOD1 G93A, 
G37R, and G85R, than with non-transgenic (NTg) or transgenic 
wild-type SOD1 (WT) astrocyte monolayers (AML). (B) 
Embryonic stem cell-derived motor neurons (ESMNs) plated on 
mutant AML behaved similarly to PMNs. (C) In contrast to 
medium conditioned (CMd) with mutant astrocytes, CMd with 
mutant cerebral cortical neurons, skeletal myotubes, microglia 
or skin fibroblasts had no effect on ESMN survival compared 
with controls. Values represent mean ± s.e.m from at least three 
independent experiments performed at least in triplicate, 
analyzed by two-way ANOVA followed by a Newman-Keuls 
post hoc test. (Nagai et al., 2007) 
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embryonic stem cell-derived motor neurons to understand whether the decline in the number of 
motor neurons after 7 days of exposure to the toxicity emanating from mutant SOD1-expressing 
astrocytes was actually due to neuronal death. To address this issue, the group compared the 
percentage of dying wild-type embryonic stem cell-derived motor neurons co-cultured with 
either mutant astrocytes or wild-type astrocytes using the DNA dye ethidium homodimer (EthD), 
which selectively permeates the damaged membranes of the dying cells. The level of EthD-
labeled embryonic stem cell-derived motor neurons at 7 days was found to be 1.34 fold higher 
upon co-culture with mutant astrocyte monolayers than with wild-type astrocyte monolayers 
[Figure 2.5a] (Nagai et al., 2007). This suggested a decrease in the survival of motor neurons that 
are co-cultured on mutant astrocyte monolayers. Then, to determine whether this astrocyte-
related non-cell autonomous mechanism kills motor neurons by apoptosis, the membrane-
permeable DNA dye Hoechst 33342 [Figure 2.5b-c], as well as immunocytochemistry for fractin 
[Figure 2.5b], which is a caspase 3-activated -actin fragment, were used (Nagai et al., 2007). 
Looking at the fractin-immunostained cells after 7 days, Nagai et al. observed that the percentage 
of fractin-positive cells with condensed nuclei was 1.51 fold higher in co-cultures with mutant 
astrocyte monolayers than in co-cultures with wild-type monolayers [Figure 2.5d] (Nagai et al., 
2007). Furthermore, all cells that stained for Hoechst 33342 also stained for the apoptotic DNA 
fragmentation marker, terminal dUTP nick-end labeling (TUNEL) [Figure 2.5c] (Nagai et al., 





Previously, it has been reported that the toxicity of mutant SOD1 involves the 
mitochondrial-dependent apoptotic machinery and, more specifically, the Bcl-2 family (Guégan 
and Przedborski, 2003; Pasinelli et al., 2004). Consistent with these observations, Nagai et al. 
have shown that the membrane-permeable pentapeptide VPMLK (V5), which inhibits the pro-
apoptotic molecule Bax (Sawada et al., 2003), mitigates the death of motor neurons caused by 
mutant SOD1-expressing astrocytes [Figure 2.5e] (Nagai et al., 2007). Subsequently, the group 
has demonstrated that deletion of the Bax gene also prevents motor neuron death in this in vitro 
model (data not shown). Based on these results, the group has concluded that mutant astrocytes 
kill motor neurons via an exogenously-activated Bax-dependent death signaling pathway. 
Figure 2.5: Embryonic stem cell-derived motor neurons die through a Bax-dependent 
mechanism when co-cultured with mutant astrocyte monolayers 
 
 
7 days after plating, the Bax inhibitor, V5, decreases the percentages of embryonic stem cell-derived motor 
neurons labeled with (A) EthD; (D) Map2 and fractin; and (E) increases the percentage of surviving 
embryonic stem cell-derived motor neurons. Furthermore, all embryonic stem cell-derived motor neurons 
immunopositive for fractin show (B) DNA condensations, as evidenced by Hoechst 33342; and (C) DNA 
fragmentation, as evidenced by TUNEL (Scale bar, 20 m). Values represent mean ± s.e.m from at least three 
independent experiments performed at least in triplicate, analyzed by two-way ANOVA followed by a 
Newman-Keuls post hoc test. (Nagai et al., 2007) 
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However, at this point, the nature of the transducing signaling pathways engaged in wild-type 
motor neurons by mutant astrocytes is still not known nor are the molecular pathways that lie 
either upstream or downstream to Bax. Therefore, the use of a combination of genomics and 
bioinformatics methodologies may represent a powerful alternative to unraveling the outstanding 
molecular questions to our hitherto marginally fruitful candidate-based approaches.  
 This new genomic approach, however, required substantial amounts of RNA from the 
cells of interest (i.e. wild-type motor neurons), as well as those transcripts being harvested at the 
optimal time for such investigations to generate meaningful information. Accordingly, the 
studies that have been carried out to address the above requirements, namely to produce and 
purify wild-type embryonic stem cell-derived motor neurons, to standardize the culture 
conditions, and to define the time-course of wild-type embryonic stem cell-derived motor 
neurons degeneration in response to mutant astrocyte-conditioned medium, are presented and 
discussed in this chapter. 
 
2.2. Results 
2.2.1. Embryonic stem cell-derived motor neurons are efficiently purified using magnetic-
activated cell sorting  
In order to validate the use of embryonic stem cell-derived motor neurons exposed to mutant 
astrocyte-conditioned medium as a non-cell autonomous model of ALS, it was first necessary to 
find an efficient method to purify these motor neurons. The aim was to obtain transcriptional 
information that pertained to motor neurons without affecting the susceptibility of the embryonic 
stem cell-derived motor neurons to mutant astrocytes. Using this rationale, the purification 
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efficiency of two well-established cell isolation methods, fluorescence-activated cell sorting 
(FACS) and magnetic-activated cell sorting (MACS), were compared.  
After following the protocol established by Wichterle et al. (2002) to differentiate 
embryonic stem cells into motor neurons, FACS was first performed to isolate motor neurons 
that expressed high levels of eGFP under the control of the motor neuron specific promoter, Hb9 
[Figure 2.6a]. Consistent with the findings from Wichterle et al (2002), eGFP
+
 neurons showed 
Figure 2.6: Embryonic stem cell-derived motor neurons are efficiently purified 
using Magnetic-Activated Cell Sorting 
 
(A) Fluorescence-Activated Cell Sorting (FACS) and (B) Magnetic-Activated Cell Sorting (MACS) work 
using embryonic stem cell-derived motor neurons that express eGFP under the Hb9 promoter for FACS 
and an extra surface marker, CD2, for MACS. (C) The comparison of MACS with FACS proves MACS to 
be the preferred isolation method for embryonic stem cell-derived motor neurons.  
(FACS image source: http://www.bio.davidson.edu/courses/genomics/method/facs.html) 
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more than 90% purity in culture [Figure 2.6c]. Furthermore, neurons that were treated with 
neurotrophic factors, such as ciliary neurotrophic factor (CNTF), glial cell line-derived 
neurotrophic factor (GDNF), and brain-derived neurotrophic factor (BDNF), extended long 
processes 2 days after purification. However, the total yield of eGFP
+
 neurons obtained from this 
method was small having started with about 50 million differentiated but non-purified embryonic 
stem cell-derived motor neurons before the purification process and ending with less than 3 
million embryonic stem cell-derived motor neurons after the process [Figure 2.6c]. This 
suggested that FACS puts a mechanical constraint on the motor neurons, which could potentially 
result in the selection of more resistant cells in the population. To avoid this potential problem, it 
was decided to utilize the mechanically gentler MACS technique to purify embryonic stem cell-
derived motor neurons. 
For MACS, initially, the p75
NTR
 antibody, which is one of the earliest markers for motor 
neurons, was used to select motor neurons from the embryonic stem cell population. However, 
none of the commercially available antibodies that were tried managed to bind mouse motor 
neurons efficiently (data not shown). Therefore, motor neuron cultures derived from embryonic 
stem cells engineered to express cluster of differentiation-2 (CD2), a cell adhesion molecule 
found on the surface of T and natural killer cells (Peterson and Seed, 1987), were used. These 
modified embryonic stem cells expressed both eGFP and CD2 under the Hb9 promoter [Figure 
2.6b]. To obtain this embryonic stem cell line, Gist Croft, from the Henderson group, had cloned 
the full-length rat CD2 gene into a vector downstream to the 9kb mouse Hb9 promoter. He 
followed the cloning with these subsequent steps: (1) insertion of a neomycin (Neo)-resistant 
gene under the control of the mouse phosphoglycerate kinase (PGK) promoter; (2) transfection 
of the HBG1 Hb9::GFP cell line, which was the same as the 9kb promoter used before; (3) 
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selection of stable neomycin-resistant clones; (4) differentiation of these clones into motor 
neurons; (5) screening for CD2 expression in Hb9::GFP motor neurons; and (6) screening for the 
ability of five of the best CD2-expressing lines to facilitate the MACS purification. He found 
clone-9 to be the best MACS purified line (data not shown), and consequently, this was the cell 
line used for the studies in this thesis. 
Incidentally, among a host of surface markers, CD2 was selected to isolate embryonic 
stem cell-derived motor neurons by MACS for several reasons. First of all, CD2 is a well-
described epitope that is immunologically tractable (i.e. a good number of working antibodies 
against this marker have been established). Secondly, it is not trypsin sensitive, which is 
important since trypsin is used during the differentiation of embryonic stem cell-derived motor 
neurons. Third, CD2 is not expressed in neural cells, which were the target cells to purify. And 
fourth, these cells expressing CD2 never showed any difference in survival or outgrowth when 
compared with their HBG1 parental lines (data not shown), suggesting that expression of CD2 
does not cause any detectable phenotype. Thus, the comparison of purification methods for 
mouse embryonic stem cell-derived motor neurons could now be performed.  
Similar to FACS, once embryonic stem cell-derived motor neurons were differentiated, 
the MACS protocol, which consisted of incubating the cells with anti-rat CD2 antibody 
(Invitrogen) followed by anti-mouse magnetic microbeads (Miltenyi Biotec) as a secondary 
antibody, was carried out. The cells were then passed through a magnetic column (Miltenyi 
Biotec) to separate Hb9::GFP-CD2
+
 cells from other types of cells in culture [Figure 2.6b]. Post-
sorting, the cells were then collected in embryonic stem cell-derived motor neuron medium and 
plated for culture (please see the Experimental Methods for more details). In comparison to 
FACS, MACS proved to be a more efficient purification method in that, the entire process for 
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MACS took about 4 hours, whereas for FACS, it took about 6 hours to achieve the same degree 
of purity of over 90%. Also important is the fact that the yield of motor neurons was about 5-fold 
greater with MACS than with FACS, since constantly, about 15 million motor neurons were 
obtained with MACS versus less than 3 million with FACS, starting from the same number of 
about 50 million before the purification process [Figure 2.6c]. Therefore, MACS, as opposed to 
FACS, was used for this project.  
Once it was determined that MACS was the preferred method of purifying embryonic 
stem cell-derived motor neurons, the next 
step was to assess the changes in the 
percentage of cell types in the purified 
versus the non-purified cell cultures. 
Following the MACS purification, the 
number of GFAP
+
 cells in culture dropped 
from approximately 25% to 3% and the 
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Figure 2.7: Purified embryonic stem cell 
cultures yield of over 90% motor neurons 
 
Immunostaining (A-B) and counting (C-D) show that 





 motor neurons is about 32%, this percentage 
is about 92% in the purified cultures. Values represent 
mean ± s.e.m from five independent experiments 




purified, as well as in non-
purified, cultures [Figure 2.8]. 
This indicates a strong correlation 
between purified motor neurons 
and the well-established motor 
neuron markers. Finally, all of 
these data strengthen the point 
that MACS is a very effective 
method for purifying embryonic 
stem cell-derived motor neurons 
for these studies. 
 
2.2.2. Exposure to mutant 
astrocyte-conditioned medium 
kills purified embryonic stem 
cell-derived motor neurons in 
culture over a 7-day period 
After establishing the purification 
method, next to be tested was whether motor neuron death similar to that previously observed 
under the same conditions using non-purified primary and embryonic stem cell-derived motor 
neurons (Nagai et al., 2007) could be observed in the purified embryonic stem cell-derived motor 
neurons. Using the new in vitro model discussed above, the number of surviving purified 
embryonic stem cell-derived motor neurons that were exposed to either mutant astrocyte-
Figure 2.8: Purified embryonic stem cell-derived 
motor neurons strongly correlate with other motor 
neuronal markers 
 
This figure, consisting of images formed by immunostaining (A-C) 
and graphs by counting (D-F), exhibits how strongly (over 95%) 
eGFP
+ 
purified embryonic stem cell-derived motor neurons are 
immunoreactive for other motor neuron markers, such as Hb9 (A, 
D); Islet1 (B, E); and ChAT (C, F). The stainings were either done 
on purified or non-purified embryonic stem cell-derived motor 
neurons that were put in fresh media for 2 days or on neurons 
exposed to astrocyte-conditioned media for 7 days. Values represent 
mean ± s.e.m from five independent experiments performed at least 
in triplicate, analyzed by Student’s t-test. 
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conditioned medium or wild-type astrocyte-conditioned medium (i.e. non-toxic control) up to 14 
days in vitro were examined [Figure 2.9a].  
This experiment showed the following: Up to 2 days in vitro, the number of GFP
+
 
embryonic stem cell-derived motor neurons exposed to mutant astrocyte-conditioned medium 
did not differ from the number of neurons exposed to wild-type astrocyte-conditioned medium 
[Figure 2.9b]. In contrast, after 7 days of exposure to mutant astrocyte-conditioned medium, the 
number of surviving embryonic stem cell-derived motor neurons was 50 ± 4% (mean ± s.e.m, 
n=5), lower than that of neurons exposed to wild-type medium [Figure 2.9b]. Interestingly, 
Figure 2.9: Exposure to mutant astrocyte-conditioned medium kills purified embryonic 




(A) Purified embryonic stem cell-derived motor neurons (ES-MNs) were exposed to astrocyte-conditioned 














 days in vitro 
(DIV). (B) The time course revealed a progressive decay in number of surviving ES-MNs exposed to mutant (Tg) 
ACM until 7 days of exposure, after which cell number maintained a plateau until 14 days in vitro.  (C) The 
schematic showing the hours of ES-MN exposure to ACM. The survival assessment was done every 24 hours 
during the 7-day period. (D) ES-MNs that were exposed to Tg vs. non-transgenic (NTg) ACM showed a 
progressive decay in number until it reached about a 50% loss after 168 hours of exposure Tg ACM. Values 
represent mean ± s.e.m from five independent experiments performed at least in triplicate, analyzed by Student’s t-
test, p-value <0.05. 
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thereafter, the number of surviving motor neurons exposed to mutant astrocyte-conditioned 
medium compared to wild-type astrocyte-conditioned medium plateaued at around 50%, up to 14 
days in vitro [Figure 2.9b]. 
Because most of the decline in motor neuron number appeared to occur during the first 7 
days of exposure to mutant astrocyte-conditioned medium, the time-course experiment was 
repeated, but this time with a greater time resolution (i.e. every day) between 0 to 7 days 
exposure to mutant astrocyte-conditioned medium [Figure 2.9c]. In this study, a similar 
reduction in number of surviving embryonic stem cell-derived motor neurons up to 48 hours (i.e. 
2 days) was found, reaching about 50% loss after 168 hours (i.e. 7 days in vitro) [Figure 2.9d]. In 
addition, after 72 hours of exposure to mutant astrocyte-conditioned medium, the number of 
surviving embryonic stem cell-derived motor neurons was only 16 ± 4% lower than the number 
of surviving motor neurons exposed to wild-type astrocyte-conditioned medium [Figure 2.9d]. 
All of these time-course results were in agreement with previous published findings (Nagai et al., 
2007) on non-purified primary and embryonic stem cell-derived motor neurons. This fact 
provided strong reassurance that purified embryonic stem cell-derived motor neurons do not 
have altered sensitivities to mutant astrocyte-induced toxicity. Furthermore, since there were no 
differences in the number of surviving motor neurons exposed to mutant astrocyte-conditioned 
medium for 7 to 14 days in vitro, exposure of cells to mutant medium for 7 days was used for the 






2.2.3. Purified embryonic stem cell-derived motor neurons are sensitive to mutant 
astrocyte-conditioned medium regardless of their cell culture age 
After assessing the time course of survival of purified embryonic stem cell-derived motor 
neurons exposed to mutant astrocyte-conditioned medium, we wanted to test whether cell culture 
age plays any role in the sensitivity of motor neurons to the toxicity emanating from mutant 
astrocytes. We thought this test was necessary to better understand our in vitro model system. 
Thus, to examine this question, we investigated whether the same magnitude of death is observed 
in purified embryonic stem cell-derived motor neurons that spend an extra 7 days in fresh 
medium prior to being exposed to mutant astrocyte-conditioned medium for 7 days, in 
comparison to motor neurons that are exposed to mutant astrocyte-conditioned medium for 7 
days directly after purification [Figure 2.10a]. It was found that, at the end of 7 days of exposure 
to fresh medium followed by 7 days of exposure to mutant astrocyte-conditioned medium, 
purified embryonic stem cell-derived motor neurons show a similar loss in number compared to 
the cells that are directly exposed to mutant astrocyte-conditioned medium [Figure 2.10b]. This 
result suggested that purified embryonic stem cell-derived motor neurons are equally sensitive to 
mutant astrocyte-conditioned medium regardless of whether they are a week older. Similar 
results were found when the experiment was repeated using non-purified primary motor neurons 
(data not shown), indicating that primary and purified embryonic stem cell-derived motor 
neurons are equally sensitive to toxicity coming from mutant astrocytes. These results showed 
the time-independent sensitivity of this in vitro model system to mutant astrocytes, which is 





2.2.4. The 50% motor neuron loss upon exposure to mutant astrocyte-conditioned medium 
is not due to the loss of toxic activity 
One of the main questions about the in vitro non-cell autonomous ALS model was the maximum 
50% cell death observed after exposure to mutant astrocyte-conditioned medium and whether 
this maximum level of death is due to a time-dependent decline in toxic activity of the mutant 
medium. To address this question, the potency of mutant astrocyte-derived toxic activity on 
purified embryonic stem cell-derived motor neurons was investigated by replenishing the 
medium with a new batch of astrocyte-conditioned medium on the third day of the 7-day 
incubation [Figure 2.11a] or on the seventh day of the 14-day incubation [Figure 2.11c]. For this, 
a maximum of about 50% loss in GFP
+ 
motor neurons was observed in both groups with or 
Figure 2.10: Purified embryonic stem cell-derived motor neurons are sensitive to 
mutant astrocyte-conditioned medium regardless of their cell culture age 
 
(A) Purified embryonic stem cell-derived motor neurons were put in fresh medium for an extra 7 days prior 
to being exposed to mutant astrocyte-conditioned medium. (B) However, the motor neurons that were put in 
fresh medium for an extra 7 days showed a similar loss in number after 7 days of exposure to mutant 
astrocyte-conditioned medium as motor neurons that were put in mutant medium immediately. Values 




without mutant astrocyte-conditioned medium replenishment [Figure 2.11b, d]. These findings 
suggested that the observed 50% loss in motor neurons is not due to the loss of toxic activity, but 
is likely reflecting the maximum level of cell loss that can be achieved in this model system 
under the current experimental conditions. This finding also suggested that, in these cultures, 
there might be a susceptible and a resistant motor neuron subpopulation. In addition, the medium 
Figure 2.11: The 50% motor neuron loss upon exposure to mutant astrocyte-conditioned 
medium is not due to the loss of toxic activity 
 
 (A) Astrocyte-conditioned medium (ACM) was replenished 72 hours after with a new aliquot from the same 
batch of ACM. The survival of motor neurons was assessed at the end of 7-day period. (B) Purified embryonic 
stem cell-derived motor neurons (ES-MNs) showed the same loss in number after 7 days of exposure to mutant 
ACM with or without replenishment. (C) The study was replicated with longer duration where the media was 
replenished on the 7
th
 day of exposure and the total ACM exposure was for 14 days. (D) The same results as in 
(B) were observed. (E) Another study was performed to test the effect of media replenishment on ES-MNs, 
where the survival of ES-MNs was assessed immediately before, immediately after, and 2 hours after the media 
replenishment in the 7-day period. (F) There was no difference in the number of ES-MNs that were fixed 
immediately before, immediately after or 2 hours after their media being replenished. Values represent mean ± 




replenishment study with the 7-day incubation period was also performed on primary spinal 
motor neurons and similar results were obtained (data not shown).  
While performing the above experiments, it became apparent that replenishing medium 
might cause a mechanical stress on the embryonic stem cell-derived motor neurons, which could 
promote cell detachment and spurious alterations in motor neuron numbers. To address this 
question, purified embryonic stem cell-derived motor neurons were fixed after the third day of 
incubation immediately before, immediately after and 2 hours after the replenishment with 
mutant medium [Figure 2.11e]. Regardless of the incubation conditions, the same numbers of 
GFP
+
 embryonic stem cell-derived motor neurons before and after fresh medium additions were 
noted [Figure 2.11f]. This result indicates that the act of medium replenishment does not cause 
any alteration in cell numbers in this experimental system, and so, the observed changes in motor 
neuron number are due to the toxicity emanating from mutant astrocytes.  
 
2.2.5. 72 hours of mutant astrocyte-conditioned medium exposure is the point of no return 
for embryonic stem cell-derived motor neurons 
As discussed in the Introduction, during the degenerating process, neurons, like any other cells, 
become irreversibly committed to die. Accordingly, it was hypothesized that, in order to develop 
disease modifying strategies, signaling pathways prior to this point of no return may be the most 
promising targets. Thus, the next step in this work was to examine when, over the 7-day period, 
motor neurons exposed to mutant astrocyte-conditioned medium reach a point of no return, i.e. a 
point when motor neurons become committed to die. To address this question, purified 
embryonic stem cell-derived motor neurons were exposed to mutant astrocyte-conditioned 
medium for selected lengths of time and then were put into fresh medium until they reached 7 
days in vitro [Figure 2.12a].  
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This study revealed that the magnitude of motor neuron loss after 7 days in vitro, 
following 1 or 2 days of exposure to mutant astrocyte-conditioned medium was minimal [Figure 
2.12b]. On the other hand, the magnitude of motor neuron loss after 7 days in vitro, following 3 
Figure 2.12: 72 hours of mutant astrocyte-conditioned medium exposure is the point 
of no return for embryonic stem cell-derived motor neurons 
 
(A) Motor neurons were exposed to astrocyte-conditioned medium for 24, 48, and 72 hours, after which 
their medium was replaced with fresh medium until they reached 7 days in vitro.  (B) Motor neurons that 
were exposed to mutant astrocyte-conditioned medium for 24 and 48 hours, and then being exposed to 
fresh medium until 7 days in vitro, showed almost a full rescue in number. However, the motor neurons 
that were exposed to mutant astrocyte-conditioned medium for 72 hours, and then put in fresh medium 
until 7 days in vitro, showed the same loss in number as the motor neurons that were exposed to mutant 
astrocyte-conditioned medium for the whole 7-day period.  (C) The study was replicated by extending the 
exposure durations in between the 48 and 72 hours and adding 54, 60, and 66 hours of exposure to 
astrocyte-conditioned medium. (D) Purified embryonic stem cell-derived motor neurons that were exposed 
to mutant astrocyte-conditioned medium for 54, 60, 66, and 72 hours, and then put in fresh medium until 
they reached 7 days in vitro, showed a progressive decay in number until about 50% loss similar to that 
observed after 168 hours of exposure to mutant astrocyte-conditioned medium. Values represent mean ± 




days of exposure to mutant astrocyte-conditioned medium was identical to that observed after 7 
days of exposure to mutant astrocyte-conditioned medium [Figure 2.12b]. The finding that 3 
days of exposure to mutant astrocyte-conditioned medium, followed by the exposure to fresh 
medium for an additional of 4 days in vitro, contrasted with the result found in the survival time 
course of embryonic stem cell-derived motor neurons discussed in Figure 2.8d, where only about 
16% loss was observed in motor neurons after 3 days of exposure to mutant astrocyte-
conditioned medium. Taken together, these results indicate that motor neurons exposed to mutant 
astrocyte-conditioned medium for 3 days do not show an overt degeneration, but their death 
mechanisms are already turned on and cannot be reversed. This means that 3 days of exposure to 
mutant astrocyte-conditioned medium is a crucial timepoint at which to study the molecular 
mechanism underlying mutant astrocyte toxicity for motor neurons. Additionally, the same study 
was repeated using primary motor neurons, which also showed 3 days of exposure to mutant 
astrocyte-conditioned medium to be the point of no return for these motor neurons (data not 
shown). 
Since these results indicate that motor neurons are not yet committed to die up to 2 days 
of exposure to mutant astrocyte-conditioned medium, but by 3 days they are, time frames of 
exposure were increased for the temporal accuracy of the point of no return to include 54, 60, 
and 66 hours of astrocyte-conditioned medium exposure [Figure 2.12c]. Results from this aspect 
of the study show that purified embryonic stem cell-derived motor neurons exhibit a progressive 
decay in number until they reach about 50% cell loss after 72 hours of exposure to mutant 
astrocyte-conditioned medium [Figure 2.12d]. Thus, the added timepoints further validated that 
72 hours of exposure to mutant astrocyte-conditioned medium is the best estimation of the point 




2.3. Conclusion & Discussion 
The studies above enabled us to characterize purified embryonic stem cell-derived motor neurons 
exposed to mutant astrocyte-conditioned medium as a powerful in vitro model to study ALS-
linked non-cell autonomous motor neuron degeneration. In these studies, a survival timeline was 
demonstrated for the purified embryonic stem cell-derived motor neurons upon 7 days of 
exposure to mutant astrocyte-conditioned medium that is similar to the phenomenon observed in 
primary motor neurons (Nagai et al., 2007). Interestingly, the 50% motor neuronal loss observed 
after 7 days of exposure to mutant astrocyte-conditioned medium cannot be due to the loss of 
toxic activity of the medium, because even if this conditioned medium is changed half-way into 
the exposure duration, there is no significant further loss of motor neurons. Remarkably, a 
similar level of motor neuron loss has been reported by Raoul et al. (2002) in their study on Fas 
ligand toxicity in motor neurons (Raoul et al., 2002). Together these studies suggest that the 
observed 50% of the motor neurons that are spared symbolize a more resistant subpopulation of 
motor neurons.  
 Since the purpose of this project is to elucidate the molecular mechanism of non-cell 
autonomous motor neuron degeneration before neurons become committed to die, a point of no 
return was identified which will allow the capture of its molecular correlate by the RNA-Seq 
assay. Accordingly, by testing different exposure times, around 72 hours of exposure to mutant 
astrocyte-conditioned medium was noted as the time that motor neurons become irreversibly 
committed to die.  
Moreover, compared to the other currently available in vitro ALS models, the model 




neurons combined both the characteristics of postmitotic motor neurons and the fact that they 
were readily expandable; (2) mutant astrocyte-mediated toxicity was specific for motor neurons; 
and, (3) this culture system could model disease processes both extrinsic and intrinsic to motor 
neurons. All of these advantages render embryonic stem cell-derived motor neurons a unique 
tool to unravel early molecular perturbations that take place in motor neurons in response to 
ALS-linked astrocyte toxicity. 
Before the characterization of this in vitro model, there was a question as to whether the 
purification procedure might render the cells more resistant to the mutant astrocyte-induced 
toxicity. This was because the isolation method itself caused a physical stress on the cells and 
could cause or contribute to the demise of the sensitive cell subpopulation in the process. To 
avoid this scenario, purified embryonic stem cell-derived motor neurons were kept in fresh 
medium for two days prior to exposing them to mutant astrocyte-conditioned medium. This 
duration was enough time for the motor neurons to recover from the stress of the purification 
procedure and to grow processes in culture, suggesting healthy conditions of the cells (data not 
shown). Furthermore, purified embryonic stem cell-derived motor neurons showed about 50% 
decline in number after being in fresh medium for 2 days and being exposed to mutant astrocyte-
conditioned medium for the following 7 days. This confirmed the stable existence of both the 
resistant and the sensitive subpopulations in this model system similar to what was observed in 
the mixed motor neuron cultures.  
Following the above-mentioned findings, there are a number of interesting future studies 
that can be performed to study these subpopulations. For one, another batch of mutant astrocyte-




168 hours of exposure to mutant medium to see if a similar molecular mechanism is activated in 
the resistant subpopulation as was in the sensitive subpopulation. Similarly, the transcriptional 
alterations that occur in purified embryonic stem cell-derived motor neurons after 168 hours of 
exposure to mutant astrocyte-conditioned medium, when only the resistant cells survive, can be 
compared to an earlier exposure time, when sensitive cells are present but are dying. In this 
manner, the molecular mechanism that is different between the sensitive and resistant 
subpopulations may be better understood. As of yet, no one has discerned if there are molecular 
differences between these two motor neuron subpopulations or that the resistant motor neurons 
merely need more time to become committed to death.  
Another interesting future study would be to add the Bax inhibitor, V5, to purified 
embryonic stem cell-derived motor neurons after 72 hours of exposure to mutant astrocyte-
conditioned medium, when motor neurons are already committed to cell death, and to see 
whether the full rescue of motor neurons can still be observed. If a rescue is not observed, this 
experiment would further validate that 72 hours of exposure to mutant astrocyte-conditioned 
medium is the point of no return for motor neurons and their death mechanism cannot be 
reversed.  
Finally, all of the experiments performed on primary motor neurons displayed the same 
results as those performed on purified embryonic stem cell-derived motor neurons, suggesting 
strong similarities between these two types of motor neurons. However, even though embryonic 
stem cell-derived motor neurons are a powerful model system to elucidate the molecular 
mechanism underlying the ALS-linked astrocyte toxicity for motor neurons in vitro, it is still 




neurons and in transgenic animal models. In the case that a pathway would show pathogenic 
significance, both in vitro and in vivo, it would open new doors for therapeutic interventions 
aimed at targeting deleterious pathways before irreversible damage or commitment to death 




Chapter 3: Identifying gene alterations germane to the toxicity of 
mutant astrocytes by elucidating relevant molecular pathways that 
are dysregulated in motor neurons 
 
3.1. Introduction 
Following the initial publication from our laboratory on the effect of mutant SOD1-expressing 
astrocytes on the survival of spinal motor neurons (Nagai et al., 2007), a number of candidate-
based investigations were performed in an attempt to elucidate the molecular underpinning of 
this in vitro neurodegenerative phenotype. Unfortunately, none of our studies have yielded a 
promising outcome, except for the demonstration that the demise of spinal motor neurons could 
be mitigated by both the inhibition and the abrogation of the pro-cell death factor Bax. 
Consequently, we changed our approach by directing our subsequent efforts toward the 
development and utilization of an unbiased investigation. As a prerequisite for this new research 
direction, characterization of a modified version of our previous in vitro model of ALS using 
purified embryonic stem cell-derived motor neurons exposed to medium conditioned with 
mutant SOD1-expressing astrocytes was necessary. This new in vitro model represents a much 
more adaptable system than our primary co-cultures, given the need to enrich the model system 
in motor neuron molecular signatures.  
Following this characterization, an RNA-Seq assay was performed on purified embryonic 
stem cell-derived motor neurons and then the identified gene expression changes revealed by this 




engaged in the demise of motor neurons exposed to the toxicity emanating from mutant 
astrocytes. 
As explained in the Introduction, there are a few other groups that have also tried to 
identify molecular mechanisms underlying ALS-linked astrocyte toxicity for motor neurons 
using unbiased genomic approaches (Di Giorgio et al., 2008; Ferraiuolo et al., 2011b; Vargas et 
al., 2008b). However, the majority of these groups focused their attention on the transcriptional 
changes that occur in mutant astrocytes and on the analysis of what is released from these 
astrocytes, rather than focusing their attention on the motor neurons themselves, the primary 
targets of the ALS disease process. Somewhat puzzling is the fact that most of the results 
generated thus far by these groups turned out to be all different from each other. Furthermore, all 
of the groups that have reported genomic results have utilized a microarray-based method, which 
has multiple shortcomings, such as high background noise and limited dynamic range (see 
below). In their attempt to elucidate the molecular mechanism of non-cell autonomous motor 
neuron degeneration in ALS, different groups have focused their attention on the differential 
expression of a selected number of individual genes from their microarray data. This raised the 
possibility that different prioritizations might have led to different genomic outcomes, even 
though the studies might have had similar overall genetic expression signatures to begin with. 
To gain insights into the molecular underpinning of non-cell autonomous motor neuron 
degeneration in our model of ALS, our study was designed using: (i) purified embryonic stem 
cell-derived motor neurons; (ii) the new and powerful genomic technique, RNA-Seq (to be 
discussed below); and (iii) the bioinformatics algorithms that will allow the interrogation of the 




the motor neuron degenerative phenotype triggered by mutant astrocytes. Below is a discussion 
of the RNA-Seq assay followed by the reverse gene engineering algorithms. 
 
3.1.1. RNA-Seq 
RNA-Seq is a high-throughput sequencing-based transcriptome profiling method that directly 
determines the cDNA sequence. While hybridization-based microarrays are also a high-
throughput genomic profiling method, they have several disadvantages in comparison to RNA-
Seq assays which render them less potent (Wang et al., 2009): (1) Microarrays have high 
background signals due to cross-hybridization that need to be normalized using Perfect Match 
(PM) and MisMatch (MM) signals. (2) They rely heavily on existing knowledge about genome 
sequence. (3) They have a limited dynamic range of detection due to both background and 
saturation of signals. (4) Comparing expression levels between experiments is difficult because 
of complicated normalization methods.  
There are also substantial differences in the way these two methods work: In the 
microarray technique, the extracted total RNA is converted to fragmented cDNA, which is then 
hybridized with specifically selected microarrays and are read for quantification by fluorescence. 
In the RNA-Seq assays, on the other hand, the extracted total RNA is converted to a library of 
cDNA fragments with adaptors attached to one or both ends (Wang et al., 2009). Each molecule 
is then sequenced in a high-throughput manner to obtain short sequences from one or both ends 
with 30-400 base pair reads. Following sequencing, the resulting reads are either aligned to a 




produce a genome-scale transcription map that consists of both the transcriptional structure 
and/or the level of expression for each gene (Wang et al., 2009) [Figure 3.1].  
The following features of the 
RNA-Seq technology make it much 
more advantageous over the 
microarray assay (Wang et al., 2009): 
(1) RNA-Seq is not limited to detecting 
transcripts that correspond to existing 
genomic sequences, making it more 
desirable for non-model organisms 
whose genomic sequences are not yet 
established, in addition to detecting 
RNA molecules, such as microRNAs, 
and other non-coding RNAs. (2) While 
the shorter reads (about 30 base pairs) 
from RNA-Seq give information about 
how two exons are connected, longer 
reads expose connectivity between 
multiple exons, making RNA-Seq 
possible to elucidate complex transcriptomes. (3) Compared to microarrays, RNA-Seq assays 
have very low, if any, background signal. (4) They have no upper limit for quantification, only a 
number of sequences obtained, which makes analysis much easier and data more robust. (5) 
Figure 3.1: Schematic representation of a RNA-
Seq assay 
 
This figure, excerpted from Wang et al. (2009) represents 
how the RNA-Seq assay works. Briefly, long RNAs are first 
converted into a library of cDNA fragments. Then, 
sequencing adaptors are added to each cDNA fragment and a 
short sequence is obtained from each cDNA by high-
throughput sequencing technology. The resulting sequence 
reads are aligned with either a reference genome or a 
transcriptome, and classified as: junction, exonic or poly(A) 
end reads. These reads are then used to generate a base-





While microarrays are less sensitive for genes expressed either at very low or high levels, and 
thus have a smaller dynamic range, RNA-Seq has been shown to be highly accurate for 
quantifying gene expression at any level. (6) RNA-Seq requires less RNA per sample, since it 
has no amplification step, and costs less, making it a very desirable method over the microarray 
assay.  Please see Table 3.1 for a summary of the comparison of the RNA-Seq to the microarray 
assay.  
 
Table 3.1: Comparison of RNA-Seq versus microarray 
Technology Microarray RNA-Seq 
Principle Hybridization High-throughput 
sequencing 
Resolution From several to 100 base 
pairs 
Single base 
Throughput High High 
Reliance on genomic 
sequence 
Yes In some cases 
Background noise High Low 
Dynamic range to 
quantify gene 
expression level 
Up to a few hundred fold >8,000 fold 
Ability to distinguish 
different isoforms 
Limited Yes 
Ability to distinguish 
allelic expression 
Limited Yes 






Cost for mapping 
transcriptomes to large 
genomes 
High Relatively low 
 
This table, excerpted and modified from Wang et al. (2009) summarizes the technical 
(in red), applicative (in blue), and practical (in black) differences between the 
microarray and the RNA-Seq assay. This comparison reveals that the RNA-Seq assay 
has advantages at every level of transcriptomics, from being high-throughput with 
low background noise, to having the ability to distinguish allelic expression, to 
requiring a low amount of RNA with relatively low cost for mapping transcriptomes 
of large genomes, over microarrays.  
 
Although, as discussed above, RNA-Seq has several advantages over microarrays, it has 
certain challenges as well. First of all, the cDNA fragmentation step is biased towards the 
identification of sequences from the 3’ ends of transcripts. Secondly, for large transcriptomes, 
the majority of the sequence reads match multiple locations in the genome, which renders it 
necessary to proportionally assign the number of multi-matched reads mapped to their 
neighboring unique sequences (Mortazavi et al., 2008). Finally, there is the challenge of 
coverage versus cost, where the larger the genome being sequenced, the more complex the 
transcriptome needs to be and the more sequencing depth is necessary for adequate coverage 
(Wang et al., 2009). These challenges are currently addressed with the new developments in the 
field, such as the transcription start site mapping, strand-specific measurements, gene fusion 
detection, small RNA characterization and detection of alternative splicing events (Ozsolak and 
Milos, 2011), making the method much more efficient.  
Overall, with no probes or primers to design, RNA-Seq provides an unbiased, highly 
sensitive and powerful high-throughput method that records the numerical frequency of a 





3.1.2. Reverse gene engineering 
As discussed in the preceding chapter, the goal of this thesis was to elucidate the signaling 
network that is activated in motor neurons in response to the toxic activity from mutant 
astrocytes before motor neurons become committed to die. To achieve this goal, a traditional 
bioinformatics approach that focuses on a selected number of genes that are the most 
differentially expressed was not desirable. Instead, using the whole genomic data to first define 
particular molecular signatures and then using these signatures to identify transcription factors 
that most likely regulate them seemed more appropriate. In order to do this, an unbiased reverse 
gene engineering analysis pioneered by the Califano group was decided upon (Carro et al., 
2010).  
The rationale for using this reverse gene engineering analysis was the following: if it is 
assumed that when motor neurons are subjected to the exogenous insult that emanates from 
mutant astrocytes, then the astrocyte-derived putative soluble factor ligates a surface receptor, 
thereby triggering a transducing signal. Once this signal is initiated within motor neurons, 
specific transcription factors are activated, which, in turn, enhance or repress the expression of 
their target genes. Reverse gene engineering analysis computes the overlap between the 
expression of target genes of each transcription factor and the differentially expressed gene 
signatures from the RNA-Seq data to deduce a set of transcription factors that best explain the 
observed gene profiles. This analysis can be carried forward by utilizing the differential activity 
of transcription factors as a proxy to determine the activity of signaling molecules upstream to 




signaling network can be inferred instead of limiting the analysis to a restricted number of target 
genes [Figure 3.2].  
Consequently, reverse gene 
engineering analysis consists of two 
steps (Carro et al., 2010): (1) the 
estimation of the activity of 
transcription factors from that of 
their transcriptional targets using the 
Algorithm for the Reconstruction of 
Gene Regulatory Networks in a 
Mammalian Cellular Context 
(ARACNe) (Basso et al., 2005; 
Margolin et al., 2006a; Margolin et 
al., 2006b); and (2) the identification 
of transcription factors that are 
master regulators of the specific 
phenotype that is being studied, which overlap between their targets and the differential 
expression signatures extracted from the RNA-Seq (or gene array) data using the Master 
Regulator Inference algorithm (MARINa) (Lefebvre et al., 2010). Below is an explanation of 
both of these steps in more detail. 
 
 
Figure 3.2: Inferring transcription factors from the 
RNA-Seq data 
 
This schematic represents how transcription factors are inferred 
from the RNA-Seq data. When a cell receives an exogenous 
signal through its cell surface receptor, it causes the activation of 
certain signaling molecules, which are responsible from activating 
specific transcription factors that either enhance or repress the 
expression of their target genes. Reverse gene engineering 
analysis computes the overlap between the expression of target 
genes of each transcription factor and the differentially expressed 
gene signature from RNA-Seq data and infers a set of 
transcription factors as the master regulators of the cell phenotype 





Because proteins, which are gene products themselves, regulate gene expression, statistical 
associations between genes’ mRNA levels were thought to be useful to unravel gene regulatory 
mechanisms (Margolin et al., 2006a). ARACNe, as an information theory-based algorithm for 
the reverse gene engineering of transcriptional networks using microarray data, predicts potential 
functional associations among genes by identifying statistical dependencies between gene 
products (Margolin et al., 2006b). It first identifies statistically significant gene-gene co-
regulation by mutual information, which is an information theoretical measure of relatedness, 
and then eliminates indirect relationships, by applying a well-known staple of data transmission 
theory called ‘data processing inequality’, to construct a network (i.e. an interactome) with a 
high probability of representing either direct regulatory interactions or interactions mediated by 
post-transcriptional modifiers between transcription factors and their target genes that are 
undetectable from microarray data (Basso et al., 2005).  
One of the main challenges of reverse gene engineering algorithms is the complexity of 
mammalian networks. ARACNe has been tested on a few synthetic data sets and has proved to 
be a very powerful algorithm in dealing with these complex networks. For example, ARACNe 
predictions were validated for the MYC protooncogene by chromatin immunoprecipitation 
assays, which demonstrated that MYC binds in vivo to the regulatory region of 11 out of 12 genes 
selected among those inferred by the algorithm (Basso et al., 2005). ARACNe is, however, only 
the first step in understanding the molecular mechanism of a cellular network and needs to be 






MARINa is designed to infer the differential activity of transcription factors that regulate the cell 
phenotype that is being studied (Lefebvre et al., 2010). Since differential expression at the 
mRNA level is a poor indicator of a transcription factor’s regulatory activity, Essentially, 
MARINA is an enrichment algorithm that computes the activity of a transcription factor based 
on the enrichment of the factor's target genes, whose activity it induces or represses, on a 
genome-wide expression signature. 
In MARINa, first each transcription factor gets associated with a positive and a negative 
regulon using its activated and repressed targets in the interactome, respectively. Then, the 
enrichment and activity of each transcription factor is computed by Gene Set Enrichment 
Analysis and the differentially expressed target odds ratio score. Finally, MARINa is corrected 
for the transcription factor-regulon overlap to avoid false-positive master regulator inference 
(Lefebvre et al., 2010). At the end of this step, MARINa computes the statistical significance of 
the overlap between the regulon of each transcription factor and the differentially expressed gene 
signature from RNA-Seq data and infers a set of transcription factors as the master regulators of 
the certain cellular phenotype that is being studied.  
One example that combined both the ARACNe and the MARINa algorithms came in 
2010, where Carro et al. first assembled a glioma-specific regulatory network using ARACNe 
and then interrogated this interactome using MARINa to reveal a transcriptional network that 
activates the expression of mesenchymal genes in malignant glioma (Carro et al., 2010). The 
group then showed that the ectopic expression of two master regulators from the MARINa 




elimination of these regulators in glioma cells lead to the collapse of the mesenchymal signature 
(Carro et al., 2010).  
This study was the first to demonstrate the use of reverse gene engineering algorithms 
that were generated by the Califano group to successfully elucidate the molecular mechanism of 
complex mammalian cell phenotypes. While the nature of these algorithms render them 
applicable to any cell type and/or phenotype (Margolin et al., 2006a), so far the algorithms have 
primarily been used for in vivo tumor samples from patients, such as glioblastoma and 
neuroblastoma cells, and in phenotypes related to cancer. Thus, this project is the first to utilize 
these algorithms for cells other than tumor cells, and moreover, in a neurodegeneration context. 
Below is the presentation of the results gathered from the RNA-Seq data using the reverse gene 
engineering analysis.  
 
3.2. Results 
3.2.1. Experimental design 
Given the observations from the previous chapter, it was postulated that the molecular changes 
linked to the early responses of motor neurons to the toxic activity released from mutant 
astrocytes are likely to occur at timepoints  72 hours. Thus, to study these early molecular 
perturbations that occur in motor neurons after they are exposed to the toxicity emanating from 
mutant astrocytes, but before they become committed to die, the following timepoints were 
included in the RNA-Seq assay: 1) 0-hour, the time before any astrocyte-conditioned medium is 
added to the motor neurons. This was the control timepoint and was used to test for any technical 




hour, the amount of exposure time to mutant astrocyte-conditioned medium at which motor 
neurons show a minimal loss in number and their death mechanism is activated, but this can be 
reversed [Figure 2.12b]. This timepoint was selected for any acute effect of the mutant astrocyte-
conditioned medium in conjunction with minimal loss in motor neurons. 3) 72-hour, the time of 
commitment to death; and 4) 168-hour, the amount of exposure time to mutant medium when the 
sensitive motor neuron subpopulation dies and the resistant subpopulation remains in culture. 
This timepoint was selected to subtract the resistant motor neuron subpopulation signature from 
that of the susceptible subpopulation to better refine the susceptible signature.  
During the process of determining the experimental design for the RNA-Seq assay, there 
were two objectives: (1) to have an adequate number of experimentally independent sample 
replicates for the assay to be properly powered; and (2) to minimize the non-biological variation 
that is added during the handling of the samples (i.e. the batch effect). To address the first 
objective, the number of replicates necessary to do enough permutations in the MARINa analysis 
needed to estimate random enrichment scores to form a random gene expression signature was 
computed to be six samples per genotype and per timepoint; please see the Experimental 
Methods.  
Consequently, the experimental design for the RNA-Seq assay was set to be the 
extraction of total RNA samples from purified embryonic stem cell-derived motor neurons 
exposed to medium conditioned either with non-transgenic, transgenic wild-type SOD1, or 
transgenic mutant SOD1 astrocytes for either 0, 24, 72 or 168 hours with six sample replicates 





Table 3.2: Replicates per timepoint and treatment for the 
RNA-Seq assay 
Treatment Time Replicates 
MN 0 18 
NTg 24 6 
Tg 24 6 
WT 24 6 
NTg 72 6 
Tg 72 6 
WT 72 6 
NTg 168 6 
Tg 168 6 
WT 168 6 
 
The number of experimentally independent replicates obtained per 
timepoint and treatment samples for the RNA-Seq assay. In total, there 
were 72 samples. MN: Untreated motor neuron sample; NTg; non-
transgenic astrocyte-conditioned medium treatment; Tg: transgenic 
mutant SOD1 astrocyte-conditioned medium treatment; WT: transgenic 





For the second objective, to minimize potential batch effect, the following steps were 
taken in the handling of samples before proceeding with the RNA-Seq assay: (1) To minimize 
any technical variance that could have arisen from astrocyte-conditioned medium, a small 
portion of every aliquot from different types of astrocyte-conditioned medium was taken out and 
exposed to purified embryonic stem cell-derived motor neurons. After 7 days of exposure to 
these small portions of medium, the survival of motor neurons was assessed to validate that the 
medium does in fact show the desired effect on motor neurons. Once the validation was done for 
every aliquot, the separate aliquots belonging to the same type of astrocyte-conditioned medium 
were pooled together to unify their effect on motor neurons [Figure 3.3a]. (2) To minimize the 
batch effect on motor neurons, embryonic stem cells that came from the same source in 6 
different aliquots were thawed, differentiated into motor neurons and purified at the same time 
and under the same conditions [Figure 3.3b]. (3) All purified motor neurons coming from the 
same aliquot of embryonic stem cells were plated together, exposed to astrocyte-conditioned 
medium, and had their RNA extracted at the same time [Figure 3.3c]. Moreover, purified motor 
neurons for each of the samples were plated on three wells next to each other in a 12-well cell 
culture dish. Their RNAs were then pooled together as one sample to get enough total RNA for 
each sample. In the end, RNA samples coming from the same aliquot were considered to have 
the same replicate number. (4) RNA isolation and quality assessment of each of the 72 samples 
were also done at the same time. The quality of every total RNA sample was found, using 
Bioanalyzer, to have an RNA integrity number (i.e. the assessment of RNA integrity determined 




Figure 3.3: The RNA-Seq experimental design to minimize technical variance 
 
 (A) Medium conditioned with separate aliquots belonging to the same type of primary astrocytes were collected 
and pooled together to unify their effect on motor neurons (MNs), after testing out a proportion of every aliquot 
on MNs to confirm the effect of the medium; (B) Embryonic stem cells from the same source in 6 different 
aliquots were thawed, differentiated into MNs, and purified at the same time and under the same conditions; (C) 
All purified embryonic stem cell-derived MNs from the same replicates and timepoints were exposed to 
astrocyte-conditioned medium (ACM) and had their RNA extracted at the same time. RNA samples coming 
from the same aliquot were considered to have the same replicate number. Moreover, purified MNs belonging to 
the same replicate and timepoint were plated in the same 12-well cell culture dish into 3 consecutive wells per 
ACM treatment, where their RNAs would be collected and pooled together to have a single RNA sample. ES 
cells: embryonic stem cells, RA: retinoic acid, Shh: sonic hedgehog, NTg: non-transgenic medium, WT: 






At the end of these steps in the experimental design, 72 total RNA samples were 
extracted from purified embryonic stem cell-derived motor neurons with the highest RNA 
quality, minimal batch effect, and enough replicate numbers to run an efficient MARINa 
analysis. These RNA samples were then given to the Genomic Center of Columbia University 
for the RNA-Seq assay, which consisted of the fragmentation, sequencing, and mapping of the 
total RNA samples to the mouse genome. 
 
3.2.2. Data pre-processing 
The RNA-Seq data was received from the Genomic Center in the format of mapped reads, which 
consisted of the position of each 100-base long read in the mouse genome. To align the position 
of each read with a gene on a chromosome, the full mouse genome from the University of 
California San Diego database, which contained 21,761 genes, was downloaded. This genome 
was then utilized to align each read from the RNA-Seq data to a gene and the reads were 
summarized to compute how many reads per gene there were for each sample. From 21,761 
genes, 19,179 of them were detected to have at least ten reads across all samples. Ten reads in at 
least one of the samples was used as a cutoff value for a gene, where the gene that did not make 
the cutoff was removed from the analysis. This was because ten reads was the value computed 
by chance in a Poisson distribution, and thus was considered an erroneous read value.  
After the selection of the 19,179 genes, their read counts were normalized using Trimmed 
Mean of M values (TMM) normalization (Robinson and Oshlack, 2010). In this normalization 




trimmed mean of the log expression ratio between each sample and the reference sample was 
calculated. Normalization was an important step in the RNA-Seq analysis, because it allowed for 
comparisons between experiments and the control of extraneous variation among experiments, 
which could be introduced during sample preparation and processing for the assay.  
Following the normalization, the variance in the read counts was stabilized using the 
negative binomial fit method, which utilizes the linear model: noise variance = mean + deviation 
(Anders, 2010). This variance stabilization method removed the association between the variance 
and signal level of the data, making the variance independent of the mean of read counts across 
all of the genes.  
After these pre-processing steps, a scatter plot showing the relationship between the total 
counts and size-factor was drawn to ensure that the variance was successfully stabilized across 
all samples. In this scatter plot, a linear relationship between the counts and the samples was 
observed [Figure 3.4], which confirmed that there is no strong bias in any given gene that can 
distort the distribution of the read counts. In addition, supervised [Figure 3.5a] and unsupervised 
[Figure 3.5b] cluster analyses of the data showed successful segregation and clustering of the 
samples by the treatments they received and their timepoints. These visualization methods 
further confirmed the lack of technical bias in the samples, which proved the normalization and 





3.2.3. Gene expression signatures 
Next in line was the generation of gene expression 
signatures that made use of all of the timepoints of the 
RNA-Seq assay, even though the main interest, for the 
purpose of this project, was in the signature at the time 
of motor neuron commitment to die. The idea was to 
use the other signatures for future studies; please see 
the Conclusion section of this chapter. Consequently, 
five gene expression signatures were generated.  
 The initial signature was of the “early response” 
that takes place in motor neurons at the 24-hour 
timepoint versus the 0-hour timepoint; before they 
show any overt degeneration and when their death 
mechanism can be reversed. The second one was the 
“commitment to death” signature, where the gene 
expression of the 72-hour timepoint was compared to that of the 0-hour timepoint. This was 
followed by the “resistance phenotype” signature comparing the 168-hour timepoint, when the 
sensitive motor neurons die and the resistant subpopulation remains, to the 0-hour timepoint. The 
two final signatures were the “commitment vs. early response” signature comparing the 
differential gene expression between the 72-hour and 24-hour timepoints, and the “resistance vs. 
commitment” signature comparing the 168-hour to 72-hour timepoints.  
Figure 3.4: No strong bias in any 
of the genes for all of the samples 
of the RNA-Seq data 
 
This scatter plot demonstrates the 
relationship between the total counts and 
size-factor for all of the samples. The linear 
plot suggests that there is no strong bias in 
any given gene in any of the samples that 
can distort the distribution of the reads. WT-
24-4 (in red) is the 24-hour sample that was 
treated with transgenic wild-type SOD1 
astrocyte-conditioned medium whose 
replicate number was 4. While it is 
distributed away from the other samples, the 
fact that it is still linearly associated to them 





These gene expression signatures were obtained by fitting the read counts per gene across 
all samples to a linear model using the limma package from Bioconductor. The data was fitted to 
a two-factor linear model: y=  + T + B + , where  was the basal level of read counts for a 
gene,  was the coefficient of treatment between values 0 and 1,  was the coefficient of batch 
effect, and  stood for the error. Using this linear model, a two-way ANOVA test was performed, 
Figure 3.5: Cluster analyses based on the RNA-Seq data for different treatments and 
timepoints 
 
The (A) supervised and the (B) unsupervised cluster analyses on the RNA-Seq data at different treatment and 
timepoints. These visualizations of samples confirm that experimental variation coming from the replicates is 
minimal. (Batch stands for the replicate number.) NTg: non-transgenic astrocyte-conditioned medium, WT: 





per gene across all samples yielding  and  (with no computation of the interaction between the 
coefficients). Interaction between  and  was not computed because the treatment effect came 
from the astrocyte-conditioned medium, and the batch effect from the motor neurons being 
differentiated from the same source of embryonic stem cells, assuming that there is no biological 
correlation between the treatment and the batch effect. 
 After computing coefficients for every gene across all of the samples with this linear model 
fitting, the relevant signatures were obtained below by subtracting the coefficients belonging to 
the non-transgenic (NTg) and transgenic wild-type SOD1 (WT) astrocyte-conditioned medium 
treatments from that of the transgenic mutant SOD1 (Tg) astrocyte-conditioned medium. For the 
24 vs. 0, 72 vs. 0, and 168 vs. 0 hour signatures, the coefficients of 0-hour timepoint were not 
subtracted from the other timepoints, because the 0-hour timepoint coefficients for NTg, WT, 
and Tg treatments were equal (data not shown) and they canceled each other in the equation, as 
explained below in the 24 vs. 0 hour signature example: 
 
    24 vs. 0 hour signature:   
    (Tg.24 - Tg.0) – [(WT.24 –WT.0 + NTg.24 - NTg.0)/2] 
 = 2Tg.24 –2Tg.0 – WT.24 + WT.0 – NTg.24 + NTg.0 
 Since Tg.0 = WT.0 = NTg.0; 
  = 2Tg.24 –2Tg.0 – WT.24 + WT.0 – NTg.24 + NTg.0 
 = 2Tg.24 – WT.24 – NTg.24 
 = Tg.24 – [(WT.24 + NTg.24)/2]. 




Thus, the relevant signatures were obtained in the following manner: 
 
1. “Early response” - 24 vs. 0 hour:  
 (Tg.24) – [(WT.24 + NTg.24)/2]  
2. “Commitment to death” - 72 vs. 0 hour:  
 (Tg.72) – [(WT.72 + NTg.72)/2]  
3. “Resistance phenotype” - 168 vs. 0 hour:  
 (Tg.168) – [(WT.168 + NTg.168)/2]  
4. “Commitment vs. early response” - 72 vs. 24 hour:  
 (Tg.72 − Tg.24) – [(WT.72 − WT.24 + NTg.72 − NTg.24)/2]  
5. “Resistance vs. commitment” - 168 vs. 72 hour:  
 (Tg.168 − Tg.72) – [(WT.168 − WT.72 + NTg.168 − NTg.72)/2]  
 
 The subtracted coefficients represented the significance of the treatment effect per gene in 
the signature. The reason why the NTg and WT treatment coefficients were averaged instead of 
being subtracted separately from the Tg treatment was because no gene was found to be 
differentially expressed with a false discovery rate corrected p-value less than 0.05 between the 
NTg and WT treatments (data not shown). This suggested that there is no significant 
transcriptional difference motor neurons that are exposed to medium conditioned with non-
transgenic versus transgenic wild-type SOD1-expressing astrocytes.  
 Following the selection of gene expression signatures, the number of differentially 




The 72 vs. 0 and 168 vs. 0 hour signatures were found to be the most powerful, since they had 
the highest number of significantly differentially expressed genes, which renders them good 
















3.2.4. Reverse gene engineering analysis 
Next, reverse gene engineering analysis was performed to determine the differential activity of 
transcription factors that are the candidate master regulators of the molecular mechanism 
underlying the ALS-linked mutant astrocyte toxicity for motor neurons. In order to do this, 
Table 3.3: Number of differentially expressed genes 
for each signature 
Signature FDR<0.05 FDR<0.01 
24h - 0h 142 80 
72h - 0h 1247 420 
168h - 0h 1846 952 
72h - 24h 394 57 
168h - 72h 148 40 
 
The number of differentially expressed genes for each signature with 
false discover rate (FDR) corrected p-values less than 0.05 or 0.01. In 
this analysis, the 72 vs. 0 and 168 vs. 0 hour signatures have the 
highest number of genes, which makes them the most powerful 




Absolute Enrichment Master Regulator Analysis was performed ignoring the transcription factor 
mode-of-action on their targets. In this manner, a transcription factor could be identified as 
differentially active, because of the treatment, without inferring whether the transcription factor 
is more or less active than the control. This analysis was done independently using seven 
different transcriptional interactomes that were available from the Califano group. The reason 
why the analysis was performed using all of the available interactomes was to objectively 
compare the efficiency of each interactome independently to determine the one that best fits our 
data. These interactomes were a human prefrontal cortex interactome generated from the 
Harvard Brain Tissue Resource Center, a human high-grade glioma interactome from The 
Cancer Genome Atlas (TCGA) consortia, a human glioma interactome from the Philips paper 
(2006), a human glioma interactome from the Sun paper (2006), a human integrated glioma 
interactome, a neuroblastoma interactome, and finally a mouse total brain interactome. Below is 
more detailed information about each of these interactomes. 
 
3.2.4.1. The human prefrontal cortex interactome  
The human prefrontal cortex interactome was reverse-engineered from 153 normal pre-frontal 
cortex tissue samples obtained from the Harvard Brain Tissue Resource Center dataset. This 
interactome contained 1,432 transcription factors and 20,691 target genes with 267,873 
regulatory interactions. The homoloGene database, which is a system for the automated detection 
of homologs among the annotated genes of several completely sequenced eukaryotic genomes, 
was used to obtain the murine ortholog genes.  Using this database, a 1,176 transcription factors 




Transcription factors regulating the signatures were inferred with MARINa, weighing the 
contribution of each target gene according to the number of regulatory interactions each gene 
has. 
 
3.2.4.2. The human high-grade glioma interactome from TCGA consortia  
The TCGA high-grade glioma interactome was reverse-engineered from 319 glioblastoma grade 
IV samples obtained from TCGA. This interactome contained 885 transcription factors and 9510 
target genes with 187,272 regulatory interactions. The homoloGene database was used to obtain 
the murine ortholog genes and generated a 763 transcription factors x 8,934 target genes 
interactome, with 164,476 regulatory interactions. Transcription factors regulating the signatures 
were inferred with MARINa, weighing the contribution of each target gene according to the 
number of regulatory interactions each gene has. 
 
3.2.4.3. The human glioma interactome from the Philips paper (2006) 
The dataset for this interactome consisted of 154 human glioblastoma multiform samples 
profiled on the HG-U133A Affymetrix arrays. Processing this dataset with reverse engineering 
produced 8,332 probe-clusters mapping to 8,293 genes. The samples were then classified into 71 
mesenchymal, 47 proneural and 36 proliferative gene groups. The Phillips dataset-based 
transcriptional interactome consisted of 8,240 nodes and 110,979 edges, representing 711 






3.2.4.4. The human glioma interactome from the Sun paper (2006) 
The dataset for this interactome consisted of 181 human glioblastoma multiform, 131 
astrocytoma and 57 oligodendroglioma samples profiled on the HG-U133 Plus 2 Affymetrix 
platform. Processing this dataset by reverse engineering produced 14,447 probe-clusters mapping 
to 13,265 genes.  The Sun dataset-based transcriptional interactome consisted of 11,731 nodes 
and 137,913 edges, representing 1,060 transcription factors for 11,728 target gene interactions. 
 
3.2.4.5. The human integrated glioma interactome 
This interactome was built by combining all three human glioma interactomes from the TCGA 
consortia, Philips (2006) and Sun papers (2006).  
 
3.2.4.6. The human neuroblastoma interactome 
The human neuroblastoma interactome was reverse-engineered from 189 samples profiled on 
Affymetrix exon arrays. This interactome contained 1,360 transcription factors and 14,200 target 
genes with 175,499 regulatory interactions. The homoloGene database was used to obtain the 
murine ortholog genes and generated a 1,085 transcription factors x 12,104 target genes 
interactome, with 138,231 regulatory interactions. Transcription factors regulating the signatures 
were inferred with MARINa, weighing the contribution of each target gene according to the 
number of regulatory interactions each gene has.  
 
3.2.4.7. The mouse total brain interactome 




dataset containing different brain regions from different mouse strains. It represented 1,345 
transcription factors regulating 16,527 target genes through 388,550 interactions. MARINa was 
performed for each of the gene expression signatures, considering only single transcription factor 
enrichment.  
This analysis done on the mouse total brain interactome identified 0 differentially active 
transcription factors for the 24 vs. 0 hour signature, 120 for the 72 vs. 0 hour signature, 0 for the 
168 vs. 0 hour signature, 119 for the 72 vs. 24 hour signature, and 8 for the 168 vs. 72 hour 
signature for false discovery rate-corrected p-values of less than 0.05.  
  
After performing the Master Regulator Analysis on these seven interactomes, a 
comparison of these interactomes was made to decide which one would best fit the RNA-Seq 
data. This was an important selection, since none of the sources of the interactomes exactly 
matched the in vitro model cell type used for the RNA-Seq assay. For the interactome 
comparison, the absolute enrichment levels of the top 100 transcription factors across the seven 
transcriptional interactomes were compared for the 24 vs. 0, 72 vs. 0, and 168 vs. 0 hour 
signatures [Figure 3.6]. The enrichment score is represented as –log10 (p-value) to make it more 
scalable. In this comparison, the interactome that had the highest number of transcription factors 
with statistically significant p-values would be the most powerful one and the one that most 
closely matches the gene expression signatures of the RNA-Seq data.  
 By this criterion, the mouse total brain interactome outperformed all of the other 
interactomes. This outperformance was especially obvious for the strongest gene expression 




transcription factors [Figure 3.6b]. Thus, the focus was on the reverse gene engineering analysis 
results from the mouse total brain interactome with inferred master regulators from the 72 vs. 0 
hour signature for biological validation, since this signature was the strongest and had the most 
biological relevance for commitment to death. Please see the Appendix for the complete results 
on all of the five signatures from this interactome. 
 
3.2.5. Top 25 master regulators 
The main purpose of this project after the RNA-Seq assay was to demonstrate the pathological 
significance of the selected transcriptional regulators. The reverse gene engineering analysis 
from the 72 vs. 0 signature provided 120 transcription factors, which is a very large number to 
biologically validate. Therefore, the decision was to focus on the top 25 of these transcription 
Figure 3.6: The mouse total brain interactome is the most biologically relevant for the 
RNA-Seq data 
 
This figure compares the enrichment score, as –log10 (p-value), of the top 100 transcription factors from the 
MARINa analyses of the 24 vs. 0, 72 vs. 0, and 168 vs. 0 hour signatures on the seven available interactomes 
from the Califano group. Rank is the top 100 transcription factors from 1 to 100 and the line, coming from y=2, 
represents the point of significance, where p-values < 0.01. The most powerful signatures, the 72 vs. 0 and 168 
vs. 0 hour, show the mouse total brain interactome to be the most biologically relevant interactome. Gbm-
hgg176: the human glioblastoma interactome from the Philips paper, gbm-sun: the human glioblastoma 
interactome from the Sun paper, gbm-tcga: the human glioblastoma interactome from the TCGA consortia, gbm: 
the integrated human glioblastoma interactome, nbl: the human neuroblastoma interactome, pfc: the human 





factors, which consisted of Psmc3ip, Camta1, Tgif1, Tcf3, Tcf7, Trp53, Zfp503, Zfp235, Hivep2, 
Mycn, Dennd4a, Zfp36l1, Epas1, App, Irx5, Myb, Cbfa2t3, Smad3, Zfp646, Hmgb2, Nfkb1, Atf5, 
Zdhhc2, Zfp239, Aatf with functions mainly involved in the Wnt, JNK, NF-B, IFN-γ, and 
transforming growth factor-β (Tgf-) signaling pathways [Table 3.4].  
 
Table 3.4: The top 25 master regulators from the 72 vs. 0 hour signature 
TF Name p-value Function 
Psmc3ip 5.72e−06 Proteasome ATPase interacting, DNA binding protein 
Camta1 2.31e−05 Calmodulin binding transcription activator 
Tgif1 2.97e−05 
Involved in Tgf-β & JNK signaling, negative regulator of cell 
proliferation 
Tcf3 3.23e−05 T-cell specific TF, involved in Wnt & FoxO pathways 
Tcf7 5.56e−05 T-cell specific TF, involved in Wnt pathway, suppresses IFN-γ pathway 
Trp53 7.6e−05 Encodes p53, involved in ALS, apoptosis, PI3K, Tgf-β and Wnt 
pathways 
Zfp503 9.35e−05 (=Nolz1), promotes striatal neurogenesis 
Zfp235 0.000112  
Hivep2 0.000117 Represses NF-κB for cell survival, modifies Tgf-β signaling 
Mycn 0.000123 Inhibits NF-κB & c-Jun, regulated by PI3K 
Dennd4a 0.000127 Lowers blood pressure 





(=Hif2a), opposite effect of Hif1a, Hif1a is found to change in ALS 
patients and mSOD1 mice, regulates VEGF & hypoxia, regulated by NF-
κB & JNK 
App 0.000182 Involved in NF-κB & TRAF6 pathways 
Irx5 0.000251 Retinal differentiation 
Myb 0.000257 Involved in Wnt signaling, might have a similar role as NF-κB 
Cbfa2t3 0.000395  
Smad3 0.00052 Involved in Smad/Tgf-β & Wnt signaling pathways 
Zfp646 0.000524  
Hmgb2 0.000541 Enhances Wnt signaling, involved in apoptosis 
Nfkb1 0.000552 (=p50, p105) 
Atf5 0.000675 Represses p53, inhibits apoptosis 
Zdhhc2 0.000797  
Zfp239 0.00103  
Aatf 0.00104 
(=apoptosis antagonizing TF), anti-apoptotic, involved in Akt, JNK, 
p75
NTR
 & NGF pathways 
 
The most enriched transcription factors (TFs) from the 72 vs. 0 hour signature extracted from the mouse total brain 
interactome. The transcription factors are ranked by their p-values. Their known functions, which include the Wnt, 
JNK, NF-B, and Tgf- signaling pathways, are added to the table. Currently the pathological significance of these 
transcription factors is being investigated by knocking down their expression in purified embryonic stem cell-
derived motor neurons exposed to mutant astrocyte-conditioned medium, via shRNA-based lentivirus, and seeing if 
the knock-down causes any changes in the survival of these motor neurons.  
 
Validation of these transcription factors was decided to be done by knocking down their 
expression in purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-




survival of motor neurons is observed. In this experimental design, an increase or decrease in the 
survival of motor neurons would suggest the involvement of a transcription factor in the 
molecular mechanism of motor neuron death in this non-cell autonomous model of ALS and 
would confirm the transcription factor’s role as a master regulator of this mechanism. While in 
the process of validating the pathological significance of these 25 transcription factors, which is 
currently in progress, one transcription factor, namely NF-B, was of particular interest. This 
was primarily because NF-B has recently been in the spotlight for its link to different forms of 
fALS, such as for mutations in TDP-43 (Swarup et al., 2011) and OPTN (Maruyama et al., 
2010). In addition, NF-B has been inferred as one of the top master regulators of the molecular 
mechanism underlying the ALS-linked astrocyte toxicity for motor neurons. Further 
investigations into the pathological significance of NF-B in ALS are discussed in the next 
chapter. 
 
3.2.6. Gene Set Enrichment Analysis (GSEA) 
For an additional analysis of the RNA-Seq data, GSEA, which is for conventional gene class 
testing, was performed. This analysis statistically compares the number of genes in a class that 
are ‘significant’ by using Gene Ontology (GO) or other pathway categories as a source for its 
gene classes (Allison et al., 2006). Indeed, this analysis allowed the evaluation of how this more 
traditional bioinformatics approach compares to the reverse gene engineering analysis in the 
ALS model used in this project. Furthermore, while the primary aim was to perform reverse gene 
engineering analysis, GSEA would allow the comparison of the data generated here to those 




molecular mechanism of non-cell autonomous motor neuron degeneration. 
GSEA was performed for the five gene expression signatures using the three most 
commonly used databases to group genes in related functional annotations: GO biological 
processes, Kyoto Encyclopedia of Genes and Genomes (KEGG), and Reactome pathways. There 
are several differences between these functional databases that make their end results slightly 
different from one another. GO is an ontology of defined terms representing gene product 
properties under three domains: (1) the cellular component, (2) the molecular function, and (3) 
the biological process (Consortium, 2008). KEGG, on the other hand, is a collection of online 
databases dealing with genomes, enzymatic pathways, and biological chemicals (Kanehisa, 
2004). It records networks of molecular interactions in the cells including pathways and 
complexes, information about genes and proteins generated by genome projects, compounds and 
reactions. However, with KEGG, it is hard to combine all of this information in a unifying 
manner, since all of the annotations come from different data sets. Finally, Reactome is a 
species-specific online database of biological pathways (Joshi-Tope G., 2005). What is different 
with Reactome is that its core unit is the reaction, where entities (e.g. nucleic acids, proteins, 
complexes and small molecules) participating in reactions form a network of biological 
interactions that are grouped into pathways. Examples of biological pathways in Reactome 
include signaling, innate and acquired immune function, transcriptional regulation, translation, 
apoptosis and classical intermediary metabolism. Moreover, it is organized in a GO-controlled 
vocabulary, which makes it easier to understand than KEGG identifiers.  
Because of the reasons mentioned above, the Reactome database seemed the most 




molecular pathways deduced from the most differentially expressed target genes 
(GSEA/Reactome) was compared to those deduced from the most activated master regulators 
(reverse gene engineering/mouse brain interactome). By looking at the 72 vs. 0 hour signature, 
which was the primary focus of this work, no agreement was found between the two lists of 
pathways (data not shown). Similarly, by looking at the 24 vs. 0 hour signature, minimal 
concurrence between the two lists of pathways was observed (data not shown). However, by 
looking at the 24 vs. 0 hour signature from the GSEA and the 72 vs. 0 hour signature from the 
reverse gene engineering analysis, a significant concurrence was noted between the two lists of 
pathways, such as the IFN- and NF-B pathways [Tables 3.5-6]. 
 












Ccl2 13.624 3.4e-15 
A small cytokine whose knockdown was tested to 
have no effect on motor neuron survival 
2 
Usp18 13.123 8.55e-15 
A deubiquitinating protease involved in IFN- 
signaling 
3 
Irf9 12.349 7.34e-14 
An interferon regulatory factor that interacts with 
STAT 2 and STAT1, and involved in IFN- signaling 
4 
Nfkbia 10.387 5.05e-11 
Higher activity in MNs exposed to mutant ACM; 
involved in NF-B pathway 
5 Art3 9.833 3.01e-10 An ecto-ADP-ribosyltransferase 





Cxcl10 9.575 5.54e-10 
A small cytokine belonging to the CXC chemokine 
family that is regulated by NF-κB and is involved in 
IFN- signaling 
8 
Trim25 9.127 2.55e-09 
A tripartite motif-containing protein involved in NF-
κB & TRAF3 pathways 
9 
Irf1 8.882 5.67e-09 
An interferon regulatory factor involved in IFN- 
signaling 
10 
Stat1 8.787 7.27e-09 
A transcription factor involved in JAK/STAT, NF-κB, 
IFN-, and TLR pathways 
 
The top 10 most differentially expressed genes in the 24 vs. 0 hour signature with false discovery rate corrected 
p-value less than 0.01. The genes are mostly involved in the IFN- and NF-B related pathways. The genes were 
ranked by their p-values. ACM: astrocyte-conditioned medium; MN: motor neuron; TRAF: tumor necrosis factor 
receptor associated factor; JAK/STAT: Janus kinase/signal transducers and activators of transcription; TLR: Toll-
like receptor. 
 
Table 3.6: The top 10 most enriched pathways in the 24 vs. 0 hour signature 




Toll Like Receptor 9 (TLR9) 
Cascade 
3.741 0.000183 
Nfkbia, Irf7, Nfkb2, Pik3c3, Mapkapk3, Dusp3, 
Mef2c, Mapk10, Ager, Myd88, Fos, Ikbkg, Ubc, 
Mapk3, App, Atf1, Map2k6, Nod1, Map2k1, 
Irak4, Map2k3, Hmg1l1, Ppp2r5d, Pik3r4, Nfkb1, 
Rps6ka3, Rps6ka2, Tlr7 
2 
Toll Receptor Cascades 3.468 0.000525 
Nfkbia, Irf7, Nfkb2, Pik3c3, Mapkapk3, Dusp3, 
Mef2c, Lgmn, Mapk10, Ager, Ly96, Tlr2, Myd88, 
Cd180, Fos, Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, App, 
Atf1, Map2k6, Nod1, Hspd1, Map2k1, Irak4, 
Map2k3, Hmg1l1, Ppp2r5d, Ctss, Unc93b1, Irf3, 
Pik3r4, Lbp, Nfkb1, Rps6ka3, Rps6ka2, Tlr7 
3 
Toll Like Receptor 4 (TLR4) 
Cascade 
3.434 0.000596 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Ly96, Tlr2, Myd88, Cd180, Fos, 




Map2k6, Nod1, Hspd1, Map2k1, Irak4, Map2k3, 
Hmg1l1, Ppp2r5d, Irf3, Lbp, Nfkb1, Rps6ka3, 
Rps6ka2 
4 
TRAF6 Mediated Induction 
of proinflammatory cytokines 
3.084 0.00204 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Fos, Ikbkg, Ubc, Mapk3, App, 
Atf1, Map2k6, Nod1, Map2k1, Map2k3, Hmg1l1, 
Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2 
5 TRAF6 mediated NF-kB 
activation 
2.975 0.00293 Nfkbia, Trim25, Ddx58, Ifih1, Nfkb2, Ager 
6 
MyD88:Mal cascade initiated 
on plasma membrane 
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Ly96, Tlr2, Myd88, Fos, Ikbkg, 
Sigirr, Ubc, Mapk3, Tlr6, App, Atf1, Map2k6, 
Nod1, Hspd1, Map2k1, Irak4, Map2k3, Hmg1l1, 
Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
7 
Toll Like Receptor 2 (TLR2) 
Cascade 
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Ly96, Tlr2, Myd88, Fos, Ikbkg, 
Sigirr, Ubc, Mapk3, Tlr6, App, Atf1, Map2k6, 
Nod1, Hspd1, Map2k1, Irak4, Map2k3, Hmg1l1, 
Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
8 
Toll Like Receptor 
TLR1:TLR2 Cascade 
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Ly96, Tlr2, Myd88, Fos, Ikbkg, 
Sigirr, Ubc, Mapk3, Tlr6, App, Atf1, Map2k6, 
Nod1, Hspd1, Map2k1, Irak4, Map2k3, Hmg1l1, 
Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
9 
Toll Like Receptor 
TLR6:TLR2 Cascade 
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Ly96, Tlr2, Myd88, Fos, Ikbkg, 
Sigirr, Ubc, Mapk3, Tlr6, App, Atf1, Map2k6, 
Nod1, Hspd1, Map2k1, Irak4, Map2k3, Hmg1l1, 
Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
10 
MyD88 dependent cascade 
initiated on endosome 
2.876 0.00403 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Myd88, Fos, Ikbkg, Ubc, Mapk3, 
App, Atf1, Map2k6, Nod1, Map2k1, Irak4, 






The 10 most enriched pathways in the 24 vs. 0 hour signature using the Reactome pathway database. The pathways 
were ranked by their normalized enrichment scores (NES) and p-values. The leading-edge genes for each significant 
gene set at p-value less than 0.05 are also reported. The Toll-like receptor and TRAF6-mediated NF-B signaling 
pathways dominate this list. 
 
3.3. Conclusion and Discussion 
Unlike the candidate-based approach that was initially tried, using the unbiased RNA-Seq assay 
to identify gene alterations germane to the toxicity of mutant astrocytes on motor neurons has 
provided us with many promising molecular hits. This has allowed the use of the gene expression 
signatures from this assay to infer master regulators of the molecular mechanism of mutant 
astrocyte-derived motor neuron degeneration and to concentrate efforts on biologically validating 
the top 25 transcription factors that were inferred as master regulators. Of these transcription 
factors, the pathological significance of one, NF-B, has already been confirmed. This will be 
discussed in more detail in the next chapter.  
Interestingly, several of the most differentially expressed target genes of the 24 vs. 0 hour 
signature, such as Usp18, Irf9, and Irf1, belong to the IFN- molecular pathway. This signaling 
pathway has been shown by Aebischer et al. (2011) to be involved in the ALS-linked non-cell 
autonomous degeneration of motor neurons. Moreover, no significant changes in the activation 
of any known cell-autonomous motor neuron death mechanisms, such as Fas signaling and ER 
stress genes at the 24 vs. 0 or 72 vs. 0 hour signatures were noted. However, a change in the 




suggest coherency between the differentially expressed target genes from our data and from the 
data of other groups on the molecular mechanism underlying non-cell autonomous motor neuron 
degeneration.  
By looking at the differentially expressed target genes and the pathways deduced from 
these genes, using GSEA, the above comparisons were made. However, the top results from 
these analyses were limited to the NF-B and IFN- pathways. On the other hand, with the 
reverse gene engineering analysis, many transcription factors were inferred including, but not 
limited to NF-B, that elucidate the upstream signaling underlying this neurodegenerative 
mechanism that GSEA is not capable of computing. Moreover, with the reverse gene engineering 
analysis, it was not necessary to select individual target genes, since the analysis utilized the 
genomic data of target genes as a whole to infer its results. Therefore, it is thought that the results 
from the reverse gene engineering analysis provide more unbiased mechanistic information at the 
transcriptional regulation and signalization level than from the results of the GSEA.  
Moreover, the comparison of the results from the reverse gene engineering analysis and 
GSEA showed the consistent involvement of several pathways, such as IFN- and NF-B. But, 
interestingly, this resemblance arose from different signatures, in that the pathways deduced 
from differentially expressed target genes were from the 24 vs. 0 hour signature, whereas the 
pathways deduced from the differentially active transcription factors were from the 72 vs. 0 hour 
signature. This apparent temporal discrepancy was rather surprising, since the reverse gene 
engineering analysis infers master regulators that are supposedly upstream to the target genes. 




reverse gene engineering precede those generated by GSEA. A future study is therefore required 
to clarify this question.  
Additionally, several decisions and observations were made about the experimental 
design and data analysis processes to perform the RNA-Seq assay and its analysis in the most 
efficient and unbiased way possible. These decisions and observations are discussed below. 
One of the most important decisions made in the experimental design for the RNA-Seq 
assay was the inclusion of treatment of medium conditioned with transgenic wild-type SOD1 
astrocytes, as well as with non-transgenic astrocytes. It was believed that, by doing so, one could 
control for any gene expression changes that occur in motor neurons merely due to the 
overexpression of the catalytically active form of SOD1 in astrocytes. Thus, after the completion 
of the ANOVA analysis for the selected signatures, the non-transgenic astrocyte-conditioned 
medium treatment effect on motor neurons was compared with that of the transgenic wild-type 
SOD1 astrocyte-conditioned medium. Interestingly, no differentially expressed gene was found 
between these two conditions (data not shown), suggesting that the expression of wild-type 
human SOD1 in astrocytes does not cause detectable gene alterations in motor neurons. This 
treatment also provided an extra control condition to increase the power of the ANOVA analysis. 
During the experimental design process for the RNA-Seq assay, to minimize the 
technical variation, we thought to perform RNA isolation for all of the 72 total RNA samples at 
the same time. To do this in the most efficient way, two different methods were compared: (1) 
the high-throughput MagMax RNA purification kit (Applied Biosystems) using RNA binding 
magnetic beads with a 96-well plate on a magnetic stand; and (2) the RNAeasy Mini Kit Spin 




purification of RNA for 96 samples at the same time, the RNAeasy columns were for individual 
sample use which made it difficult to isolate 72 samples at the same time under the same 
technical and experimental conditions. However, test samples that were isolated using both 
methods showed very comparable RNA quality and quantity amounts (data not shown). 
Therefore, since both kits gave comparable RNA quality results, the MagMax RNA purification 
kit was selected as the preferred RNA isolation method, significantly limiting the technical 
variations that might have resulted from individual column use in the isolation of the 72 RNA 
samples.  
Once the potentially variation-introducing experimental design steps were fixed, the 
focus was on the pre-processing of the RNA-Seq data, where the aim was to introduce as little 
processing to the data as possible. Thus, instead of using the data in the traditional FPKM (i.e. 
fragments per kilobase of exon per million fragments mapped) format, which cannot be analyzed 
by methods designed for digital data, the data was received and analyzed in its rawest format, 
which is the mapped reads format. By normalizing and variance stabilizing the data in this rawest 
format, the data was kept as little processed as possible so that the results would not be affected 
by any bias.  
While the read counts could only be received in the mapped format from the Genomic 
center, there were also base reads that were not mapped to the mouse genome, which were not 
included in the analysis. There could be a few reasons why a read was not mapped to a location 
in the mouse genome: (1) if the read was mapped to more than one location in the genome, 
which would make the read non-specific for any gene; (2) if the read was contaminated with 




option was not very probable, since the mouse genome has been very well sequenced over the 
years.  Thus, the non-mapped reads were most likely either non-specific or contaminated, and 
were not included in any further analysis of the read count data. However, in case a read 
belonged to an unknown sequence in the genome that might be sequenced later, the raw non-
mapped data is stored for future studies. Indeed, the analysis can be re-run at any time should a 
more completely sequenced mouse genome become available. This non-mapped read data can 
also be used to gather read counts on the non-coding RNA, such as microRNAs. 
Despite the different strategies adopted in the experimental design to minimize potential 
batch effect, the samples with the same replicate number still showed a gene expression pattern 
closer to each other than those with other replicate numbers (data not shown). This suggested 
that the motor neuron differentiation and purification steps bring undesired technical variation to 
the data. This effect was reduced by fitting the data to the linear model: y =  + T + B + , 
where  is the coefficient factor for the batch effect.  is additive to , the coefficient factor for 
the treatment effect. Therefore, while genes with the highest  values were being computed, 
genes with the lowest batch effect were also being selected, hence minimizing the batch effect 
from the gene expression signatures.  
Although the reverse gene engineering analysis of the RNA-Seq data has been performed 
for all of the selected timepoints, the focus was on the 72 vs. 0 hour signature, as discussed in the 
preceding chapter. This timepoint seemed the most biologically relevant, since 72 hours of 
exposure to mutant astrocyte-conditioned medium is enough to make motor neurons committed 
to die and this mechanism cannot be reversed. Thus, by studying the transcriptional network 




underlying the commitment to death in motor neurons. Studies on other signatures would also be 
interesting to pursue further. For instance, the 168 vs. 0 hour signature would be especially 
interesting to study, since it could elucidate the molecular mechanism that is different between 
the resistant and sensitive motor neuron subpopulations in this model system of ALS. 
One weakness of the reverse gene engineering analysis performed on the RNA-Seq data 
was the interactomes that have been available, which mostly belonged to the human species and 
were reverse-engineered from glioblastoma or neuroblastoma cell line samples. While the 
comparison performed on the seven available interactomes revealed the mouse total brain 
interactome to be the most relevant to these data, none of the interactomes were motor neuron-
specific. Therefore, even though this analysis inferred transcription factors that are differentially 
active in the model system here, the need to validate the pathological significance of these 
transcription factors biologically still remains. Moreover, the Califano group is currently 
generating a mouse motor neuron specific interactome in collaboration with the Wichterle group. 
We are planning to re-run the reverse gene engineering analysis on the RNA-Seq data using the 
motor neuron interactome once it is completed.  
Another decision that was made about the reverse gene engineering analysis was its 
absolute enrichment aspect. Since the interactome selected was not an exact fit for the cell type 
being used, there was a lack of certainty about the enhancement or repression effect of each 
transcription factor on the expression of their target genes. This was also because it has been 
shown that certain transcription factors either activate or repress their target genes, depending on 
their cell types. Thus, Absolute Enrichment Master Regulator Analysis was performed, from 




activity could not be determined. Since the plan was to validate the pathological significance of 
each of the top 25 transcription factors by biological means, it would be more suitable to use the 
absolute enrichment analysis. If by knocking-down the expression of a factor, no change in the 
survival of motor neurons was noted, then we would over-express this factor before reaching a 
definitive conclusion about its role in the molecular mechanism of motor neuron degeneration. In 
addition, the number of transcription factors being validated could be expanded; if not enough 
transcription factors gave conclusive results.  
Finally, in the analysis of the RNA-Seq data so far, only transcriptional interactions were 
calculated. This was because the only available database to run the post-translational analysis 
was from the human glioblastoma cell line. And, like the transcriptional interactome, the 
generation of a motor neuron specific post-translational interactome is in progress and will be 
utilized as soon as it becomes available. This post-translational interactome will provide us with 
information on the signalization between the entrance of the mutant astrocyte-derived toxic 
factor to motor neurons and the activation of transcription factors that activate genes that are 
responsible for the Bax-dependent cell death. Consequently, we will have the ability to complete 
the signaling network underlying the ALS-linked astrocyte toxicity for motor neurons. 
What is unique about the reverse gene engineering method is that it makes use of the 
whole gene expression signature from the RNA-Seq data rather than selecting a few of the most 
differentially expressed target genes, which makes it more powerful and unbiased. What makes 
this project so unique is that this is the first time the reverse gene engineering method has been 
used in a model of neurodegeneration. In this model of ALS-linked non-cell autonomous motor 




involved in the molecular mechanism of this degeneration. The results from this part of the 








The Master Regulator Analysis from the RNA-Seq data, as discussed in Chapter 3, inferred NF-
κB as one of the top 25 transcription factors driving the ALS-linked astrocyte toxicity for motor 
neurons. NF-κB is also one of the most differentially expressed target genes and one of the most 
enriched pathways in this ALS model, as evidenced by GSEA. The interest in this family of 
transcription factors was further stimulated by the discoveries showing that specific subunits of 
the NF-κB complex are up-regulated in motor neurons in both sALS cases (Jiang et al., 2005b) 
and transgenic mutant SOD1 mice (Ferraiuolo et al., 2007), and that the NF-κB subunit p50 
modulates the activity of TDP-43, whose mutations give rise to a form of fALS (Swarup et al., 
2011). 
In light of these findings, the pathological significance of NF-κB in our in vitro model of 
ALS was investigated. However, prior to presenting and discussing any results, a brief review of 
what is known about NF-κB’s signaling, its function in the central nervous system, and its role in 
ALS is in order to set stage for this chapter. 
 
4.1.1. NF-κB signaling 
NF-κB was first identified over 20 years ago as a DNA-binding complex governing transcription 




thousands of papers have been published about this transcription factor being involved in a broad 
range of biological processes ranging from innate and adaptive immunological responses to cell 
survival, death, development, stress 
responses, and maturation (Hayden and 
Ghosh, 2012). While NF-κB activation 
in general protects organisms from 
environmental insults, dysregulated NF-
κB activity is observed in various 
diseases including chronic 
inflammation, cancer, and 
neurodegeneration, such as in 
Huntington’s disease and ALS (Shih et 
al., 2011).  
There are three regulatory 
components to the NF-κB pathway 
[Figure 4.1]: (1) the NF-κB/Rel family, 
(2) the inhibitor of NF-κB (IκB) family, 
and (3) the IκB kinase (IKK) complex. 
NF-κB activation is organized by a 
number of positive and negative 
regulatory elements (Hayden and 
Ghosh, 2012). In the dormant state, NF-
Figure 4.1: Components of the NF-B pathway 
 
The components of the NF-B pathway, taken from Hayden 
and Ghosh (2012). The NF-B family consists of five 
members: p65/RelA, RelB, c-Rel, and the precursor proteins 
p100 and p105 giving rise to p52 and p50, respectively. The 
IB family consist of eight members: IκB, IκB, IκB, 
IκB, BCL-3, IκBNS, p100, and p105. The IKK complex is 
formed by IKK, IKK, and NEMO. RHD: REL homology 
domain; TAD: transactivation domain; LZ: leucine zipper 
domain; GRR: glycine-rich region; ANK: Ankyrin repeat 
domain; DD: death domain; PEST: proline-rich, glutamic 
acid-rich, serine-rich, and threonine-rich; ULD: ubiquitin-
like domain; SDD: scaffolding and dimerization domain; 
NBD: NEMO-binding domain; CC: coiled-coil domain; 
IBD/DimD: IKK-binding domain/dimerization domain; 
MOD/UBD: minimal oligomerization domain/ubiquitin-





κB dimers are held inactive in the 
cytoplasm through association with 
IκB proteins. Inducing stimuli 
trigger activation of the IKK 
complex, which then 
phosphorylates, ubiquitinates, and 
degrades IκB proteins (Ferreiro and 
Komives, 2010) [Figure 4.2]. Freed 
NF-κB dimers translocate to the 
nucleus, bind to specific DNA 
sequences, and promote 
transcription of target genes. One of 
these target genes is IκB, which then 
goes back to the cytoplasm and 
binds to NF-κB in the cytoplasm, forming a negative feedback loop [Figure 4.2].  
There are five NF-κB family members in mammals; these are: p65/RelA, RelB, c-Rel, 
p50/NF-κB1 and p52/NF-κB2 [Figure 4.1]. These proteins are characterized by the presence of 
an N-terminal Rel homology domain (RHD), which is a protein domain that contains a 
recognition loop that interacts with DNA bases, and their stoichiometric inhibitor proteins, IκBs. 
NF-κB family proteins bind to κB sites as either homo- or hetero-dimers and can either turn on 
or off the transcription of their target genes. The five monomers form 15 potential dimers and the 
Figure 4.2: Activation of the NF-B signaling 
pathway 
 
The activation of the NF-B pathway, excerpted from Ferreiro et 
al. (2010). When inactive, NF-B dimers are bound to IB and 
reside in the cytoplasm. Upon the activation of the IKK complex 
through extracellular signals, IKK phosphorylates IB, which 
then gets ubiquitinated and degraded by the 26S Proteasome. 
Freed NF-B dimers, then, are translocated to the nucleus and 
transcribe new IB, as well as various other genes. The newly 
synthesized IB is either degraded, binds to NF-B in the 
cytoplasm, or enters the nucleus and binds to nuclear NF-B, 




generation of all monomers is transcriptionally regulated. p50 and p52 are also regulated by the 
processing of precursor proteins p105 and p100, respectively (Shih et al., 2011).  
The main inhibitor proteins of NF-κB are IκB, IκB, and IκB. However, precursor 
proteins p100 and p105, in addition to, IκB, IκBns, and B-cell lymphoma 3 (Bcl-3) were 
recently found to have inhibitory roles on NF-κB as well (Hayden and Ghosh, 2012) [Figure 
4.1]. IκBs, in general, have an ankyrin repeat domain, which is a 33-residue motif consisting of 
two alpha helices separated by a loop, which sequesters NF-κB into a dormant state and prevents 
DNA binding. p100 and p105, on the other hand, mediate NF-κB inhibition only when they are 
in trans, through an activity called IκB for p100 (Basak et al., 2007) and IκB for p105 
(Savinova et al., 2009), respectively.   
The NF-κB pathway is subdivided into two pathways which depend on the types of 
responses they trigger (Sun, 2011): (1) the canonical pathway, which typically activates the rapid 
and reversible inflammatory and immune responses; and (2) the non-canonical pathway, which is 
the slower pathway that activates the irreversible developmental responses. The canonical 
pathway is NF-κB essential modulator (NEMO/IKK)-dependent, where the activated IKK- 
complex phosphorylates IκB. The NF-κB dimers involved in this pathway are mostly p65, p50 
and c-Rel [Figure 4.3]. IKKs can be phosphorylated through autophosphorylation or by upstream 
kinases. Moreover, since the canonical pathway is usually activated by inflammatory stimuli, the 
known receptors that activate this signaling pathway include the Toll-like, Tumor Necrosis 
Factor, B-cell and T-cell receptors. The non-canonical pathway, on the other hand, is NEMO-
independent where the IKK complex consists of IKK and the NF-κB-inducing kinase (NIK). In 




generation of NF-κB dimers RelB and p52 (Shih et al., 2011). Finally, the known receptors of the 
non-canonical pathway are the B-cell activating factor receptor, CD40, lymptotoxin  receptor 
and receptor activator of NF-κB [Figure 4.3]. 
Even though the canonical and non-canonical pathways are generally distinct from one 
another, recent studies have revealed cross-talk between them. One example of this is the 
functional overlap found between p50/NF-κB1 and p52/NF-κB2 through the NF-κB gene 
deletion studies. Biochemical analysis of mutant cells showed that the loss of canonical p50 
Figure 4.3: The canonical and non-canonical pathways of NF-B 
 
The canonical and non-canonical pathways of NF-B, extracted from Sun et al. (2011). There are major 
differences between the pathways. While the canonical pathway, which responds to numerous inflammatory 
and immune stimuli, is rapid and transient, the non-canonical pathway responds to developmental signals and 
is slow and persistent. Moreover, some of the main receptors that activate the canonical pathway are the Toll-
like (TLR), Tumor Necrosis Factor (TNF), B-cell (BCR) and T-cell (TCR) receptors that turn on TAK1, 
which then phosphorylates the IKK, , and  (NEMO) complex. This pathway also constitutes of IB, 
RelA (p65) and p50. The non-canonical pathway is activated by B-cell activating factor receptor (BAFFR), 
CD40, lymptotoxin- receptor (LTR) and receptor activator of NF-κB (RANK), which then turns on the 






results in the formation of p65/p52 dimers and near normal p65 activation in response to 
inflammatory stimuli (Hoffmann et al., 2003). Moreover, lymph node organogenesis, which is a 
developmental phenotype normally seen under the conditions of weakened activity of the non-
canonical NF-κB pathway, has also been observed in NF-κB1-/- mice which are characterized by 
the inhibition of the activity of the canonical pathway (Basak and Hoffmann, 2008). These 
results indicate functional overlap and interdependencies between the canonical and non-
canonical pathways.  
  Although the activating cell surface receptors may vary, research on NF-κB signaling 
discovered a convergence of signaling intermediates upstream to the IKK complex. These 
intermediates include Receptor-interacting protein (RIP) and tumor necrosis factor receptor 
associated factor (TRAF) families of proteins. In most cases, both RIP and TRAF family proteins 
lead to the activation of IKK (Hayden and Ghosh, 2012). However, while the TRAF family 
proteins are required in both the canonical and non-canonical pathways, the RIP family is 
selectively used in the canonical pathway. Similarly, Tgf-β-activated kinase 1 (TAK1) is 
generally accepted as an IKK kinase of the canonical pathway. All of these regulatory aspects of 
NF-κB signaling are to control for the multiple functions of NF-κB, which are discussed in the 
next section. 
 
4.1.2. Functions of NF-κB in the nervous system 
NF-κB has a wide array of cellular functions, including stress and immune responses, 
differentiation, proliferation, apoptosis and cell survival. Moreover, its diverse functions extend 




synaptic plasticity, behavior, and cognition. In addition, recent literature in the field has revealed 
NF-κB’s role in various neurodegenerative diseases, such as Alzheimer’s, Parkinson’s, and 
Huntington’s diseases, proving it to be a highly versatile molecule.  
A wide array of stimuli activate NF-κB in the immune system as well as in the nervous 
system, such as cytokines (e.g. tumor necrosis factor alpha [TNF] and interleukin-1), 
chemokines, lipopolysaccharide, HIV, oxidative stress caused by SOD, and nitric oxide (Memet, 
2006). Additionally, certain stimuli activate NF-κB only in the nervous system. These stimuli are 
neurotrophins (NGF and S100), neurotransmitters (glutamate, metabotropic glutamate receptor 
type 5 agonists), membrane depolarization, synaptic activity, amyloid  peptide, neural cell 
adhesion molecule, and sleep deprivation (Memet, 2006).  
For the activation of NF-κB, types of host cells, dimers, and the specificity of stimulus all 
play an important role. For example, while interleukin-1 induces activity only in astrocytes 
(Srinivasan et al., 2004), glutamate activates NF-κB p65/p50 only in neurons (Kaltschmidt et al., 
1995). Activation of NF-κB in neurons is also triggered by several cascades including the 
p21/ras phosphatidylinositol-3-kinase (PI3K) AKT, protein kinase C and calcium-calmodulin-
dependent kinase II (Memet, 2006). NF-κB activity in the nervous system, on the other hand, can 
be negatively regulated by a number of molecules, such as Tgf-, glycogen synthase kinase-3, 
interleukin-4, interleukin-10, and glucocorticoids. Subsequently, some of the well-known target 
genes of NF-κB in the nervous system are the neural cell adhesion molecule, inducible nitric 
oxide synthase, amyloid  precursor protein (APP), -secretase (BACE, which is the first and 
rate-limiting enzyme for APP cleavage), BDNF, inducible cyclooxygenase-2, and 




One of the main associations of NF-κB in the nervous system has been in 
neurodevelopment. In fact, increase in NF-κB binding activity has been reported to occur during 
nervous system development. During embryogenesis, NF-κB activity was detected in the central 
nervous system as early as E12.5 in the spinal cord and certain nuclei of the rhombencephalon 
(i.e. portions of the central nervous system that includes the medulla, pons, and cerebellum) of 
transgenic mice expressing the reporter gene lacZ under the control of κB sites from the p105 
gene (Schmidt-Ullrich et al., 1996). Moreover, during neural development, NF-κB signaling has 
been found to promote neurogenesis (Denis-Donini et al., 2008) and the growth of neuronal 
processes of maturing neurons (Gutierrez et al., 2005; Koulich et al., 2001; Lezoualc'h et al., 
1998; Maggirwar et al., 1998; Middleton et al., 2000), as well as cell differentiation and survival 
(Bhakar et al., 2002; Chiarugi, 2002; Koulich et al., 2001; Maggirwar et al., 1998; Middleton et 
al., 2000) through regulation of Bcl-2-family antiapoptotic genes (Bhakar et al., 2002; Chiarugi, 
2002). Signaling via CNTF- and NGF-p75
NTR
-, but not BDNF-mediated signaling, has been 
shown to be responsible for the NF-κB-dependent survival of developing embryonic neurons 
(Hamanoue et al., 1999; Middleton et al., 2000).  
In addition to having a role in neurodevelopment, NF-κB is considered to be a participant 
in synaptic plasticity. It has been proposed that synaptic plasticity leads to information storage as 
a result of glutamate release from the presynaptic site followed by a modification of the 
presynaptic release process (Routtenberg, 2000). This process requires a retrograde messenger 
that travels along the axon to turn on gene expression in order to replenish the presynaptic 
protein supply. NF-κB is thought to be involved in this process of synaptic plasticity. Evidence 




which contain presynaptic proteins that are sealed and stabilized by postsynaptic density 
(Kaltschmidt et al., 1993); (2) NF-κB activation in mouse hippocampus by long-term 
potentiation, in rat amygdala by fear-potentiated startle, and in crab brain after retrieval (Memet, 
2006); and (3) blocking long-term potentiation induction in the hippocampus and amygdala 
through inhibition of NF-κB using a κB decoy DNA, as well as ablation of TNF signaling 
pathway in TNFR
-/- 
mice (Collister and Albensi, 2005). 
Research in the field suggests that NF-κB also plays a role in memory formation, 
cognition, and behavior. Use of κB decoy DNA indicated the involvement of NF-κB in long-
term retention of fear memory in rats, inhibitory avoidance long-term memory and spatial long-
term memory in the Morris water maze task in mice (Memet, 2006). More specifically, deficits 
of contextual fear memory were found in mice lacking c-Rel. These deficits impaired anxiety 
responses seen in p50-deficient mice, while mice lacking p65 demonstrated deficits in spatial 
memory (Marini et al., 2007). Altogether, these various studies indicate that NF-κB activation is 
essential for the mechanisms of long-term memory formation, especially those requiring the 
hippocampus. 
Besides its role in synaptic plasticity and memory, NF-κB has been shown to promote 
neuronal death as well as to protect against it. For example, global ischemia was demonstrated to 
activate p50/p65 dimers in neurons of rats, mice, and humans, where this activation of dimers 
has been shown to promote cell death (Memet, 2006). Similarly, NF-κB was found to modulate 
the response of the tumor suppressor protein p53 in neurons with DNA damage and to be 
involved in the cell death process (Aleyasin et al., 2004). TNF pretreatment, on the other hand, 




XL, and the expression of a dominant negative form of IκB has been shown to inhibit the ability 
of TNF to protect hippocampal neurons (Tamatani et al., 1999). A pro-survival role for NF-κB 
has also been seen in the increased neurotoxin-induced damage to neuronal cells of mice lacking 
p50 (Yu et al., 1999).  
Alternatively, activation of NF-κB in glial cells (especially in microglia and astrocytes) 
has been suggested to indirectly promote neuronal death, since NF-κB activation in both 
astrocytes and microglia results in the production of inflammatory mediators, including 
chemokines and cytokines, such as TNF, interleukin-1, interleukin-6, and matrix 
metalloproteinase-9. Interestingly, NF-κB has a prosurvival role in oligodendrocytes and 
promotes maturation of oligodendrocyte progenitor cells (Memet, 2006). Similarly, NF-κB has 
been shown to play a major role in the differentiation of Schwann cells into cells exhibiting the 
myelinating phenotype in the peripheral nervous system (Nickols et al., 2003).  
All of these studies suggest that NF-κB’s role in cell survival or death is cell-context and 
stimulus specific. In fact, it is suggested that while p50/65 dimers are more responsive to 
environmental neurotoxic signals and can drive gene programs leading to neuronal cell death, the 
activation of c-Rel-containing dimers is triggered by neuroprotective signals and increases 
neuronal resistance to stressful conditions by inducing the expression of anti-apoptotic genes 
(Pizzi and Spano, 2006) [Figure 4.4]. 
Finally, the NF-κB signaling pathway is altered in several chronic neurodegenerative 
diseases, including Alzheimer’s, Parkinson’s, and Huntington’s diseases, as well as ALS. For 
example, increased p65 immunoreactivity has been found in both neurons and glial cells of 




Alzheimer’s disease patients (Memet, 2006), suggesting increased NF-κB activation in those 
cells. Similarly, a significant increase in 
the nuclear NF-κB staining in cholinergic 
neurons from Alzheimer’s disease 
patients was also observed (Boissiere et 
al., 1997), indicating an association 
between NF-κB activation and the 
process of cholinergic degeneration in 
Alzheimer’s disease. Moreover, exposure 
of cultured neurons to amyloid β-peptide 
or a secreted form of APP has been found 
to induce NF-κB activation, indicating a 
role for proteolytic products of APP in 
NF-κB activation in Alzheimer’s disease 
brain cells (Mattson and Meffert, 2006).  
Inhibition of NF-κB transcriptional 
activity with decoy DNA resulted in 
increased vulnerability of neurons to death induced by APP (Mattson and Guo, 1997). All of 
these studies suggest that the activation of neuronal NF-κB in Alzheimer’s disease may be a 
neuroprotective response against death induced by APP.   
A role for NF-κB in Parkinson’s disease has also been proposed. For example, a 70-fold 
increase in dopaminergic neurons exhibiting p65 immunoreactivity was observed postmortem in 
Figure 4.4: Diverse NF-κB complexes can be 
involved in opposite effects on neuronal 
survival 
 
The activation of different NF-κB dimers may have opposite 
effects on neuronal survival by either promoting or 
protecting against degeneration, taken from Pizzi and Spano 
(2006). While p50/65 dimers are necessary for glutamate- 
(NMDA) and amyloid  (A)-induced cell death program, c-
Rel containing dimers (p50/c-Rel and p65/c-Rel) have been 
shown to mediate pro-survival effects of interleukin-1 (IL-
1), mGlu5 receptor agonist CHPG, and S100B. The c-Rel 
dependent anti-apoptotic pathway includes the expression of 
anti-apoptotic genes, such as MnSOD and Bcl-XL, which are 
responsible for neuroprotection. ROS: reactive oxygen 




the brains of Parkinson’s disease patients. Moreover, NF-κB has been described as either 
promoting or delaying dopamine-induced apoptosis in PC12 cells (Memet, 2006). On the other 
hand, contrary to Alzheimer’s disease, in Huntington’s disease, NF-κB was found to regulate the 
polyglutamine-induced neurodegeneration (Memet, 2006). Wild-type Huntingtin protein, whose 
loss of normal function caused by the expansion of a polyglutamine tract results in Huntington’s 
disease, has been shown to stimulate the transport of NF-κB out of dendritic spines and supports 
a high level of active NF-κB in neuronal nuclei (Marcora and Kennedy, 2010). Marcora et al. 
(2010) have further shown that this NF-κB-related function of Huntingtin is impaired by its 
polyglutamine tract expansion, which suggest that NF-κB activation might contribute to 
neurodegeneration observed in Huntington’s disease. Similar to other cellular contexts in the 
nervous system regarding neuronal survival or death, NF-κB is involved in the pathogenesis of 
different neurological disorders, either by mitigating or promoting these disorders. Thus, in order 
to find therapeutic solutions to these diseases, the perspective agents should be cell-type selective 
in their actions.  
 
4.1.3. NF-κB’s role in ALS 
In addition to Alzheimer’s, Parkinson’s, and Huntington’s diseases, NF-κB has also been 
associated with ALS in numerous studies. For example, NF-κB was found to be among the most 
up-regulated genes in a gene expression profile of degenerating spinal motor neurons isolated 
from autopsied patients with sALS (Jiang et al., 2005a). This finding was confirmed by several 
other groups studying motor neurons autopsied from human ALS patients, as well as motor 




the findings on NF-κB related to ALS have been somewhat conflicting on whether NF-κB has a 
pro-survival or pro-death role on motor neurons. Some of these findings are discussed below.  
Table 4.1: Expression of NF-κB in existing motor neuron gene array data 
Study Species/ 
System 
Platform Comparison NF-κB expression 




4.8K Array sALS vs. Ctrl NF-κB p65 is one of the most 
up-regulated genes in ALS 
MNs (18
th
, w/ 4.52 fc) 
(Kirby et al., 
2005) 
NSC34 Cells Affy 
U74Av2A 
Array 
WT SOD1 vs. 
G93A SOD1 
IκBα is one of the most 
down-regulated genes in 




Rat E14 SC 
MN LCM 
Affy Rat 230 
v 2.0 
WT SOD1 vs. 
G93A SOD1 
NF-κB p65 is slightly higher 








G93A vs. WT 
SOD1 at 60, 90, 
120 days 
NF-κB p65 expression is 
about the same at 60 days, 
20% higher at 90 days, 50% 
higher at 120 days in G93A 
MNs 





Exon 1.0 ST 
sALS vs. Ctrl  NF-κB p65 expression is 40% 
higher in sALS MNs 







fALS vs. Ctrl NF-κB p65 expression is 
about the same  




fALS vs. Ctrl NF-κB p65 expression is 
about the same  
 
The expression of NF-κB in existing gene array studies that were performed on motor neurons either from human 
ALS patients or transgenic rodents expressing mutant SOD1. Overall, NF-κB p65 expression is slightly higher in 
ALS motor neurons. MN: motor neuron; LCM: laser capture microscopy; SC: spinal cord; Affy: Affymetrix; sALS: 




Evidence suggesting the pro-survival role of NF-κB is the following: In riluzole-treated 
mutant SOD1 mice, increased nuclear expression of NF-κB was observed. Moreover, a 
pharmacological histone deactylase inhibitor, sodium phenylbutyrate, which was shown to 
significantly extend survival of mutant SOD1 mice, was also shown to induce the nuclear 
expression of NF-κB, the phosphorylated IκB, and the anti-apoptotic Bcl-2 (Ryu et al., 2005). 
This suggests that the pharmacological induction of NF-κB-dependent transcription is 
neuroprotective in mutant SOD1 mice. Similarly, the administration of another neuroprotective 
agent, EGCG, to mutant transgenic mice also caused an increase in the expression of nuclear NF-
κB. These findings propose a pro-survival role for NF-κB, especially given its known anti-
apoptotic target genes, such as the X-linked inhibitor of apoptosis (Xiap) and Bcl-2. However, all 
of these data were found through pharmacological means and do not allow one to conclude with 
certainty that NF-κB is neuroprotective in ALS.  
 On the other hand, the data supporting the pro-death role of NF-κB appear more 
compelling. First of all, motor neuron-neuroblastoma hybrid cells that express mutant SOD1 
were found to be more vulnerable to glutamate excitotoxicity and to show higher NF-κB activity 
and nuclear c-Rel expression in comparison to the hybrid cells that express wild-type SOD1 (Pyo 
et al., 2010). Furthermore, this same group demonstrated that glutamate treatment decreased 
Xiap expression and increased caspase-3 activity in mutant SOD1 hybrid cells (Pyo et al., 2010). 
Others have reported that treatment with a pharmacological peroxisome proliferators-activated 
receptor gamma agonist, pioglitazone, which is thought to block NF-κB, extended survival in 
mutant SOD1 mice, as well as reducing the expression of induced nitric oxide synthase, NF-κB, 




shown to be involved in the glutamate-induced spinal cord motor neuron death through TNF 
potentiation in ALS, where increased extracellular glutamate levels caused by co-exposure to  
TNF and glutamate-uptake inhibitor threohydroxyaspartate were prevented by NF-κB 
inhibition in spinal cord motor neurons (Tolosa et al., 2011).  
 More importantly, NF-κB has been associated with motor neuron death in the context of 
different forms of ALS. Maruyama et al. (2010) identified mutations in OPTN in patients with 
fALS or sALS. The authors demonstrated that nonsense and missense mutations of OPTN 
eliminated the inhibition of NF-B, indicating that NF-B inhibitors might be useful to treat 
ALS. Moreover, in patients with sALS or OPTN-ALS, the expression pattern of NF-κB was 
altered when compared to that of normal controls, where NF-κB immunoreactivity tended to be 
absent from neuronal nucleus and was increased in microglia (Sako et al., 2012). Similarly, a 
recent study by Swarup et al. (2011) showed that TDP-43 and p65 expression is higher in spinal 
cords of ALS patients. Moreover, the group demonstrated that TDP-43 interacts and co-localizes 
with p65 in glial and neuronal cells from ALS patients, as well as in mice expressing wild-type 
and mutant TDP-43, but not in cells from healthy individuals or non-transgenic mice (Swarup et 
al., 2011). Interestingly, this group showed that when the mutant TDP-43 mice were treated with 
an NF-B activity inhibitor, they observed reduced denervation in the neuromuscular junction 
and delayed ALS disease symptoms, suggesting that TDP-43 deregulation contributes to the 
ALS pathogenesis by enhancing NF-B activity. Furthermore, FUS has been found to be a co-
activator of NF-B (Uranishi et al., 2001) and mutant VCP increase NF-B activity (Custer et 




 Finally, an in vivo study has been performed by knocking-down the expression of NF-B 
in astrocytes and studying the effects in mutant SOD1 mice. Because astrocytes become reactive 
in transgenic mice expressing mutant SOD1, and hence, supposedly, release cytokines and nitric 
oxide, it was suggested that NF-B might be mediating some of the inflammatory events seen in 
these mice. To test this hypothesis, Crosio et al. (2011) generated double transgenic mice 
expressing the mutant SOD1
G93A 
ubiquitously and the dominant negative form of IB in 
GFAP-expressing cells only. These investigators found no effect on the age of onset of disease 
manifestations or disease progression (Crosio et al., 2011).  
While this study suggests that NF-B expression in astrocytes might not be involved in 
the ALS disease process, it may be prudent to take this conclusion with caution for the following 
reasons: (1) the GFAP promoter, which was used here to drive the expression of mutant IB, is 
known to be a weak promoter, unless astrocytes are activated, which does not occur in a 
conspicuous manner in asymptomatic mutant SOD1 mice. Instead, Aldh1l1 might have been a 
better promoter to use in this study. (2) The study never showed how much inhibition in the 
activity of NF-B was observed in the animals and which subunits were specifically targeted. 
The latter is especially important, since compensatory pathways (e.g. non-canonical versus 
canonical) might have been recruited, e.g. the activation of p52 instead of p50 to form a dimer 
with p65, which is a very common phenomenon. (3) Since the toxic stimulus through mutant 
SOD1 is persistent, alternative inflammatory pathways might have been activated in mice that 
caused the disease to occur in its usual progression.  
All of these data suggest that NF-B may constitute a therapeutic target for different 




functions of NF-B, it is important to investigate its differential activity and pathological 
significance in the well-controlled model system that is used here and to see which dimers and 
pathways are specifically activated. Results for this are discussed below.  
 
4.2. Results 
4.2.1. The canonical NF-κB pathway is activated in motor neurons exposed to mutant 
astrocyte-conditioned medium 
As indicated above, the NF-B pathway is subdivided into two different pathways, the canonical 
and non-canonical pathways, which are composed of specific dimer groups that are related to 
different functions associated with the particular pathway. Therefore, it is important, in the 
investigation of the differential activity of NF-B in our model system, to know which pathway 
and which subunits are specifically activated. Accordingly, the first step was to quantify the 
DNA-binding activity of different NF-B subunits in purified embryonic stem cell-derived 
motor neurons exposed to mutant versus wild-type astrocyte-conditioned medium for different 
lengths of time using the TransAM assay (Active Motif), which is a highly sensitive enzyme-
linked ELISA-based assay.  
Unlike other methods that are used to study the activity of NF-B, such as gel-shift 
assays, immunostaining and Western blot, the TransAM assay does not limit its investigation of 
NF-B subunit activity to the subunit nuclear localization, but instead looks specifically for the 
active form of transcription factor in the nuclear extract of cells through antibody binding. 
Specifically, when the nuclear extracts of motor neurons are added to the assay, which 




transcription factors bind the oligonucleotides at their consensus binding sites and are quantified 
using the included antibodies that are specific to the bound and active form of the transcription 
factors. This aspect of the TransAM assay makes it a more precise method to measure NF-B 
subunit DNA-binding activity, since it has been shown that NF-B may sometimes be bound to 
IB and be inactive, even if it is located in the nucleus (Hayden and Ghosh, 2012). Moreover, 
the Ghosh group has also recently found that the translocation of NF-B to the nucleus is not 
sufficient to drive the transcription of target genes. The specific phosphorylation of p65 is also 
required for both efficient DNA-binding and transcription activity of nuclear NF-B (Hayden 
and Ghosh, 2012). Thus, nuclear localization of NF-B does not directly correspond to its 
binding activity. 
Consequently, the TransAm assay was performed on motor neurons exposed to mutant 
versus wild-type astrocyte-conditioned medium for 0, 24, 48, 72, and 168 hours for four NF-B 
subunits: p65, p50, p52, and RelB; an antibody for c-Rel was not available for mouse and thus  
could not be tested. Following this assay, a significantly higher binding activity for p65 was 
found in nuclear extracts of purified embryonic stem cell-derived motor neurons exposed to 
mutant astrocyte-conditioned medium for 24, 48, and 72 hours [Figure 4.5a]. Similarly, a 
significantly higher binding activity was observed for p50 in nuclear extracts of purified 
embryonic stem cell-derived motor neurons exposed to mutant medium for 24 hours [Figure 
4.5a]. Interestingly, after 168 hours of exposure to mutant medium, this binding activity went 
down to levels similar to that in nuclear extracts of motor neurons exposed to wild-type 
astrocyte-conditioned medium [Figure 4.5a], a time when all of the sensitive cells had died. This 




dying or that they are activated only in the subpopulation of motor neurons that are vulnerable. 
Finally, no significant binding activity was observed for NF-B subunits p52 and RelB [Figure 
4.5b], which belong to the non-canonical pathway. These results imply that the canonical 
pathway is activated in motor neurons exposed to mutant astrocyte-conditioned medium, in a 
time-dependent manner. As shown in Figure 4.5, p65 especially responds to the toxic signal 




Figure 4.5: The canonical NF-κB pathway is activated in motor neurons exposed to 
mutant astrocyte-conditioned medium 
 
The TransAM assay demonstrates that the NF-κB subunits belonging to (A) the canonical pathway (p65 and 
p50) have a significantly higher DNA-binding activity in motor neurons that were exposed to transgenic (Tg) 
mutant SOD1 astrocyte-conditioned medium vs. non-transgenic (NTg) medium for 24, 48, and 72 hours. The 
NF-κB subunits belonging to (B) the non-canonical pathway, p52 and RelB, on the other hand, did not show any 
significant DNA-binding activity. The optical density (OD) values were normalized to the OD of motor neurons 
exposed to NTg astrocyte-conditioned medium for 0 hours. Values represent mean ± s.e.m from three 




4.2.2. NF-κB is localized more in the nuclei of motor neurons exposed to mutant astrocyte-
conditioned medium 
Next, came the confirmation of the differential activity of p65 in motor neurons by performing 
subcellular fractionation on motor neurons exposed to mutant versus wild-type astrocyte-
conditioned medium and testing to see whether an increased nuclear localization of p65 is 
observed using Western blot. In three independent experiments, an increase in the nuclear 
content of p65 was observed in motor neurons exposed to mutant astrocyte-conditioned medium 
for 24, 48, and 72 hours [Figure 4.6]. While this experiment confirmed what was observed in the 
Figure 4.6: Increase in nuclear NF-κB expression in motor neurons exposed to 
mutant astrocyte-conditioned medium 
 
There is an increase in the nuclear expression of NF-κB p65 in motor neurons exposed to mutant 
transgenic (T-Tg) vs. non-transgenic (N-NTg) astrocyte-conditioned medium (ACM) for 24, 48 and 72 
hours, using Western blot. In this study, GAPDH is used as a cytoplasmic and Histone H3 as a nuclear 
marker. The NF-κB protein amount expression was measured by normalizing each value to its 
corresponding amount of NTg ACM. NF-κB ctrl was a cell extract provided from Cell Signaling to test 
the p65 antibody. Values represent mean ± s.e.m from three independent experiments, analyzed by 




TransAM assay, the amount of increase in nuclear p65 in motor neurons exposed to mutant 
medium was not the same as the amount of increase in the p65 binding activity in nuclear 
extracts of motor neurons exposed to mutant medium (about 1.5 fold increase in Western blot 
versus 4 fold in the TransAM assay). This may be due to the greater sensitivity of the TransAm 
assay versus Western blot, as well as the possibility that there is a certain amount of inactive p65 
in the nuclei of motor neurons that were exposed to wild-type astrocyte-conditioned medium that 
was not detected by the TransAM assay, since the assay specifically measures the binding 
activity, which was not the case with Western blot. 
 
4.2.3. Phosphorylated IκB is increased in motor neurons exposed to mutant astrocyte-
conditioned medium 
After the demonstration that the NF-B canonical pathway is differentially activated in motor 
neurons exposed to mutant astrocyte-conditioned medium, as evidenced by the TransAM assay 
and p65 nuclear localization, the question of how much phosphorylated IB was present in 
purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-conditioned 
medium arose. This was an important to know for validation, because IB is the main inhibitor 
of NF-B dimers in the canonical pathway and its phosphorylation is key to its ubiquitination 
and degradation, which is necessary for the nuclear localization and activation of NF-B dimers. 
Therefore, the amount of phosphorylated IB is an upstream marker for active NF-B 




Figure 4.7: Increase in expression of 
phosphorylated IκB in motor neurons 




p-IB - 40 kDa 
β-actin - 42 kDa 
 0hr        24hr             48hr             72hr               168hr       
 FM    NTg   Tg      NTg    Tg      NTg    Tg      NTg    Tg 
  
IB - 39 kDa 
Purified ES-MN  
(mean ± SEM; n=4)  
There is an increase in the expression of phosphorylated 
IκB (p- IκB) in motor neurons exposed to mutant (Tg) vs. 
non-transgenic (NTg) astrocyte-conditioned medium 
(ACM) for 24, 48 and 72 hours, using Western blot. In 
this study, -actin is used as a loading control. The 
phosphorylated IκB protein expression was measured by 
normalizing each value to its corresponding amount of 
IκB. FM: motor neurons in fresh media used as a 
negative control. Values represent mean ± s.e.m from 
four independent experiments, analyzed by Student’s t-
test.  
Using Western blots of motor 
neuron extracts, in three independent 
experiments, it was observed that there is 
an increase in phosphorylated IB in 
purified embryonic stem cell-derived motor 
neurons that are exposed to mutant 
astrocyte-conditioned medium for 24, 48, 
and 72 hours in comparison to motor 
neurons exposed to wild-type medium 
[Figure 4.7]. Similar to what was observed 
in the TransAm assay, this increase was 
slightly higher after 24 hours versus 72 
hours of mutant medium exposure, and the 
expression was completely absent after 168 
hours of exposure to mutant astrocyte-
conditioned medium [Figure 4.7]. These 
results suggested one more time that the 
canonical pathway of NF-B activity is up-






4.2.4. IKK inhibitor rescues motor neurons exposed to mutant astrocyte-conditioned 
medium  
Even though we confirmed that the NF-B canonical pathway is differentially activated in 
purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-conditioned 
medium, more needed to be done to reach a firm conclusion about the pathological significance 
of NF-B in this model system of ALS. Therefore, the effect of inhibiting NF-B activity was 
investigated in purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-
conditioned medium by blocking the upstream IKK activity with a pharmacological inhibitor of 
IKK, and then assessing the change this inhibition causes in the survival of motor neurons. In 
doing so, depending on the changes in the number of motor neurons after the cell survival 
assessment, we could determine whether NF-B promotes or protects against motor neuron 
death.    
To do this investigation, Wedelolactone (Calbiochem), a cell-permeable, selective, and 
irreversible inhibitor of IKK and  kinase activity, that inhibits NF-B-mediated gene 
transcription by blocking the phosphorylation and degradation of IB, was used at 
concentrations ranging from 50 nM to 5 M. Starting at concentrations from 500 nM, the 
addition of Wedelolactone to purified embryonic stem cell-derived motor neurons exposed to 
mutant astrocyte-conditioned medium rescued these neurons fully in our in vitro model [Figure 
4.8]. Similarly, the addition of 1 µM Wedelolactone to purified embryonic stem cell-derived 
motor neurons exposed to mutant astrocyte-conditioned medium also fully rescued these neurons 
(data not shown). All of these results were confirmed by five independent experiments. While 




Figure 4.8: IKK inhibitor rescues motor 
neurons exposed to mutant astrocyte-
conditioned medium 
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The treatment with IKK inhibitor, Wedelolactone, 
rescues motor neurons exposed to mutant astrocyte-
conditioned medium (ACM) starting from 500 nM. In 
this study, purified embryonic stem cell-derived motor 
neurons exposed to either mutant (Tg) or non-
transgenic (NTg) ACM were treated with 
Wedelolactone at concentrations 50 nM, 200 nM, 500 
nM, and 5 M at their first day in vitro. After seven 
days in vitro, the motor neurons were fixed and their 
survival was assessed using immunostaining. This 
experiment was repeated five times for the 
Wedelolactone concentrations 50 nM, 500 nM, and 5 
M, and three times for the 200 nM concentration. All 
the values represent the number of neurons as 
percentage of NTg ACM, with mean ± s.e.m from at 
least three independent experiments, analyzed by 
Student’s t-test. The values in pink are the p-values.  
 
mild rescue effect on motor neurons exposed to mutant astrocyte-conditioned medium [Figure 
4.8], suggesting a half maximal inhibitory concentration of the pharmacological inhibitor 
compound in our culture model. Overall, this experiment showed that the loss of NF-B activity 
rescues motor neurons exposed to mutant 
astrocyte-conditioned medium, indicating 
that increase in NF-B activity regulates the 
ALS-linked mutant astrocyte toxicity for 
motor neurons.  
 
4.2.5. IKK inhibitor does not rescue motor 
neurons from other toxicities 
Using a pharmacological inhibitor to 
investigate the pathological significance of 
NF-B brought up a concern about the 
specificity of its effect on motor neurons, 
since pharmacological agents often exert non-
specific effects. Wedelolactone was 
previously shown to have no effect on non-
NF-B pathways, such as p38, MAPK, and 
AKT pathways (Kobori et al., 2004). 
However, to ensure that the protection of 




astrocyte-induced toxicity, motor neurons were exposed to two other death stimuli that are 
known to kill motor neurons, namely Fas ligand and domoic acid, via a non-NF-B-dependent 
mechanism. 
As explained in the Introduction, Raoul et al. (2002) found that 48 hours after treatment 
with Fas ligand primary motor neurons showed 50% loss in vitro. This cell-autonomous motor 
neuron death was mediated by Ask1, p38, and neuronal nitric oxide synthase signaling (Raoul et 
al., 2002). Similarly, domoic acid, an excitotoxin that is an agonist of the non-N-methyl-D-
aspartate (non-NMDA) AMPA kainate receptor, was also shown to cause about 40% loss in 
motor neurons through an increase in reactive oxygen species, but not through NF-B signaling 
(Xu et al., 2008).  
To perform this investigation, first tested was the effectiveness of Wedelolactone on 
primary motor neurons, from E12.5 mice, that were exposed to mutant astrocyte-conditioned 
medium, since Fas receptor (to which Fas ligand binds to) is not completely formed in 
embryonic stem cell-derived motor neurons. We found that, similar to its effect on purified 
embryonic stem cell-derived motor neurons, Wedelolactone showed a full rescue on primary 
motor neurons that were exposed to mutant astrocyte-conditioned medium [Figure 4.9a].  
Once the effect of Wedelolactone was established on primary motor neurons exposed to 
mutant astrocyte-conditioned medium, primary motor neurons were treated next, in fresh motor 
neuron medium, with Fas ligand and domoic acid, with or without Wedelolactone. We found 
that, by 48 hours of exposure, motor neurons treated with Fas ligand or domoic acid showed 
about 40% loss in comparison to the neurons kept in fresh medium with no treatment [Figure 




Figure 4.9: IKK inhibitor does not rescue 
motor neurons from other toxicities 
 
The IKK inhibitor does not protect motor neurons 
(MNs) from other toxicities whose mechanisms do not 
include NF-B. For this study, primary MNs were 
used, (A) where first tested was the protective effect 
of Wedelolactone (5µM) on MNs that were exposed 
to mutant (Tg) vs. non-transgenic (NTg) astrocyte-
conditioned medium (ACM). (B) Once the effect was 
confirmed, primary MNs, kept in fresh medium for 
five days in vitro, were either treated with Fas ligand 
(10ng/ml) or domoic acid (1µM), where after 48 
hours; they showed about 40% demise in comparison 
to the MNs that were kept in fresh medium without 
treatment. The MNs that were treated with Fas ligand 
or domoic acid, in addition to Wedelolactone at four 
days in vitro, were fully rescued. Ctrl: control where 
Wedelolactone is not added. All the values represent 
number of surviving MNs as percentage of NTg ACM 
or fresh media control with mean ± s.e.m from three 
independent experiments, analyzed by Student’s t-test. 
The values in pink are the p-values.   
 
neurons. Next, we showed that there was no rescue effect on motor neurons that were treated 
with Wedelolactone once Fas ligand or domoic 
acid was added to them [Figure 4.9b]. This 
study was repeated for three independent 
experiments, all with the same results, 
suggesting that Wedelolactone has a motor 
neuron rescue effect specific to mutant 
astrocyte-derived toxicity. 
 
4.2.6. Super repressive IκB viral vector 
rescues motor neurons exposed to mutant 
astrocyte-conditioned medium 
Since Wedelolactone is a pharmacological 
inhibitor and can have non-specific effects, 
even though the specificity of its motor neuron 
rescue effect on other toxicities was tested, we 
wanted to investigate further the effect of loss 
of NF-B activity on motor neurons using 
another method: a dominant negative adeno-
associated viral vector expressing super 
repressive IB. Mutations in IB serines 32 








phosphorylation and the degradation of the IB, where the infected mutant IB competes with 
endogenous IB molecules in the cell to block NF-B activation (Magne et al., 2006). This 
mutant molecule is therefore referred to as a super repressive IB. By infecting motor neurons 
with the viral vector expressing this mutant molecule, the aim was to block NF-B activity in 
motor neurons.  
For an efficient infection of purified embryonic stem cell-derived motor neurons with 
proper inhibition of NF-B activity, different titrations of the adenovirus at varying multiplicities 
of infection (MOI) were tested first using an adenovirus titration kit (Clontech). This kit was 
designed around a hexon-specific antibody, which was used to label infected cells. The hexon 
protein is encoded by the adenoviral genome and is an essential component of the adenoviral 
capsid required for adenoviral replication. Thus, only the infected cells produce the hexon 
protein, which is then labeled and utilized to count infected cells. Using this kit, purified 
embryonic stem cell-derived motor neurons were found to exhibit about a 100% infection rate 
starting from 50 MOI (data not shown). The virus was toxic to the cells starting from 150 MOI 
(data not shown), providing us with a very narrow infection window to work with.  
Making use of this titration data, next tested was the effect of the super repressive viral 
vector on the amount of phosphorylated NF-B in motor neurons, since a decrease in the NF-B 
activity would result in the decrease in the amount of phosphorylated NF-B. Infection with the 
viral vector (at 50 and 100 MOIs) showed a significant decrease in the amount of phosphorylated 
NF-B in purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-
conditioned medium in comparison to those infected with viral vectors expressing green 




Figure 4.10: Super repressive IB viral 
vector decreases the amount of 
phosphorylated NF-B in motor neurons 
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The adeno-associated viral vector expressing super 
repressive IB (IBSR) blocks NF-B activity by 
decreasing the amount of phosphorylated NF-B (p-NF-
B) in purified embryonic stem cell-derived motor 
neurons exposed to mutant (Tg) vs. non-transgenic 
(NTg) astrocyte-conditioned medium (ACM) for 24 
hours in comparison to motor neurons infected by viral 
vector expressing green fluorescent protein (GFP) only, 
using Western blot. In this study, -actin is used as a 
loading control. The phosphorylated NF-B protein 
expression was measured by normalizing each value to 
its corresponding amount of NF-B. Values represent 
mean ± s.e.m from three independent experiments, 
analyzed by Student’s t-test.  
 
decrease in the amount of phosphorylated NF-B in motor neurons [Figure 4.10], corresponding 
to the partial viral vector infection observed 
in the cells. This study confirmed the 
functional effect of the super repressive IB 
viral vector blockade of NF-B activity in 
motor neurons. 
Finally, the effect of this viral vector 
on the survival of motor neurons was tested 
to see whether the loss of NF-B activity 
would rescue motor neurons exposed to 
mutant astrocyte-derived toxicity as shown 
using Wedelolactone. To test this 
hypothesis, we infected purified embryonic 
stem cell-derived motor neurons exposed to 
mutant astrocyte-conditioned medium with 
viral vectors expressing either green 
fluorescent protein only or with super 
repressive IB. In three independent 
experiments, we observed an almost full 
rescue effect on motor neurons that were 




medium and infected with viral vectors expressing super repressive IB (at 50 MOI) [Figure 
4.11]. Similar to what was observed in the study with the Wedelolactone treatment, this study 
showed that the loss of NF-B activity via the infection with super repressive IB viral vector 
rescues motor neurons from toxicity 
emanating from mutant astrocytes, 
indicating that NF-B regulates the mutant 
astrocyte-derived motor neuron death in this 
model system of ALS.  
                                                                                                                                                                                                
4.3. Conclusion & Discussion 
This section of the thesis confirmed that 
NF-B, which was one of the top 25 
transcription factors inferred by the Master 
Regulator Analysis performed on the 72 vs. 
0 hour signature from the RNA-Seq data, 
regulates the ALS-linked mutant astrocyte 
toxicity for motor neurons. Despite its 
complex regulatory and stimulus-selective 
response mechanisms, an increase in NF-B activity was demonstrated in purified embryonic 
stem cell-derived motor neurons exposed to mutant astrocyte-conditioned medium before they 
become committed to die. Moreover, it was shown that this increase in NF-B activity promotes 
motor neuron death and that this activity is specific to the canonical pathway of NF-B involving 
Figure 4.11: Super repressive IB viral 
vector rescues motor neurons exposed to 
mutant astrocyte-conditioned medium 
 
The infection with the adeno-associated viral vector 
expressing super repressive IB (IBSR) vs. green 
fluorescent protein (GFP) rescues motor neurons 
exposed to mutant (Tg) vs. non-transgenic (NTg) 
astrocyte-conditioned medium (ACM). In this study, 
motor neurons were infected with the viral vector one 
day after the addition of ACM, and cell survival was 
assessed after seven days in vitro. All the values 
represent number of surviving motor neurons as 
percentage of NTg ACM with mean ± s.e.m from three 
independent experiments, analyzed by Student’s t-test. 





p65, and to some extent p50. One additional experiment that could be performed is to test the 
super repressive IB viral vector on motor neurons with another stressor, just like we have done 
with Wedelolactone, to test the specificity of the rescue effect of the viral vector on motor 
neurons. 
Even though we saw that NF-B differential activity occurs in motor neurons specifically 
in the canonical pathway through the involvement of p65, p50, and IB in our model system, 
we cannot fully exclude the possibility of the involvement of the non-canonical NF-B pathway. 
That is because there is evidence of cross-talk between the canonical and non-canonical 
pathways involving p65 forming dimers with p52, instead of p50, as a compensatory mechanism. 
Also, while observing no differential activity of p52 and RelB in the TransAM assay, we could 
not measure the binding activity for c-Rel. Thus, no conclusive statement can be made about the 
involvement of c-Rel in the mechanism of non-cell autonomous motor neuron degeneration in 
our model system. However, overall, the canonical pathway seems to be the main pathway that is 
activated in motor neurons exposed to mutant astrocyte-conditioned medium. 
Since it is known that the canonical pathway is involved in mutant astrocyte-derived 
motor neuron death, it would be interesting to investigate the involvement of known molecules 
that are upstream to the IKK complex that activate the canonical NF-B pathway, such as TAK1, 
TRAF6, interleukin-1 receptor associated kinase-1 (IRAK1), and RIP1. The immunology field is 
vast with knowledge on the signalization of the NF-B pathway and this knowledge can be used 
to decipher what is upstream to NF-B in our model system. This is especially true with the help 




preliminary checkpoint to see whether these upstream mediators are present in the RNA-Seq 
data. 
Furthermore, one could use the literature from the immunology field to link NF-B with 
the downstream signalization leading to programmed cell death, which Nagai et al. has shown to 
be activated in motor neurons that are exposed to mutant astrocyte-conditioned medium, such as 
Bax and caspase 3 (Nagai et al., 2007). For example, it has been shown that when the cell 
receives inflammatory stimuli, activated nuclear NF-B transcribes anti-apoptotic Bcl-2 and Bcl-
XL, which then inhibit Bax activation (Hayden and Ghosh, 2012). This finding suggests that NF-
B activation inhibits Bax activation in cell survival-promoting circumstances. However, since 
in our model system, NF-B promotes cell death, its activation might have the opposite effect on 
Bax activation, which needs to be investigated. One way to investigate this hypothesis would be 
to treat motor neurons, exposed to mutant astrocyte-conditioned medium, with Wedelolactone 
and see if the neurons still show increased Bax activation, which can be measured by the 
increase in the translocation of Bax to mitochondria. Similarly, motor neurons could be treated 
with a Bax inhibitor to see if an increase in NF-B activity is still observed. This study may help 
us demonstrate whether or not Bax and NF-B are on the same linear molecular pathway and to 
confirm that NF-B is upstream to Bax in this death cascade.  
Another question that would be interesting to address would be whether NF-B gets 
activated upon exposure to mutant astrocyte-conditioned medium only in sensitive motor 
neurons or also in the resistant subpopulation. In order to investigate this question, we could add 
mutant astrocyte-conditioned medium to motor neurons that are already exposed to mutant 




differentially activated in these cells in comparison to those exposed to wild-type astrocyte 
conditioned-medium. This study would help our understanding of how specific the NF-B 
response is in motor neurons exposed to mutant astrocyte-conditioned medium. 
So far, the pathological significance of NF-B in ALS has been shown only in vitro 
(Swarup et al., 2011). However, it is also important, as a future study, to validate NF-B’s role in 
motor neuron death in vivo. For this, four approaches could be followed: (1) performing a 
longitudinal immunohistochemistry study to look at nuclear NF-B motor neuron expression in 
spinal cords of mutant SOD1
G93A
 mice at pre-symptomatic (i.e. P30, P60), symptomatic (i.e. 
P90), and end-stage (i.e. P120); (2) performing a similar immunohistochemistry study in 
postmortem spinal cords of ALS patients; and (3) generating transgenic mice expressing mutant 
SOD1
G93A 
, which also carry motor neuron-specific null mutations for p65 or NEMO gene, either 
by using the Cre-lox system or gene therapy methods. These double-engineered mice would then 
be used to assess the impact of the p65 or NEMO deletion, only within motor neurons, on the 
survival, onset of disease manifestations, and disease duration caused by mutant SOD1. (4) 
Finally, known inhibitors of NF-B activity, such as celastrol or Withaferin A, can be 
administered to mutant SOD1 mice before the onset of disease symptoms (i.e. P30) and their 
effect on disease duration and survival in these mice could be studied. Performing these in vivo 
studies would further validate the involvement of NF-B in ALS-linked motor neuron 
degeneration.  
Finally, NF-B was only one of the top transcription factors inferred by the Master 
Regulator Analysis. While this endeavor was a success in validating NF-B as a master 




pathological significance of the other transcription factors needs to be investigated, as well. Only 
in doing so, the molecular mechanism underlying the ALS-linked mutant astrocyte toxicity for 





Chapter 5: Conclusion and Discussion 
 
ALS, like many other prominent adult-onset neurodegenerative diseases, such as 
Alzheimer’s and Parkinson’s diseases, is characterized by the demise of specific subsets of 
neurons. Although ALS is essentially a sporadic disorder, the investigations of the rare ALS-
causing genetic mutations, which have been discussed in the Introduction, have led to several 
breakthroughs in our understanding of the neurobiology of this fatal paralytic disorder including, 
but not limited to, protein misfolding, ER stress, and the recruitment of the apoptotic machinery. 
Another key advance in the pathogenesis of ALS is linked to our growing recognition of 
the importance played by non-neuronal cells, such as glia, in the demise of motor neurons. 
Although thus far, this line of investigation relies on mutant SOD1 and in vitro studies, the 
consensus in the field of ALS research is that insights gained via this particular disease model 
system might provide important clues into the pathogenesis of the prominent sALS. In support of 
this idea is the recent work done with human cells from sALS patients, which produced very 
similar results as those generated with mouse mutant SOD1-expressing cells (see below).  
Probably, the most salient results published thus far about the role of glial cells in the 
ALS neurodegenerative process in experimental models are the following. It has been shown that 
the selective reduction of mutant SOD1 by a Cre-Lox system in motor neurons, microglia, or 
astrocytes, prolongs survival in transgenic SOD1
G37R
 mice compared to their germ-line 
littermates (Boillee et al., 2006; Yamanaka et al., 2008b). It has also been shown that transgenic 
mice in which mutant SOD1 is restricted to both motor neurons and astrocytes develop a severe 




Nagai et al. and others (Di Giorgio et al., 2007; Nagai et al., 2007; Vargas et al., 2006) have 
found that astrocytes expressing mutant SOD1 trigger the death of primary and embryonic stem 
cell-derived motor neurons, regardless of whether or not they express mutant SOD1. Nagai et al. 
further showed that the contribution of the mutant astrocytes to the death of motor neurons in 
vitro is caused by a soluble factor (Nagai et al., 2007). Interestingly, medium conditioned with 
mutant SOD1-expressing astrocytes impairs motor neuron survival whereas medium conditioned 
with mutant microglia does not (Nagai et al., 2007). Moreover, Nagai et al. also showed that 
motor neurons are selectively vulnerable to this mutant astrocyte-derived toxic activity, since 
GABAergic interneurons cultured on astrocyte layers or dorsal root ganglion neurons cultured in 
astrocyte-conditioned medium are not affected (Nagai et al., 2007). 
Extending these in vitro mouse cell findings, it has been shown that astrocytes derived 
from neural progenitor cells obtained from postmortem spinal cords of human sALS patients are 
also toxic to spinal motor neurons (Haidet-Phillips et al., 2011). We have confirmed this result 
using human primary astrocytes from sALS patients (data not shown). It has also been reported 
that mutant SOD1-expressing glial-restricted precursors grafted into spinal cords of wild-type 
rats produce motor neuron loss in living animals (Papadeas et al., 2011). Thus, as indicated 
above, these observations provide substantial support to the idea that the toxic phenotype caused 
by ALS astrocytes is not restricted to in vitro systems, to mouse cells, or to fALS. Given these 
facts, we thought that the mutant SOD1 model of non-cell autonomous degeneration of motor 
neurons may be ideal to shed more light into how and why motor neurons degenerate in ALS.  
The goal of this thesis work has thus been to exploit this unique in vitro ALS model of 




non-cell autonomous components of ALS pathogenesis. However, given the minimal success we 
had in addressing this outstanding question using a candidate-based approach, employed here 
was a combination of genomic and bioinformatics methodologies to try to elucidate the 
molecular underpinning of the mutant astrocyte toxicity for motor neurons, especially 
before these neurons become committed to die.  
As shown and discussed in Chapter 2, prior to embarking on the actual genomic analyses, 
it was necessary to further characterize the planned in vitro model to assure that the work could 
be conducted under the most suitable conditions. Since the aim was to study the transcriptional 
alterations that take place in motor neurons in response to the toxic insult emanating from mutant 
astrocytes, it was crucial to use only motor neurons for this work. Nagai et al. has found that 
motor neurons exposed to mutant astrocyte-conditioned medium display the same amount of 
degeneration as the motor neurons co-cultured on mutant astrocyte monolayers (Nagai et al., 
2007). Therefore, it sufficed to expose motor neurons to mutant astrocyte-conditioned medium to 
bring about the toxic phenotype and, as such, to eliminate glial cells from the culture setting. Yet, 
this was not sufficient to assure that we were dealing with motor neurons only, since embryonic 
stem cells differentiated by current protocols only produced about 30% motor neurons; the rest 
being other types of neurons and even non-neuronal cells. Thus, for the efficient purification of 
embryonic stem cell-derived motor neurons, two different methods were tested, namely FACS 
and MACS. Through the work presented in Chapter 2, we found MACS to be the more efficient 
method of the two. Thus, the combination of the mutant astrocyte-conditioned medium and the 
MACS purification method allowed obtaining cultures made up of more than 90% of motor 




Next, we asked what would be the most relevant timepoints, after exposure to mutant 
astrocyte-conditioned medium, to harvest motor neurons and extract their RNA. First, we found 
the timeline of motor neuron degeneration to be quite similar to that previously reported for 
primary non-purified motor neurons (Nagai et al., 2007). Indeed, the number of purified 
embryonic stem cell-derived motor neurons exposed to mutant astrocyte-conditioned medium 
declines by about 50% after 7 days in vitro without further changes up to 14 days in vitro. Worth 
noting is the fact that the incomplete neuronal loss observed after 7 days of exposure to mutant 
astrocyte-conditioned medium cannot be due to the loss of toxic activity of the medium, since we 
found that even if this conditioned medium is changed at 7 days and the motor neurons are 
allowed to remain in culture for an additional 7 days, there is no significant further loss of motor 
neurons. Interestingly, a similar (about 50%) loss of motor neurons was reported by Raoul and 
collaborators (2002) in their study on Fas ligand toxicity in motor neurons. Based on what is 
currently known about the toxic mechanisms driving mutant astrocytes and Fas ligand, these two 
models do not intersect and thus may well operate by very different signaling pathways, at least 
at the proximal level of their respective death cascades. Therefore, it is surmised that about 50% 
of the spared motor neurons epitomize a more resilient subpopulation of motor neurons. Perhaps, 
it may be valuable to design future studies to explore the molecular basis of this differential 
sensitivity, which could be readily extracted from some of the already available genomic 
signatures that have generated during this work. 
Since the purpose of this project has been to elucidate the molecular mechanisms of non-
cell autonomous motor neuron degeneration before motor neurons become committed to die, it 




experiments could be designed to properly capture the intended early molecular events. 
Accordingly, by testing different exposure times, ranging from 24 to 168 hours, we found that at 
around 72 hours of exposure to mutant astrocyte-conditioned medium, motor neurons become 
irreversibly committed to die. Therefore, in light of this information, it was assumed that the 
most significant signatures of early perturbations had to take place in motor neurons no later than 
72 hours of exposure to mutant astrocyte-conditioned medium.  
With the above-mentioned information and the RNA-Seq data for different selected 
timepoints, the early event signatures linked to motor neuron degeneration were extracted by 
performing a reverse gene engineering analysis. This powerful bioinformatics algorithm is 
inferential in nature, since it is based on interrogation of a database which is ideally constructed 
with the information generated from the same species and cell type as the ones used in RNA-Seq 
experiments. Unfortunately, at this time, a mouse motor neuron interactome is not available, 
although we are aware that such an interactome is in development (data not shown). Thus, for the 
time being, all seven interactomes that are available from the Califano group were interrogated. 
As shown in Figure 3.6, of these seven interactomes, the mouse brain interactome was found to 
be the most trustworthy for analyzing the RNA-Seq data. Also, the 72 vs. 0 hour signature was 
found to be the “strongest” signature, because it yielded the highest number of transcription 
factors and differentially expressed genes. These findings were assuring given the fact that the 
aim was to focus on molecular events up to 72 hours.  
Next, to validate the significance of the master regulators inferred by the mouse brain 
interactome using the 72 vs. 0 hour signature in Chapter 3, particular attention was given to the 




Table 3.4.) Of the 25 selected master regulators, NF-B was especially intriguing. This was not 
only because NF-B was one of the top master regulators, most differentially expressed genes, 
and most enriched pathways, but also recent discoveries in ALS research have hinted at its 
dysregulation in the disease process. For example, NF-B was found to be up-regulated in sALS 
patients (Jiang et al., 2005b) and in transgenic mutant SOD1 mice (Ferraiuolo et al., 2007). 
Moreover, NF-B has been found to be involved in the TDP-43- and OPTN-linked ALS 
pathogenesis (Maruyama et al., 2010; Swarup et al., 2011). All of these findings render NF-B a 
very interesting master regulator candidate to investigate in relation to its pathological 
significance in ALS. 
Thus, as shown in Chapter 4, the significance of NF-B was validated in our in vitro ALS 
model of non-cell autonomous motor neuron degeneration. Using a DNA binding assay, 
subcellular fractionation and Western blot, a time-dependent increase of NF-B activity was 
noted in purified embryonic stem cell-derived motor neurons exposed to mutant astrocyte-
conditioned medium. This activity culminated prior to 72 hours of exposure to mutant medium 
and involved the canonical pathway of the NF-B complex, as evidenced by the nuclear 
localization of the p65 subunit. Even more important, we found that, by inhibiting NF-B 
through both pharmacological and genetic means, the toxicity of mutant astrocyte-conditioned 
medium for motor neurons was abrogated. These results indicated that NF-B is indeed 
instrumental in our non-cell autonomous scenario of ALS pathogenesis. Based on the above 
findings, it can be concluded that this overall approach represents a proof of principle that, with 




This finding on the involvement of NF-B in the mutant SOD1-linked non-cell 
autonomous model of motor neuron degeneration coincided with the previous discoveries on the 
TDP-43 and OPTN ALS models. Until now, it has been a mystery, in the field, of how genetic 
mutations in fALS, as well as in sALS, which are so different from one another, can result in 
such a similar clinical and pathological phenotype. And, it has been suggested that perhaps 
distinct preliminary molecular mechanisms may intersect at a common point. Can it be that NF-
B is that common point between the molecular mechanisms of different genetic mutations of 
fALS and sALS?  
While not much is known about the molecular machinery involved in NF-B in these 
ALS models, it has been shown that TDP-43 acts as a co-activator of p65 (Swarup et al., 2011), 
which is a subunit of the canonical NF-B pathway. Similarly, it has been suggested that the 
ALS-related OPTN mutations lack inhibitory effects toward NEMO, the IKK complex member 
specific to the canonical NF-B pathway, resulting in a subsequent increase in the ubiquitination 
of RIP and in the activity of the canonical NF-B pathway (Maruyama et al., 2010). These 
findings, taken together, suggest the involvement of the canonical pathway of NF-B in the 
motor neuron degeneration of ALS for the TDP-43 and OPTN models, which matches with the 
findings which used the mutant SOD1 non-cell autonomous model. 
Since NF-B is a highly studied molecule in the field of immunology, the activation of 
the NF-B canonical pathway can shed light on what is upstream to this signaling. For example, 
as described in Chapter 4, TAK1 is a kinase that selectively phosphorylates the IKK complex of 
the canonical NF-B pathway. Similarly, RIP family proteins, which form a complex with the 




and TRAF, and subsequently phosphorylate the IKK kinases of the canonical pathway, are also 
specific to the canonical pathway. Although these results on the molecular machinery 
responsible for the activation of the NF-B pathway comes mostly from the field of 
immunology, it would be an interesting future study to target some of the molecules mentioned 
above to test their involvement in our model system, by inhibiting their activity in motor neurons 
through pharmacological or genetic means, and investigating their effects on the survival of these 
neurons. Furthermore, to understand the complete molecular mechanism underlying the ALS-
linked astrocyte toxicity for motor neurons, it would be important to investigate the rest of the 
top 25 master regulators from the 72 vs. 0 hour signature for their pathological significance in 
motor neuron death. This investigation is currently on going. 
Finally, one of the interesting observations made from the analysis of the RNA-Seq data 
was that the pathways that were activated early on in motor neurons exposed to mutant astrocyte-
conditioned medium primarily belonged to the NF-B and IFN- signaling pathways. 
Remarkably, an increase in IFN--dependent signaling has also been observed by other groups, 
such as by the groups of Raoul (Aebischer et al., 2011) and Maniatis (unpublished work), in 
motor neurons exposed to the toxicity emanating from mutant astrocytes. Moreover, IFN- has 
been found to induce DNA binding of NF-B in a STAT1-independent manner (Deb et al., 
2001), suggesting a potential link between the two pathways. Similarly, PI3K pathway, which is 
also one of the signaling pathways activated early on in motor neurons exposed to mutant 
astrocyte-conditioned medium, has been found to be activated by IFN- signaling (Nguyen et al., 
2001). This pathway, upon activation, has been shown to activate the canonical NF-B pathway  




In addition, of the pathways activated early in motor neurons exposed to mutant 
astrocyte-conditioned medium, a cross talk between Wnt and NF-κB signaling has also been 
reported. In the nucleus of breast and colon cancer cells that express β-catenin aberrantly, the 
ability of NF-κB to bind DNA has been shown to be suppressed by its association with β-catenin 
(Deng et al., 2002). Furthermore, through screening deubiquinating enzymes involved in Wnt 
signaling, CYLD, a negative regulator of NF-κB signaling, has been identified as an important 
regulator of the β-catenin pathway (Tauriello et al., 2010). Moreover, the cross talk between NF-
κB and Wnt signaling has also been demonstrated in the β-catenin-independent pathway, mainly 
through Wnt5a. In endothelial cells, Wnt5a has been found to induce translocation of NF-κB into 
the nucleus through the Ca
2+
/PKC pathway to cause inflammation (Kim et al., 2010).  
Similarly, recent data suggest that there is also a cross talk between JNK and NF-κB 
signaling, where TAK1 and TRAF6 are the common upstream activators of these pathways 
through the involvement of either Toll-like, TNF, p75
NTR
, interleukin-1, or Tgf-β receptors 
(Landstrom, 2010). Furthermore, it has been found that, in murine embryonic fibroblasts, an NF-
κB target gene, Xiap, inhibits JNK activation (Tang et al., 2001). On the other hand, inhibition of 
JNK by overexpression of a dominant negative SEK1 has been shown to impair degradation of 
IκBα and activation of NF-κB induced by vanadate in macrophages (Chen and Davis, 1999). 
Moreover, in Jurkat T cells, Xiap and Siva bound to TAK1 have been found to be the switch 
between NF-κB and JNK pathways (Resch et al., 2009). All of these data on NF-κB and JNK 
signaling indicate a strong interaction between these two pathways. However, it is difficult to 
determine which of the pathways regulate the other. Moreover, since none of the findings on 




PI3K, Wnt and JNK pathways with NF-κB by inhibiting the activation of NF-κB in motor 
neurons exposed to mutant astrocyte-conditioned medium and examining the changes in the 
activity of the other pathways, and vice versa. This way, we could determine more accurately 
whether these pathways interact with NF-κB signaling, and if they do, which pathway acts 
upstream to the other. 
While the published and unpublished results discussed above are consistent with our 
findings, some of the data generated here diverge from those of some other groups. For example, 
we did not find Fas to be differentially regulated in the RNA-Seq data, which was found to be 
involved in the cell autonomous motor neuron degeneration in ALS by Raoul et al. (2002). We 
also did not observe any increase in the activity of ER stress, which has been found to be 
involved early in the ALS disease process in vivo in motor neurons of mutant SOD1 mice by 
Saxena et al. (2009). One possible explanation as to why we did not observe any changes in 
these molecular pathways might pertain to the fact that they may belong primarily to the cell 
autonomous mechanisms and not to the non-cell autonomous mechanisms involved in the demise 
of motor neurons. It is well established in the field that motor neurons in ALS may die through 
many pathogenic processes. Therefore, it is possible that the non-cell autonomous mechanism is 
involved in the more inflammatory-linked NF-B and IFN- pathways, whereas the cell 
autonomous mechanism is involved in the pathogenic processes affecting the ER among other 
cellular systems. Thus, depending of the experimental conditions, one may see evidence of some 
pathways over others. If this is the correct assumption, then one should expect to see, for 




SOD1-expressing motor neurons and mutant SOD1-expressing astrocyte-conditioned medium 
are used in this model system. 
If NF-B is validated as a significant regulator of human ALS, then it would be a 
promising, but not necessarily straightforward therapeutic target for the disease. The reason is 
that NF-B is a critical regulator involved in the homeostasis of a host of vital functions. 
Therefore, for the treatment of ALS, the chronic inhibition of NF-B cannot be generalized. 
Instead, strategies to deliver treatments specifically to motor neurons of patients may need to be 
developed. Perhaps, one such targeted delivery could be achieved by gene therapy using viral 
vectors expressing super repressive IB under the Hb9 promoter. Since ALS is a chronic disease, 
it is also possible that a mild inhibition of NF-B might suffice to modify the natural course of 
the disease and to prolong survival beyond the effect of riluzole. Along this line, it is worth 
noting that achieving a mild inhibition of NF-B could be feasible by using a natural compound, 
such as Withania somnifera, which is a plant also known as Indian ginseng or wild cherry. In this 
case, enough NF-B inhibition may be achieved to slow the progression of the disease without 
triggering major side effects in patients. This idea has been tested by the Julien group, where the 




 mice before the 
onset of disease symptoms, and found the treatment to improve the disease phenotype, as well as 
to extend the life span of these animals (data not shown).  
In conclusion, early diagnosis of ALS is difficult and is often delayed by the subtle onset 
of manifestations that mimic other conditions. Moreover, clinical trials are still very slow in 
determining whether a treatment is effective. All of these difficulties necessitate the discovery of 




of ALS, as well as to develop new therapies aimed at mitigating motor neuron degeneration. An 
increasing body of evidence suggests that non-cell autonomous processes play critical roles 
during the initiation and progression of ALS pathology. Therefore, it may be extremely 
important to discover, not only early cell autonomous, but also early non-cell autonomous 
pathogenic mechanisms in order to acquire a deeper understanding of the neurobiology of 
ALS and to be able to devise effective therapeutic approaches for preventing or reversing 
the progression of ALS. We believe that, by using well-controlled in vitro models and reverse 






Chapter 6: Experimental Methods 
 
Primary cultures of rodent astrocytes and preparation of astrocyte-conditioned medium  
Astrocyte monolayers were prepared from spinal cords or cortices of newborn mouse and rat 




 rodents with wild-type 
animals. For each pup, tail DNA was extracted for genotyping by PCR, and spinal cord and 
cortex were dissected. Basically, meninges were removed, and spinal cords and cortices were 
dissociated mechanically (20 passages through 18G needles). Cell suspensions were plated 
individually on 75 or 25 cm
2
 flasks in glial medium: Dubelco Modified Eagle’s medium 
(DMEM; Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Invitrogen), 100 U/mL 
penicillin and 100 µg/mL streptomycin (Invitrogen). Cultures were, then, maintained for two 
weeks in a humidified incubator at 37°C under 5% CO2. Medium was changed twice a week. 
After 2 weeks, these primary glial cultures contained 95% GFAP
+
 astrocytes, 5% of CD11b
+
 
microglia, and no neurons or oligodendrocytes as indicated by the lack of respectively MAP2 or 
2’-3’-cyclic nucleotide phosphohydrolase immunoreactivity. To eliminate microglia, 2-week-old 
flasks were agitated on a rotary shaker (200 rpm; 6 h) and carefully washed twice with PBS 
before being placed with motor neuron medium: Neurobasal medium (Invitrogen) containing 2% 
horse serum (heat inactivated; Invitrogen), B27 supplement, 0.5 mM glutamine (Invitrogen), 25 
µM -mercaptoethanol, 100 U/mL penicillin, and 100 µg/mL streptomycin supplemented with 
0.5 ng/mL glia-derived neurotrophic factor (GDNF), 1 ng/mL brain-derived neurotrophic factor 
(BDNF), and 10 ng/mL ciliary neurotrophic factor (CNTF), all trophic factors from R&D 




eliminate floating cells. Supernatants from different genotypically-matched astrocyte cultures 
were collected mixed together and frozen in several aliquots. On the day of assay, conditioned 
medium was supplemented with 4.5 g/mL D-glucose (final concentration), 
penicillin/streptomycin, and trophic factors (as described above) and filtered through a 0.22 m 
filter before being added to the motor neuron cultures.  
 
Embryonic stem cell-derived motor neuron cultures  
Embryonic stem cells were derived from Tg Hlxb9-GFP1Tmj mice expressing eGFP or eGFP 
and CD2 driven by the mouse HB9 promoter (Wichterle et al., 2002) and were differentiated into 
motor neurons as described previously (Wichterle et al., 2002) with some modifications. To form 
embryoid bodies, embryonic stem cells were first grown for 2 days in 1:1 (v/v) DMEM 
(Invitrogen)/Ham’s F-12 media (Invitrogen) medium containing the B27 supplement 
(Invitrogen), 100 U/mL penicillin, 100 µg/mL streptomycin, and 0.1 mM -mercaptoethanol 
(Sigma, Saint Louis, MO). They were then treated with 1 µM retinoic acid (Sigma) and 400 nM 
sonic hedgehog agonist (Hh-Ag1.3, Curis Inc., Cambridge, MA) for 5 days before being 
dissociated with a papain solution (Worthington, Lakewood, NJ). The produced cell suspensions 
were washed with the motor neuron medium described above and resuspended in PBS 
containing 1% BSA at the concentration of ~ 20 x 10
6 
cells per mL to be processed by FACS or 







Sorting of GFP-positive motor neurons by FACS  
Prior to sorting, cell suspensions (~20 x 10
6 
cells per mL, in 1% BSA PBS) were filtered through 
filter top tubes (Falcon 12X75mm Cat#2235). Cell sorting was performed using a Becton 
Dickinson FACS Aria cytometer (BD Biosciences) at the Flow Cytometry Core Facility of 
Columbia University (http://www.ccc.columbia.edu/FCCF/flow_cytometry.html). Forward 
scatter (FS) and side scatter (SSC) were collected through a filter. The GFP signal was collected 
in the FL1 channel. A light scatter gate was drawn in the SSC versus FS plot to exclude debris 
and include the viable cells. Cells in the gate were displayed in a single-parameter histogram for 
GFP and final gate settings determined to collect the GFP-positive cells. Post-sorting, the cells 
were collected in motor neuron medium supplemented with 20% FBS. Before plating, the pure 
motor neuron suspension were collected by centrifugation (300xg, 5 min) and resuspended in 
motor neuron medium.   
 
Sorting of CD2-positive motor neurons by MACS 
Upon dissociation and wash with L15 medium consisting of L15 solution (Sigma), 50 µM 
EDTA, 4% BSA (Sigma), 25 mM glucose, 2% Horse Serum (Sigma), 40 µg/mL DNAse, 500 
µg/mL Insulin (Sigma), 0.01M Putrecine (Sigma), 10 mg/mL Conalbumin (Sigma), 30 µM 
Sodium Selenite (Sigma), cell suspensions were incubated with 80 µl of L15 medium and 10 µl 
of anti-rat CD2 antibody (Invitrogen; per 15 million dissociated cells) for 20 minutes at 4
0
C.  
After washing again with L15 medium, cells were then incubated with anti-mouse magnetic 
microbeads (Miltenyi Biotec) for 20 minutes at 4
0




magnetic column to separate CD2-GFP-positive cells from the other types.  Post-sorting, the 
cells were collected in motor neuron medium and were plated for culture. 
 
Primary motor neuron cultures  
Spinal neuronal cultures were performed from E12.5 Hlxb9-GFP1Tmj transgenic rodents as 





 for Hlxb9::eGFP either on coverslips coated with 0.01% poly-D-lysine and 10 
µg ml
–1
 laminin (poly-D-lysine/laminin) or on astrocyte monolayers. The culture medium was 
either motor neuron medium supplemented with a cocktail of trophic factors composed of 0.5 ng 
ml
–1
 GDNF, 1 ng ml
–1
 BDNF and 10 ng ml
–1
 CNTF (trophic factor cocktail, R&D Systems); or 
astrocyte-conditioned motor neuron medium. 
 
Immunocytochemistry  
For immunocytochemistry, cells were processed as we previously described (Nagai et al., 2007; 
Przedborski et al., 1996). Primary antibodies used were: rabbit polyclonal anti–eGFP (1:1000; 
Molecular Probes), rabbit anti–HB9 (1:1000, Abcam); goat polyclonal anti–ChAT (1:100; 
Chemicon, Temecula, CA), and mouse monoclonal anti–MAP–2 (1:1000; Chemicon), rabbit 
anti–GFAP (1:200; DAKO Z0334), and mouse anti–Islet 1 (1:100; from Dr. Jessell’s lab).  
 
Verification of astrocyte-conditioned medium toxicity 
Prior to their use for the RNA-Seq assay, the toxicity of transgenic SOD1
G93A
 astrocyte-
conditioned medium versus non-transgenic and transgenic SOD1
WT




were confirmed. For that, embryonic stem cell-derived motor neurons plated (1500 cells per cm
2
) 
on laminin-coated coverslips were incubated with the conditioned medium for 7 days, and, at 
that time, the number of GFP-positive surviving cells were counted as described below. Only 
transgenic SOD1
G93A
 conditioned medium that generated the expected 50 ± 10 % motor neuron 
loss after 7 days incubation compared to transgenic SOD1
WT 
or non-transgenic conditioned 
medium were used. 
 
Handling of the samples for the RNA-Seq assay 
At the specified timepoints, total mRNA samples from purified embryonic stem cell-derived 
motor neurons were extracted using TRI Reagent Solution (Ambion) and isolated with 
MagMAX-96 total RNA Isolation kit (Ambion).  Total RNA samples were, then, quantified by 
Nanodrop (Thermo Scientific) and their RNA integrity was assessed using a 2100 Bioanalyzer 
(Agilent Technologies, Palo Alto, CA); only those RNAs with an integrity number >9 were used 
for the RNA-seq.  Then, high quality total RNA samples were sent to the Columbia Genome 
Center, where sequencing libraries were prepared, 20 million raw 100 base pair Single End reads 
were sequenced on Illumina HiSeq2000 instruments, the reads were mapped on reference 
genomes and the normalized expression level of known genes and transcripts were estimated. 
 
Sample size estimation for the in vitro studies and Master Regulator Analysis   
6 biological replicates per timepoint and treatment were used based on the following argument: if 
the false positive rate was fixed at 0.01, then 10,000 permutations would be needed to estimate 




in groups of k elements with reposition is .  Thus, by using 5 biological replicates, we 
cannot get enough combinations: = 2,002, but with 6 we d:o = 12,376.  The 
variance of the RNA-seq data was stabilized by log transformation and gene expression 
signatures was obtained by Student’s t-test and ANOVA. Gene expression signatures were 
obtained by Student’s t-test and ANOVA. Expression data transformation and analysis were 
performed on the R-system platform. 
 
Master Regulator Inference algorithm (MARINa)   
MARINa was developed to identify transcriptional regulators (i.e. transcription factors) 
controlling a specific gene expression signature.  It was used previously to identify the regulatory 
module controlling the mesenchymal phenotype in human high grade glioma (Carro et al., 2010), 
and to identify the transcription factors controlling the gene expression program for the 
differentiation of naïve human B-cells in the germinal center reaction (Lefebvre et al., 2010).  A 
modified version of Gene Set Enrichment Analysis (GSEA) was used to compute the enrichment 
of the targets for each transcription factor (its regulon) on the susceptibility and commitment 
gene expression signatures. Transcription factor regulons (i.e. the set of target genes 
transcriptionally regulated by a transcription factor) were obtained from related, previously 
assembled transcriptional networks, which were constructed by reverse engineering of large gene 
expression datasets using ARACNe (Basso et al., 2005).  Spearman correlation was used to infer 
whether a transcription factor activated or repressed an inferred target gene and this information 
was used in the modified GSEA to estimate the relative activity of each transcription factor in 




factor was estimated in association with a given gene expression signature based on the 
enrichment of its regulon among genes belonging to the tails of the gene expression signature.  
Nominal p-values for differential enrichment/activity were computed by uniformly shuffling the 
samples 10,000 times. Transcription factors, whose activity was significantly associated with the 
commitment and susceptibility signatures, were prioritized according to the level of enrichment.  
 
Nuclear/ cytoplasmic subcellular fractionation 
Harvested cells were homogenized in buffer A (250 mM sucrose, 20mM Hepes, 10 mM KCl, 1.5 
mM Mg Cl2, 2 mM EDTA, pH 7.4) supplemented with a protease inhibitor cocktail (Complete 
mini, Roche Applied Science, Indianapolis, IN). For each preparation, an aliquot of cell 
homogenate was saved and the rest was centrifuged. The pellet (P1) was used for nuclear 
purification, whereas the supernatant (S1) was used for the cytosolic purification. To purify 
nuclei, P1 was re-homogenized in buffer B (2 M sucrose, 50 mM Tris-HCl, 5 mM MgCl2, 1 mM 
DTT and 1 mM PMSF, pH 7.4) supplemented with the protease inhibitor cocktail and then 
centrifuged through a cushion of buffer B. The resulting pellet was enriched with nuclei and was 
designated as nuclear fraction. As S1, it was centrifuged. The resulting supernatant was further 
centrifuged. The supernatant of the latter centrifugation was designated as the cytosolic fraction. 
After each preparation and prior to using, the purities of the subcelluar fractions were confirmed 
by Western blot using the following antibodies: anti-Histone H3 (Cell Signaling) for nuclei and 
anti-GAPDH (Cell Signaling) for cytosol. These antibodies were also used to assure equivalent 





TransAM NF-κB binding assay 
Using the TransAM NF-κB transcription factor assay kit (Active Motif, Carlsbad, California), 20 
μg of nuclear extract was added per sample diluted with Complete Lysis Buffer per well in a 96-
well cell culture plate with 30 μl Complete Binding Buffer provided with the kit. Then, the plate 
was incubated for 1 hour at room temperature with mild agitation, followed by three washes with 
200 μl of 1X Wash Buffer. 100 μl of diluted NF-κB antibody was added (1:1000) to each well 
being used in the plate and the plate was incubated again for 1 hour at room temperature without 
agitation, followed by three washes with 200 μl of 1X Wash Buffer. This step was repeated this 
time with the 100 μl HRP-conjugated antibody (1:1000). Finally, 100 μl Developing Solution 
was added to the wells being used. The plate was incubated for 1 minute away from the light and 
100 μl Stop Solution was added, where the blue color turned yellow depending on the binding 
activity of the transcription factor. This activity was read using a spectrophotometer at 450 nm 
after 5 minutes. Every sample had three replicates and all values were expressed as mean ± 
s.e.m. 
 
Western blots of total and phosphorylated proteins 
After exposure to astrocyte-conditioned medium or infection with viral vector, motor neurons 
were harvested in lysis buffer containing sodium orthovanadate and sodium fluoride to avoid 
dephosphorylation. The following primary antibodies were used: rabbit anti-phosphorylated NF-
κB p65 antibody (Cell Signaling) anti-NF-κB p65 antibody (Cell Signaling), anti-GAPDH 
antibody (Cell Signaling), anti-Histone H3 (Cell Signaling), anti-phosphotylated IκB (Cell 




for all the antibodies was 1:1000, except for β-actin, for which the concentration was 1:20,000. 
Western blots using antibodies raised against the cytosolic and nuclear markers cited above were 
used as loading controls. All bands were quantified by Odyssey Infrared Imaging system using 
IRDye dye-labeled secondary antibodies (LI-COR). Results were expressed as ratios of arbitrary 
fluorescence units for the protein of interest over arbitrary fluorescence units for loading controls 
or as ratios of phosphorylated protein of interest over total protein of interest. 
 
Pharmacological treatments 
Wedelolactone (Calbiochem) was dissolved in DMSO and added to motor neurons, to final 
concentrations ranging from 50 nM –5 μM, 1 day after addition of astrocyte-conditioned medium 
to motor neurons. Fas ligand (Sigma) and domoic acid (Sigma) were added to motor neurons at 
concentrations 10 ng/ml and 1 μM, respectively, after five days in vitro of being in fresh 
medium. Cell survival was evaluated at 7 days in vitro by counting eGFP
+ 
neurons as described 
below. 
 
Adeno-associated viral vector titration and infection 
The adeno-associated viral vectors expressing GFP and GFP + super repressive IκB were 
obtained from Dr. David Park’s group in University of Ottawa, Canada. Motor neurons were 
infected with GFP-expressing viral vectors one day after being plated, at concentrations ranging 
from 25-250 μM and their titration was tested using the Adenovirus Titration Kit (Clontech) five 
days after infection with the viral vectors. Similarly, for Western blot and cell counting, motor 




astrocyte-conditioned medium addition and their survival was assessed or protein were extracted 
six and five days after the infection, respectively. 
 
Statistics for cell counting and Western blot  
Each experiment was repeated at least 3-5 times. Results for the cell counting were the average 
of 3-6 coverslips. Each coverslip was counted in its entirety at x100 under fluorescent 
examination. All values were expressed as mean ± s.e.m unless stated otherwise. Differences 
between means were analyzed using a two-tailed Student’s t test. Differences among means were 
analyzed using a two-way ANOVA with the different genotypes and times after exposure to the 
conditioned medium as the independent factors. When ANOVA showed significant differences, 
pair-wise comparisons among means were tested by Newman-Keuls post-hoc testing. All data 
sets were tested for normality and equality of variance and, when either or both criteria were 
violated, the appropriate nonparametric test was used. In all analyses, the null hypothesis was 
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Camta1 0.45 4.233 1.846 3.61 2.426 0.653 2.31e-05 0.065 0.000306 0.0152 
Zbtb48 1.317 1.785 1.371 1.908 1.714 0.188 0.0743 0.17 0.0564 0.0865 
Zmym6 0.558 0.546 1.074 0.636 1.91 0.577 0.585 0.283 0.525 0.0562 
Akna 0.225 0.038 0.479 0.117 0.105 0.822 0.97 0.632 0.907 0.916 
Zfand2a 0.313 0.67 0.121 0.934 0.821 0.754 0.503 0.904 0.35 0.412 
Zfp518b 1.088 1.467 1.123 1.344 1.169 0.277 0.142 0.261 0.179 0.242 
Nfxl1 0.637 1.814 3.053 0.91 0.257 0.524 0.0696 0.00227 0.363 0.797 
Zfp513 0.433 0.001 0.279 0.026 0.733 0.665 0.999 0.78 0.979 0.463 
Zfp282 1.553 2.556 1.896 2.182 1.489 0.121 0.0106 0.058 0.0291 0.137 
Tada3 0.023 0.219 0.135 0.176 1.064 0.982 0.827 0.893 0.86 0.287 
Taf5l 1.522 0.226 0.502 0.517 1.391 0.128 0.821 0.616 0.605 0.164 
Zdhhc7 0.602 0.393 1.152 0.54 1.341 0.547 0.694 0.249 0.589 0.18 
Snapc2 0.965 0.832 0.1 1.152 2.126 0.334 0.405 0.92 0.249 0.0335 
Hinfp 0.26 0.141 0.366 0.061 0.523 0.795 0.888 0.714 0.951 0.601 
Dennd4a 0.751 3.832 1.55 4.389 1.464 0.453 0.000127 0.121 1.14e-05 0.143 
Zc3h10 0.67 0.098 0.141 0.148 0.69 0.503 0.922 0.888 0.882 0.49 
Zfp692 0.717 0.369 1.456 0.631 0.341 0.474 0.712 0.145 0.528 0.733 
Hoxb2 0.871 0.84 0.628 0.279 0.404 0.384 0.401 0.53 0.78 0.686 
Etv5 0.524 2.52 2.768 1.639 0.935 0.6 0.0118 0.00565 0.101 0.35 
Isl2 0.9 0.304 0.51 0.224 0.928 0.368 0.761 0.61 0.823 0.353 
Barhl2 1.158 1.744 1.618 1.049 0.999 0.247 0.0811 0.106 0.294 0.318 
Rcor2 0.778 0.857 0.916 1.005 2.5 0.436 0.391 0.36 0.315 0.0124 
Rhox9 1.417 1.122 1.065 1.909 0.211 0.157 0.262 0.287 0.0562 0.833 
E2f4 0.72 1.931 0.239 1.265 0.371 0.471 0.0535 0.811 0.206 0.711 
Cggbp1 0.01 0.123 1.685 0.009 1.254 0.992 0.902 0.0919 0.993 0.21 
Zc3h7a 0.089 0.745 1.627 0.27 1.537 0.929 0.456 0.104 0.787 0.124 
Rrn3 0.202 0.221 0.129 0.132 0.422 0.84 0.825 0.897 0.895 0.673 
Tcf19 1.017 1.574 1.448 1.045 1.264 0.309 0.116 0.148 0.296 0.206 
Btaf1 0.116 0.393 0.824 0.116 0.188 0.908 0.694 0.41 0.908 0.851 




Ovol2 2.192 2.061 0.403 1.533 0.696 0.0284 0.0393 0.687 0.125 0.486 
Prrxl1 1.308 0.697 0.376 0.577 0.43 0.191 0.486 0.707 0.564 0.667 
Ankrd1 0.041 1.001 0.061 0.783 0.601 0.967 0.317 0.951 0.434 0.548 
Bmyc 1.064 2.519 2.996 2.165 0.864 0.287 0.0118 0.00274 0.0304 0.387 
Scml2 0.978 0.485 0.129 1.088 0.064 0.328 0.628 0.897 0.276 0.949 
Whsc1 0.389 1.613 1.906 1.291 1.389 0.697 0.107 0.0567 0.197 0.165 
Gcm2 0.281 0.516 0.204 0.593 1.246 0.779 0.606 0.838 0.553 0.213 
Taf9 0.249 0.529 0.107 0.03 0.211 0.803 0.597 0.915 0.976 0.833 
Foxp1 1.147 0.786 1.18 1.051 1.336 0.251 0.432 0.238 0.293 0.182 
Zdhhc15 0.305 2.272 0.269 1.002 0.607 0.76 0.0231 0.788 0.316 0.544 
Zzz3 0.768 0.305 2.51 0.15 1.307 0.442 0.76 0.0121 0.881 0.191 
E2f8 0.836 1.485 0.803 1.219 1.159 0.403 0.137 0.422 0.223 0.247 
Slc30a9 0.598 1.039 0.244 1.171 1.034 0.55 0.299 0.807 0.241 0.301 
Rlf 0.965 0.021 1.42 0.838 0.734 0.335 0.983 0.156 0.402 0.463 
Tbx10 0.753 0.118 0.346 0.231 0.058 0.451 0.906 0.729 0.817 0.954 
Lmo1 0.243 0.489 1.269 0.211 0.613 0.808 0.625 0.204 0.833 0.54 
Mzf1 0.426 0.874 1.14 0.68 0.775 0.67 0.382 0.254 0.496 0.438 
Zfp91 1.821 1.115 1.489 1.02 0.592 0.0686 0.265 0.136 0.308 0.554 
Zbtb25 0.166 0.116 0.004 0.09 0.18 0.868 0.908 0.997 0.928 0.857 
Hivep1 1.029 1.43 1.975 0.884 1.866 0.304 0.153 0.0482 0.377 0.0621 
Lmx1a 0.654 0.004 0.018 0.094 0.167 0.513 0.997 0.986 0.925 0.867 
Nr3c2 0.24 0.324 0.14 0.338 0.709 0.81 0.746 0.889 0.735 0.478 
Tshz1 0.502 2.479 1.935 1.482 2.205 0.616 0.0132 0.053 0.138 0.0275 
Foxp2 1.211 1.361 2.621 2.502 1.26 0.226 0.174 0.00877 0.0124 0.208 
Zfp295 0.599 0.131 0.275 0.3 0.859 0.549 0.896 0.783 0.764 0.39 
Zmynd10 0.51 0.315 0.04 0.131 0.753 0.61 0.753 0.968 0.896 0.452 
Prdm15 0.095 2.497 2.593 1.789 2.357 0.924 0.0125 0.00951 0.0736 0.0184 
Gtf2ird2 0.972 0.735 1.34 0.662 0.984 0.331 0.462 0.18 0.508 0.325 
Ferd3l 0.35 0.546 0.181 0.161 0.715 0.726 0.585 0.856 0.872 0.475 
Vsx1 1.147 0.41 0.183 1.052 0.466 0.251 0.682 0.855 0.293 0.641 
Adnp 1.018 0.362 0.444 0.775 0.938 0.309 0.717 0.657 0.439 0.348 
Aebp1 0.838 1.441 0.826 1.655 1.452 0.402 0.15 0.409 0.0979 0.147 
Aebp2 0.698 0.026 0.229 0.395 0.256 0.485 0.979 0.819 0.693 0.798 
Nr0b1 0.008 0.313 0.063 0.118 0.392 0.994 0.754 0.95 0.906 0.695 
Ahr 1.407 1.637 1.912 1.289 0.381 0.16 0.102 0.0558 0.197 0.703 
Aire 0.43 0.116 0.102 0.748 0.412 0.667 0.908 0.919 0.454 0.68 
Foxn4 0.493 0.03 0.478 0.44 0.74 0.622 0.976 0.633 0.66 0.459 




Mta1 0.846 0.864 0.679 1.283 2.025 0.398 0.388 0.497 0.199 0.0429 
Mta3 0.253 1.593 1.36 1.491 0.948 0.8 0.111 0.174 0.136 0.343 
Alx3 0.749 1.573 1.27 1.635 1.139 0.454 0.116 0.204 0.102 0.255 
Alx4 0.917 1.706 0.308 1.718 1.932 0.359 0.0881 0.758 0.0857 0.0534 
Nr2f2 0.809 1.41 1.766 1.483 0.953 0.418 0.158 0.0773 0.138 0.341 
App 0.616 3.743 1.542 3.313 1.147 0.538 0.000182 0.123 0.000924 0.251 
Ar 1.088 2.999 2.444 2.423 0.802 0.277 0.00271 0.0145 0.0154 0.423 
Klf16 0.381 1.529 1.054 0.598 1.12 0.703 0.126 0.292 0.55 0.263 
Phox2a 0.277 0.417 2.139 0.147 1.268 0.782 0.677 0.0324 0.883 0.205 
Arnt 1.165 2.422 1.732 2.214 1.718 0.244 0.0154 0.0832 0.0269 0.0857 
Arnt2 0.335 0.779 0.677 0.202 0.103 0.738 0.436 0.498 0.84 0.918 
Arntl 0.628 0.837 0.746 1.096 0.592 0.53 0.402 0.456 0.273 0.554 
Arx 0.828 1.509 0.856 0.909 1.105 0.408 0.131 0.392 0.363 0.269 
Zfhx3 1.011 1.125 0.152 1.053 0.66 0.312 0.261 0.879 0.292 0.509 
Atf1 1.143 2.524 2.569 1.548 0.871 0.253 0.0116 0.0102 0.122 0.384 
Atf2 1.289 1.915 1.431 2.705 2.815 0.197 0.0555 0.152 0.00683 0.00487 
Atf3 0.192 0.356 0.533 0.561 0.092 0.848 0.722 0.594 0.575 0.927 
Atf4 0.282 0.458 1.249 0.396 1.439 0.778 0.647 0.212 0.692 0.15 
Atoh1 0.667 0.015 0.111 0.434 0.02 0.505 0.988 0.912 0.664 0.984 
Neurod6 0.781 2.747 1.369 1.963 0.986 0.435 0.00602 0.171 0.0497 0.324 
Neurog2 0.718 1.23 1.17 0.22 0.719 0.473 0.219 0.242 0.826 0.472 
Neurog3 0.604 0.294 3.176 0.392 1.405 0.546 0.769 0.00149 0.695 0.16 
Bach1 0.475 0.581 1.868 0.247 1.683 0.635 0.561 0.0618 0.805 0.0924 
Nkx3-2 0.109 0.135 0.043 0.243 0.126 0.913 0.893 0.966 0.808 0.9 
Barx2 0.411 0.058 0.04 0.332 0.298 0.681 0.954 0.968 0.74 0.766 
Bcl6b 1.026 2.367 1.097 1.305 1.233 0.305 0.0179 0.273 0.192 0.218 
Bcl3 0.166 1.392 1.389 1.191 2.504 0.868 0.164 0.165 0.234 0.0123 
Bcl6 0.991 0.817 1.926 0.757 1.874 0.321 0.414 0.0541 0.449 0.0609 
Prdm1 0.739 1.834 1.162 1.169 1.041 0.46 0.0667 0.245 0.242 0.298 
Bnc1 0.537 2.469 2.418 0.983 0.552 0.591 0.0135 0.0156 0.326 0.581 
Zfp36l1 1.273 3.813 0.863 2.018 2.07 0.203 0.000137 0.388 0.0436 0.0384 
Zfp36l2 0.619 0.008 0.142 0.011 0.816 0.536 0.994 0.887 0.991 0.415 
Klf5 0.338 1.469 0.468 1.07 0.698 0.735 0.142 0.64 0.284 0.485 
Nr1i3 0.325 0.178 0.016 0.331 0.147 0.745 0.859 0.987 0.741 0.883 
Ctnnb1 0.75 0.461 0.844 0.41 0.358 0.453 0.645 0.399 0.682 0.72 
Runx2 0.727 1.841 1.463 0.899 0.947 0.467 0.0657 0.144 0.369 0.344 
Runx1 1.048 1.416 0.968 1.417 0.368 0.295 0.157 0.333 0.157 0.713 




Cbfa2t3 0.116 3.544 2.504 1.464 1.141 0.908 0.000395 0.0123 0.143 0.254 
Runx3 1.148 0.059 0.068 0.669 0.299 0.251 0.953 0.946 0.503 0.765 
Cbfb 0.38 0.217 1.419 0.207 0.392 0.704 0.828 0.156 0.836 0.695 
Cbl 0.38 0.288 0.476 0.183 0.514 0.704 0.773 0.634 0.855 0.607 
Cbx2 0.691 0.019 0.004 0.053 0.122 0.489 0.985 0.997 0.958 0.903 
Ccrn4l 0.174 1.445 0.702 0.141 0.522 0.862 0.148 0.482 0.888 0.602 
Cdkn2a 0.476 0.758 0.372 0.403 0.719 0.634 0.448 0.71 0.687 0.472 
Cdx1 0.701 0.298 0.021 0.671 0.207 0.484 0.766 0.983 0.502 0.836 
Cdx2 1.199 0.05 0.108 0.385 0.078 0.23 0.96 0.914 0.7 0.938 
Cdx4 0.513 0.001 0.429 0.004 0.425 0.608 0.999 0.668 0.997 0.671 
Cebpa 0.231 0.286 1.192 0.041 0.724 0.817 0.775 0.233 0.967 0.469 
Cebpz 1.043 0.809 1.806 0.48 0.688 0.297 0.418 0.0709 0.631 0.492 
Cebpb 0.377 1.214 1.787 0.406 2.44 0.706 0.225 0.0739 0.685 0.0147 
Cebpd 1.085 1.368 0.784 1.303 1.222 0.278 0.171 0.433 0.193 0.222 
Cebpg 0.281 0.354 0.206 0.414 0.206 0.779 0.723 0.837 0.679 0.837 
Vsx2 0.217 0.14 0.349 0.064 0.264 0.828 0.889 0.727 0.949 0.792 
Cited1 0.645 0.693 0.38 0.987 0.248 0.519 0.488 0.704 0.324 0.804 
Clock 1.165 0.996 1.003 1.86 2.412 0.244 0.319 0.316 0.0628 0.0159 
Cnbp 0.196 1.632 1.139 0.465 0.542 0.845 0.103 0.255 0.642 0.588 
Creb1 0.035 0.599 1.997 0.399 2.073 0.972 0.549 0.0458 0.69 0.0381 
Creb3 0.783 0.425 0.147 0.855 0.726 0.434 0.671 0.883 0.392 0.468 
Crebbp 0.921 0.102 0.444 0.093 0.088 0.357 0.919 0.657 0.926 0.93 
Atf6b 0.415 1.019 2.183 0.76 1.418 0.678 0.308 0.029 0.447 0.156 
Crem 2.215 0.866 1.666 2.211 0.927 0.0267 0.386 0.0957 0.027 0.354 
Crx 0.354 0.131 0.192 0.069 0.57 0.723 0.896 0.848 0.945 0.569 
Ctbp1 1.634 0.809 0.896 0.895 0.984 0.102 0.419 0.37 0.371 0.325 
Ctbp2 1.201 1.032 1.364 1.217 0.91 0.23 0.302 0.173 0.224 0.363 
Ctcf 0.193 0.982 1.536 0.249 0.041 0.847 0.326 0.124 0.803 0.967 
Cux1 0.243 0 0.545 0.121 0.05 0.808 1 0.586 0.904 0.96 
Cux2 0.818 1.79 1.383 1.578 0.337 0.414 0.0735 0.167 0.115 0.736 
Dach1 0.112 0.61 0.559 0.089 0.962 0.911 0.542 0.576 0.929 0.336 
Dbp 0.656 1.225 3.232 1.349 1.024 0.512 0.22 0.00123 0.177 0.306 
Dbx1 0.38 0.671 1.841 1.778 1.748 0.704 0.502 0.0657 0.0754 0.0805 
Ddit3 0.188 0.876 0.313 0.105 1.87 0.851 0.381 0.754 0.916 0.0615 
Twist2 0.98 1.214 1.528 0.255 1.459 0.327 0.225 0.126 0.799 0.145 
Dlx1 1.086 1.548 2.732 1.191 1.878 0.277 0.122 0.0063 0.233 0.0604 
Dlx2 0.871 1.378 2.218 0.712 1.648 0.384 0.168 0.0265 0.476 0.0993 




Dlx4 0.229 0.507 0.72 0.132 0.418 0.819 0.612 0.472 0.895 0.676 
Dlx5 0.881 2.129 1.694 2.537 2.111 0.378 0.0332 0.0902 0.0112 0.0348 
Dlx6 1.791 2.276 1.488 2.945 2.535 0.0733 0.0229 0.137 0.00323 0.0112 
Dnmt3a 0.437 0.415 0.151 0.809 1.307 0.662 0.678 0.88 0.419 0.191 
Dnmt3b 1.187 0.801 0.095 0.441 0.548 0.235 0.423 0.924 0.659 0.584 
Slc26a3 0.599 0.06 0.019 0.539 0.281 0.549 0.952 0.985 0.59 0.779 
Arid3a 0.763 0.036 0.159 0.909 0.175 0.445 0.971 0.874 0.364 0.861 
E2f1 0.772 1.483 0.327 0.399 0.558 0.44 0.138 0.744 0.69 0.577 
E2f3 0.653 1.804 1.338 2.388 2.461 0.514 0.0713 0.181 0.0169 0.0139 
E2f5 1.235 0.349 1.23 0.16 1.291 0.217 0.727 0.219 0.873 0.197 
E4f1 0.751 0.775 0.559 1.767 2.13 0.453 0.439 0.576 0.0773 0.0331 
Ebf1 0.895 0.708 1.636 0.74 0.619 0.371 0.479 0.102 0.46 0.536 
Ebf2 0.59 0.331 1.71 1.086 0.187 0.555 0.741 0.0872 0.277 0.852 
Ebf3 0.219 0.253 2.214 0.124 1.237 0.827 0.8 0.0268 0.901 0.216 
Egr1 0.555 2.366 2.161 1.402 2.206 0.579 0.018 0.0307 0.161 0.0274 
Egr2 0.51 1.225 0.772 1.037 0.492 0.61 0.221 0.44 0.3 0.623 
Egr3 0.164 0.173 0.604 0.056 0.982 0.87 0.863 0.546 0.955 0.326 
Egr4 1.144 2.423 1.585 2.417 0.887 0.253 0.0154 0.113 0.0157 0.375 
Ehf 0.598 0.009 0.004 0.089 0.031 0.55 0.993 0.997 0.929 0.975 
Elf1 0.84 1.114 1.303 0.934 0.578 0.401 0.265 0.192 0.35 0.563 
Elf3 0.48 0.684 0.639 0.312 0.173 0.631 0.494 0.523 0.755 0.863 
Elf5 1.065 0.108 0.436 0.512 0.174 0.287 0.914 0.663 0.609 0.862 
Elk1 0.965 1.053 1.162 1.081 0.626 0.334 0.292 0.245 0.28 0.531 
Elk3 0.421 1.145 2.212 0.519 1.061 0.674 0.252 0.027 0.604 0.289 
Elk4 0.688 0.036 0.243 0.156 0.536 0.491 0.971 0.808 0.876 0.592 
Emx1 0.01 0.221 1.204 0.074 0.499 0.992 0.825 0.229 0.941 0.618 
Emx2 0.19 2.443 2.224 1.329 0.565 0.849 0.0145 0.0262 0.184 0.572 
En1 1.192 2.042 1.397 1.212 1.329 0.233 0.0411 0.162 0.226 0.184 
En2 1.133 0.024 0.902 0.9 1.695 0.257 0.981 0.367 0.368 0.09 
Eomes 1.661 0.117 1.678 0.07 1.568 0.0968 0.907 0.0933 0.944 0.117 
Epas1 0.645 3.768 1.788 2.364 0.822 0.519 0.000165 0.0737 0.0181 0.411 
Nr2f6 1.254 0.698 2.009 0.923 1.702 0.21 0.485 0.0445 0.356 0.0887 
Nr2f1 0.744 2.461 1.912 1.721 1.109 0.457 0.0139 0.0559 0.0852 0.267 
Erf 0.282 0.51 0.246 0.366 0.295 0.778 0.61 0.806 0.714 0.768 
Erg 0.809 0.432 0.291 0.986 0.716 0.418 0.666 0.771 0.324 0.474 
Esr1 1.165 1.392 0.365 1.052 1.14 0.244 0.164 0.715 0.293 0.254 
Esr2 0.98 0.008 0.21 0.104 0.079 0.327 0.994 0.834 0.917 0.937 




Etv2 0.426 0.229 0.509 0.625 0.858 0.67 0.819 0.611 0.532 0.391 
Etv1 0.589 1.207 2.413 1.164 1.442 0.556 0.227 0.0158 0.244 0.149 
Mecom 0.161 0.04 0.093 0.064 0.457 0.872 0.968 0.926 0.949 0.648 
Bcl11a 0.543 1.669 2.749 1.098 1.377 0.587 0.0951 0.00598 0.272 0.169 
Evx1 0.485 0.246 0.21 0.884 1.156 0.628 0.806 0.834 0.377 0.248 
Evx2 0.138 0.003 0.029 0.005 0.054 0.89 0.998 0.977 0.996 0.957 
Ewsr1 0.578 0.617 1.761 0.303 0.208 0.563 0.537 0.0782 0.762 0.835 
Dmbx1 0.389 0.011 0.026 0.256 0.152 0.697 0.991 0.979 0.798 0.879 
Zfp358 0.325 0.716 2.002 0.385 0.898 0.745 0.474 0.0453 0.7 0.369 
Bhlhe23 0.198 0.018 1.852 0.494 1.896 0.843 0.986 0.0641 0.621 0.058 
Foxh1 0.855 0.04 0.281 0.418 0.411 0.393 0.968 0.779 0.676 0.681 
Foxi1 0.019 1.008 0.503 0.173 0.964 0.985 0.313 0.615 0.863 0.335 
Foxc2 0.934 1.908 1.351 1.072 0.947 0.35 0.0564 0.177 0.284 0.344 
Foxm1 0.973 0.008 0.02 0.084 0.878 0.331 0.994 0.984 0.933 0.38 
Foxn2 0.299 0.098 0.073 0.045 0.116 0.765 0.922 0.942 0.964 0.908 
Foxd4 0.04 0.224 0.561 0.792 0.066 0.968 0.823 0.575 0.428 0.947 
Foxf2 0.549 1.23 0.124 1.084 0.899 0.583 0.219 0.901 0.278 0.369 
Foxs1 0.251 0.21 0.045 0.537 0.503 0.802 0.834 0.964 0.591 0.615 
Foxb2 0.353 0.102 0.503 0.571 0.039 0.724 0.919 0.615 0.568 0.969 
Fli1 0.454 0.068 0.636 0.187 0.166 0.65 0.946 0.525 0.852 0.868 
Zcchc14 0.21 1.007 1.095 1.275 1.025 0.834 0.314 0.274 0.202 0.305 
Fos 0.935 1.572 0.796 0.239 0.513 0.35 0.116 0.426 0.811 0.608 
Fosb 1.31 0.529 3.004 0.266 1.439 0.19 0.597 0.00266 0.79 0.15 
Fosl1 1.413 1.097 1.019 1.997 0.787 0.158 0.273 0.308 0.0458 0.431 
Fosl2 1.01 0.506 0.129 0.234 0.415 0.313 0.613 0.897 0.815 0.678 
Gabpa 0.722 0.373 2.169 0.026 1.113 0.471 0.709 0.0301 0.979 0.266 
Gabpb1 1.029 2.332 1.013 1.453 0.592 0.304 0.0197 0.311 0.146 0.554 
Gas7 0.643 1.835 0.278 1.303 0.436 0.52 0.0666 0.781 0.193 0.663 
Gata1 0.285 0.237 0.356 0.053 0.157 0.776 0.813 0.722 0.958 0.875 
Gata2 2.975 0.197 0.011 0.093 0.911 0.00293 0.844 0.991 0.926 0.362 
Gata3 0.539 2.058 1.543 1.367 0.743 0.59 0.0396 0.123 0.171 0.458 
Gata4 0.43 0.19 0.305 0.533 0.329 0.667 0.849 0.76 0.594 0.742 
Gata5 1.225 0.462 0.004 0.617 0.114 0.221 0.644 0.997 0.537 0.909 
Gata6 0.948 1.697 1.767 1.753 0.871 0.343 0.0897 0.0773 0.0796 0.384 
Gbx2 0.675 0.546 0.458 1.522 0.335 0.5 0.585 0.647 0.128 0.738 
Gcm1 0.574 0.015 0.402 0.024 0.332 0.566 0.988 0.688 0.981 0.74 
Nr6a1 0.161 0.828 0.111 0.687 0.998 0.872 0.407 0.912 0.492 0.318 




Gfi1b 0.077 0.387 0.516 0.15 0.008 0.939 0.699 0.606 0.881 0.994 
Tsc22d3 0.432 0.671 1.767 1.552 0.789 0.666 0.502 0.0773 0.121 0.43 
Gli1 0.504 0.014 0.221 0.349 0.312 0.614 0.989 0.825 0.727 0.755 
Gli2 0.024 0.975 1.359 0.278 0.772 0.981 0.33 0.174 0.781 0.44 
Gli3 0.368 1.735 1.041 0.826 1.443 0.713 0.0827 0.298 0.409 0.149 
Nr3c1 0.53 0.614 1.354 0.924 1.884 0.596 0.539 0.176 0.355 0.0596 
Gsc 0.586 1.856 2.149 1.73 0.695 0.558 0.0634 0.0316 0.0836 0.487 
Gsx1 0.908 0.008 0.1 0.053 0.217 0.364 0.994 0.92 0.958 0.828 
Gsx2 1.854 0.57 1.005 1.047 1.226 0.0637 0.569 0.315 0.295 0.22 
Nkx6-2 0.041 0.936 2.672 0.373 0.909 0.967 0.349 0.00753 0.709 0.363 
Hand1 0.166 0.673 0.961 0.546 1.158 0.868 0.501 0.337 0.585 0.247 
Hand2 0.157 0.033 2.235 0.031 0.909 0.875 0.974 0.0254 0.975 0.363 
Hcfc1 1.446 0.513 0.87 0.886 1.253 0.148 0.608 0.384 0.376 0.21 
Hcls1 0.448 0.523 0.942 0.264 0.147 0.654 0.601 0.346 0.792 0.883 
Hdac2 0.265 1.578 0.313 0.377 1.097 0.791 0.115 0.754 0.706 0.273 
Hdgf 0.228 2.442 0.728 1.475 1.507 0.82 0.0146 0.466 0.14 0.132 
Hes1 0.901 0.729 1.79 1.191 2.174 0.367 0.466 0.0735 0.234 0.0297 
Hes2 0.45 0.244 0.131 0.376 0.282 0.653 0.807 0.896 0.707 0.778 
Hes3 0.251 0.55 0.27 0.212 0.266 0.802 0.582 0.787 0.832 0.79 
Hes5 0.183 0.598 0.88 0.369 1.39 0.855 0.55 0.379 0.712 0.165 
Hesx1 0.238 0.006 0.338 0.02 0.233 0.812 0.995 0.735 0.984 0.816 
Hey1 0.678 3.075 1.282 1.263 1.155 0.498 0.00211 0.2 0.206 0.248 
Hey2 0.338 2.406 1.823 1.123 1.276 0.735 0.0161 0.0683 0.261 0.202 
Foxn1 0.432 0.567 0.034 0.846 0.773 0.666 0.571 0.973 0.397 0.439 
Foxq1 1.002 0.248 0.66 0.384 0.138 0.316 0.804 0.509 0.701 0.89 
Foxd3 1.004 1.357 1.772 0.55 0.66 0.315 0.175 0.0764 0.582 0.509 
Foxj1 0.392 0.329 0.013 0.81 0.114 0.695 0.742 0.99 0.418 0.909 
Foxf1a 0.112 0.695 1.318 0.217 0.206 0.911 0.487 0.187 0.828 0.837 
Foxg1 0.542 2.076 1.872 0.913 0.611 0.588 0.0379 0.0613 0.361 0.541 
Foxd1 1.244 1.284 0.487 0.832 2.356 0.214 0.199 0.626 0.406 0.0185 
Hhex 0.53 0.642 0.369 0.721 0.482 0.596 0.521 0.712 0.471 0.63 
Hic1 0.84 0.362 0.112 0.384 0.716 0.401 0.717 0.911 0.701 0.474 
Hif1a 0.243 0.792 2.189 0.565 0.295 0.808 0.428 0.0286 0.572 0.768 
Hira 0.192 0.596 0.292 0.288 0.349 0.848 0.551 0.77 0.773 0.727 
Hivep2 0.487 3.852 1.63 4.193 1.019 0.626 0.000117 0.103 2.75e-05 0.308 
Hlx 1.163 1.152 0.423 1.311 2.059 0.245 0.249 0.672 0.19 0.0395 
Mnx1 0.371 0.021 0.118 0.104 0.18 0.711 0.983 0.906 0.917 0.857 




Hmga1 0.422 3.271 1.255 2.657 2.349 0.673 0.00107 0.21 0.0079 0.0188 
Hmga2 0.381 0.253 0.135 0.459 0.331 0.703 0.8 0.893 0.646 0.741 
Nr4a1 0.291 2.093 0.077 0.686 0.697 0.771 0.0363 0.939 0.493 0.486 
Hmx1 0.167 0.147 0.951 0.071 0.331 0.867 0.883 0.342 0.943 0.741 
Hmx2 0.234 0.436 0.118 0.479 0.862 0.815 0.663 0.906 0.632 0.389 
Hmx3 0.197 0.151 0.114 0.174 0.24 0.844 0.88 0.909 0.862 0.81 
Foxa1 0.479 0.097 0.345 0.197 0.493 0.632 0.923 0.73 0.844 0.622 
Foxa2 0.22 0.197 0.549 0.437 0.517 0.826 0.844 0.583 0.662 0.605 
Foxa3 0.357 0.129 0.088 0.286 0.249 0.721 0.897 0.93 0.775 0.803 
Hnf4a 0.183 0.693 0.722 0.799 0.229 0.855 0.489 0.47 0.424 0.819 
Onecut1 0.204 0.028 0.005 0.005 0.762 0.838 0.978 0.996 0.996 0.446 
Hnrnpab 0.349 2.113 0.622 1.469 1.162 0.727 0.0346 0.534 0.142 0.245 
Hoxa1 0.646 0.197 0.55 0.522 0.83 0.518 0.844 0.582 0.602 0.406 
Hoxa10 1.144 1.307 1.433 1.532 0.633 0.253 0.191 0.152 0.126 0.527 
Hoxa11 0.396 0.572 0.423 1.994 1.201 0.692 0.567 0.672 0.0461 0.23 
Hoxa13 0.118 0.112 0.003 0.026 0.129 0.906 0.911 0.998 0.979 0.897 
Hoxa2 0.198 0.179 0.129 0.411 0.761 0.843 0.858 0.897 0.681 0.447 
Hoxa3 0.43 0.642 0.599 1.075 0.197 0.667 0.521 0.549 0.282 0.844 
Hoxa4 0.111 0.077 0.176 0.371 0.698 0.912 0.939 0.86 0.711 0.485 
Hoxa5 0.555 0.497 0.321 0.533 0.295 0.579 0.619 0.748 0.594 0.768 
Hoxa6 0.344 0.385 0.681 0.85 0.305 0.731 0.7 0.496 0.395 0.76 
Hoxa7 0.468 0.132 0.066 0.14 0.353 0.64 0.895 0.947 0.889 0.724 
Hoxa9 0.765 2.106 1.757 1.343 1.279 0.445 0.0352 0.079 0.179 0.201 
Hoxb1 0.755 0.135 1.1 0.233 0.179 0.45 0.893 0.271 0.816 0.858 
Hoxb13 0.943 1.018 1.608 1.065 0.654 0.345 0.309 0.108 0.287 0.513 
Hoxb3 0.873 2.249 0.238 1.351 2.275 0.383 0.0245 0.812 0.177 0.0229 
Hoxb4 1.147 0.1 0.034 0.871 0.102 0.251 0.92 0.973 0.384 0.919 
Hoxb5 0.09 0.059 1.855 0.001 0.188 0.928 0.953 0.0636 0.999 0.851 
Hoxb6 1.096 0.05 0.188 0.198 0.781 0.273 0.96 0.851 0.843 0.435 
Hoxb8 0.798 0.83 0.05 1.761 0.272 0.425 0.407 0.96 0.0782 0.786 
Hoxb9 0.868 0.752 0.243 1.666 0.705 0.386 0.452 0.808 0.0957 0.481 
Hoxc12 0.693 0.07 0.213 0.327 0.3 0.488 0.944 0.831 0.744 0.764 
Hoxc13 0.433 0.728 1.143 0.341 0.028 0.665 0.466 0.253 0.733 0.978 
Hoxc4 0.014 0.868 0.23 0.74 1.03 0.989 0.386 0.818 0.46 0.303 
Hoxc5 0.333 1.043 0.478 0.415 0.739 0.739 0.297 0.633 0.678 0.46 
Hoxc6 0.393 2.486 0.514 1.585 0.948 0.694 0.0129 0.607 0.113 0.343 
Hoxc8 1.615 1.297 0.476 1.168 0.121 0.106 0.195 0.634 0.243 0.904 




Hoxd1 0.611 0.395 0.601 0.208 0.555 0.541 0.693 0.548 0.835 0.579 
Hoxd10 0.324 0.1 0.705 0.08 0.772 0.746 0.92 0.481 0.936 0.44 
Hoxd11 0.094 0.048 0.634 0.075 0.61 0.925 0.962 0.526 0.94 0.542 
Hoxd12 1.239 0.758 0.114 0.925 1.199 0.215 0.448 0.909 0.355 0.231 
Hoxd13 1.385 1.21 1.206 1.266 0.148 0.166 0.226 0.228 0.205 0.882 
Hoxd3 0.404 0.013 0.366 0.238 0.167 0.686 0.99 0.714 0.812 0.867 
Hoxd4 1.88 0.171 0 1.07 0.142 0.0601 0.864 1 0.284 0.887 
Hoxd8 1.009 0.448 0.904 0.94 1.009 0.313 0.654 0.366 0.347 0.313 
Hoxd9 0.607 3.217 0.412 2.288 0.268 0.544 0.0013 0.68 0.0221 0.789 
Hr 1.282 1.495 3.235 1.632 1.191 0.2 0.135 0.00122 0.103 0.234 
Hsf1 0.796 1.351 0.421 0.464 1.411 0.426 0.177 0.674 0.643 0.158 
Hsf2 0.625 0.02 0.895 0.116 0.166 0.532 0.984 0.371 0.908 0.868 
Irf8 1.071 1.035 0.216 0.371 0.946 0.284 0.301 0.829 0.711 0.344 
Id1 0.687 3.209 0.841 1.975 2.363 0.492 0.00133 0.4 0.0483 0.0181 
Id3 0.396 0.869 1.198 1.306 3.242 0.692 0.385 0.231 0.192 0.00119 
Ilf3 0.073 0.844 0.784 0.656 0.44 0.942 0.399 0.433 0.512 0.66 
Irf1 0.648 1.529 0.593 1.416 1.02 0.517 0.126 0.553 0.157 0.308 
Irf2 0.556 0.561 1.553 0.724 1.955 0.578 0.575 0.121 0.469 0.0506 
Irf4 0.575 1.608 0.598 1.759 0.933 0.565 0.108 0.55 0.0785 0.351 
Irx1 0.628 0.751 1.542 0.836 0.013 0.53 0.453 0.123 0.403 0.99 
Irx2 0.944 0.324 0.104 0.18 0.931 0.345 0.746 0.917 0.857 0.352 
Irx3 0.482 0.159 0.119 0.665 0.836 0.63 0.874 0.905 0.506 0.403 
Irf9 0.637 0.137 0.155 0.06 0.769 0.524 0.891 0.877 0.952 0.442 
Isl1 0.281 1.424 2.343 1.227 1.507 0.779 0.154 0.0191 0.22 0.132 
Jarid2 0.073 2.328 1.859 0.882 1.506 0.942 0.0199 0.063 0.378 0.132 
Jun 0.387 1.13 1.608 1.675 0.868 0.699 0.258 0.108 0.094 0.385 
Junb 0.231 1.454 1.479 0.387 3.527 0.817 0.146 0.139 0.699 0.00042 
Jund 0.279 0.078 0.684 0.113 0.897 0.78 0.938 0.494 0.91 0.37 
Klf1 0.589 0.069 0.073 0.524 0.229 0.556 0.945 0.942 0.6 0.819 
Klf12 0.639 2.928 1.12 2.627 0.843 0.523 0.00341 0.263 0.0086 0.399 
Klf2 1.16 0.849 1.076 1.138 1.898 0.246 0.396 0.282 0.255 0.0577 
Klf3 0.317 2.173 0.902 1.708 1.607 0.751 0.0298 0.367 0.0877 0.108 
Klf4 0.841 1.646 1.893 1.477 1.497 0.4 0.0998 0.0584 0.14 0.135 
Klf9 0.665 1.672 0.903 1.025 1.628 0.506 0.0945 0.367 0.305 0.104 
Hivep3 0.266 0.654 1.328 0.038 0.636 0.79 0.513 0.184 0.97 0.525 
Mafb 1.028 0.229 0.668 0.675 0.886 0.304 0.819 0.504 0.5 0.376 
Aff3 1.697 3.058 2.472 3.079 0.81 0.0898 0.00223 0.0134 0.00208 0.418 




Lbx2 0.102 0.079 0.038 0.396 0.454 0.919 0.937 0.97 0.692 0.65 
Lef1 0.439 1.316 0.379 0.662 1.086 0.661 0.188 0.705 0.508 0.277 
Lhx1 1.188 1.257 0.892 0.788 0.667 0.235 0.209 0.372 0.431 0.505 
Lhx2 0.795 1.942 2.308 1.575 1.125 0.426 0.0522 0.021 0.115 0.261 
Lhx3 0.485 0.45 0.033 0.941 0.668 0.628 0.653 0.974 0.347 0.504 
Lhx4 0.127 1.849 1.734 1.468 0.628 0.899 0.0645 0.0829 0.142 0.53 
Lhx5 0.357 0.278 0.971 0.132 1.437 0.721 0.781 0.331 0.895 0.151 
Lhx6 0.4 0.222 0.028 0.336 0.804 0.689 0.824 0.978 0.737 0.422 
Lhx8 0.671 0.183 0.055 0.307 0.507 0.502 0.855 0.956 0.759 0.612 
Lhx9 0.774 1.041 0.974 0.789 0.71 0.439 0.298 0.33 0.43 0.478 
Lmo4 0.77 1.538 1.885 1.107 0.64 0.441 0.124 0.0594 0.268 0.522 
Lmx1b 0.672 1.248 0.928 0.513 0.238 0.502 0.212 0.354 0.608 0.812 
Mycl1 0.7 1.677 0.759 1.909 2.263 0.484 0.0935 0.448 0.0563 0.0236 
Zbtb7a 1.692 0.944 0.412 2.418 1.201 0.0907 0.345 0.68 0.0156 0.23 
Sp7 0.601 0.083 0.372 0.174 1.005 0.548 0.934 0.71 0.862 0.315 
Ubn1 0.604 0.399 1.023 1.723 0.79 0.546 0.69 0.306 0.0849 0.429 
Scrt1 0.542 0.155 0.957 0.307 0.562 0.588 0.877 0.338 0.759 0.574 
Zscan5b 0.061 0.433 0.294 0.124 0.835 0.951 0.665 0.769 0.901 0.404 
Zfp287 2.029 0.17 0.084 1.334 0.4 0.0424 0.865 0.933 0.182 0.689 
Zfp704 0.536 1.684 3.191 1.449 3.047 0.592 0.0922 0.00142 0.147 0.00231 
Rfxap 0.105 0.104 0.244 0.024 0.246 0.916 0.917 0.807 0.981 0.806 
Lyl1 0.357 0.213 0.148 0.118 0.454 0.721 0.831 0.882 0.906 0.65 
Mxd1 0.154 1.777 1.092 1.68 0.754 0.878 0.0756 0.275 0.093 0.451 
Mxd3 1.669 1.811 0.704 3.41 0.668 0.095 0.0702 0.482 0.000648 0.504 
Mxd4 0.802 0.595 1.493 0.817 0.908 0.423 0.552 0.136 0.414 0.364 
Smad1 0.642 1.04 1.733 0.337 0.755 0.521 0.298 0.083 0.736 0.45 
Smad3 0.571 3.47 2.165 2.471 1.706 0.568 0.00052 0.0304 0.0135 0.0881 
Smad4 1.783 1.717 1.867 1.703 1.959 0.0746 0.0859 0.0619 0.0885 0.0501 
Smad5 0.903 0.812 3.901 1.582 0.461 0.366 0.417 9.59e-05 0.114 0.645 
Smad6 1.698 2.304 0.522 2.977 3.246 0.0895 0.0212 0.602 0.00291 0.00117 
Smad7 1.139 1.44 0.953 0.97 0.975 0.255 0.15 0.341 0.332 0.329 
Maf 0.524 1.32 1.34 0.981 1.303 0.6 0.187 0.18 0.327 0.193 
Maff 0.069 0.329 0.404 0.234 0.142 0.945 0.742 0.686 0.815 0.887 
Mafg 0.397 0.548 0.921 0.485 1.319 0.691 0.584 0.357 0.628 0.187 
Mafk 0.221 1.015 0.543 0.753 1.559 0.825 0.31 0.587 0.452 0.119 
Ascl1 0.614 0.673 1.765 0.204 1.255 0.539 0.501 0.0775 0.838 0.21 
Ascl2 0.616 1.332 1.861 0.445 1.126 0.538 0.183 0.0627 0.656 0.26 




Maz 0.459 1.23 2.501 0.72 0.097 0.646 0.219 0.0124 0.472 0.923 
Mbd1 1.166 1.51 1.191 0.836 0.281 0.244 0.131 0.234 0.403 0.779 
Mecp2 0.876 0.706 1.757 0.571 1.898 0.381 0.48 0.0789 0.568 0.0577 
Mef2a 0.423 0.667 1.059 0.546 1.624 0.672 0.505 0.289 0.585 0.104 
Mef2b 0.303 1.713 0.689 2.234 1.871 0.762 0.0867 0.491 0.0255 0.0613 
Mef2c 0.741 2.871 2.699 2.407 1.018 0.459 0.00409 0.00696 0.0161 0.309 
Mef2d 1.108 0.013 0.673 0.014 0.099 0.268 0.99 0.501 0.989 0.921 
Meis1 1.289 0.082 0.665 0.748 0.033 0.198 0.935 0.506 0.454 0.974 
Meox1 0.16 0.011 0.092 0.003 0.092 0.873 0.991 0.927 0.998 0.927 
Meox2 1.881 0.361 1.242 1.402 0.701 0.0599 0.718 0.214 0.161 0.483 
Mesp1 0.352 0.774 0.208 0.53 0.282 0.725 0.439 0.835 0.596 0.778 
Mesp2 0.656 0.162 0.184 0.426 0.034 0.512 0.871 0.854 0.67 0.973 
Foxc1 1.127 1.289 0.964 1.098 1.21 0.26 0.198 0.335 0.272 0.226 
Foxd2 0.981 0.325 0.159 0.833 2.28 0.327 0.745 0.874 0.405 0.0226 
Bhlha15 0.103 0.678 0.513 0.48 0.841 0.918 0.498 0.608 0.631 0.4 
Mitf 1.834 0.237 1.814 0.455 0.656 0.0667 0.813 0.0696 0.649 0.512 
Mllt10 0.034 0.604 0.568 0.357 0.02 0.973 0.546 0.57 0.721 0.984 
Aff1 0.344 0.005 0.014 0.238 0.201 0.731 0.996 0.989 0.812 0.841 
Mmp14 0.482 0.966 0.828 0.757 1.349 0.63 0.334 0.408 0.449 0.177 
Foxk1 0.26 0.201 0.198 0.251 0.082 0.795 0.841 0.843 0.802 0.935 
Mnt 0.59 0.119 0.1 0.461 0.206 0.555 0.905 0.92 0.645 0.837 
Morc1 0.715 0.796 0.141 0.788 0.369 0.475 0.426 0.888 0.431 0.712 
Meis2 1.249 1.206 2.086 1.22 1.438 0.212 0.228 0.037 0.223 0.15 
Meis3 0.303 0.443 0.107 0.183 0.054 0.762 0.658 0.915 0.855 0.957 
Msc 1.407 1.147 0.03 2.252 0.111 0.16 0.252 0.976 0.0243 0.912 
Cited2 0.486 1.71 2.765 0.63 0.578 0.627 0.0872 0.00569 0.529 0.563 
Msl3 0.324 1.604 1.395 0.95 0.662 0.746 0.109 0.163 0.342 0.508 
Msx1 0.722 0.003 0.003 0.05 0.171 0.471 0.998 0.998 0.96 0.864 
Msx2 0.311 0.141 0.496 0.097 0.259 0.756 0.888 0.62 0.923 0.796 
Msx3 0.48 0.099 0.299 0.065 0.003 0.631 0.921 0.765 0.948 0.998 
Mtf1 0.164 0.762 0.196 0.122 0.189 0.87 0.446 0.845 0.903 0.85 
Mtf2 1.293 0.52 1.809 0.816 2.077 0.196 0.603 0.0705 0.414 0.0378 
Myb 0.014 3.655 0.751 1.72 1.021 0.989 0.000257 0.453 0.0854 0.307 
Mybl1 0.395 0.143 0.184 0.599 0.509 0.693 0.886 0.854 0.549 0.611 
Mybl2 1.312 0.479 0.269 0.253 0.097 0.19 0.632 0.788 0.8 0.923 
Myc 0.202 2.808 2.623 1.585 0.156 0.84 0.00499 0.00872 0.113 0.876 
Mycs 0.219 0.315 0.281 0.26 0.396 0.827 0.753 0.779 0.795 0.692 




Myf6 0.457 0.234 0.135 0.502 0.344 0.648 0.815 0.893 0.616 0.731 
Myod1 0.61 0.312 1.081 0.141 1.046 0.542 0.755 0.28 0.888 0.296 
Myog 0.448 0.872 0.257 0.381 0.981 0.654 0.383 0.797 0.703 0.327 
Myt1 0.999 1.306 0.815 1.788 1.62 0.318 0.191 0.415 0.0738 0.105 
Myt1l 0.785 3.069 2.01 3.274 1.57 0.433 0.00215 0.0444 0.00106 0.116 
Neurod2 1.271 2.612 1.492 2.604 1.682 0.204 0.00901 0.136 0.00923 0.0926 
Neurog1 0.371 0.015 0.014 0.309 0.102 0.711 0.988 0.989 0.757 0.919 
Nfatc1 0.439 1.463 0.685 0.841 0.897 0.661 0.143 0.493 0.4 0.37 
Nfatc2 0.791 0.755 0.991 1.457 0.608 0.429 0.45 0.322 0.145 0.543 
Nfatc3 1.096 1.387 2.219 2.075 1.997 0.273 0.165 0.0265 0.038 0.0459 
Nfe2 0.473 0.279 0.138 0.141 0.233 0.636 0.78 0.89 0.888 0.816 
Nfe2l1 0.804 0.589 2.068 0.744 0.989 0.422 0.556 0.0386 0.457 0.323 
Nfe2l2 0.47 2.529 0.959 1.81 1.464 0.638 0.0114 0.338 0.0702 0.143 
Nfe2l3 1.25 1.153 0.919 1.212 0.614 0.211 0.249 0.358 0.226 0.539 
Nfia 0.273 0.244 0.972 0.036 0.887 0.785 0.807 0.331 0.971 0.375 
Nfib 0.084 1.468 3.168 0.259 1.114 0.933 0.142 0.00154 0.796 0.265 
Nfic 0.639 0.827 2.272 0.58 1.642 0.523 0.408 0.0231 0.562 0.101 
Nfil3 1.139 1.556 2.153 1.759 0.972 0.254 0.12 0.0313 0.0787 0.331 
Nfix 0.699 0.845 1.662 1.259 2.385 0.485 0.398 0.0966 0.208 0.0171 
Nfkb1 0.387 3.454 1.365 2.006 1.387 0.699 0.000552 0.172 0.0448 0.165 
Nfkb2 0.452 2.848 2.291 1.365 1.619 0.651 0.0044 0.022 0.172 0.106 
Nfya 1.132 1.953 0.596 2.1 0.897 0.257 0.0508 0.551 0.0358 0.369 
Nfyb 0.822 0.23 0.653 0.774 1.01 0.411 0.818 0.514 0.439 0.312 
Nfyc 0.278 1.202 1.375 0.97 1.176 0.781 0.23 0.169 0.332 0.24 
Nhlh1 1.086 0.296 0.436 0.683 0.593 0.277 0.767 0.663 0.495 0.553 
Nhlh2 0.286 0.372 0.381 0.493 0.026 0.775 0.71 0.703 0.622 0.979 
Nkx2-2 1.49 1.815 1.833 0.506 0.448 0.136 0.0695 0.0669 0.613 0.654 
Nkx2-3 0.206 0.023 0.09 0.199 0.179 0.837 0.982 0.928 0.842 0.858 
Nkx2-5 1.047 1.338 0.337 1.393 1.302 0.295 0.181 0.736 0.164 0.193 
Nkx2-6 0.358 0.051 0.269 0.782 0.105 0.72 0.959 0.788 0.435 0.916 
Nkx2-9 0.259 0.166 0.068 0.259 0.296 0.796 0.868 0.946 0.796 0.767 
Nkx3-1 1.84 0.995 0.348 1.103 0.533 0.0658 0.32 0.728 0.27 0.594 
Nkx6-1 0.674 0.147 0.117 0.433 0.135 0.5 0.883 0.907 0.665 0.893 
Nme2 0.604 1.771 0.079 1.779 1.06 0.546 0.0765 0.937 0.0752 0.289 
Mycn 0.66 3.839 2.424 2.475 0.646 0.509 0.000123 0.0154 0.0133 0.518 
Nr4a3 0.138 2.76 1.422 2.408 1.197 0.89 0.00578 0.155 0.016 0.231 
Notch1 0.126 1.126 1.505 0.342 2.57 0.9 0.26 0.132 0.732 0.0102 




Notch3 0.332 0.504 0.114 1.314 0.662 0.74 0.614 0.909 0.189 0.508 
Notch4 0.3 1.232 0.527 2.502 0.941 0.764 0.218 0.598 0.0123 0.347 
Zfml 0.611 0.545 0.691 0.826 2.253 0.541 0.586 0.49 0.409 0.0242 
Uhrf1 0.34 0.238 1.196 0.754 0.503 0.734 0.812 0.232 0.451 0.615 
Npas1 0.202 1.386 2.005 0.679 0.849 0.84 0.166 0.0449 0.497 0.396 
Npas2 0.288 1.561 1.269 0.907 0.54 0.773 0.118 0.204 0.364 0.589 
Nr1i2 1.637 0.064 0.093 0.257 0.213 0.102 0.949 0.926 0.797 0.831 
Nrf1 0.492 0.282 0.558 0.767 0.108 0.623 0.778 0.577 0.443 0.914 
Nrl 0.311 0.295 0.212 0.662 0.004 0.756 0.768 0.832 0.508 0.997 
Nr4a2 0.601 1.955 2.83 1.188 1.638 0.548 0.0505 0.00465 0.235 0.101 
Nobox 0.887 0.279 0.568 0.222 0.155 0.375 0.78 0.57 0.824 0.877 
Sebox 0.159 0.061 0.353 0.231 1.045 0.874 0.951 0.724 0.817 0.296 
Otp 0.193 0.304 0.294 0.181 0.527 0.847 0.761 0.769 0.856 0.598 
Otx1 1.18 0.328 0.794 0.141 0.623 0.238 0.743 0.427 0.888 0.533 
Otx2 1.542 0.729 0.084 0.298 1.377 0.123 0.466 0.933 0.766 0.169 
Ovol1 0.07 0.354 0.648 0.381 0.071 0.944 0.723 0.517 0.703 0.943 
Pax1 0.701 0.066 0.126 0.019 0.265 0.484 0.947 0.9 0.985 0.791 
Pax2 1.026 0.005 0.249 0.055 0.502 0.305 0.996 0.803 0.956 0.616 
Pax3 1.36 2.225 0.871 2.432 0.631 0.174 0.0261 0.384 0.015 0.528 
Pax4 1.024 0.222 1.34 0.295 1.189 0.306 0.824 0.18 0.768 0.235 
Pax5 0.207 0.751 2.47 0.098 0.845 0.836 0.452 0.0135 0.922 0.398 
Pax6 0.494 0.559 0.786 0.459 1.082 0.621 0.576 0.432 0.646 0.279 
Pax7 0.05 0 0.058 0.011 0.041 0.96 1 0.954 0.991 0.967 
Pax8 0.868 1.121 1.387 1.073 0.526 0.385 0.262 0.166 0.283 0.599 
Pax9 0.348 0.299 0.192 0.577 0.073 0.728 0.765 0.848 0.564 0.942 
Pbx1 0.611 1.767 1.371 1.149 1.174 0.541 0.0772 0.17 0.251 0.241 
Pbx2 0.396 1.863 0.664 1.141 1.479 0.692 0.0625 0.507 0.254 0.139 
Pbx3 1.041 1.438 2.458 1.292 1.81 0.298 0.151 0.014 0.197 0.0703 
Pdx1 0.278 0.099 0.715 1.298 1.807 0.781 0.921 0.475 0.194 0.0708 
Etv4 0.472 0.015 0.031 0.025 0.437 0.637 0.988 0.975 0.98 0.662 
Peg3 0.938 0.112 0.005 1.362 0.17 0.348 0.911 0.996 0.173 0.865 
Rhox5 0.982 1.131 2.406 0.782 1.273 0.326 0.258 0.0161 0.434 0.203 
Pgr 0.295 0.54 0.699 1.011 0.486 0.768 0.589 0.485 0.312 0.627 
Phf2 0.5 1.963 0.741 1.319 0.779 0.617 0.0497 0.459 0.187 0.436 
Phtf1 1.837 0.013 0.58 0.094 0.274 0.0662 0.99 0.562 0.925 0.784 
Pou1f1 0.244 1.678 0.345 0.03 0.026 0.807 0.0934 0.73 0.976 0.979 
Pitx1 1.487 0.023 0.1 0.287 0.152 0.137 0.982 0.92 0.774 0.879 




Pitx3 0.572 0.045 0.167 0.418 0.265 0.567 0.964 0.867 0.676 0.791 
Pknox1 0.546 0.429 0.074 0.033 0.452 0.585 0.668 0.941 0.974 0.651 
Pa2g4 0.593 2.379 0.567 2.16 1.974 0.553 0.0174 0.571 0.0308 0.0484 
Pml 0.795 1.271 1.897 0.372 1.568 0.427 0.204 0.0578 0.71 0.117 
Prrx1 1.279 0.504 0.242 1.843 1.67 0.201 0.614 0.809 0.0654 0.095 
Phox2b 0.295 0.049 0.102 0.044 0.317 0.768 0.961 0.919 0.965 0.751 
Cnot7 0.174 0.146 0.799 0.262 1.798 0.862 0.884 0.424 0.793 0.0722 
Pou2f1 0.905 0.622 2.193 0.596 0.636 0.366 0.534 0.0283 0.551 0.525 
Pou2f2 0.274 0.013 0.132 0.01 0.051 0.784 0.99 0.895 0.992 0.959 
Pou2f3 1.353 0.393 2.559 1.326 0.504 0.176 0.694 0.0105 0.185 0.614 
Pou3f1 0.968 0.592 1.838 1.214 0.949 0.333 0.554 0.066 0.225 0.343 
Pou3f2 0.127 0.187 0.132 0.466 0.798 0.899 0.852 0.895 0.641 0.425 
Pou3f3 0.787 1.905 1.906 2.014 0.779 0.431 0.0568 0.0566 0.044 0.436 
Pou3f4 0.353 1.438 1.244 0.288 0.637 0.724 0.15 0.214 0.773 0.524 
Pou4f1 0.829 1.943 2.312 1.043 0.674 0.407 0.052 0.0208 0.297 0.5 
Pou4f2 0.024 0.509 1.388 1.002 1.962 0.981 0.611 0.165 0.316 0.0498 
Pou4f3 0.662 0.128 0.683 0.558 0.465 0.508 0.898 0.494 0.577 0.642 
Pou5f1 0.765 0.316 0.239 0.613 0.324 0.444 0.752 0.811 0.54 0.746 
Pou6f1 0.188 0.767 1.131 0.151 0.512 0.851 0.443 0.258 0.88 0.609 
Ppara 0.419 0.562 0.199 1.676 0.253 0.675 0.574 0.842 0.0937 0.8 
Ppard 0.211 2.293 1.547 1.902 1.978 0.833 0.0219 0.122 0.0572 0.0479 
Pparg 0.201 0.152 0.126 0.145 1.268 0.841 0.879 0.9 0.885 0.205 
Prkdc 0.752 0.277 2.014 0.015 1.263 0.452 0.782 0.044 0.988 0.207 
Mapk8ip1 0.344 1.34 2.179 0.74 0.519 0.731 0.18 0.0294 0.459 0.604 
Prop1 1.092 0.048 0.026 1.135 0.113 0.275 0.962 0.979 0.256 0.91 
Prox1 0.291 0.065 2.186 0.194 0.982 0.771 0.948 0.0288 0.846 0.326 
Psmc3ip 0.864 4.536 2.39 2.228 1.687 0.388 5.72e-06 0.0168 0.0259 0.0915 
Rhox6 0.116 0.354 0.279 0.281 0.637 0.908 0.723 0.78 0.779 0.524 
Ptf1a 0.768 0.73 2.247 0.457 0.865 0.443 0.465 0.0246 0.648 0.387 
Ash1l 0.208 2.753 1.744 2.081 2.002 0.835 0.0059 0.0812 0.0374 0.0453 
Zfp286 0.689 1.199 1.474 1.482 2.094 0.491 0.23 0.14 0.138 0.0362 
Pura 0.278 1.181 1.322 1.003 1.699 0.781 0.237 0.186 0.316 0.0894 
Purb 0.758 2.33 1.203 1.336 1.309 0.448 0.0198 0.229 0.182 0.19 
Zfp3 0.937 0.764 0.898 1.513 1.466 0.349 0.445 0.369 0.13 0.143 
Zfp184 0.36 0.083 1.187 0.038 0.303 0.719 0.934 0.235 0.97 0.762 
Zbtb12 0.166 1.896 0.145 0.509 0.273 0.868 0.058 0.885 0.611 0.785 
Rara 0.571 1.314 1.647 1.648 0.918 0.568 0.189 0.0996 0.0994 0.359 




Rax 0.249 1.086 0.235 0.559 1.08 0.803 0.278 0.814 0.576 0.28 
Klf11 0.651 0.028 0.553 0.061 0.584 0.515 0.978 0.58 0.951 0.559 
Rhox4e 0.235 0.723 0.233 0.233 0.206 0.814 0.469 0.816 0.816 0.837 
Zzef1 0.14 0.073 0.391 0.039 0.16 0.889 0.942 0.696 0.969 0.873 
Gsc2 0.975 0 0 0.235 0.119 0.33 1 1 0.814 0.905 
Grhl1 0.493 1.374 2.421 1.072 1.455 0.622 0.169 0.0155 0.284 0.146 
Rb1 0.035 0.927 2.01 0.643 0.06 0.972 0.354 0.0445 0.52 0.952 
Rbl1 1.084 3.03 1.363 1.794 0.893 0.278 0.00245 0.173 0.0729 0.372 
Rbl2 0.169 1.322 1.766 0.457 0.626 0.866 0.186 0.0774 0.648 0.531 
Rbpj 0.693 1.857 0.581 0.916 1.143 0.488 0.0633 0.561 0.359 0.253 
Rbpjl 0.114 0.08 0.773 0.253 0.202 0.909 0.936 0.439 0.8 0.84 
Rel 0.327 0.137 0.879 0.107 0.141 0.744 0.891 0.38 0.915 0.888 
Rela 0.761 2.38 0.8 2.548 2.539 0.447 0.0173 0.424 0.0108 0.0111 
Relb 0.731 0.823 0.388 0.225 0.112 0.465 0.41 0.698 0.822 0.911 
Rest 1.35 1.951 0.885 2.647 1.763 0.177 0.051 0.376 0.00811 0.0779 
Trim27 0.879 1.116 0.861 1.295 2.077 0.379 0.264 0.389 0.195 0.0378 
Rfx1 0.752 0.353 0.06 0.921 0.605 0.452 0.724 0.952 0.357 0.545 
Rfx2 0.337 0.073 0.283 0.044 0.823 0.736 0.942 0.777 0.965 0.411 
Rfx3 1.339 1.732 1.347 1.303 0.786 0.181 0.0832 0.178 0.192 0.432 
Rfxank 0.375 0.001 0.061 0.053 0.255 0.708 0.999 0.951 0.958 0.799 
Rnf4 0.121 1.71 0.262 1.168 0.67 0.904 0.0873 0.793 0.243 0.503 
Rora 0.425 0.859 4.569 0.502 3.25 0.671 0.39 4.89e-06 0.616 0.00116 
Rorc 0.459 0.421 1.86 0.362 0.548 0.646 0.674 0.0628 0.717 0.584 
Rpl7 0.228 2.176 0.341 1.592 1.052 0.82 0.0295 0.733 0.111 0.293 
Rxra 0.261 0.028 0.217 0.226 0.166 0.794 0.978 0.828 0.821 0.868 
Rxrb 0.215 1.462 1.851 1.71 0.739 0.83 0.144 0.0641 0.0873 0.46 
Rxrg 1.124 1.955 1.914 1.788 1.234 0.261 0.0505 0.0556 0.0737 0.217 
Ncor1 0.04 1.207 0.722 0.559 1.141 0.968 0.227 0.47 0.576 0.254 
Nr1h4 0.768 0.088 0.138 0.534 0.83 0.442 0.93 0.89 0.593 0.407 
Prrx2 0.211 0.685 2.699 0.634 0.783 0.833 0.493 0.00695 0.526 0.434 
Satb1 1.281 2.526 1.434 2.602 0.999 0.2 0.0115 0.152 0.00926 0.318 
Nkx1-2 0.251 0.225 0.676 0.324 0.224 0.802 0.822 0.499 0.746 0.823 
Scx 0.18 0.67 0.832 0.188 0.395 0.857 0.503 0.405 0.851 0.693 
Foxp3 0.499 1.694 1.404 1.236 0.543 0.618 0.0902 0.16 0.216 0.587 
Sfpi1 0.65 0.837 1.008 0.524 0.709 0.516 0.403 0.314 0.6 0.478 
Zfp106 0.181 0.726 0.255 0.789 0.492 0.856 0.468 0.799 0.43 0.623 
Shox2 0.388 1.659 0.308 1.387 1.36 0.698 0.0971 0.758 0.166 0.174 




Sim2 0.65 0.188 0.046 0.312 0.159 0.516 0.851 0.963 0.755 0.874 
Sin3a 1.497 1.992 1.401 3.696 1.205 0.134 0.0464 0.161 0.000219 0.228 
Six1 0.141 2.002 1.069 2.458 1.951 0.888 0.0453 0.285 0.014 0.051 
Six2 1.456 0.256 0.504 0.828 0.021 0.145 0.798 0.614 0.408 0.983 
Six3 0.302 0.164 0 0.113 0.234 0.763 0.87 1 0.91 0.815 
Six4 0.73 3.074 1.68 1.072 0.949 0.466 0.00211 0.093 0.284 0.343 
Six5 0.098 0.328 0.794 0.059 0.018 0.922 0.743 0.427 0.953 0.986 
Six6 0.277 0.114 0.308 0.337 0.725 0.782 0.909 0.758 0.736 0.469 
Snai2 0.52 0.558 0.989 0.976 1.136 0.603 0.577 0.323 0.329 0.256 
Hltf 1.644 1.868 0.7 1.06 2.081 0.1 0.0617 0.484 0.289 0.0374 
Smarca4 0.798 1.082 0.623 1.012 1.586 0.425 0.279 0.533 0.312 0.113 
Kdm5c 0.133 1.69 1.239 1.809 2.777 0.894 0.0911 0.215 0.0705 0.00549 
Snai1 0.43 2.33 0.985 1.849 1.291 0.667 0.0198 0.325 0.0645 0.197 
Sox1 0.17 0.033 0.061 0.132 0.04 0.865 0.974 0.951 0.895 0.968 
Sox10 0.52 1.012 2.546 0.593 0.806 0.603 0.311 0.0109 0.553 0.42 
Sox11 0.833 1.403 2.718 0.946 1.245 0.405 0.161 0.00657 0.344 0.213 
Sox13 1.078 0.815 1.471 0.792 1.094 0.281 0.415 0.141 0.428 0.274 
Sox14 0.408 0.043 0.311 0.048 0.727 0.683 0.966 0.756 0.962 0.467 
Sox15 0.732 0.29 0.344 0.251 0.519 0.464 0.772 0.731 0.802 0.604 
Sox17 0.616 0.331 0.034 0.517 0.337 0.538 0.741 0.973 0.605 0.736 
Sox18 0.084 2.059 3.248 0.3 0.806 0.933 0.0395 0.00116 0.764 0.42 
Sox2 1.001 2.49 0.803 2.148 0.667 0.317 0.0128 0.422 0.0317 0.505 
Sox4 0.523 1.655 2.626 1.798 1.01 0.601 0.0979 0.00864 0.0722 0.312 
Sox5 2.46 2.054 1.837 3.029 0.346 0.0139 0.04 0.0662 0.00245 0.729 
Sox6 0.008 0.901 0.024 0.036 0.206 0.994 0.368 0.981 0.971 0.837 
Sox7 0.09 0.221 0.403 0.087 0.183 0.928 0.825 0.687 0.931 0.855 
Sox8 0.421 1.49 0.759 1.316 1.845 0.674 0.136 0.448 0.188 0.0651 
Sox9 0.941 1.068 0.317 0.9 1.35 0.347 0.286 0.751 0.368 0.177 
Sp1 0.534 2.515 2.742 1.274 0.65 0.593 0.0119 0.0061 0.203 0.516 
Sp3 0.023 0.147 2.149 0.016 0.64 0.982 0.883 0.0316 0.987 0.522 
Sp4 2.297 0.365 0.18 0.068 0.21 0.0216 0.715 0.857 0.946 0.834 
Zbtb7c 0.113 0.092 0.434 0.029 0.17 0.91 0.927 0.664 0.977 0.865 
Spic 1.68 0.063 0.617 0.365 0.084 0.0929 0.95 0.537 0.715 0.933 
Csrnp2 1.093 0.426 1.121 1.019 0.45 0.274 0.67 0.262 0.308 0.653 
Srebf1 0.497 3.192 1.681 3.196 2.419 0.619 0.00142 0.0928 0.0014 0.0156 
Srebf2 0.953 0.664 1.532 0.972 1.386 0.341 0.507 0.125 0.331 0.166 
Srf 0.979 0.375 1.198 0.908 1.203 0.327 0.708 0.231 0.364 0.229 




Mlxip 1.129 1.33 2.031 0.877 1.097 0.259 0.183 0.0423 0.38 0.272 
Stat1 0.898 1.77 1.147 3.48 2.088 0.369 0.0767 0.251 0.000502 0.0368 
Stat2 0.395 1.312 1.591 0.685 0.986 0.693 0.189 0.112 0.493 0.324 
Stat3 0.77 0.001 0.029 0.415 0.233 0.441 0.999 0.977 0.678 0.816 
Stat4 3.917 0.842 0.458 1.743 0.303 
8.97e-
05 
0.4 0.647 0.0813 0.762 
Stat5a 0.031 0.899 1.325 0.16 1.003 0.975 0.369 0.185 0.873 0.316 
Stat5b 1.08 1.76 1.964 1.372 1.573 0.28 0.0785 0.0496 0.17 0.116 
Stat6 0.433 3.015 0.176 3.782 1.473 0.665 0.00257 0.86 0.000155 0.141 
Creb3l2 1.11 1.318 1.526 1.605 1.102 0.267 0.187 0.127 0.109 0.27 
Creb3l3 0.41 0.005 0.181 0.059 0.333 0.682 0.996 0.856 0.953 0.739 
Zdhhc9 1.445 0.377 1.02 0.59 0.581 0.148 0.706 0.308 0.555 0.561 
Bhlhe40 1.049 1.071 2.556 1.298 1.533 0.294 0.284 0.0106 0.194 0.125 
Zfp280c 0.348 0.269 2.091 0.175 1.79 0.728 0.788 0.0365 0.861 0.0735 
Zc3hav1l 0.581 0.602 0.712 0.745 1.04 0.561 0.547 0.477 0.456 0.298 
Supt4h1 0.758 0.59 0.331 0.646 0.999 0.449 0.555 0.741 0.518 0.318 
Zfp710 0.213 1.278 0.294 0.659 1.642 0.831 0.201 0.769 0.51 0.101 
Supt6h 0.578 0.776 0.67 0.472 0.999 0.563 0.438 0.503 0.637 0.318 
Tcfe3 0.104 0.671 1.046 0.77 1.53 0.917 0.502 0.295 0.441 0.126 
Hoxc10 0.904 0.465 0.643 1.859 0.69 0.366 0.642 0.52 0.063 0.49 
T 1.477 0.261 1.497 0.936 0.886 0.14 0.794 0.134 0.349 0.376 
Zfp719 0.598 0.23 2.46 0.497 0.935 0.55 0.818 0.0139 0.619 0.35 
Zfp180 0.988 1.149 0.503 0.55 1.589 0.323 0.25 0.615 0.582 0.112 
Zkscan2 0.436 1.802 0.967 1.357 1.019 0.663 0.0715 0.334 0.175 0.308 
Zfp526 0.991 0.264 0.519 0.369 0.084 0.322 0.792 0.604 0.712 0.933 
Zfp677 1.069 0.23 1.454 0.43 1.324 0.285 0.818 0.146 0.667 0.186 
Mkx 1.203 1.484 0.328 0.335 0.4 0.229 0.138 0.743 0.738 0.689 
Kcnh8 0.682 1.322 0.688 0.324 1.684 0.495 0.186 0.491 0.746 0.0921 
Tfdp2 0.926 1.145 2.248 2.45 1.502 0.354 0.252 0.0246 0.0143 0.133 
Zfyve26 0.639 1.572 0.261 0.561 0.025 0.523 0.116 0.794 0.575 0.98 
Cc2d1a 0.315 0.015 1.128 0.061 0.1 0.753 0.988 0.259 0.951 0.92 
Zswim4 0.71 0.119 0.176 0.38 0.368 0.478 0.905 0.86 0.704 0.713 
Lcor 0.57 0.537 1.022 0.645 2.057 0.569 0.591 0.307 0.519 0.0397 
Satb2 0.99 1.458 1.208 1.2 1.312 0.322 0.145 0.227 0.23 0.19 
Gabpb2 1.159 0.5 5.073 0.243 1.436 0.247 0.617 3.92e-07 0.808 0.151 
Zbbx 0.035 0.155 0.832 0.273 0.014 0.972 0.877 0.405 0.785 0.989 
Taf1b 0.058 0.151 0.305 0.024 0.112 0.954 0.88 0.76 0.981 0.911 




Tal1 0.845 0.021 0.138 0.117 0.187 0.398 0.983 0.89 0.907 0.852 
Tal2 0.349 0.213 0.075 0.478 0.08 0.727 0.831 0.94 0.633 0.936 
Tbl1x 1.035 0.261 0.261 1.548 1.096 0.301 0.794 0.794 0.122 0.273 
Tbp 0.199 0.762 0.979 0.674 0.244 0.842 0.446 0.328 0.5 0.807 
Tbr1 0.97 3.079 1.413 2.167 0.946 0.332 0.00208 0.158 0.0302 0.344 
Zfp598 1.207 2.969 1.853 1.626 1.355 0.228 0.00298 0.0639 0.104 0.175 
Tbx1 1.248 0.155 0.23 0.165 0.298 0.212 0.877 0.818 0.869 0.766 
Tbx15 0.279 1.097 1.157 1.516 1.81 0.78 0.272 0.247 0.129 0.0703 
Tbx2 1.232 0.72 0 0.194 1.325 0.218 0.471 1 0.846 0.185 
Tbx3 0.944 0.805 1.145 1.072 1.4 0.345 0.421 0.252 0.284 0.162 
Tbx4 0.327 0.239 0.472 0.469 0.685 0.744 0.811 0.637 0.639 0.493 
Tbx5 0.454 0.169 0.059 0.217 0.063 0.65 0.866 0.953 0.828 0.95 
Tbx6 0.533 0.545 0.285 0.668 0.756 0.594 0.586 0.776 0.504 0.45 
Hnf1a 0.507 0.179 0.319 0.878 0.228 0.612 0.858 0.75 0.38 0.82 
Tcf12 0.659 1.912 2.614 0.891 0.426 0.51 0.0558 0.00895 0.373 0.67 
Tcf15 0.536 0.961 1.034 0.145 0.457 0.592 0.336 0.301 0.885 0.648 
Zfp354a 0.604 2.761 1.9 2.286 1.614 0.546 0.00576 0.0575 0.0222 0.107 
Hnf1b 1.189 0.473 0.504 0.419 0.787 0.234 0.636 0.614 0.675 0.431 
Sox30 0.73 0.636 0.876 1.342 0.718 0.465 0.525 0.381 0.18 0.473 
Tcf20 0.83 0.368 0.294 0.008 0.198 0.406 0.713 0.769 0.994 0.843 
Tcf21 0.493 0.634 0.003 0.464 0.196 0.622 0.526 0.998 0.643 0.845 
Tcf4 0.651 3.078 1.128 3.457 1.223 0.515 0.00209 0.259 0.000546 0.221 
Tcf7 0.316 4.031 1.257 3.736 1.923 0.752 5.56e-05 0.209 0.000187 0.0545 
Tcf7l1 0.303 0.714 0.108 0.862 0.735 0.762 0.476 0.914 0.388 0.462 
Tcf7l2 0.788 1.184 1.593 2.007 1.209 0.431 0.237 0.111 0.0447 0.227 
Mll1 1.179 0.015 0.891 0.203 1.584 0.238 0.988 0.373 0.839 0.113 
Zeb1 0.077 0.213 0.71 0.02 0.794 0.939 0.831 0.478 0.984 0.427 
Tcfap2a 2.475 0.628 1.431 0.631 0.224 0.0133 0.53 0.152 0.528 0.823 
Tcfap2b 0.53 0.626 1.352 0.354 1.089 0.596 0.531 0.176 0.723 0.276 
Tcfap2c 0.321 1.936 2.098 0.622 1.216 0.748 0.0528 0.0359 0.534 0.224 
Tcfcp2 0.587 0.005 1.162 0.03 1.42 0.557 0.996 0.245 0.976 0.156 
Tcf3 0.34 4.157 1.668 2.364 1.264 0.734 3.23e-05 0.0954 0.0181 0.206 
Tcfeb 0.797 0.155 1.231 0.552 1.385 0.426 0.877 0.218 0.581 0.166 
Tcfec 0.643 0.17 0.305 0.141 0.082 0.52 0.865 0.76 0.888 0.935 
Vps72 1.051 0.113 0.185 0.447 1.685 0.293 0.91 0.853 0.655 0.092 
Mlx 0.969 0.479 0.745 0.888 1.529 0.333 0.632 0.456 0.374 0.126 
Zcchc6 0.226 0.131 0.344 0.286 0.069 0.821 0.896 0.731 0.775 0.945 




Kdm5a 1.611 0.003 1.988 0.238 1.292 0.107 0.998 0.0468 0.812 0.196 
Csrnp1 0.251 0.475 0.451 0.008 0.21 0.802 0.635 0.652 0.994 0.834 
Zmat1 0.204 0.653 0.927 0.867 2.098 0.838 0.514 0.354 0.386 0.0359 
Zfp365 0.526 2.042 2.425 1.328 1.064 0.599 0.0411 0.0153 0.184 0.288 
Alx1 1.175 0.184 0.099 0.033 0.088 0.24 0.854 0.921 0.974 0.93 
Phf1 0.451 1.142 2.347 0.879 1.979 0.652 0.254 0.0189 0.379 0.0478 
Tead1 0.951 1.432 1.131 1.118 0.196 0.342 0.152 0.258 0.263 0.845 
Tead2 0.984 1.803 0.676 1.709 1.701 0.325 0.0714 0.499 0.0875 0.0889 
Tead3 1.119 1.756 0.113 1.077 0.824 0.263 0.079 0.91 0.281 0.41 
Tead4 0.797 0.044 0.094 0.038 0.298 0.426 0.965 0.925 0.97 0.766 
Tef 0.466 2.3 1.888 1.463 0.636 0.641 0.0214 0.059 0.144 0.525 
Tada2a 0.729 0.368 0.465 0.496 2.08 0.466 0.713 0.642 0.62 0.0375 
Trim25 0.766 3.154 2.961 1.483 0.705 0.444 0.00161 0.00307 0.138 0.481 
Hlf 0.664 2.581 1.962 1.793 0.871 0.507 0.00986 0.0498 0.073 0.384 
Myst2 0.264 0.683 0.738 0.626 0.202 0.792 0.494 0.46 0.531 0.84 
Nr1d1 0.545 0.766 1.138 0.65 0.763 0.586 0.443 0.255 0.516 0.446 
Baz1a 0.555 1.58 1.867 1.052 1.017 0.579 0.114 0.0619 0.293 0.309 
Zfand3 1.201 0.19 0.079 0.617 0.937 0.23 0.849 0.937 0.537 0.349 
Zfyve1 0.274 1.37 1.584 1.356 0.41 0.784 0.171 0.113 0.175 0.682 
Tfam 0.203 1.619 0.01 0.998 0.238 0.839 0.105 0.992 0.318 0.812 
Tfdp1 0.656 1.941 2.503 1.424 0.759 0.512 0.0522 0.0123 0.155 0.448 
Pou6f2 0.16 0.383 0.06 0.673 0.704 0.873 0.702 0.952 0.501 0.481 
Tsc22d1 0.586 1.037 0.78 0.35 0.549 0.558 0.3 0.436 0.726 0.583 
Zfp322a 0.572 0.167 0.57 1.041 1.367 0.567 0.867 0.569 0.298 0.171 
Tgif1 0.662 4.176 3.72 3.936 1.629 0.508 2.97e-05 2e-04 8.27e-05 0.103 
Thra 0.677 2.52 2.726 1.757 1.134 0.499 0.0117 0.00641 0.079 0.257 
Thrb 0.464 1.811 1.059 1.225 1.207 0.643 0.0702 0.29 0.221 0.228 
Zfyve16 0.189 1.034 1.701 0.992 0.389 0.85 0.301 0.0889 0.321 0.697 
Klf10 0.522 1.177 0.952 0.598 1.266 0.602 0.239 0.341 0.55 0.206 
Trim28 1.254 1.361 1.284 1.489 2.281 0.21 0.173 0.199 0.136 0.0226 
Mier3 0.278 0.251 1.51 0.164 1.053 0.781 0.802 0.131 0.87 0.292 
Nkx2-1 1.096 1.109 1.172 1.804 0.077 0.273 0.267 0.241 0.0713 0.939 
Rarb 0.584 1.836 1.729 2.923 1.401 0.559 0.0664 0.0839 0.00347 0.161 
Zfp503 0.391 3.907 0.61 2.586 1.587 0.696 9.35e-05 0.542 0.0097 0.113 
Tle4 0.727 1.57 1.245 1.665 1.577 0.467 0.116 0.213 0.096 0.115 
Nr2e1 0.634 1.028 2.294 0.914 0.338 0.526 0.304 0.0218 0.36 0.735 
Tlx1 0.698 0.187 0.345 0.561 0.64 0.485 0.852 0.73 0.575 0.522 




Zmym5 0.464 0.854 1.441 0.809 1.937 0.643 0.393 0.149 0.418 0.0528 
Hmbox1 0.116 0.156 0.324 0.124 0.523 0.908 0.876 0.746 0.901 0.601 
Top2a 0.451 3.263 0.485 3.683 1.833 0.652 0.0011 0.628 0.000231 0.0668 
Top2b 1.078 0.309 1.669 0.553 1.486 0.281 0.757 0.0952 0.58 0.137 
Nr2c1 0.665 0.253 0.811 0.167 0.485 0.506 0.8 0.418 0.867 0.628 
Nr2c2 0.875 2.694 1.529 2.119 1.965 0.382 0.00706 0.126 0.0341 0.0494 
Trp53 0.242 3.957 0.478 2.811 1.716 0.809 7.6e-05 0.633 0.00493 0.0861 
Trp63 0.121 0.084 0.019 0.473 0.364 0.904 0.933 0.985 0.636 0.716 
Trp73 0.565 0 0.231 0.088 0.29 0.572 1 0.817 0.93 0.772 
Twist1 1.105 3.233 1.291 3.214 0.863 0.269 0.00123 0.197 0.00131 0.388 
Zrsr2 0.732 0.328 0.377 0.455 0.559 0.464 0.743 0.706 0.649 0.576 
Ubp1 0.414 0.169 2.096 0.425 1.232 0.679 0.866 0.0361 0.671 0.218 
Uncx 1.407 0.098 1.384 0.147 0.912 0.16 0.922 0.166 0.883 0.362 
Nr1h3 0.118 0.203 0.025 0.192 1.02 0.906 0.839 0.98 0.848 0.308 
Nr1h2 0.68 0.212 0.499 1.298 2.571 0.497 0.832 0.618 0.194 0.0101 
Usf1 1.427 0.395 0.058 0.493 1.695 0.154 0.693 0.954 0.622 0.09 
Usf2 0.286 1.241 2.592 0.723 1.305 0.775 0.215 0.00954 0.47 0.192 
Utf1 0.366 0.104 0.206 0.252 1.375 0.714 0.917 0.837 0.801 0.169 
Sox21 0.029 0.809 0.954 0.375 1.417 0.977 0.418 0.34 0.708 0.156 
Vav1 0.596 1.574 0.482 1.74 1.7 0.551 0.115 0.63 0.0818 0.0891 
Vax1 1.031 0 0.019 0.03 0.009 0.302 1 0.985 0.976 0.993 
Vdr 0.371 0.117 0.193 0.64 0.377 0.711 0.907 0.847 0.522 0.706 
Zc3h3 0.162 0.025 0.123 0.069 0.596 0.871 0.98 0.902 0.945 0.551 
Zfp7 0.489 1.1 1.469 1.482 0.987 0.625 0.271 0.142 0.138 0.324 
Zbed4 0.27 0.802 1.373 0.102 0.183 0.787 0.423 0.17 0.919 0.855 
Dbx2 1.025 1.426 0.866 0.753 0.892 0.305 0.154 0.387 0.451 0.372 
Baz1b 1.195 0.543 0.667 0.397 1.685 0.232 0.587 0.505 0.691 0.092 
Atf7 0.88 0.628 1.568 0.637 2.345 0.379 0.53 0.117 0.524 0.019 
Zmat3 0.27 0.426 0.533 0.412 0.567 0.787 0.67 0.594 0.68 0.571 
Wiz 0.589 1.295 0.903 1.324 1.06 0.556 0.195 0.366 0.185 0.289 
Dzip3 0.905 2.048 0.204 3.866 1.469 0.365 0.0405 0.838 0.000111 0.142 
Wt1 0.714 1.334 1.607 0.986 0.572 0.475 0.182 0.108 0.324 0.567 
Xbp1 0.939 2.861 0.941 1.814 1.256 0.347 0.00423 0.347 0.0697 0.209 
Zdhhc14 0.727 1.369 2.641 0.897 0.851 0.467 0.171 0.00826 0.37 0.395 
Flywch1 0.844 0.95 0.718 0.936 1.098 0.399 0.342 0.473 0.349 0.272 
Zfp523 0.813 1.43 2.744 0.749 0.599 0.416 0.153 0.00608 0.454 0.549 
Trerf1 0.608 0.354 0.151 0.357 0.029 0.543 0.723 0.88 0.721 0.977 




Zfp521 1.915 0.63 2.077 0.699 1.807 0.0555 0.529 0.0378 0.485 0.0708 
Onecut2 1.157 0.873 1.314 1.108 1.934 0.247 0.383 0.189 0.268 0.0531 
Npas4 1.054 1.758 2.5 0.532 0.749 0.292 0.0787 0.0124 0.595 0.454 
Gm98 0.373 0.085 0.009 0.098 0.162 0.709 0.932 0.993 0.922 0.871 
Rorb 0.425 1.047 0.166 0.861 0.006 0.671 0.295 0.868 0.389 0.995 
Dmrt2 0.713 0.099 0.586 0.189 0.327 0.476 0.921 0.558 0.85 0.744 
Glis3 0.021 0.016 0.068 0.204 0 0.983 0.987 0.946 0.838 1 
Ybx1 0.51 2.7 2.793 1.205 0.919 0.61 0.00694 0.00523 0.228 0.358 
Taf5 1.41 0.536 0.287 0.459 0.542 0.159 0.592 0.774 0.646 0.588 
Yy1 0.248 0.962 0.095 1.107 0.43 0.804 0.336 0.924 0.268 0.667 
Zfp1 0.693 1.016 0.795 0.443 1.692 0.488 0.31 0.426 0.658 0.0907 
Zranb3 0.534 0.011 1.993 0.102 0.181 0.593 0.991 0.0462 0.919 0.856 
Zbtb17 0.151 0.034 1.341 0.05 0.489 0.88 0.973 0.18 0.96 0.625 
Zfp281 0.73 0.636 0.927 1.579 0.536 0.465 0.525 0.354 0.114 0.592 
Zfp105 0.329 0.423 1.185 0.653 0.693 0.742 0.672 0.236 0.514 0.488 
Zbtb41 0.447 0.112 1.291 0.034 1.527 0.655 0.911 0.197 0.973 0.127 
Zfp11 0.066 0.507 0.147 0.146 0.38 0.947 0.612 0.883 0.884 0.704 
Zfp13 0.775 0.313 0.054 0.054 0.419 0.439 0.754 0.957 0.957 0.675 
Pcgf2 0.222 0.415 0.524 0.441 0.556 0.824 0.678 0.6 0.659 0.578 
Zfp148 0.384 0.104 0.877 0.025 1.748 0.701 0.917 0.381 0.98 0.0805 
Atf6 0.483 0.482 1.002 0.328 1.145 0.629 0.63 0.316 0.743 0.252 
Zfp161 0.797 0.006 0.268 0.444 0.673 0.425 0.995 0.789 0.657 0.501 
Ahctf1 0.412 1.684 2.953 0.917 0.905 0.68 0.0922 0.00315 0.359 0.365 
Zfp2 0.643 2.699 2.483 3.028 2.061 0.52 0.00695 0.013 0.00247 0.0393 
Zfp207 0.018 1.746 1.703 0.785 0.208 0.986 0.0808 0.0885 0.432 0.835 
Zfand5 0.373 1.206 0.728 0.639 1.79 0.709 0.228 0.466 0.523 0.0735 
Zfp239 0.731 3.281 1.685 2.8 1.417 0.465 0.00103 0.0919 0.00511 0.157 
Zfp26 0.909 0.184 0.567 0.421 1.94 0.363 0.854 0.571 0.674 0.0524 
Tcfap2d 0.239 1.056 2.159 1.603 0.377 0.811 0.291 0.0309 0.109 0.706 
Zfp28 0.617 0.006 1.138 0.087 1.548 0.537 0.995 0.255 0.931 0.122 
Zscan2 0.178 0.387 0.035 0.478 0.251 0.859 0.699 0.972 0.633 0.802 
Zfp30 0.749 1.427 1.705 1.17 1.006 0.454 0.154 0.0882 0.242 0.314 
Zfp36 0.696 2.957 1.426 1.888 1.286 0.486 0.0031 0.154 0.059 0.198 
Zfp37 0.219 0.256 0.292 0.421 0.434 0.827 0.798 0.77 0.674 0.664 
Zscan21 0.976 1.371 1.765 0.754 0.645 0.329 0.171 0.0776 0.451 0.519 
Zfp42 0.523 0.331 0.346 0.216 1.971 0.601 0.741 0.729 0.829 0.0487 
Zfp46 0.61 0.181 0.051 0.388 0.189 0.542 0.856 0.959 0.698 0.85 




Zfp57 0.08 1.299 1.019 0.162 0.604 0.936 0.194 0.308 0.871 0.546 
Zfp62 0.156 0.26 1.419 0.366 2.059 0.876 0.795 0.156 0.714 0.0395 
Zfp64 1.143 3.254 1.042 2.23 1.7 0.253 0.00114 0.297 0.0258 0.0892 
Zbtb7b 0.451 0.006 0.157 0.197 0.229 0.652 0.995 0.875 0.844 0.819 
Zcchc2 0.596 1.984 2.488 1.425 0.55 0.551 0.0473 0.0128 0.154 0.582 
Zfp9 1.425 0.207 0.534 0.52 1.455 0.154 0.836 0.593 0.603 0.146 
Zfp90 0.234 0.099 0.324 0.377 0.736 0.815 0.921 0.746 0.706 0.462 
Zfp92 0.657 0.221 0.001 0.358 0.185 0.511 0.825 0.999 0.72 0.853 
Zkscan5 0.568 0.124 0.113 0.124 0.145 0.57 0.901 0.91 0.901 0.885 
Zscan12 0.239 1.788 1.202 1.874 2.409 0.811 0.0739 0.229 0.0609 0.016 
Zfpm1 0.982 0.9 1.531 0.798 1.032 0.326 0.368 0.126 0.425 0.302 
Zfpm2 0.999 2.106 1.843 1.483 1.179 0.318 0.0352 0.0653 0.138 0.238 
Zfr 0.194 1.303 0.943 0.741 1.06 0.846 0.193 0.346 0.459 0.289 
Zfx 0.216 0.261 0.181 0.275 1.397 0.829 0.794 0.856 0.783 0.162 
Snapc4 0.377 0.019 0.864 0.103 1.047 0.706 0.985 0.388 0.918 0.295 
Rexo4 0.574 0.35 0.344 0.668 1 0.566 0.726 0.731 0.504 0.317 
Zhx1 0.417 0.004 0.962 0.044 1.608 0.677 0.997 0.336 0.965 0.108 
Zic1 0.656 1.949 1.758 1.473 1.296 0.512 0.0513 0.0788 0.141 0.195 
Zic2 0.229 0.178 0.123 0.479 1.477 0.819 0.859 0.902 0.632 0.14 
Zic3 0.404 1.344 1.372 1.101 1.994 0.686 0.179 0.17 0.271 0.0461 
Zik1 0.083 0.83 1.636 0.733 1.73 0.934 0.407 0.102 0.464 0.0836 
Ikzf1 1.116 1.705 1.706 1.371 0.637 0.264 0.0882 0.088 0.17 0.524 
Ikzf2 0.803 0.151 0.147 0.287 1.052 0.422 0.88 0.883 0.774 0.293 
Ikzf3 0.519 0.028 0.425 0.26 0.911 0.604 0.978 0.671 0.795 0.362 
Ikzf4 0.07 0 0 0.197 0.14 0.944 1 1 0.844 0.889 
Zdhhc5 0.623 2.17 2.185 2.062 0.968 0.533 0.03 0.0289 0.0392 0.333 
Zfp770 0.053 0.16 0.358 0.014 1.228 0.958 0.873 0.72 0.989 0.219 
Ebf4 0.009 1.234 0.434 0.407 0.054 0.993 0.217 0.664 0.684 0.957 
Nkx2-4 0.277 0.024 0.054 0.256 0.239 0.782 0.981 0.957 0.798 0.811 
Zfp341 1.628 0.02 0.237 0.335 2.63 0.104 0.984 0.813 0.738 0.00854 
Phf20 0.268 1.242 1.134 0.696 0.412 0.789 0.214 0.257 0.487 0.68 
Tgif2 0.869 2.628 0.834 1.8 1.066 0.385 0.00859 0.404 0.0718 0.286 
Zfp334 0.813 1.181 0.574 1.199 0.558 0.416 0.237 0.566 0.231 0.577 
Zmynd8 0.058 0.406 1.142 0.396 0.344 0.954 0.685 0.253 0.692 0.731 
Tshz2 0.608 1.668 1.286 0.194 0.711 0.543 0.0954 0.199 0.846 0.477 
Zfp217 0.213 0.659 0.321 0.526 0.85 0.831 0.51 0.748 0.599 0.395 
Zgpat 2.445 0.162 0.917 0.49 0.713 0.0145 0.871 0.359 0.624 0.476 




Znhit6 0.58 0.739 0.204 1.24 0.572 0.562 0.46 0.838 0.215 0.567 
Prdm13 0.523 1.016 0.237 0.723 1.541 0.601 0.31 0.813 0.469 0.123 
Zbtb5 0.015 2.592 0.995 2.17 2.051 0.988 0.00955 0.32 0.03 0.0403 
Zfp189 0.604 0.093 0.354 0.519 0.137 0.546 0.926 0.723 0.604 0.891 
Glis1 0.197 0.029 0.213 0.726 0.162 0.844 0.977 0.831 0.468 0.871 
Zcchc11 0.512 0.602 1.922 0.571 1.06 0.609 0.547 0.0546 0.568 0.289 
Zfyve9 0.055 0.004 0.008 0.003 0.27 0.956 0.997 0.994 0.998 0.787 
Foxj3 1.107 2.57 2.179 2.384 1.62 0.269 0.0102 0.0294 0.0171 0.105 
Zc3h12a 0.396 0.011 0.102 0.113 0.348 0.692 0.991 0.919 0.91 0.728 
Zbtb40 0.509 0.272 0.66 0.308 0.428 0.611 0.786 0.509 0.758 0.669 
Tardbp 0.593 1.685 2.217 1.462 0.369 0.553 0.0919 0.0266 0.144 0.712 
Gbx1 0.365 0.516 0.818 0.523 0.894 0.715 0.606 0.413 0.601 0.371 
Zfyve28 0.58 2.255 1.45 1.884 1.098 0.562 0.0241 0.147 0.0596 0.272 
Trafd1 0.252 0.929 1.424 0.671 0.315 0.801 0.353 0.154 0.502 0.753 
Zfp12 0.1 0.443 1.076 0.5 1.32 0.92 0.658 0.282 0.617 0.187 
Jazf1 0.43 3.066 1.382 1.803 1.593 0.667 0.00217 0.167 0.0713 0.111 
Creb5 0.383 0.667 0.756 0.465 0.068 0.702 0.505 0.449 0.642 0.946 
Zfp637 0.929 0.184 0.948 0.199 1.345 0.353 0.854 0.343 0.842 0.179 
Zc3hc1 0.155 0.01 0.073 0.078 0.117 0.877 0.992 0.942 0.938 0.907 
Zfp212 1.39 0.679 0.35 0.657 1.31 0.164 0.497 0.726 0.511 0.19 
Zfp628 0.024 1.309 1.239 1.324 0.476 0.981 0.191 0.215 0.186 0.634 
Zfp418 0.335 0.793 1.614 0.86 0.89 0.738 0.428 0.107 0.39 0.374 
Zscan22 1.304 0.217 0.104 0.839 0.761 0.192 0.828 0.917 0.401 0.446 
Grlf1 0.133 1.068 0.193 0.468 0.132 0.894 0.285 0.847 0.64 0.895 
Mypop 0.383 1.171 1.972 1.153 1.011 0.702 0.242 0.0486 0.249 0.312 
Zfp428 0.665 0.876 1.984 0.744 1.01 0.506 0.381 0.0473 0.457 0.312 
Zfp574 0.681 0.105 0.083 0.444 0.265 0.496 0.916 0.934 0.657 0.791 
Zfp790 1.628 0.815 0.909 1.792 1.298 0.103 0.415 0.363 0.0732 0.194 
Zfp592 0.233 0.112 0.371 0.039 0.296 0.816 0.911 0.711 0.969 0.767 
Crebzf 0.561 0.89 1.461 1.511 2.643 0.575 0.373 0.144 0.131 0.00823 
Zfp553 0.775 0.173 0.732 0.01 0.559 0.438 0.863 0.464 0.992 0.576 
Zfp768 0.07 0.794 0.589 0.237 1.323 0.944 0.427 0.556 0.813 0.186 
Zfp764 0.099 0.118 0.668 0 0.317 0.921 0.906 0.504 1 0.751 
Zfp646 0.758 3.468 1.747 0.936 1.742 0.448 0.000524 0.0806 0.349 0.0815 
Gatad2a 0.883 1.333 0.838 2.003 0.733 0.377 0.183 0.402 0.0452 0.463 
Zfp612 0.118 2.306 2.132 2.869 3.053 0.906 0.0211 0.033 0.00412 0.00226 
Zfp426 1.292 0.307 0.239 0.476 0.608 0.197 0.759 0.811 0.634 0.543 




Nfrkb 0.665 0.253 1.544 0.097 1.827 0.506 0.8 0.123 0.923 0.0677 
Zbtb16 0.131 0.014 0.143 0.141 0.291 0.896 0.989 0.886 0.888 0.771 
Zfp280d 0.225 0.169 1.665 0.485 1.977 0.822 0.866 0.096 0.628 0.0481 
Zfp445 0.824 0.66 0.66 1.335 1.41 0.41 0.509 0.509 0.182 0.159 
Zfp825 0.929 0.194 0.81 0.754 1.148 0.353 0.846 0.418 0.451 0.251 
Zfp709 0.345 0.377 0.212 0.734 0.344 0.73 0.706 0.832 0.463 0.731 
Zc3h12d 0.812 1.268 0.063 1.671 1.664 0.417 0.205 0.95 0.0946 0.0961 
Zfp454 0.49 0.616 1.26 0.315 1.596 0.624 0.538 0.208 0.753 0.111 
Ash2l 1.004 1.47 0.082 1.061 0.428 0.315 0.141 0.935 0.289 0.669 
Arid4a 0.493 0.294 0.823 0.302 0.634 0.622 0.769 0.41 0.763 0.526 
C130039O16Rik 0.457 0.194 0.02 0.064 0.68 0.648 0.846 0.984 0.949 0.497 
Klf6 0.348 1.286 0.983 0.714 0.35 0.728 0.198 0.325 0.476 0.726 
Dmtf1 1.074 0.063 1.031 0.412 1.179 0.283 0.95 0.303 0.68 0.239 
Zfp367 0.422 0.92 1.823 0.934 0.908 0.673 0.357 0.0684 0.35 0.364 
Ets1 0.951 0.499 1.775 1.378 0.845 0.342 0.618 0.0759 0.168 0.398 
Ets2 0.388 1.889 1.719 1.387 0.844 0.698 0.0589 0.0855 0.165 0.399 
Fiz1 0.66 0.907 0.493 0.492 1.309 0.509 0.364 0.622 0.623 0.191 
Mta2 0.03 0.773 0.053 0.494 1.902 0.976 0.44 0.958 0.621 0.0572 
Zfp647 1.494 0.063 0.317 0.224 0.934 0.135 0.95 0.751 0.823 0.35 
Nr0b2 0.708 0.331 0.377 0.286 0.073 0.479 0.741 0.706 0.775 0.942 
Nr2e3 0.882 0.146 0.356 0.432 0.36 0.378 0.884 0.722 0.666 0.719 
Zfp641 0.313 0.376 0.128 0.036 0.01 0.754 0.707 0.898 0.971 0.992 
Zfp799 0.524 0.141 0.439 0.27 0.737 0.6 0.888 0.661 0.787 0.461 
Zfp563 0.239 0.918 0.176 1.036 0.847 0.811 0.359 0.86 0.3 0.397 
Zfp438 0.58 0.001 0.041 0.019 0.365 0.562 0.999 0.967 0.985 0.715 
Adnp2 0.373 1.091 1.289 0.476 1.74 0.709 0.275 0.197 0.634 0.0818 
Zfp407 0.577 0.221 0.157 0.307 0.548 0.564 0.825 0.875 0.759 0.584 
St18 0.754 2.403 1.444 1.539 0.987 0.451 0.0163 0.149 0.124 0.324 
Taf7 1.441 0.029 1.47 0.58 0.529 0.15 0.977 0.142 0.562 0.597 
Zbtb37 0.333 0.192 0.217 0.128 0.225 0.739 0.848 0.828 0.898 0.822 
Rbck1 1.209 0.061 0.17 0.94 0.575 0.227 0.951 0.865 0.347 0.565 
Carf 0.399 0.634 0.184 0.251 0.053 0.69 0.526 0.854 0.802 0.958 
Vax2 0.407 0.238 0.136 0.52 0.406 0.684 0.812 0.892 0.603 0.685 
Zbtb6 0.753 0.727 0.225 0.441 0.273 0.452 0.467 0.822 0.659 0.785 
Zeb2 0.754 1.798 1.033 1.036 0.558 0.451 0.0723 0.302 0.3 0.577 
Lass6 0.282 1.283 0.415 0.814 1.122 0.778 0.199 0.678 0.416 0.262 
Zfp385b 0.924 1.703 1.928 1.597 1.606 0.355 0.0887 0.0538 0.11 0.108 




L3mbtl1 0.906 1.715 0.761 2.55 1.423 0.365 0.0864 0.447 0.0108 0.155 
Zfp697 0.73 0.586 0.277 0.441 0.215 0.465 0.558 0.782 0.659 0.83 
Zfp462 1.302 1.346 1.489 1.966 1.463 0.193 0.178 0.137 0.0493 0.143 
Bnc2 0.958 0.469 0.261 0.384 0.021 0.338 0.639 0.794 0.701 0.983 
Dmrta1 0.406 0.202 0.049 0.192 0.069 0.685 0.84 0.961 0.848 0.945 
Dmrta2 0.642 0.84 1.206 0.327 0.795 0.521 0.401 0.228 0.744 0.426 
E2f2 1.157 1.682 2.438 2.375 0.939 0.247 0.0925 0.0148 0.0176 0.347 
Zfp128 0.826 0.233 1.068 0.517 0.278 0.409 0.816 0.285 0.605 0.781 
Zfp324 0 1.006 2.445 0.307 1.26 1 0.314 0.0145 0.759 0.208 
Zfp14 0.577 1.931 1.645 2.604 0.069 0.564 0.0535 0.1 0.00922 0.945 
Tshz3 2.675 1.177 2.268 1.4 1.07 0.00747 0.239 0.0233 0.162 0.285 
Zfp536 0.567 1.681 2.771 0.646 1.034 0.571 0.0927 0.00559 0.518 0.301 
Zfp473 0.107 0.138 0.21 0.026 1.548 0.915 0.89 0.834 0.979 0.122 
Zdhhc13 1.19 0.433 0.754 0.164 1.656 0.234 0.665 0.451 0.87 0.0977 
Zfp771 0.251 0.529 2.601 0.411 0.987 0.802 0.597 0.00929 0.681 0.324 
Zfp668 0.399 0.473 0.715 0.821 0.436 0.69 0.636 0.475 0.412 0.663 
Zfp317 0.197 0.127 1.085 0.556 0.126 0.844 0.899 0.278 0.578 0.9 
Zfp846 0.226 1.241 2.101 1.386 3.156 0.821 0.215 0.0356 0.166 0.0016 
Npat 1.344 1.845 1.597 1.874 2.106 0.179 0.065 0.11 0.061 0.0352 
Zbtb38 0.454 2.332 0.292 2.81 1.855 0.65 0.0197 0.77 0.00496 0.0636 
Zfp300 0.23 0.437 0.044 0.58 0.36 0.818 0.662 0.965 0.562 0.719 
Hsf3 1.126 0.543 0.403 0.529 0.851 0.26 0.587 0.687 0.597 0.395 
Tbx22 0.308 0.183 0.084 0.111 0.092 0.758 0.855 0.933 0.912 0.927 
Tgif2lx1 1.401 0.713 1.706 1.213 0.61 0.161 0.476 0.0879 0.225 0.542 
Zfp711 0.628 1.62 0.36 2.426 1.19 0.53 0.105 0.719 0.0153 0.234 
Hdx 1.468 1.172 0.457 1.133 1.416 0.142 0.241 0.648 0.257 0.157 
Klf8 1.074 0.507 0.23 0.244 1.024 0.283 0.612 0.818 0.807 0.306 
Onecut3 0.581 0.371 1.795 0.226 0.235 0.561 0.711 0.0727 0.821 0.814 
Zfp277 0.317 0.152 0.249 0.014 0.082 0.751 0.879 0.803 0.989 0.935 
Obox3 1.267 0.336 0.282 0.126 1.896 0.205 0.737 0.778 0.9 0.0579 
Grhl2 0.379 0.639 0.422 0.879 0.542 0.705 0.523 0.673 0.38 0.588 
Fev 0.451 0.493 0.689 0.851 0.844 0.652 0.622 0.491 0.395 0.399 
Ciao1 0.595 0.44 0.485 0.381 0.634 0.552 0.66 0.628 0.703 0.526 
Esrra 0.68 0.864 1.072 0.468 1.404 0.496 0.388 0.284 0.64 0.16 
Esrrb 0.814 1.325 1.472 0.678 0.698 0.415 0.185 0.141 0.498 0.485 
Esrrg 0.813 0.59 0 1.137 0.078 0.416 0.555 1 0.256 0.938 
Hsf4 0.519 0.8 2.895 0.29 0.369 0.604 0.423 0.00379 0.772 0.712 




Nr5a2 1.126 0.492 0.208 0.602 0.157 0.26 0.623 0.835 0.547 0.875 
Creb3l1 0.558 0.977 0 0.935 0.141 0.577 0.329 1 0.35 0.888 
Zfp146 0.188 0.001 0.996 0.003 0.051 0.851 0.999 0.319 0.998 0.959 
Zfp260 0.939 0.777 1.561 0.907 1.622 0.348 0.437 0.118 0.364 0.105 
Scml4 0.071 0.105 0.188 0.07 0.537 0.943 0.916 0.851 0.944 0.591 
Zkscan17 0.884 2.95 2.007 1.97 1.553 0.377 0.00318 0.0447 0.0488 0.121 
Zbtb1 0.743 0.571 0.704 0.035 0.281 0.458 0.568 0.482 0.972 0.779 
Zfp608 0.902 0.999 1.285 1.479 0.691 0.367 0.318 0.199 0.139 0.49 
Zfp346 0.066 0.536 0.741 0.016 0.458 0.947 0.592 0.459 0.987 0.647 
Foxl2 0.503 0.058 0.041 0.273 0.084 0.615 0.954 0.967 0.785 0.933 
Ecsit 0.94 0.946 1.319 1.001 1.148 0.347 0.344 0.187 0.317 0.251 
Zscan20 0.75 0.03 0.05 0.499 0.288 0.453 0.976 0.96 0.618 0.773 
Chd5 1.148 2.306 4.042 2.163 0.975 0.251 0.0211 5.3e-05 0.0305 0.33 
Zfp512 1.331 1.689 0.523 1.334 1.008 0.183 0.0912 0.601 0.182 0.314 
Zfp384 1.085 0 0.457 0.041 0.362 0.278 1 0.648 0.967 0.717 
Nat14 0.746 2.275 2.565 1.585 0.786 0.456 0.0229 0.0103 0.113 0.432 
Zfp446 1.052 0.059 0.815 1.085 1.479 0.293 0.953 0.415 0.278 0.139 
Foxi2 0.323 0.084 0.136 0.143 0.464 0.747 0.933 0.892 0.886 0.643 
Etv3 0.393 0.026 0.302 0.087 0.476 0.694 0.979 0.763 0.931 0.634 
Irf5 1.033 0.711 0.613 1.22 2.081 0.302 0.477 0.54 0.222 0.0374 
Zbtb11 1.344 1.602 0.371 1.187 1.281 0.179 0.109 0.711 0.235 0.2 
Tlx3 0.319 0.103 0.275 0.08 0.512 0.75 0.918 0.783 0.936 0.609 
Nrk 1.558 0.008 0.366 0.206 0.414 0.119 0.994 0.714 0.837 0.679 
Mixl1 0.548 0.503 0.075 1.474 1.275 0.584 0.615 0.94 0.141 0.202 
Arntl2 0.165 2.444 0.559 0.567 0.48 0.869 0.0145 0.576 0.571 0.631 
Zfp398 0.251 2.925 2.268 1.935 0.08 0.802 0.00344 0.0233 0.053 0.936 
Spib 0.853 0.154 0.083 0.228 0.085 0.394 0.878 0.934 0.82 0.932 
Zfp354b 1.226 0.57 2.865 0.818 0.55 0.22 0.569 0.00417 0.414 0.582 
Npas3 1.03 0.252 1.087 0.458 1.127 0.303 0.801 0.277 0.647 0.26 
Zdhhc8 0.222 0.751 1.273 0.556 0.49 0.824 0.452 0.203 0.578 0.624 
Znhit2-ps 0.838 0.35 0.466 0.536 0.962 0.402 0.726 0.641 0.592 0.336 
Mga 0.407 0.52 0.772 0.348 0.974 0.684 0.603 0.44 0.728 0.33 
Zfp385a 0.252 0.225 0.337 0.883 0.023 0.801 0.822 0.736 0.377 0.982 
Scmh1 0.108 0.06 0.192 0.466 0.43 0.914 0.952 0.848 0.641 0.667 
Zfp292 0.105 0.389 0.617 0.55 1.724 0.916 0.697 0.537 0.582 0.0847 
Spdef 0.522 0.198 1.164 0.281 1.334 0.602 0.843 0.244 0.779 0.182 
Foxe3 0.499 0.62 0.583 0.888 1.319 0.618 0.535 0.56 0.374 0.187 




Zfp238 0.614 2.424 1.866 1.196 0.887 0.539 0.0153 0.062 0.232 0.375 
Zfp330 0.407 0.275 0.137 0.379 0.01 0.684 0.783 0.891 0.705 0.992 
Pttg1 0.48 3.027 0.861 2.505 1 0.631 0.00247 0.39 0.0123 0.317 
Hnf4g 0.876 0.055 0.296 0.046 0.003 0.381 0.956 0.767 0.963 0.998 
Zfp354c 0.448 1.731 1.891 0.971 1.465 0.654 0.0834 0.0587 0.332 0.143 
Zfp672 0.88 0.745 0.648 0.277 0.869 0.379 0.456 0.517 0.782 0.385 
Zfp750 0.622 0.016 0.226 0.497 0.01 0.534 0.987 0.821 0.619 0.992 
Zfp182 0.228 1.465 0.303 0.288 1.62 0.82 0.143 0.762 0.773 0.105 
Zfp653 0.507 0.766 0.436 0.466 1.328 0.612 0.444 0.663 0.641 0.184 
Zfyve27 0.567 0.727 1.913 0.485 0.688 0.571 0.467 0.0557 0.628 0.491 
Rfx7 0.422 0.234 1.163 0.64 1.835 0.673 0.815 0.245 0.522 0.0665 
Rc3h2 0.095 0.031 0.365 0.087 1.358 0.924 0.975 0.715 0.931 0.175 
Taf2 0.645 0.071 0.155 0.094 0.247 0.519 0.943 0.877 0.925 0.805 
Zdhhc17 1.284 1.715 1.613 1.539 0.713 0.199 0.0864 0.107 0.124 0.476 
Zmat4 0.556 1.634 0.45 1.426 0.414 0.578 0.102 0.653 0.154 0.679 
Fubp3 0.048 0.447 0.261 0.564 0.599 0.962 0.655 0.794 0.573 0.549 
Zbtb26 0.26 0.071 0.004 0.642 1.378 0.795 0.943 0.997 0.521 0.168 
Zhx3 0.455 0.199 0.118 0.432 0.372 0.649 0.842 0.906 0.666 0.71 
L3mbtl4 0.697 0.345 0.759 0.259 0.803 0.485 0.73 0.448 0.796 0.422 
Rfx6 0.342 0.244 0.572 0.443 0.111 0.732 0.807 0.567 0.658 0.912 
Zmiz1 0.748 0.65 0.171 0.795 0.251 0.454 0.516 0.864 0.427 0.802 
Ep300 1.191 0.006 1.775 0.013 1.198 0.234 0.995 0.0759 0.99 0.231 
Zfp414 2.078 0.602 1.852 0.253 1.331 0.0377 0.547 0.064 0.8 0.183 
Zfp236 0.403 0.47 1.099 0.552 0.142 0.687 0.638 0.272 0.581 0.887 
Zfp516 0.464 0.9 0.809 0.912 0.464 0.643 0.368 0.418 0.362 0.643 
Zfp335 0.308 0.011 0.346 0.004 0.728 0.758 0.991 0.729 0.997 0.466 
Zfp786 0.34 0.613 1.4 0.723 0.584 0.734 0.54 0.162 0.469 0.559 
AW146020 1.552 0.109 1.291 0.614 0.633 0.121 0.913 0.197 0.539 0.527 
Zfp78 0.479 0.26 0.145 0.388 0.138 0.632 0.795 0.885 0.698 0.89 
Zfp82 0.173 0.013 0.59 0.001 0.02 0.863 0.99 0.555 0.999 0.984 
Snapc5 0.628 0.425 0.79 0.151 0.768 0.53 0.671 0.429 0.88 0.443 
Zmynd12 0.759 0.117 1.041 0.947 0.519 0.448 0.907 0.298 0.344 0.604 
Zfp780b 0.682 0.507 1.036 0.996 2.305 0.495 0.612 0.3 0.319 0.0212 
Morc3 0.365 0.842 1.81 0.623 0.165 0.715 0.4 0.0703 0.533 0.869 
Nr1d2 0.344 0.302 0.957 0.552 1.761 0.731 0.763 0.339 0.581 0.0783 
Zranb1 0.559 0.851 1.242 0.975 0.604 0.576 0.395 0.214 0.329 0.546 
Batf3 1.798 0.262 0.204 0.265 1.508 0.0721 0.793 0.838 0.791 0.132 




Zhx2 1.238 1.766 1.419 1.914 1.32 0.216 0.0774 0.156 0.0556 0.187 
Baz2b 0.319 0.152 2.127 0.159 2.103 0.75 0.879 0.0334 0.874 0.0354 
Hdac1 0.878 1.798 2.977 1.403 1.055 0.38 0.0722 0.00291 0.161 0.292 
Hmg1l1 0.112 1.252 1.087 0.286 0.294 0.911 0.211 0.277 0.775 0.769 
Zfp560 0.114 0.204 1.71 0.503 1.301 0.909 0.838 0.0872 0.615 0.193 
Znhit3 0.659 0.332 0.344 0.602 0.464 0.51 0.74 0.731 0.547 0.643 
Zfp960 0.625 0.018 1.76 0.011 1.926 0.532 0.986 0.0783 0.991 0.0541 
Zbtb9 1.008 0.738 0.51 0.982 0.482 0.314 0.461 0.61 0.326 0.63 
E2f6 1.078 1.342 1.419 1.198 1.349 0.281 0.179 0.156 0.231 0.177 
Sall2 0.984 2.372 1.175 2.219 0.716 0.325 0.0177 0.24 0.0265 0.474 
Fbxw7 0.707 2.93 1.579 2.373 0.908 0.479 0.00339 0.114 0.0176 0.364 
Klf13 0.626 0.077 0.93 0.259 1.26 0.531 0.939 0.352 0.796 0.208 
Dmrt1 1.342 0.503 0.154 0.742 0.331 0.18 0.615 0.878 0.458 0.741 
Solh 0.473 0.152 1.079 0.028 1.248 0.636 0.879 0.281 0.978 0.212 
Hmgn5 0.353 2.234 1.743 1.899 1.099 0.724 0.0255 0.0813 0.0576 0.272 
Preb 0.74 0.473 0.379 0.379 1.118 0.459 0.636 0.705 0.705 0.263 
Olig2 0.127 0.026 0.094 0.024 0.107 0.899 0.979 0.925 0.981 0.915 
Olig1 0.559 1.16 1.495 0.503 0.861 0.576 0.246 0.135 0.615 0.389 
Irx4 1.371 0.063 0.097 0.121 0.494 0.17 0.95 0.923 0.904 0.621 
Fubp1 0.799 1.737 1.121 1.398 0.575 0.424 0.0824 0.262 0.162 0.565 
Ankzf1 0.695 1.28 1.222 0.928 0.499 0.487 0.2 0.222 0.354 0.618 
Zfp644 0.173 0.1 0.951 0.234 1.407 0.863 0.92 0.342 0.815 0.159 
Carhsp1 0.522 1.829 1.025 1.497 1.957 0.602 0.0674 0.305 0.135 0.0504 
Zfp622 0.802 0.926 0.607 0.256 0.247 0.423 0.354 0.544 0.798 0.805 
Zfp410 1.2 0.604 0.86 0.812 0.512 0.23 0.546 0.39 0.417 0.609 
Zkscan6 1.486 0.274 1.219 0.654 1.397 0.137 0.784 0.223 0.513 0.162 
Dnlz 2.223 0.225 0.009 0.533 1.308 0.0262 0.822 0.993 0.594 0.191 
Zmiz2 0.762 0.114 0.255 0.028 0.083 0.446 0.909 0.799 0.978 0.934 
Batf 0.444 0.131 0.519 0.234 0.034 0.657 0.896 0.604 0.815 0.973 
Atoh7 0.414 1.928 1.176 0.564 1.081 0.679 0.0538 0.24 0.573 0.28 
Hif3a 0.192 0.296 0.135 0.362 0.993 0.848 0.767 0.893 0.717 0.321 
Ybx2 0.338 0.213 0 0.159 0.011 0.735 0.831 1 0.874 0.991 
Insm1 0.654 0.921 2.551 0.819 1.2 0.513 0.357 0.0107 0.413 0.23 
Zranb2 1.591 0.327 0.784 0.861 0.837 0.112 0.744 0.433 0.389 0.403 
Rfx5 0.189 1.395 3.117 0.68 0.667 0.85 0.163 0.00183 0.497 0.505 
Irf7 0.085 0.008 0.001 0.092 0.194 0.932 0.994 0.999 0.927 0.846 
Irf3 1.338 1.678 0.99 2.087 0.473 0.181 0.0934 0.322 0.0369 0.636 




Irx5 1.269 3.661 1.667 2.235 1.183 0.204 0.000251 0.0955 0.0254 0.237 
Zfp326 0.095 0.243 1.318 0.028 0.425 0.924 0.808 0.187 0.978 0.671 
Barhl1 0.861 0.248 0.309 0.613 1.187 0.389 0.804 0.757 0.54 0.235 
Nfat5 1.324 0.066 0.004 0.637 0.157 0.185 0.947 0.997 0.524 0.875 
Zkscan4 0.3 0.216 0.048 0.253 0.105 0.764 0.829 0.962 0.8 0.916 
Scrt2 0.469 0.67 0.36 0.509 1.324 0.639 0.503 0.719 0.611 0.186 
Foxo4 0.469 0.278 0.165 0.487 0.255 0.639 0.781 0.869 0.626 0.799 
Plagl2 1.049 0.22 0.272 0.255 0.255 0.294 0.826 0.786 0.799 0.799 
Fezf2 0.722 1.674 1.255 1.449 1.097 0.47 0.0941 0.209 0.147 0.273 
Rcan1 0.407 2.116 2.245 1.443 0.763 0.684 0.0344 0.0248 0.149 0.446 
Tfip11 0.625 0.404 0.559 0.553 0.275 0.532 0.686 0.576 0.58 0.783 
Hes6 0.73 0.923 0.871 1.361 1.446 0.465 0.356 0.384 0.174 0.148 
Smad9 0.303 0.099 0.128 0.01 0.041 0.762 0.921 0.898 0.992 0.967 
Tcerg1 0.628 0.234 1.284 0.085 0.157 0.53 0.815 0.199 0.932 0.875 
Msgn1 1.22 0.429 0.121 0.825 0.009 0.222 0.668 0.904 0.409 0.993 
Heyl 0.249 1.641 2.42 0.465 1.188 0.803 0.101 0.0155 0.642 0.235 
Patz1 1.118 0.898 2.541 0.847 1.364 0.264 0.369 0.0111 0.397 0.173 
Dmrtb1 0.104 0.368 1.642 0.09 0.102 0.917 0.713 0.101 0.928 0.919 
Zfp113 0.246 0.565 0.371 0.53 0.269 0.806 0.572 0.711 0.596 0.788 
Aatf 1.24 3.279 0.961 3.04 1.899 0.215 0.00104 0.336 0.00237 0.0575 
Zmym3 0.219 1.182 1.377 0.145 2.041 0.827 0.237 0.169 0.885 0.0413 
Spen 0.489 1.718 0.202 1.255 2.184 0.625 0.0857 0.84 0.21 0.0289 
Csda 0.553 2.142 0.918 2.499 2.058 0.58 0.0322 0.359 0.0125 0.0396 
Foxo1 0.872 0.759 1.69 1.209 1.297 0.383 0.448 0.0911 0.227 0.195 
Foxo3 0.136 0.129 0.025 0.102 0.097 0.892 0.897 0.98 0.919 0.923 
Zbtb20 0.112 1.287 3.567 1.219 2.01 0.911 0.198 0.000362 0.223 0.0444 
Elf4 0.475 0.348 0.361 0.577 0.665 0.635 0.728 0.718 0.564 0.506 
Zfp235 0.256 3.862 1.5 2.492 1.794 0.798 0.000112 0.133 0.0127 0.0728 
Zfp111 0.995 0.082 2.097 0.122 0.59 0.32 0.935 0.036 0.903 0.555 
Plag1 0.161 0.031 0.187 0.073 0.001 0.872 0.975 0.852 0.942 0.999 
Litaf 0.384 2.893 1.098 1.67 1.174 0.701 0.00382 0.272 0.0948 0.24 
Ascl3 1.603 0.832 0.422 1.742 1.018 0.109 0.406 0.673 0.0814 0.309 
Zbtb33 0.952 1.38 0.52 1.791 0.81 0.341 0.168 0.603 0.0733 0.418 
Gmeb1 0.469 0.626 0.075 0.598 0.469 0.639 0.531 0.94 0.55 0.639 
Insm2 1.059 0.011 0.033 0.333 0.18 0.29 0.991 0.974 0.739 0.857 
Gtf2ird1 0.984 1.641 1.185 1.258 1.041 0.325 0.101 0.236 0.209 0.298 
Tbx20 0.824 0.365 0.126 0.38 0.321 0.41 0.715 0.9 0.704 0.748 




Zc3h8 0.487 0.822 0.963 0.75 0.862 0.626 0.411 0.336 0.453 0.388 
Zmynd15 0.61 0.024 0.015 0.114 0.1 0.542 0.981 0.988 0.909 0.92 
Zfp112 0.296 0.68 1.229 0.631 1.368 0.767 0.497 0.219 0.528 0.171 
Tbx21 0.161 1.262 1.565 1.056 2.299 0.872 0.207 0.118 0.291 0.0215 
Rbak 0.155 0.198 1.282 0.447 1.358 0.877 0.843 0.2 0.655 0.174 
Zfp318 0.292 1.3 1.642 0.063 1.013 0.77 0.194 0.101 0.95 0.311 
Hic2 0.85 1.53 0.01 1.9 1.194 0.395 0.126 0.992 0.0574 0.232 
Sall1 0.122 1.386 0.437 0.906 1.984 0.903 0.166 0.662 0.365 0.0473 
Zbtb32 0.432 1.896 1.055 0.432 0.866 0.666 0.0579 0.291 0.666 0.387 
Bcl11b 0.762 1.518 1.91 1.174 1.158 0.446 0.129 0.0561 0.241 0.247 
Mlxipl 0.894 0.008 0.025 0.345 0.001 0.371 0.994 0.98 0.73 0.999 
Thap11 0.003 1.638 2.594 1.349 2.307 0.998 0.101 0.00949 0.177 0.021 
Edf1 0.233 0 0.107 0.005 0.156 0.816 1 0.915 0.996 0.876 
Zfp191 0.564 0.901 1.153 0.608 1.141 0.573 0.368 0.249 0.543 0.254 
Foxj2 0.668 1.874 0.281 2.024 0.702 0.504 0.061 0.779 0.043 0.483 
Zfp872 0.523 0.018 1.345 0.043 2 0.601 0.986 0.179 0.966 0.0455 
Zcchc17 0.671 1.723 3.156 1.131 0.752 0.502 0.0849 0.0016 0.258 0.452 
Klf14 0.818 0.099 0.691 0.097 0.651 0.413 0.921 0.49 0.923 0.515 
Zfp827 0.758 1.899 1.352 2.081 1.227 0.448 0.0576 0.176 0.0374 0.22 
Zfp800 0.338 1.196 1.166 0.59 0.114 0.735 0.232 0.244 0.555 0.909 
Zfp296 0.642 0.715 0.092 1.519 1.177 0.521 0.475 0.927 0.129 0.239 
Yeats4 0.005 1.625 1.802 0.402 1.252 0.996 0.104 0.0715 0.688 0.211 
Foxb1 0.262 0.321 1.1 0.196 1.516 0.793 0.748 0.272 0.845 0.13 
Irx6 0.094 0.001 0.078 0.001 0.043 0.925 0.999 0.938 0.999 0.966 
Sp5 0.43 0.459 0.063 0.482 0.478 0.667 0.646 0.95 0.63 0.633 
Zfp280b 0.66 0.48 0.94 0.033 0.534 0.509 0.631 0.347 0.974 0.593 
Zfp110 1.479 0.883 2.352 0.835 1.165 0.139 0.377 0.0187 0.404 0.244 
Zfand6 0.021 0.469 1.243 0.068 1.503 0.983 0.639 0.214 0.946 0.133 
Zfp784 0.613 0.006 0.036 0.108 0.257 0.54 0.995 0.971 0.914 0.797 
Zfp524 0.969 1.809 2.029 0.735 0.461 0.333 0.0705 0.0424 0.462 0.645 
Sarnp 0.342 0.021 1.271 0.357 1.337 0.732 0.983 0.204 0.721 0.181 
Zdhhc12 0.929 0.063 0.058 0.433 0.131 0.353 0.95 0.954 0.665 0.896 
Dmap1 0.455 0.85 0.123 0.991 1.28 0.649 0.395 0.902 0.322 0.201 
Klf15 0.045 0.013 2.155 0.02 1.706 0.964 0.99 0.0312 0.984 0.0881 
Blzf1 1.319 0.243 1.037 0.961 0.29 0.187 0.808 0.3 0.336 0.772 
Zfand1 1.038 2.324 1.076 2.556 1.28 0.299 0.0201 0.282 0.0106 0.2 
Taf12 1.481 2.899 0.487 1.875 1.61 0.139 0.00375 0.626 0.0608 0.107 




Zmynd11 0 0.534 0.512 0.048 0.648 1 0.593 0.609 0.962 0.517 
2210012G02Rik 0.821 0.333 0.931 0.299 1.107 0.412 0.739 0.352 0.765 0.268 
Drap1 0.23 0.77 0.472 0.54 0.967 0.818 0.442 0.637 0.589 0.333 
Zfp474 1.736 0.102 0.192 0.745 0.482 0.0825 0.919 0.848 0.457 0.63 
Zxdb 0.204 1.178 0.178 0.87 1.196 0.838 0.239 0.859 0.384 0.232 
Tcf25 1.015 1.343 1.511 1.358 0.946 0.31 0.179 0.131 0.175 0.344 
Lztr1 0.82 0.968 1.293 0.54 1.079 0.412 0.333 0.196 0.589 0.281 
Hmg20a 0.073 0.485 0.549 0.046 0.199 0.942 0.628 0.583 0.963 0.842 
Cir1 0.051 0.174 1.459 0.02 0.611 0.959 0.862 0.145 0.984 0.541 
Zdhhc6 0.48 0.242 0.586 0.29 0.869 0.631 0.809 0.558 0.772 0.385 
Zfp830 0.888 0.313 0.915 0.273 0.273 0.375 0.754 0.36 0.785 0.785 
Zbtb8os 0.373 0.244 0.048 0.159 0.372 0.709 0.807 0.962 0.874 0.71 
Zfp787 0.733 0.302 0.87 0.181 1.161 0.463 0.763 0.384 0.856 0.246 
Rnf141 1.213 2.395 0.948 2.018 1.168 0.225 0.0166 0.343 0.0435 0.243 
Zmat5 0.716 1.393 0.756 1.721 2.654 0.474 0.163 0.449 0.0852 0.00797 
Zmynd19 0.385 0.513 0.951 0.808 1.424 0.7 0.608 0.342 0.419 0.154 
Zcrb1 0.478 0.497 0.298 0.596 0.483 0.633 0.619 0.766 0.551 0.629 
Pfdn1 0.353 0.189 0.005 0.775 0.051 0.724 0.85 0.996 0.438 0.959 
Gatad1 1.023 0.837 1.02 0.568 0.302 0.306 0.403 0.308 0.57 0.763 
Zfp329 0.654 0.653 0.978 0.204 1.05 0.513 0.514 0.328 0.838 0.294 
Zkscan14 1.118 0.711 0.24 0.256 0.444 0.263 0.477 0.81 0.798 0.657 
Zfp422 1.396 0.934 0.946 0.55 0.529 0.163 0.35 0.344 0.582 0.597 
Lass4 0.82 0.19 0.026 0.308 0.636 0.412 0.849 0.979 0.758 0.525 
Zc3h13 1.03 3.182 2.233 2.738 1.588 0.303 0.00146 0.0255 0.00619 0.112 
Gcfc1 0.358 1.055 2.371 0.534 1.52 0.72 0.292 0.0177 0.593 0.128 
Zfp606 1.834 0.169 0.972 0.642 2.2 0.0667 0.866 0.331 0.521 0.0278 
Zfp639 0.303 0.107 1.096 0.16 0.803 0.762 0.915 0.273 0.873 0.422 
Ilf2 0.815 0.646 0.695 0.257 0.507 0.415 0.518 0.487 0.797 0.612 
Mrrf 0.418 1.393 0.07 1.123 1.224 0.676 0.164 0.944 0.261 0.221 
Zfp169 0.08 0.611 0.219 0.192 1.189 0.936 0.541 0.827 0.848 0.234 
Zcchc3 1.526 2.069 1.618 1.702 0.754 0.127 0.0386 0.106 0.0887 0.451 
Zcchc10 0.487 0.979 2.181 0.206 0.517 0.626 0.328 0.0292 0.837 0.605 
Zfp706 0.532 0.809 0.984 0.503 0.429 0.595 0.418 0.325 0.615 0.668 
Zfp593 1.05 0.479 0.452 0.604 1.349 0.294 0.632 0.651 0.546 0.177 
Rchy1 1.132 1.69 0.183 1.188 0.387 0.258 0.0909 0.855 0.235 0.699 
Zdhhc21 0.107 0.221 0.025 0.142 0.082 0.915 0.825 0.98 0.887 0.935 
Zmym1 0.561 0.639 0.053 0.268 0.556 0.575 0.523 0.958 0.789 0.578 




Phf5a 0.445 2.776 0.264 2.116 1.369 0.656 0.0055 0.792 0.0343 0.171 
Zfp579 0.403 0.911 0.509 0.013 0.36 0.687 0.362 0.611 0.99 0.719 
Zfyve21 1.029 1.533 0.119 1.719 0.916 0.304 0.125 0.905 0.0857 0.36 
Mrpl28 0.674 1.116 0.184 1.103 1.377 0.5 0.264 0.854 0.27 0.168 
Zfp740 1.184 1.246 1.4 2.051 1.801 0.236 0.213 0.161 0.0402 0.0717 
Rreb1 0.564 1.097 0.718 0.04 0.923 0.573 0.273 0.473 0.968 0.356 
Phtf2 2.279 2.115 2.083 1.814 0.828 0.0227 0.0344 0.0372 0.0696 0.407 
Zfand2b 0.215 0.005 1.014 0.055 1.05 0.83 0.996 0.311 0.956 0.294 
Foxk2 0.906 0.135 0.57 0.404 0.524 0.365 0.893 0.569 0.686 0.6 
Tulp4 0.19 0.36 1.44 0.315 0.568 0.849 0.719 0.15 0.753 0.57 
Zfp467 1.236 1.114 1.036 1.211 1.297 0.216 0.265 0.3 0.226 0.195 
Zfp580 0.395 0.432 0.36 0.433 0.707 0.693 0.666 0.719 0.665 0.48 
Thap7 0.778 0.016 0.542 0.407 1.205 0.437 0.987 0.588 0.684 0.228 
Zfp707 0.265 0.432 0.485 0.41 1.25 0.791 0.666 0.628 0.682 0.211 
Zdhhc3 0.503 0.783 1.077 0.858 0.981 0.615 0.433 0.282 0.391 0.326 
Zc3h15 0.009 0.097 0.648 0 0.441 0.993 0.923 0.517 1 0.659 
Zcchc9 0.537 0.083 1.601 0.07 1.172 0.591 0.934 0.109 0.944 0.241 
Cnot8 0.833 0.776 0.931 1.083 1.937 0.405 0.438 0.352 0.279 0.0528 
Zfp688 0.338 0.445 0.187 0.342 0.812 0.735 0.656 0.852 0.732 0.417 
Zfp397 0.436 0.014 1.086 0.237 2.194 0.663 0.989 0.277 0.813 0.0282 
Elf2 2.627 1.176 1.525 0.905 0.243 0.00861 0.239 0.127 0.366 0.808 
Arap1 0.237 0.135 0.131 0.124 0.872 0.813 0.893 0.896 0.901 0.383 
Casz1 0.957 1.394 0.696 1.054 0.332 0.338 0.163 0.486 0.292 0.74 
Zswim7 0.114 0.843 1.593 1.472 0.349 0.909 0.399 0.111 0.141 0.727 
Zfp511 0.336 0.019 0.09 0.028 0.58 0.737 0.985 0.928 0.978 0.562 
Tcf23 0.316 0.008 0.001 0.008 0.023 0.752 0.994 0.999 0.994 0.982 
Zfp219 0.031 0.021 0.21 0.018 0.44 0.975 0.983 0.834 0.986 0.66 
Znhit1 0.324 0.292 0.403 0.304 0.429 0.746 0.77 0.687 0.761 0.668 
Mier2 0.482 0.562 0 0.542 0.852 0.63 0.574 1 0.588 0.394 
Atad2 0.793 1.755 1.178 0.884 1.055 0.428 0.0792 0.239 0.377 0.291 
Bbx 0.602 0.741 1.788 0.048 0.41 0.547 0.458 0.0738 0.962 0.682 
Zdhhc2 0.76 3.354 1.854 3.425 1.522 0.447 0.000797 0.0637 0.000614 0.128 
Zc3h11a 0.619 0.82 2.28 0.315 1.278 0.536 0.412 0.0226 0.753 0.201 
Zdhhc24 0.179 0.113 0.562 0.064 0.295 0.858 0.91 0.574 0.949 0.768 
Zcchc8 0.507 0.734 2.076 0.164 0.875 0.612 0.463 0.0379 0.87 0.382 
Prdm16 1.087 0.034 0.303 0.299 0.434 0.277 0.973 0.762 0.765 0.664 
Nolc1 0.902 1.074 0.143 0.626 0.911 0.367 0.283 0.886 0.531 0.362 




Pcgf6 0.292 2.889 0.403 0.571 1.193 0.77 0.00386 0.687 0.568 0.233 
Zfp597 1.283 0.082 0.066 0.664 0.29 0.2 0.935 0.947 0.507 0.772 
Hsfy2 0.296 0.639 0.055 0.857 0.27 0.767 0.523 0.956 0.392 0.787 
Atoh8 0.425 0.147 0.665 0.023 0.262 0.671 0.883 0.506 0.982 0.793 
Zfp689 0.464 0.222 0.056 0.373 0.203 0.643 0.824 0.955 0.709 0.839 
Rfx4 0.371 2.292 0.744 0.969 0.664 0.711 0.0219 0.457 0.333 0.507 
Mier1 0.58 0.154 0.17 0.312 0.161 0.562 0.878 0.865 0.755 0.872 
Zdhhc11 0.542 0.147 0.601 0.309 0.006 0.588 0.883 0.548 0.757 0.995 
Dmrtc2 0.419 0.084 0.253 0.341 0.215 0.675 0.933 0.8 0.733 0.83 
Foxn3 0.622 1.178 1.827 0.873 1.022 0.534 0.239 0.0677 0.383 0.307 
Obox1 0.823 0.07 0.611 0.124 0.426 0.41 0.944 0.541 0.901 0.67 
Isx 0.49 0.769 0.522 0.434 1.477 0.624 0.442 0.602 0.664 0.14 
Cic 0.051 1.213 0.152 0.601 1.468 0.959 0.225 0.879 0.548 0.142 
Zbtb43 0.565 0.536 0.23 0.791 1.121 0.572 0.592 0.818 0.429 0.262 
Zswim2 1.096 0.213 0.782 0.031 0.065 0.273 0.831 0.434 0.975 0.948 
Zcchc24 0.447 0.757 0.62 0.583 0.899 0.655 0.449 0.535 0.56 0.369 
Lass5 0.436 0.043 0.358 0.114 0.584 0.663 0.966 0.72 0.909 0.559 
Nanog 1.199 0.043 1.006 0.608 0.417 0.231 0.966 0.314 0.543 0.677 
Zswim1 0.697 0.005 0.216 0.077 0.346 0.486 0.996 0.829 0.939 0.729 
Zfyve19 0.408 0.112 0.466 0.058 0.822 0.683 0.911 0.641 0.954 0.411 
Zfp654 0.005 1.012 1.744 0.118 1.557 0.996 0.311 0.0812 0.906 0.119 
Tsc22d2 0.411 1.135 0.651 0.246 0.368 0.681 0.256 0.515 0.806 0.713 
Zbed3 0.882 1.998 0.587 2.695 1.962 0.378 0.0457 0.557 0.00703 0.0498 
Zfp157 0.476 0.039 0.737 0.216 0.707 0.634 0.969 0.461 0.829 0.479 
Zfp661 1.022 0.097 0.194 0.845 0.656 0.307 0.923 0.846 0.398 0.512 
Zfp558 0.327 0.682 0.483 0.513 1.369 0.744 0.495 0.629 0.608 0.171 
Zfp777 0.154 0.013 0.238 0.024 0.336 0.878 0.99 0.812 0.981 0.737 
Zfp131 0.124 0.315 0.607 0.211 0.607 0.901 0.753 0.544 0.833 0.544 
Zfp566 0.771 0.696 0.423 0.341 1.37 0.441 0.487 0.672 0.733 0.171 
Bclaf1 0.187 0.126 1.114 0.095 1.51 0.852 0.9 0.265 0.924 0.131 
Zufsp 0.731 0.126 0.23 0.056 0.029 0.465 0.9 0.818 0.955 0.977 
Zfp655 0.275 0.132 1.118 0.079 0.188 0.783 0.895 0.264 0.937 0.851 
Zfp444 0.323 0.45 1.792 0.143 0.839 0.747 0.653 0.0731 0.886 0.401 
Zfp518a 0.794 0.148 0.114 1.09 0.803 0.427 0.882 0.909 0.276 0.422 
Zcchc12 1.147 2.9 0.838 2.698 1.299 0.251 0.00373 0.402 0.00697 0.194 
Zfp248 1.541 0.317 0.651 0.512 0.919 0.123 0.751 0.515 0.609 0.358 
Zfp74 1.042 0.074 1.684 0.211 2.464 0.297 0.941 0.0922 0.833 0.0137 




Zfp839 1.08 0.126 0.196 1.028 0.157 0.28 0.9 0.845 0.304 0.875 
Prdm4 0.059 0.637 0.026 0.657 0.935 0.953 0.524 0.979 0.511 0.35 
Zdhhc4 0.852 0.216 0.085 0.911 0.345 0.394 0.829 0.932 0.362 0.73 
Fezf1 1.628 2.205 0.478 1.912 0.478 0.104 0.0275 0.633 0.0558 0.633 
Gpbp1 0.206 0.006 1.103 0.079 0.928 0.837 0.995 0.27 0.937 0.353 
Hbp1 1.023 0.273 0.219 0.717 0.468 0.306 0.785 0.827 0.473 0.64 
Rhox13 0.277 0.231 0.003 0.092 0.043 0.782 0.817 0.998 0.927 0.966 
Zbtb8a 1.105 1.477 0.364 0.487 0.562 0.269 0.14 0.716 0.626 0.574 
Zdbf2 0.122 0.503 0.173 0.839 1.441 0.903 0.615 0.863 0.401 0.15 
Ift57 0.466 1.61 1.628 1.935 2.805 0.641 0.107 0.104 0.053 0.00504 
Zfp263 2.077 0.365 1.036 0.651 0.745 0.0378 0.715 0.3 0.515 0.456 
Foxp4 0.321 1.49 0.233 1.344 0.719 0.748 0.136 0.816 0.179 0.472 
Rnf6 0.097 0.838 0.572 0.3 0.543 0.923 0.402 0.567 0.764 0.587 
Nfx1 1.281 1.161 0.636 0.295 0.948 0.2 0.246 0.525 0.768 0.343 
Zdhhc16 0.502 0.315 1.656 0.089 0.79 0.616 0.753 0.0976 0.929 0.429 
Hopx 0.957 1.165 2.679 1.013 1.39 0.339 0.244 0.00739 0.311 0.164 
Cxxc1 1.184 0.408 0.786 0.754 0.934 0.236 0.683 0.432 0.451 0.35 
Crtc2 1.204 1.674 1.302 1.213 0.893 0.229 0.0942 0.193 0.225 0.372 
Zfp84 0.864 0.038 0.41 0.184 0.86 0.388 0.97 0.682 0.854 0.39 
Zfp819 0.353 0.292 0.231 0.203 0.65 0.724 0.77 0.817 0.839 0.516 
Sohlh2 1.107 0.206 0.083 0.169 0.564 0.268 0.837 0.934 0.866 0.573 
Zswim5 0.875 0.031 0.623 0.49 0.428 0.381 0.975 0.533 0.624 0.669 
Batf2 0.261 0.421 0.003 0.103 0.376 0.794 0.674 0.998 0.918 0.707 
Morc2a 0.512 0.927 0.852 0.344 0.688 0.609 0.354 0.394 0.731 0.491 
Gzf1 0.317 0.103 0.203 0.524 0.128 0.751 0.918 0.839 0.6 0.898 
Nkx6-3 1.519 0.155 0.041 0.622 0.844 0.129 0.877 0.967 0.534 0.399 
Zkscan1 0.553 0.738 1.826 0.445 1.79 0.58 0.46 0.0679 0.656 0.0734 
Zmynd17 1.142 1.037 0.67 0.84 0.345 0.253 0.3 0.503 0.401 0.73 
Zcchc13 0.376 0.031 0.016 0.024 0.178 0.707 0.975 0.987 0.981 0.859 
Zbtb49 0.578 0.136 0.003 0.21 0.107 0.563 0.892 0.998 0.834 0.915 
Zbtb3 0.949 0 0 0.38 0.028 0.342 1 1 0.704 0.978 
Taf1d 0.278 2.089 2.454 1.575 0.733 0.781 0.0367 0.0141 0.115 0.464 
Wbp7 1.163 0.224 0.222 0.977 1.111 0.245 0.823 0.824 0.328 0.266 
Pou5f2 1.106 0.418 1.343 0.841 2.006 0.269 0.676 0.179 0.4 0.0449 
Zc3h14 0.014 0.058 0.617 0.066 0.821 0.989 0.954 0.537 0.947 0.412 
Zbtb4 0.67 2.209 1.982 1.627 0.71 0.503 0.0272 0.0475 0.104 0.478 
Kdm5b 1.096 1.637 0.634 1.454 0.215 0.273 0.102 0.526 0.146 0.83 




Klf17 0.305 0.005 0.199 0.118 0.611 0.76 0.996 0.842 0.906 0.541 
Zfp821 0.192 0.389 0.004 0.268 0.911 0.848 0.697 0.997 0.789 0.362 
Zdhhc20 0.24 0.079 0.294 0.202 0.38 0.81 0.937 0.769 0.84 0.704 
Zmym2 0.399 0.68 1.453 0.671 2.004 0.69 0.496 0.146 0.502 0.045 
Zc3h18 0.502 1.049 0.686 1.357 1.691 0.616 0.294 0.493 0.175 0.0909 
Gon4l 0.851 0.021 0.114 0.296 0.702 0.395 0.983 0.909 0.767 0.483 
Tbx18 1.149 2.167 1.832 1.031 0.465 0.251 0.0303 0.0669 0.303 0.642 
Msrb2 0.556 0.097 0.167 0.073 0.751 0.578 0.923 0.867 0.942 0.453 
Lass2 0.709 1.918 1.844 1.188 1.392 0.478 0.0551 0.0652 0.235 0.164 
Gpbp1l1 0.198 0.418 0.705 0.432 0.572 0.843 0.676 0.481 0.666 0.567 
A930001N09Rik 0.829 1.215 0.329 1.164 0.745 0.407 0.224 0.742 0.245 0.456 
Zfp142 1.085 1.158 0.847 1.017 0.731 0.278 0.247 0.397 0.309 0.465 
Nkrf 0.944 1.679 1.185 1.473 0.992 0.345 0.0931 0.236 0.141 0.321 
Zfp266 0.985 0.053 1.776 0.171 1.462 0.325 0.958 0.0758 0.864 0.144 
Prdm8 0.87 1.736 2.856 1.448 1.001 0.384 0.0825 0.00429 0.148 0.317 
Csrnp3 0.91 0.028 0.025 0.148 0.507 0.363 0.978 0.98 0.882 0.612 
Zfp712 0.389 0.533 1.753 0.117 0.767 0.697 0.594 0.0797 0.907 0.443 
Zfp687 1.219 1.402 1.344 1.951 0.854 0.223 0.161 0.179 0.0511 0.393 
Creb3l4 0.14 0.103 0.181 0.008 0.251 0.889 0.918 0.856 0.994 0.802 
Zfyve20 0.601 1.985 1.658 2.112 1.526 0.548 0.0471 0.0974 0.0347 0.127 
Zfp449 0.335 0.228 0.851 0.128 0.941 0.738 0.82 0.395 0.898 0.347 
Brd8 1.526 0.147 0.011 1.418 0.034 0.127 0.883 0.991 0.156 0.973 
Zc3h6 0.698 1.335 1.021 1.265 1.018 0.485 0.182 0.307 0.206 0.309 
Zc3hav1 0.779 1.173 0.383 0.978 0.805 0.436 0.241 0.702 0.328 0.421 
Brpf1 1.481 0.616 0.968 1.857 1.929 0.139 0.538 0.333 0.0634 0.0538 
Zcchc4 1.148 0.959 0.727 0.711 0.802 0.251 0.338 0.467 0.477 0.422 
Tsc22d4 0.92 0.008 0.671 0.001 0.029 0.358 0.994 0.502 0.999 0.977 
Zfp623 0.928 0.341 0.033 0.475 0.065 0.353 0.733 0.974 0.635 0.948 
Scyl1 0.437 1.714 0.473 0.851 1.84 0.662 0.0866 0.636 0.395 0.0657 
Sp2 0.975 0.025 0.154 0.519 0.464 0.33 0.98 0.878 0.604 0.643 
Zfp319 0.105 1.282 1.048 1.293 0.095 0.916 0.2 0.295 0.196 0.924 
Bhlhe41 0.108 0.004 0.34 0.046 0.757 0.914 0.997 0.734 0.963 0.449 
Spz1 1.089 0.02 0.357 0.265 0.458 0.276 0.984 0.721 0.791 0.647 
Zxdc 0.05 0.614 0.246 0.816 0.451 0.96 0.539 0.806 0.415 0.652 
Pbx4 0.882 2.156 2.857 1.021 1.189 0.378 0.0311 0.00427 0.307 0.234 
Mynn 0.173 0.706 1.498 0.029 2.283 0.863 0.48 0.134 0.977 0.0225 
Zfhx4 0.058 1.337 2.091 1.536 2.76 0.954 0.181 0.0365 0.125 0.00578 




Tbl1xr1 0.796 0.598 0.156 0.716 0.389 0.426 0.55 0.876 0.474 0.697 
Zbtb22 0.801 1.061 1.605 0.965 0.502 0.423 0.289 0.109 0.335 0.616 
Jdp2 0.256 2.9 0.32 1.132 1.711 0.798 0.00373 0.749 0.258 0.087 
Tcfcp2l1 0.716 0.344 0.299 0.093 0.423 0.474 0.731 0.765 0.926 0.672 
Zfpl1 0.522 0.018 0.726 0.164 1.519 0.602 0.986 0.468 0.87 0.129 
Tcfap4 1.302 1.88 0.697 1.795 2.001 0.193 0.0601 0.486 0.0726 0.0454 
Glis2 1.075 0.127 0.066 0.248 0.552 0.282 0.899 0.947 0.804 0.581 
Trps1 0.485 0 0.001 0 0.003 0.628 1 0.999 1 0.998 
Tbx19 0.299 0.108 0.294 0.387 0.203 0.765 0.914 0.769 0.699 0.839 
Hes7 0.64 0.113 0.157 0.506 1.041 0.522 0.91 0.875 0.613 0.298 
Zfp192 0.86 0.053 0.055 0.117 0.699 0.39 0.958 0.956 0.907 0.484 
Klf7 0.189 0.995 1.266 1.258 1.323 0.85 0.32 0.205 0.209 0.186 
Aff4 0.183 0.428 0.958 0.235 1.3 0.855 0.669 0.338 0.814 0.194 
Strn3 0.396 0.095 2.208 0.252 2.479 0.692 0.924 0.0273 0.801 0.0132 
Zfp423 0.381 1.96 1.172 0.545 1.053 0.703 0.05 0.241 0.586 0.293 
Olig3 0.662 0.406 0.342 0.237 0.581 0.508 0.685 0.732 0.813 0.561 
Hmgb2 1.09 3.459 2.423 2.164 0.725 0.276 0.000541 0.0154 0.0305 0.469 
Zfp451 0.953 1.651 0.237 0.445 1.492 0.341 0.0988 0.813 0.656 0.136 
Mael 0.462 0.083 0.138 0.016 0.844 0.644 0.934 0.89 0.987 0.399 
Znfx1 1.361 0.905 1.16 1.022 1.297 0.174 0.365 0.246 0.307 0.195 
Sall4 0.545 0.014 0.114 0.216 0.262 0.586 0.989 0.909 0.829 0.793 





8.2. The Reactome pathways for the 24 vs. 0 hour signature 
Set  NES  p-value  Ledge  
Toll Like Receptor 9 (TLR9) 
Cascade  
3.741 0.000183 
Nfkbia, Irf7, Nfkb2, Pik3c3, Mapkapk3, Dusp3, Mef2c, 
Mapk10, Ager, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, 
Map2k6, Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, 
Pik3r4, Nfkb1, Rps6ka3, Rps6ka2, Tlr7 
Toll Receptor Cascades  3.468 0.000525 
Nfkbia, Irf7, Nfkb2, Pik3c3, Mapkapk3, Dusp3, Mef2c, 
Lgmn, Mapk10, Ager, Ly96, Tlr2, Myd88, Cd180, Fos, 
Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, App, Atf1, Map2k6, Nod1, 
Hspd1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Ctss, 
Unc93b1, Irf3, Pik3r4, Lbp, Nfkb1, Rps6ka3, Rps6ka2, Tlr7 
Toll Like Receptor 4 (TLR4) 
Cascade  
3.434 0.000596 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Ly96, Tlr2, Myd88, Cd180, Fos, Ikbkg, Sigirr, Ubc, 
Mapk3, Tlr6, App, Atf1, Map2k6, Nod1, Hspd1, Map2k1, 
Irak4, Map2k3, Hmg1l1, Ppp2r5d, Irf3, Lbp, Nfkb1, 
Rps6ka3, Rps6ka2 
TRAF6 Mediated Induction of 
proinflammatory cytokines  
3.084 0.00204 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, Nod1, 
Map2k1, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, 
Rps6ka2 
TRAF6 mediated NF-kB activation  2.975 0.00293 Nfkbia, Trim25, Ddx58, Ifih1, Nfkb2, Ager 
MyD88:Mal cascade initiated on 
plasma membrane  
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Tlr2, Myd88, Fos, Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, 
App, Atf1, Map2k6, Nod1, Hspd1, Map2k1, Irak4, Map2k3, 
Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
Toll Like Receptor 2 (TLR2) 
Cascade  
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Tlr2, Myd88, Fos, Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, 
App, Atf1, Map2k6, Nod1, Hspd1, Map2k1, Irak4, Map2k3, 
Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
Toll Like Receptor TLR1:TLR2 
Cascade  
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Tlr2, Myd88, Fos, Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, 




Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
Toll Like Receptor TLR6:TLR2 
Cascade  
2.949 0.00319 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Tlr2, Myd88, Fos, Ikbkg, Sigirr, Ubc, Mapk3, Tlr6, 
App, Atf1, Map2k6, Nod1, Hspd1, Map2k1, Irak4, Map2k3, 
Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, Rps6ka2, Ppp2cb, 
Mapk14, Tirap, Saa3 
MyD88 dependent cascade initiated 
on endosome  
2.876 0.00403 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, 
Rps6ka3, Rps6ka2, Tlr7 
Toll Like Receptor 7/8 (TLR7/8) 
Cascade  
2.876 0.00403 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, 
Rps6ka3, Rps6ka2, Tlr7 
Activated TLR4 signalling  2.867 0.00414 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Ly96, Tlr2, Myd88, Fos, Ikbkg, Sigirr, Ubc, Mapk3, 
Tlr6, App, Atf1, Map2k6, Nod1, Hspd1, Map2k1, Irak4, 
Map2k3, Hmg1l1, Ppp2r5d, Irf3, Nfkb1, Rps6ka3, Rps6ka2 
MyD88-independent cascade 
initiated on plasma membrane  
2.845 0.00444 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Ly96, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Map2k3, Hmg1l1, Ppp2r5d, Irf3, Nfkb1, 
Rps6ka3, Rps6ka2 
NFkB and MAP kinases activation 
mediated by TLR4 signaling 
repertoire 
2.804 0.00504 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, Nod1, 
Map2k1, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, 
Rps6ka2 
TRAF6 mediated induction of 
NFkB and MAP kinases upon 
TLR7/8 or 9 activation  
2.737 0.0062 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, Nod1, 
Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, Rps6ka3, 
Rps6ka2, Tlr7 
Androgen biosynthesis  2.723 0.00648 Srd5a1, Srd5a2, Hsd3b1, Cga, Hsd3b2, Hsd17b3 
TAK1 activates NFkB by 
phosphorylation and activation of 
IKKs complex  




Interferon alpha/beta signaling  2.583 0.00979 
Usp18, Irf9, Irf1, Stat1, Ifitm3, Irf7, Stat2, Ifi27l1, Oas1a, 
Ifi35, Gm14446, Isg15, Irf4, Oasl1, H2-Q2, H2-Q10 
Signal regulatory protein (SIRP) 
family interactions  
2.577 0.00995 Ptk2, Sirpa, Skap2, Cd47, Fyb, Sirpb1a, Tyrobp 
Platelet calcium homeostasis  2.575 0.01 
Trpc7, Stim1, Atp2b4, Atp2b1, Atp2a3, P2rx1, Trpc6, 
Slc8a1, Atp2b2 
Toll Like Receptor 3 (TLR3) 
Cascade  
2.563 0.0104 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, Nod1, 
Map2k1, Map2k3, Hmg1l1, Ppp2r5d, Irf3, Nfkb1, Rps6ka3, 
Rps6ka2, Zbp1, Ppp2cb, Mapk14, Saa3 
TRIF mediated TLR3 signaling  2.563 0.0104 
Nfkbia, Irf7, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, 
Ager, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, Nod1, 
Map2k1, Map2k3, Hmg1l1, Ppp2r5d, Irf3, Nfkb1, Rps6ka3, 
Rps6ka2, Zbp1, Ppp2cb, Mapk14, Saa3 
RIG-I/MDA5 mediated induction 
of IFN-alpha/beta pathways  
2.457 0.014 
Nfkbia, Trim25, Irf1, Ddx58, Irf7, Tnfaip3, Ifih1, Nfkb2, 
Isg15 
CDO in myogenesis  2.419 0.0156 
Mef2c, Cdon, Mef2d, Bnip2, Ctnna1, Map2k6, Myog, 
Myod1, Tcf12, Mapk14, Ctnna2 
Myogenesis  2.419 0.0156 
Mef2c, Cdon, Mef2d, Bnip2, Ctnna1, Map2k6, Myog, 
Myod1, Tcf12, Mapk14, Ctnna2 
Innate Immune System  2.331 0.0197 
Nfkbia, Trim25, Irf1, Ddx58, Irf7, Tnfaip3, Birc3, Ifih1, 
Nfkb2, Txnip, Pik3c3, C8b, Isg15, Mapkapk3, Dusp3, Mef2c, 
Lgmn, C1qc, Mapk10, C8a, Ager, Ly96, Tlr2, Myd88, Bcl2, 
Cd180, Ube2l6, Fos, Ikbkg, Sigirr, Ubc, Casp4, Mapk3, Tlr6, 
App, Atf1, Map2k6, Nod1, Dak, Gm15386, Hspd1, Map2k1, 
Irak4, Map2k3, Hmg1l1, Ppp2r5d, Otud5, Ctss, Unc93b1, 
Irf3, C6, Pik3r4, Dhx58, Lbp, Nfkb1, Casp9, Rps6ka3, 
Rps6ka2, Tlr7 
Post-translational modification: 
synthesis of GPI-anchored proteins  
2.322 0.0202 
Pigl, Pigv, Dpm2, Pigf, Pigw, Pigt, Pign, Pigp, Dpm1, Pigx, 
Dpm3, Pigq, Piga, Pigc, Plaur, Pgap1, Pigh, Sema6d, Gpaa1, 
Pigu, Pigk 
RIP-mediated NFkB activation via 
DAI  




Viral dsRNA:TLR3:TRIF Complex 
Activates RIP1  
2.302 0.0213 Nfkbia, Nfkb2, Ager 
Basigin interactions  2.235 0.0254 
Slc7a8, Slc3a2, Ppil2, Slc7a11, Atp1b1, Slc16a3, Slc7a5, 
Bsg, Cav1 
Cytosolic sensors of pathogen-
associated DNA  
2.208 0.0273 
Nfkbia, Nfkb2, Ager, Ikbkg, App, Hmg1l1, Irf3, Nfkb1, 
Zbp1, Saa3 
DAI mediated induction of type I 
IFNs  
2.208 0.0273 
Nfkbia, Nfkb2, Ager, Ikbkg, App, Hmg1l1, Irf3, Nfkb1, 
Zbp1, Saa3 
Platelet homeostasis  2.191 0.0284 
Pde3a, Kcnmb1, Gng4, Trpc7, Stim1, Atp2b4, Pde2a, 
Atp2b1, Nos1, Pde5a, Atp2a3, Gng13, Gng8, Gucy1a2, 
P2rx1, Apob, Pde9a, Trpc6, Ppp2r5d, Pecam1, Gucy1b3, Fgr, 
Ppp2cb, Mapk14, Slc8a1 
Interferon gamma signaling  2.185 0.0289 
Irf9, Irf1, Stat1, Vcam1, Irf7, Oas1a, Gbp3, Icam1, Irf4, Pml, 
Oasl1, Gbp7, H2-Q2, B2m, H2-Q10, Camk2d, Mt2 
CDC6 association with the 
ORC:origin complex  
2.142 0.0322 Orc1, Mcm8, Cdc6, E2f1, Orc4, E2f2, Orc3, Orc2, Orc6 
MyD88 cascade initiated on plasma 
membrane  
2.089 0.0368 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, 
Rps6ka3, Rps6ka2 
Toll Like Receptor 10 (TLR10) 
Cascade  
2.089 0.0368 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, 
Rps6ka3, Rps6ka2 
Toll Like Receptor 5 (TLR5) 
Cascade  
2.089 0.0368 
Nfkbia, Nfkb2, Mapkapk3, Dusp3, Mef2c, Mapk10, Ager, 
Ly96, Myd88, Fos, Ikbkg, Ubc, Mapk3, App, Atf1, Map2k6, 
Nod1, Map2k1, Irak4, Map2k3, Hmg1l1, Ppp2r5d, Nfkb1, 
Rps6ka3, Rps6ka2 
Synthesis of 
glycosylphosphatidylinositol (GPI)  
2.088 0.0368 Pigl, Pigv, Dpm2, Pigf, Pigw, Pign, Pigp 
Signaling by the B Cell Receptor 
(BCR)  
2.079 0.0376 
Nfkbia, Cdkn1a, Trpc1, Nfkbie, Plcg2, Rasgrp1, Sykb, Stim1, 
Lyn, Card11, Btk, Cd79a, Ikbkg, Pik3ap1, Ubc, Psmb8, 




Kras, Foxo4, Nfkb1, Casp9, Mlst8, Psmd7, Dapp1, Psma2 
Antigen Activates B Cell Receptor 
Leading to Generation of Second 
Messengers  
2.071 0.0383 Trpc1, Plcg2, Sykb, Stim1, Lyn, Btk, Cd79a, Pik3ap1 
Effects of PIP2 hydrolysis  2.065 0.0389 
Dgka, Trpc7, Dgkb, Dgki, Rasgrp1, Prkcd, Dgkh, Prkcq, 
Trpc6 
Nitric oxide stimulates guanylate 
cyclase  
2.009 0.0446 
Pde3a, Kcnmb1, Pde2a, Nos1, Pde5a, Gucy1a2, Pde9a, 
Gucy1b3 
Trafficking and processing of 
endosomal TLR  
1.998 0.0457 Lgmn, Ctss, Unc93b1, Tlr7, Tlr8, Ctsb 
Interferon Signaling  1.961 0.0499 
Usp18, Irf9, Trim25, Irf1, Stat1, Ddx58, Ifitm3, Vcam1, Irf7, 
Stat2, Ifi27l1, Eif2ak2, Oas1a, Ifi35, Gm14446, Gbp3, Icam1, 
Isg15, Irf4, Pml, Oasl1, Gbp7, H2-Q2, B2m, H2-Q10, 





8.3. The Reactome pathways for the 72 vs. 0 hour signature 
 
Set  NES  p-value  Ledge  
Cyclin A/B1 associated events 
during G2/M transition  
3.95 7.82e-05 
Cdc25b, Ccna2, Cdk1, Ccnb2, Cdc25c, Mnat1, Plk1, Wee1, 
Cdc25a 
G alpha (z) signalling events  3.601 0.000317 
Prkce, Gng2, Gnai1, Rgs17, Rgs4, Adcy5, Gng3, Adcy2, 
Adra2a, Gnai2, Prkch, Gng12, Rgs20, Gnb4, Gnaz, Prkca, 
Adcy1, Adcy7, Gng10 
Interleukin-6 signaling  3.417 0.000633 Il6st, Stat3, Jak2, Stat1, Ptpn11, Socs3, Il6ra, Tyk2 
N-glycan trimming in the ER and 
Calnexin/Calreticulin cycle  
3.396 0.000684 
Ganab, Man1b1, Uggt1, Calr, Pdia3, Mlec, Prkcsh, Mogs, 
Canx, Edem1 
Signaling by Robo receptor  3.283 0.00103 
Pak7, Robo2, Cap2, Nck2, Pfn2, Pak1, Clasp2, Srgap1, 
Arhgap39, Sos1, Srgap2, Slit2, Pak3, Evl, Pak4, Robo1, 
Clasp1, Pfn1 
Opioid Signalling  3.276 0.00105 
Gnal, Pde4b, Gng2, Gnai1, Ppp3cc, Prkar1b, Ppp3ca, Ppp1r1b, 
Adcy5, Camk4, Plcb3, Plcb4, Gng3, Adcy2, Ppp3r1, Gnao1, 
Prkar2a, Prkacb, Gnai2, Gng12, Pde4a, Pde1a, Mapk1, Gnb4, 
Oprm1, Gnaz, Prkar2b, Prkca, Adcy1, Adcy7, Gng10, Plcb1, 
Plcb2, Ppp1ca, Itpr2 
DARPP-32 events  3.197 0.00139 
Pde4b, Ppp3cc, Prkar1b, Ppp3ca, Ppp1r1b, Ppp3r1, Prkar2a, 
Prkacb, Pde4a 
Gap-filling DNA repair synthesis 
and ligation in GG-NER  
3.163 0.00156 
Lig1, Pole, Rpa1, Pold3, Pold1, Pcna, Pole2, Rfc1, Rfc4, Rfc3, 
Rfc5, Pold2, Rfc2 
Gap-filling DNA repair synthesis 
and ligation in TC-NER  
3.163 0.00156 
Lig1, Pole, Rpa1, Pold3, Pold1, Pcna, Pole2, Rfc1, Rfc4, Rfc3, 
Rfc5, Pold2, Rfc2 
DSCAM interactions  3.025 0.00249 Dcc, Ntn1, Mapk8, Dscam, Mapk12, Pak1, Dscaml1 
Calnexin/calreticulin cycle  3.005 0.00266 Ganab, Man1b1, Uggt1, Calr, Pdia3, Prkcsh, Canx, Edem1 
Activation of Rac  3.002 0.00268 Pak7, Nck2, Pak1, Sos1, Slit2, Pak3, Pak4, Robo1 
Processive synthesis on the C-




strand of the telomere  
N-glycan antennae elongation in 
the medial/trans-Golgi  
2.97 0.00298 
St8sia3, Fut8, B4galt5, Mgat3, Mgat4b, B4galt6, Man2a1, 
St3gal4 
Repair synthesis for gap-filling by 
DNA polymerase in TC-NER  
2.961 0.00307 
Pole, Rpa1, Pold3, Pold1, Pcna, Pole2, Rfc1, Rfc4, Rfc3, Rfc5, 
Pold2, Rfc2 
Repair synthesis of patch ~27-30 
bases long by DNA polymerase  
2.961 0.00307 
Pole, Rpa1, Pold3, Pold1, Pcna, Pole2, Rfc1, Rfc4, Rfc3, Rfc5, 
Pold2, Rfc2 
Base Excision Repair  2.931 0.00338 
Lig1, Pold3, Pold1, Pcna, Fen1, Xrcc1, Mpg, Mutyh, Pold2, 
Apex1, Lig3, Mbd4, Nthl1, Pold4 
Resolution of Abasic Sites (AP 
sites)  
2.931 0.00338 
Lig1, Pold3, Pold1, Pcna, Fen1, Xrcc1, Mpg, Mutyh, Pold2, 
Apex1, Lig3, Mbd4, Nthl1, Pold4 
Amino acid synthesis and 
interconversion (transamination)  
2.922 0.00347 Gpt2, Psat1, Psph, Gls, Phgdh, Pycr1, Asns 
Transport to the Golgi and 
subsequent modification  
2.904 0.00369 
St8sia3, Man1a, Fut8, B4galt5, Mgat3, Mgat4b, B4galt6, 
Sec31a, Man2a1, St3gal4, Lman1, Man1c1, Man1a2, Sec13, 
Sec23a, Mgat5, Mcfd2, St6gal1 
Botulinum neurotoxicity  2.888 0.00387 
Vamp1, Stx7, Stx1a, Stx6, Stx12, Vamp2, Syt2, Syt1, Stx1b, 
Snap25, Stx11, Stx2 
Removal of DNA patch 
containing abasic residue  
2.867 0.00414 Lig1, Pold3, Pold1, Pcna, Fen1, Mpg, Mutyh, Pold2 
Resolution of AP sites via the 
multiple-nucleotide patch 
replacement pathway 
2.867 0.00414 Lig1, Pold3, Pold1, Pcna, Fen1, Mpg, Mutyh, Pold2 
DNA Replication  2.86 0.00424 
Lig1, Ccna2, Cenpn, Mcm2, Aurkb, Mcm5, Kntc1, Pole, 
Mcm6, Cdca8, Rpa1, Mcm4, Birc5, Pold3, Incenp, E2f2, 
Bub1b, Pold1, Pcna, Cenpa, Zw10, Spc25, Nup107, Spc24, 
Kif23, Fen1, Kif20a, Smc1a, Psmc1, Fbxo5, Cdc7, Psma1, 
Dbf4, Prim1, Kif2c, Ska1, Dna2, Fam33a, Mcm10, Mcm3, 
Psmc4, Ccdc99, Bub1, Gmnn, Plk1, Nsl1, Sgol1, Pmf1, Pole2, 
Zwilch, Cdc45, Rfc1, Pola2, Cenpo, Ercc6l, Cenpf, Cdk2, 
Nup85, Gins2, Cdc6, Cdc20, Rcc2, Cenpq, Rfc4, Nuf2, Mcm7, 
Ppp2r5e, Cdt1, Dsn1, Orc2, Sgol2, Rfc3, Mad2l1, Gins4, 




Rad21, Pold2, Cenpm, Gins1, Ppp2r5b, Ndc80, Clasp2, Rfc2, 
Cdkn1b, Mlf1ip, Pafah1b1, Psmd4, Psmd7, Mcm8, Zwint, 
Psma4, Psmd5, Psmd12, Psmc3, Sec13, Clasp1, Psmc6, 
Mapre1, Casc5, Psmb2, Xpo1, Gorasp1 
Neuronal System 2.859 0.00425 
Gnal, Cacna2d3, Vamp1, Kcnab1, Gng2, Stx7, Hcn1, Hcn4, 
Grin2a, Gnai1, Gabrg3, Camk2g, Slc38a2, Chrnb2, Gria4, 
Kcnb2, Dlg4, Kcnj2, Kcnk10, Syn2, Gabbr2, Grip1, Stx1a, 
Kcnb1, Gabbr1, Gls, Kcnh1, Gjc1, Akap5, Stx6, Grik2, Adcy5, 
Camk4, Kcnn1, Stx12, Kcnj6, Kcnh8, Gabrb3, Plcb3, Vamp2, 
Syn1, Syt2, Syt1, Gad1, Panx1, Kcnh7, Cacng4, Gng3, Kcnq2, 
Stx1b, Dnajc5, Kcnma1, Adcy2, Rasgrf2, Cacna1b, Grin2b, 
Cacna2d1, Rps6ka3, Grip2, Hspa8, Gabrg2, Slc1a7, Nsf, 
Snap25, Camkk1, Gria2, Kcng2, Slc1a3, Grin1, Gjd2, Ap2b1, 
Prkacb, Gabra5, Kcna5, Kcnv1, Gnai2, Gad2, Cplx1, Kcnn2, 
Cacnb1, Gng12, Camk2b, Gabra3, Hcn3, Stx11, Comt, Stxbp1, 
Cacna1a, Kcnc1, Chrna4, Arhgef9, Ap2a2, Gria1, Kcnmb2, 





St8sia3, Gfpt2, Man1a, Fut8, Alg2, B4galt5, Ganab, Man1b1, 
Uggt1, Mgat3, Mgat4b, B4galt6, Tusc3, Rpn2, Sec31a, Calr, 
Dpagt1, Pgm3, Pdia3, Ddost, Man2a1, Alg3, Stt3a, St3gal4, 
Lman1, Man1c1, Man1a2, Sec13, Mlec, Prkcsh, Sec23a, Alg8, 
Mogs, Mgat5, Canx, Mcfd2, Edem1 
Transport of the SLBP Dependant 
Mature mRNA  
2.833 0.0046 
Ncbp1, Nup205, Nup188, Nup107, Nup93, Slbp, Nup50, 
Nup85, Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, 
Rae1, Nxf1, Thoc4, Nup88, Ncbp2, Nup43 
Removal of the Flap Intermediate 
from the C-strand  
2.81 0.00495 Rpa1, Pold3, Pold1, Pcna, Fen1, Dna2 
S Phase  2.799 0.00513 
Lig1, Cdc25b, Ccna2, Mcm2, Mcm5, Pole, Mcm6, Rpa1, 
Mcm4, Pold3, Pold1, Pcna, Skp2, Fen1, Cdk4, Psmc1, Psma1, 
Prim1, Dna2, Mcm3, Psmc4, Mnat1, Ccne1, Pole2, Cdc45, 
Rfc1, Pola2, Cdk2, Gins2, Cdc6, Rfc4, Mcm7, Cdt1, Orc2, 
Rfc3, Gins4, Psmc2, Rfc5, Myc, Max, Pold2, Wee1, Gins1, 
Rfc2, Cdkn1b, Cdc25a, Psmd4, Psmd7, Mcm8, Psma4, Psmd5, 
Psmd12, Psmc3 
Transport of the SLBP 
independent Mature mRNA  
2.772 0.00558 
Ncbp1, Nup205, Nup188, Nup107, Nup93, Nup50, Nup85, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, Rae1, Nxf1, 




Extension of Telomeres  2.765 0.0057 
Lig1, Pole, Rpa1, Pold3, Pold1, Pcna, Fen1, Prim1, Dna2, 
Pole2, Rfc1, Pola2, Rfc4, Rfc3, Ruvbl1, Rfc5, Ruvbl2, Pold2, 
Rfc2 
Transport of Ribonucleoproteins 
into the Host Nucleus  
2.735 0.00624 
Nup205, Nup188, Nup107, Kpnb1, Nup93, Nup50, Nup85, 
Kpna1, Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, 
Rae1 
Transport of Mature mRNAs 
Derived from Intronless 
Transcripts 
2.714 0.00665 
Ncbp1, Nup205, Nup188, Nup107, Nup93, Slbp, Nup50, 
Nup85, Nup62, Nup37, Nupl1, Nup133, Nup214, Cpsf1, 
Nup155, Rae1, Nxf1, Thoc4, Nup88, Ncbp2, Nup43 
Neurotransmitter Receptor 
Binding And Downstream 
Transmission In The Postsynaptic 
Cell  
2.713 0.00667 
Gnal, Gng2, Grin2a, Gnai1, Gabrg3, Camk2g, Chrnb2, Gria4, 
Dlg4, Kcnj2, Gabbr2, Grip1, Gabbr1, Akap5, Grik2, Adcy5, 
Camk4, Kcnj6, Gabrb3, Plcb3, Cacng4, Gng3, Adcy2, Rasgrf2, 
Grin2b, Rps6ka3, Grip2, Gabrg2, Nsf, Camkk1, Gria2, Grin1, 
Ap2b1, Prkacb, Gabra5, Gnai2, Gng12, Camk2b, Gabra3, 
Chrna4, Arhgef9, Ap2a2, Gria1, Mapk1, Gnb4, Cacng3, 
Rasgrf1 
Interactions of Vpr with host 
cellular proteins  
2.691 0.00712 
Nup205, Nup188, Nup107, Slc25a5, Nup93, Nup50, Nup85, 
Kpna1, Nup62, Nup37, Nupl1, Nup133, Nup214, Banf1, 
Nup155, Rae1 
Mitotic M-M/G1 phases  2.687 0.00721 
Cenpn, Mcm2, Aurkb, Mcm5, Kntc1, Pole, Mcm6, Cdca8, 
Rpa1, Mcm4, Birc5, Incenp, E2f2, Bub1b, Cenpa, Zw10, 
Spc25, Nup107, Spc24, Kif23, Kif20a, Smc1a, Psmc1, Fbxo5, 
Cdc7, Psma1, Dbf4, Prim1, Kif2c, Ska1, Fam33a, Mcm10, 
Mcm3, Psmc4, Ccdc99, Bub1, Gmnn, Plk1, Nsl1, Sgol1, Pmf1, 
Pole2, Zwilch, Cdc45, Pola2, Cenpo, Ercc6l, Cenpf, Cdk2, 
Nup85, Cdc6, Cdc20, Rcc2, Cenpq, Nuf2, Mcm7, Ppp2r5e, 
Cdt1, Dsn1, Orc2, Sgol2, Mad2l1, Cenph, Nup37, Cenpe, 
Nup133, Cenpk, Psmc2, Kif2a, Rad21, Cenpm, Ppp2r5b, 
Ndc80, Clasp2, Mlf1ip, Pafah1b1, Psmd4, Psmd7, Mcm8, 
Zwint, Psma4, Psmd5, Psmd12, Psmc3, Sec13, Clasp1, Psmc6, 
Mapre1, Casc5, Psmb2, Xpo1, Gorasp1 
Transport of Mature mRNA 
Derived from an Intronless 
Transcript 
2.651 0.00801 
Ncbp1, Nup205, Nup188, Nup107, Nup93, Nup50, Nup85, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Cpsf1, Nup155, 
Rae1, Nxf1, Thoc4, Nup88, Ncbp2, Nup43 
Telomere C-strand (Lagging 
Strand) Synthesis  
2.6 0.00932 
Lig1, Pole, Rpa1, Pold3, Pold1, Pcna, Fen1, Prim1, Dna2, 




Proteolytic cleavage of SNARE 
complex proteins  
2.599 0.00934 
Vamp1, Stx7, Stx1a, Stx6, Stx12, Vamp2, Stx1b, Snap25, 
Stx11, Stx2 
Lagging Strand Synthesis  2.588 0.00964 
Lig1, Rpa1, Pold3, Pold1, Pcna, Fen1, Prim1, Dna2, Rfc1, 
Pola2, Rfc4, Rfc3, Rfc5, Pold2, Rfc2 
DNA strand elongation  2.585 0.00975 
Lig1, Mcm2, Mcm5, Mcm6, Rpa1, Mcm4, Pold3, Pold1, Pcna, 
Fen1, Prim1, Dna2, Mcm3, Cdc45, Rfc1, Pola2, Gins2, Rfc4, 
Mcm7, Rfc3, Gins4, Rfc5, Pold2, Gins1, Rfc2, Mcm8 
Cyclin A:Cdk2-associated events 
at S phase entry 
2.577 0.00998 
Cdc25b, Ccna2, Skp2, Psmc1, Psma1, Psmc4, Mnat1, Ccne1, 
Cdk2, Psmc2, Myc, Max, Wee1, Cdkn1b, Cdc25a, Psmd4, 
Psmd7, Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2, Cks1b 
Synthesis of DNA  2.568 0.0102 
Lig1, Ccna2, Mcm2, Mcm5, Pole, Mcm6, Rpa1, Mcm4, Pold3, 
Pold1, Pcna, Fen1, Psmc1, Psma1, Prim1, Dna2, Mcm3, 
Psmc4, Pole2, Cdc45, Rfc1, Pola2, Cdk2, Gins2, Cdc6, Rfc4, 
Mcm7, Cdt1, Orc2, Rfc3, Gins4, Psmc2, Rfc5, Pold2, Gins1, 
Rfc2, Cdkn1b, Psmd4, Psmd7, Mcm8, Psma4, Psmd5, Psmd12, 
Psmc3, Psmc6, Psmb2 
M Phase 2.558 0.0105 
Cenpn, Aurkb, Kntc1, Cdca8, Birc5, Incenp, Bub1b, Cenpa, 
Zw10, Spc25, Nup107, Spc24, Kif23, Kif20a, Smc1a, Fbxo5, 
Kif2c, Ska1, Fam33a, Ccdc99, Bub1, Plk1, Nsl1, Sgol1, Pmf1, 
Zwilch, Cenpo, Ercc6l, Cenpf, Nup85, Cdc20, Rcc2, Cenpq, 
Nuf2, Ppp2r5e, Dsn1, Sgol2, Mad2l1, Cenph, Nup37, Cenpe, 
Nup133, Cenpk, Kif2a, Rad21, Cenpm, Ppp2r5b, Ndc80, 
Clasp2, Mlf1ip, Pafah1b1, Zwint, Sec13, Clasp1, Mapre1, 
Casc5, Xpo1, Gorasp1 
Cell Cycle, Mitotic  2.558 0.0105 
Lig1, Cdc25b, Ccna2, Cenpn, Mcm2, Top2a, Aurkb, Mcm5, 
Kntc1, Pole, Mcm6, Cdca8, Rpa1, Mcm4, Birc5, Cdk1, Ccnb2, 
Pold3, Incenp, E2f2, Bub1b, Pold1, Dhfr, Ube2d1, Pcna, 
Cenpa, Tubgcp2, Zw10, Spc25, Nup107, Spc24, Skp2, Kif23, 
Fen1, Kif20a, Aurka, Cdk4, Cdc25c, Smc1a, Psmc1, Fbxo5, 
Cdc7, Psma1, Dbf4, Prim1, Kif2c, Ska1, Nek2, Dna2, Cenpj, 
Fam33a, Mcm10, Mcm3, Psmc4, Ube2c, Ccdc99, Mnat1, 
Ccne1, Bub1, Gmnn, Plk1, Nsl1, Sgol1, Pmf1, Pole2, Zwilch, 
Rrm2, Cdc45, Rfc1, Ccnd3, Pola2, Cenpo, Ercc6l, Rbl1, Cenpf, 
Cdk2, Mybl2, Nup85, Gins2, Cdc6, Cdc20, Rcc2, Cenpq, Rfc4, 
Nuf2, Mcm7, Cep152, Ppp2r5e, Tyms, Cdt1, Dsn1, Orc2, 
Sgol2, Rfc3, Mad2l1, Gins4, Csnk1d, Cdc23, Cenph, Nup37, 
Cenpe, Nup133, Cdc26, Cenpk, Psmc2, Rfc5, Myc, Kif2a, 
Dync1i2, Max, Rad21, Plk4, Tubg1, Pold2, Cenpm, Wee1, 




Cdc25a, E2f4, Mlf1ip, Ywhag, Pafah1b1, Psmd4, Cdc16, 
Psmd7, Nedd1, Pttg1, Cep76, Mcm8, Zwint, Cetn2, Anapc1, 
Psma4, Psmd5, Psmd12, Psmc3, Cdkn2c, Sec13, Clasp1, 
Psmc6, Mapre1, Dyrk1a, Cep135, Casc5, Psmb2, Prkar2b, 
Xpo1, Gorasp1, Cks1b 
CRMPs in Sema3A signaling  2.554 0.0106 
Nrp1, Plxna2, Plxna4, Crmp1, Dpysl3, Cdk5r1, Sema3a, 
Dpysl5, Fyn, Gsk3b 
Nuclear import of Rev protein  2.532 0.0113 
Nup205, Nup188, Nup107, Kpnb1, Ran, Nup93, Nup50, Rcc1, 
Nup85, Nup62, Nup37, Nupl1, Nup133, Npm1, Nup214, 
Nup155, Rae1 
Transmission across Chemical 
Synapses  
2.518 0.0118 
Gnal, Cacna2d3, Gng2, Grin2a, Gnai1, Gabrg3, Camk2g, 
Slc38a2, Chrnb2, Gria4, Dlg4, Kcnj2, Syn2, Gabbr2, Grip1, 
Stx1a, Gabbr1, Gls, Akap5, Grik2, Adcy5, Camk4, Kcnj6, 
Gabrb3, Plcb3, Vamp2, Syn1, Syt1, Gad1, Cacng4, Gng3, 
Dnajc5, Adcy2, Rasgrf2, Cacna1b, Grin2b, Cacna2d1, 
Rps6ka3, Grip2, Hspa8, Gabrg2, Slc1a7, Nsf, Snap25, Camkk1, 
Gria2, Slc1a3, Grin1, Ap2b1, Prkacb, Gabra5, Gnai2, Gad2, 
Cplx1, Cacnb1, Gng12, Camk2b, Gabra3, Comt, Stxbp1, 
Cacna1a, Chrna4, Arhgef9, Ap2a2, Gria1, Cacnb4, Slc1a1, 
Mapk1, Gnb4, Cacng3, Rasgrf1 
Unwinding of DNA  2.516 0.0119 
Mcm2, Mcm5, Mcm6, Mcm4, Mcm3, Cdc45, Gins2, Mcm7, 
Gins4, Gins1, Mcm8 
Vpr-mediated nuclear import of 
PICs 
2.504 0.0123 
Nup205, Nup188, Nup107, Nup93, Nup50, Nup85, Kpna1, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Banf1, Nup155, Rae1 
Mitotic Prometaphase  2.498 0.0125 
Cenpn, Aurkb, Kntc1, Cdca8, Birc5, Incenp, Bub1b, Cenpa, 
Zw10, Spc25, Nup107, Spc24, Smc1a, Kif2c, Ska1, Fam33a, 
Ccdc99, Bub1, Plk1, Nsl1, Sgol1, Pmf1, Zwilch, Cenpo, 
Ercc6l, Cenpf, Nup85, Cdc20, Rcc2, Cenpq, Nuf2, Ppp2r5e, 
Dsn1, Sgol2, Mad2l1, Cenph, Nup37, Cenpe, Nup133, Cenpk, 
Kif2a, Rad21, Cenpm, Ppp2r5b, Ndc80, Clasp2, Mlf1ip, 
Pafah1b1, Zwint, Sec13, Clasp1, Mapre1, Casc5, Xpo1 
NEP/NS2 Interacts with the 
Cellular Export Machinery  
2.471 0.0135 
Nup205, Nup188, Nup107, Ran, Nup93, Nup50, Nup85, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, Rae1, Xpo1, 
Nup88, Nup43 
Cell Cycle  2.442 0.0146 Lmnb1, Lig1, Cdc25b, Ccna2, Cenpn, Mcm2, Top2a, Aurkb, 




Ccnb2, Pold3, Incenp, E2f2, Bub1b, Pold1, Dhfr, Ube2d1, 
Pcna, Cenpa, Tubgcp2, Zw10, Spc25, Nup107, Hjurp, Spc24, 
Skp2, Kif23, Fen1, Kif20a, Aurka, Cdk4, Cdc25c, Smc1a, 
Psmc1, Tinf2, Fbxo5, Cdc7, Psma1, Dbf4, Hus1, Prim1, Kif2c, 
Ska1, Nek2, Dna2, Cenpj, Fam33a, Mcm10, Mcm3, Brca1, 
Psmc4, Ube2c, Ccdc99, Mnat1, Ccne1, Bub1, Gmnn, Plk1, 
Nsl1, Sgol1, Pmf1, Pole2, Zwilch, Rrm2, Cdc45, Rfc1, Ccnd3, 
Pola2, Cenpo, Ercc6l, H2afz, Rbl1, Cenpf, Cdk2, Clspn, 
Mybl2, Nup85, Gins2, Cdc6, Cdc20, Rcc2, Cenpq, Rfc4, Nuf2, 
Mcm7, Cep152, Ppp2r5e, Tyms, Cdt1, Dsn1, Orc2, Sgol2, 
Terf1, Rfc3, Mad2l1, Gins4, Csnk1d, Cdc23, Cenph, Nup37, 
Cenpe, Syne1, Nup133, Ruvbl1, Cdc26, Npm1, Cenpk, Psmc2, 
Rec8, Rfc5, Myc, Kif2a, Dync1i2, Max, Rad21, Plk4, Tubg1, 
Ruvbl2, Pold2, Cenpm, Wee1, Gins1, Ppp2r5b, Ndc80, Clasp2, 
Mis18bp1, Chek1, Rfc2, Hdac1, Cdkn1b, Cdc25a, E2f4, 
Mlf1ip, Ywhag, Pafah1b1, Psmd4, Cdc16, Rbbp7, Psmd7, 
Nedd1, Pttg1, Cep76, Mcm8, Zwint, Chek2, Cetn2, Anapc1, 
Psma4, Psmd5, Trp53, 2610039C10Rik, Dkc1, Psmd12, 
Psmc3, Cdkn2c, Sec13, Clasp1, Psmc6, Mapre1, Dyrk1a, 
Cep135, Casc5, Psmb2, Prkar2b, Xpo1, Gorasp1, Cks1b 
G beta:gamma signalling through 
PLC beta  
2.439 0.0147 
Gng2, Plcb3, Gng3, Gng12, Gnb4, Gng10, Plcb1, Plcb2, Gng7, 
Gnb5, Gng4, Gngt2 
Cell Cycle Checkpoints  2.43 0.0151 
Mcm2, Mcm5, Mcm6, Rpa1, Mcm4, Cdk1, Ccnb2, Bub1b, 
Ube2d1, Cdc25c, Psmc1, Cdc7, Psma1, Dbf4, Hus1, Mcm10, 
Mcm3, Psmc4, Ube2c, Ccne1, Cdc45, Cdk2, Clspn, Cdc6, 
Cdc20, Rfc4, Mcm7, Orc2, Rfc3, Mad2l1, Cdc23, Cdc26, 
Psmc2, Rfc5, Wee1, Chek1, Rfc2, Cdkn1b, Cdc25a, Psmd4, 
Cdc16, Psmd7, Mcm8, Chek2, Anapc1, Psma4, Psmd5, Trp53, 
Psmd12, Psmc3, Psmc6, Psmb2 
Leading Strand Synthesis  2.426 0.0153 
Pold3, Pold1, Pcna, Prim1, Rfc1, Pola2, Rfc4, Rfc3, Rfc5, 
Pold2, Rfc2 
Polymerase switching  2.426 0.0153 
Pold3, Pold1, Pcna, Prim1, Rfc1, Pola2, Rfc4, Rfc3, Rfc5, 
Pold2, Rfc2 
Polymerase switching on the C-
strand of the telomere  
2.426 0.0153 
Pold3, Pold1, Pcna, Prim1, Rfc1, Pola2, Rfc4, Rfc3, Rfc5, 
Pold2, Rfc2 
Rev-mediated nuclear export of 
HIV-1 RNA 
2.416 0.0157 
Nup205, Nup188, Nup107, Ran, Nup93, Nup50, Rcc1, Nup85, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, Rae1, 




Disease  2.414 0.0158 
Pcsk2, Prkce, Lig1, Vamp1, Grb2, Stx7, Stam, App, Srpr, 
Igfbp4, Pag1, Cdk1, Adam12, Ap1s2, Ncbp1, Atp6v0d1, 
Nup205, Nup188, Nup107, Cxcr4, Spry2, Fen1, Pdia6, Stx1a, 
Psmc1, Bche, Psma1, Hspa5, Ap1m1, Hsp90b1, Prkar1b, 
Mmp2, Dnajb11, Adam17, Stx6, Psmc4, Elmo1, Kpnb1, 
Adcy5, Slc25a5, Ran, Camk4, Mnat1, Nup93, Stx12, Gtf2e1, 
Mbtps1, Tpp1, Herpud1, Ssrp1, Vamp2, Syt2, Asns, Syt1, 
Nup50, Rcc1, H2afz, Tln1, Stx1b, Nup85, Ywhab, Them4, 
Pik3r1, Kpna1, Casp9, Supt16h, Trib3, Atf4, Sec31a, Adcy2, 
Hdgf, Myo5a, Ddx11, Mfge8, Calr, Nup62, Rngtt, Snap25, 
Ptpn11, Exosc8, Akt3, Sh3kbp1, Rps3a, Sh3gl2, Exosc3, Serp1, 
Igf2, Nup37, Xrcc5, Gtf2e2, Th1l, Dock2, Prkar2a, Nupl1, 
Igf2bp2, Ap2b1, Nup133, Prkacb, Npm1, Pten, Psmc2, Acadvl, 
Myc, Nup214, Mapkap1, Rpl6, Banf1, Shc1, Rps23, Mapk3, 
Nup155, Dnajc3, Ppp2r5b, Taf6, Fyn, Stx11, Igf1, Cdkn1b, 
Ap2a2, Phlpp1, Pappa2, Pde1a, Sos1, Gsk3b, Psmd4, Rae1, 
Egfr, Psmd7, Exoc5, Rplp0, Rps5, Mapk1, Rps6, Psma4, Stx2, 
Psmd5, Igf2bp1, Ranbp1, Hyou1, Psmd12, Apcs, Psmc3, Rpl4, 
Rpl19, Rpl27a, Igfbp5, Cul7, Exosc2, Rnmt, Taf12, Cd28, 
Gtf2f2, Ssr1, Srprb, Rps8, Psmc6, Igfbp2, Psmb2, Prkar2b, 
Hist1h3c, Xpo1, Prkca, Nup88, Adcy1, Rps7, Pacs1, Rps16, 
Gtf2h4, Actb, Polr2j, Exoc6, Ncbp2, Wipi1, Adcy7, Hist3h2bb-
ps, Rps10, Exosc9, Hist2h2be, Gtf2h3, Nup43, Kdelr3, 
Slc30a5, Snca, Exoc8, Rpl3, Nfyc, Canx, Pcsk1, Rdbp, Edem1, 
Gtf2f1, Itpr2, Rpl18a, Rpsa, Rps11, Rps4x, Stx5a, Rps9, 
Arhgef7 
Axon guidance  2.373 0.0177 
Gfra2, Cntn1, Plxnc1, Grb2, Nrp1, Pak7, Robo2, Scn3b, Dcc, 
Rgmb, Met, Cdk1, Unc5c, Gfra1, Sema4a, Prnp, Dlg4, Plxna2, 
Ntn1, Dcx, Plxna4, Cap2, Unc5d, Crmp1, Nfasc, Sema6d, 
Dnm3, Cacna1i, Nrcam, Myo10, Col1a2, Col5a1, Alcam, 
4930506M07Rik, Ank3, Dpysl3, Erbb2, Cdk5r1, Scn3a, Spnb2, 
Nck2, Sema3a, Tln1, Kcnq2, Col2a1, Ywhab, Hsp90ab1, 
Scn2a1, Limk2, Rps6ka3, Sema7a, Ptpn11, Ablim1, Kif4, 
Ablim3, Sh3gl2, L1cam, Pitpna, Dpysl5, Ap2b1, Ncam1, 
Cacna1d, Scn8a, Neo1, Pfn2, Cacna1h, Rdx, St8sia4, Cacnb1, 
Chl1, Mapk3, Ezr, Pak1, Lama1, Clasp2, Scn9a, Fyn, Col3a1, 
Srgap1, Ap2a2, Arhgap39, Cacnb4, Sos1, Gsk3b, Srgap2, 
Unc5a, Egfr, Slit2, Fgfr1, Cacna1c, Spnb3, Stip1, Mapk1, Pak3, 
Evl, Sdcbp, Pak4, Cntnap1, Robo1, Ncan, Clasp1 
Interactions of Rev with host 
cellular proteins  
2.372 0.0177 
Nup205, Nup188, Nup107, Kpnb1, Ran, Nup93, Nup50, Rcc1, 
Nup85, Nup62, Nup37, Nupl1, Nup133, Npm1, Nup214, 




Processing of Capped Intron-
Containing Pre-mRNA 
2.37 0.0178 
Hnrnpl, Hnrnpf, Ptbp1, Srsf2, Sf3a3, Ncbp1, Nup205, Nup188, 
Nup107, Hnrnpm, Eftud2, Smc1a, Sf3b2, Nup93, Slbp, Pcbp2, 
Nup50, Hnrnpul1, Snrnp200, Nup85, Prpf4, Lsm2, Mettl3, 
Nup62, Hnrnpa2b1, Sf3b3, Nup37, Hnrnpu, Snrpa, Dhx38, 
Nupl1, Nup133, Sf3a1, Nup214, Hnrnpa1, Pcbp1, Srsf1, Srsf3, 
Cpsf1, Nup155, Snrnp70, Prpf8, Rae1, Cstf1, Magoh, Ddx23, 
Sf3b4, Snrpb, Cd2bp2, U2af1, Gtf2f2, Nxf1, Thoc4, Srsf6, 
Nup88, Polr2j, Nudt21, Ncbp2, Nup43 
G2/M Checkpoints  2.368 0.0179 
Mcm2, Mcm5, Mcm6, Rpa1, Mcm4, Cdk1, Ccnb2, Cdc25c, 
Cdc7, Dbf4, Hus1, Mcm10, Mcm3, Cdc45, Cdk2, Clspn, Cdc6, 
Rfc4, Mcm7, Orc2, Rfc3, Rfc5, Wee1, Chek1, Rfc2, Cdc25a, 
Mcm8, Chek2 
Resolution of AP sites via the 
single-nucleotide replacement 
pathway 
2.363 0.0181 Xrcc1, Mpg, Mutyh, Apex1, Lig3, Mbd4, Nthl1 
GABA synthesis, release, 
reuptake and degradation  
2.361 0.0182 
Stx1a, Vamp2, Syt1, Gad1, Dnajc5, Hspa8, Snap25, Gad2, 
Cplx1, Stxbp1, Slc6a13, Abat 
mRNA Processing  2.36 0.0183 
Hnrnpl, Hnrnpf, Ptbp1, Srsf2, Sf3a3, Ncbp1, Nup205, Nup188, 
Nup107, Hnrnpm, Eftud2, Smc1a, Sf3b2, Mnat1, Nup93, Slbp, 
Pcbp2, Nup50, Hnrnpul1, Snrnp200, Nup85, Prpf4, Lsm2, 
Mettl3, Nup62, Rngtt, Hnrnpa2b1, Sf3b3, Nup37, Hnrnpu, 
Snrpa, Dhx38, Nupl1, Nup133, Sf3a1, Nup214, Hnrnpa1, 
Pcbp1, Srsf1, Lsm11, Srsf3, Cpsf1, Nup155, Snrnp70, Prpf8, 
Rae1, Cstf1, Magoh, Ddx23, Sf3b4, Snrpb, Rnmt, Cd2bp2, 
U2af1, Gtf2f2, Nxf1, Thoc4, Srsf6, Nup88, Gtf2h4, Polr2j, 
Nudt21, Ncbp2, Gtf2h3, Nup43 
Processive synthesis on the 
lagging strand  
2.33 0.0198 Lig1, Rpa1, Pold3, Pold1, Pcna, Fen1, Prim1, Dna2, Pola2 
Ion transport by P-type ATPases 2.302 0.0213 
Atp8a1, Atp9a, Atp10a, Atp10b, Atp2b2, Atp1a1, Atp4b, 
Atp11c, Atp1a3, Atp8b1, Atp2a3, Atp8a2, Atp11b, Atp2b1 
DNA Replication Pre-Initiation  2.301 0.0214 
Mcm2, Mcm5, Pole, Mcm6, Rpa1, Mcm4, E2f2, Psmc1, Cdc7, 
Psma1, Dbf4, Prim1, Mcm10, Mcm3, Psmc4, Gmnn, Pole2, 
Cdc45, Pola2, Cdk2, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, Psmd4, 
Psmd7, Mcm8, Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2 
M/G1 Transition  2.301 0.0214 Mcm2, Mcm5, Pole, Mcm6, Rpa1, Mcm4, E2f2, Psmc1, Cdc7, 




Cdc45, Pola2, Cdk2, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, Psmd4, 
Psmd7, Mcm8, Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2 
Removal of licensing factors from 
origins  
2.289 0.0221 
Ccna2, Mcm2, Mcm5, Mcm6, Mcm4, Psmc1, Psma1, Mcm10, 
Mcm3, Psmc4, Gmnn, Cdk2, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, 
Cdkn1b, Psmd4, Psmd7, Mcm8, Psma4, Psmd5, Psmd12, 
Psmc3, Psmc6, Psmb2 
Transport of Mature mRNA 
derived from an Intron-
Containing Transcript  
2.288 0.0221 
Srsf2, Ncbp1, Nup205, Nup188, Nup107, Nup93, Nup50, 
Nup85, Nup62, Nup37, Dhx38, Nupl1, Nup133, Nup214, Srsf1, 
Srsf3, Nup155, Rae1, Magoh, U2af1, Nxf1, Thoc4, Srsf6, 
Nup88, Ncbp2, Nup43 
Ion channel transport  2.265 0.0235 
Atp8a1, Atp9a, Gabrg3, Atp10a, Atp10b, Gabrb3, Atp2b2, 
Gabrg2, Atp1a1, Atp4b, Gabra5, Glra3, Atp11c, Gabra3, 
Atp1a3, Atp8b1, Arhgef9, Atp2a3, Atp8a2, Atp11b, Glra2, 
Atp2b1 
Activation of ATR in response to 
replication stress  
2.259 0.0239 
Mcm2, Mcm5, Mcm6, Rpa1, Mcm4, Cdc25c, Cdc7, Dbf4, 
Hus1, Mcm10, Mcm3, Cdc45, Cdk2, Clspn, Cdc6, Rfc4, 
Mcm7, Orc2, Rfc3, Rfc5, Chek1, Rfc2, Cdc25a, Mcm8 
Regulation of Glucokinase by 
Glucokinase Regulatory Protein  
2.245 0.0248 
Nup205, Nup188, Nup107, Nup93, Nup50, Nup85, Nup62, 
Nup37, Nupl1, Nup133, Nup214, Nup155, Rae1 
G-protein mediated events  2.243 0.0249 
Gnal, Gnai1, Prkar1b, Adcy5, Camk4, Plcb3, Plcb4, Adcy2, 
Gnao1, Prkar2a, Prkacb, Gnai2, Pde1a, Mapk1, Gnaz, Prkar2b, 
Prkca, Adcy1, Adcy7, Plcb1, Plcb2, Itpr2 
Removal of the Flap Intermediate  2.241 0.025 Rpa1, Pold3, Pold1, Pcna, Fen1, Prim1, Dna2, Pola2 
Orc1 removal from chromatin  2.239 0.0252 
Ccna2, Mcm2, Mcm5, Mcm6, Mcm4, Psmc1, Psma1, Mcm3, 
Psmc4, Cdk2, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, Cdkn1b, 
Psmd4, Psmd7, Mcm8, Psma4, Psmd5, Psmd12, Psmc3, 
Psmc6, Psmb2 
Switching of origins to a post-
replicative state  
2.239 0.0252 
Ccna2, Mcm2, Mcm5, Mcm6, Mcm4, Psmc1, Psma1, Mcm3, 
Psmc4, Cdk2, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, Cdkn1b, 
Psmd4, Psmd7, Mcm8, Psma4, Psmd5, Psmd12, Psmc3, 
Psmc6, Psmb2 
Regulation of DNA replication  2.234 0.0255 
Ccna2, Mcm2, Mcm5, Mcm6, Mcm4, E2f2, Psmc1, Psma1, 
Mcm10, Mcm3, Psmc4, Gmnn, Cdk2, Cdc6, Mcm7, Cdt1, 




Psmd12, Psmc3, Psmc6, Psmb2 
Transport of Mature Transcript to 
Cytoplasm  
2.231 0.0257 
Srsf2, Ncbp1, Nup205, Nup188, Nup107, Nup93, Slbp, Nup50, 
Nup85, Nup62, Nup37, Dhx38, Nupl1, Nup133, Nup214, Srsf1, 
Srsf3, Cpsf1, Nup155, Rae1, Magoh, U2af1, Nxf1, Thoc4, 
Srsf6, Nup88, Ncbp2, Nup43 
L1CAM interactions  2.222 0.0263 
Cntn1, Nrp1, Scn3b, Dlg4, Dcx, Nfasc, Dnm3, Nrcam, Alcam, 
4930506M07Rik, Ank3, Scn3a, Spnb2, Kcnq2, Scn2a1, 
Rps6ka3, Kif4, Sh3gl2, L1cam, Ap2b1, Ncam1, Scn8a, Rdx, 
Chl1, Mapk3, Ezr, Pak1, Lama1, Scn9a, Ap2a2, Egfr, Fgfr1, 
Spnb3, Stip1, Mapk1, Sdcbp, Cntnap1, Ncan, Dnm1, Scn1a, 
Scn2b, Dpysl2, Ank1, Spna2, Scn1b, Kcnq3, Csnk2b, Itga1, 
Dlg3 
Depolarization of the Presynaptic 
Terminal Triggers the Opening of 
Calcium Channels  
2.21 0.0271 
Cacna2d3, Cacng4, Cacna1b, Cacna2d1, Cacnb1, Cacna1a, 
Cacnb4 
Cyclin E associated events during 
G1/S transition  
2.187 0.0287 
Ccna2, Skp2, Psmc1, Psma1, Psmc4, Mnat1, Ccne1, Cdk2, 
Psmc2, Myc, Max, Wee1, Cdkn1b, Cdc25a, Psmd4, Psmd7, 
Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2, Cks1b 
G1/S Transition  2.177 0.0295 
Ccna2, Mcm2, Mcm5, Pole, Mcm6, Rpa1, Mcm4, Cdk1, Dhfr, 
Pcna, Skp2, Psmc1, Fbxo5, Cdc7, Psma1, Dbf4, Prim1, 
Mcm10, Mcm3, Psmc4, Mnat1, Ccne1, Pole2, Rrm2, Cdc45, 
Pola2, Cdk2, Cdc6, Mcm7, Tyms, Cdt1, Orc2, Psmc2, Myc, 
Max, Wee1, Cdkn1b, Cdc25a, Psmd4, Psmd7, Mcm8, Psma4, 
Psmd5, Psmd12, Psmc3, Psmc6, Psmb2, Cks1b 
Netrin-1 signaling  2.172 0.0298 
Dcc, Rgmb, Unc5c, Ntn1, Unc5d, Myo10, Ptpn11, Ablim1, 
Ablim3, Pitpna, Neo1, Ezr, Fyn, Unc5a, Slit2, Robo1 
Netrin mediated repulsion signals  2.148 0.0317 Dcc, Unc5c, Ntn1, Unc5d, Ptpn11, Fyn, Unc5a 
Regulation of Insulin Secretion  2.147 0.0318 
Gng2, Gnai1, Chrm3, Stx1a, Kcnb1, Prkar1b, Akap5, Adcy5, 
Slc25a5, Rapgef4, Plcb3, Vamp2, Gng3, Ctnnb1, Gna14, 
Adra2a, Snap25, Gnao1, Kcng2, Prkar2a, Cacna1d, Prkacb, 
Gnai2, Gng12, Stxbp1, Cacna1a, Cacna1c, Gnb4, Gnaq, 
Gpr119, Prkar2b, Dpp4, Prkca, Kcnc2, Abcc8, Cacnb3, Gng10, 
Plcb1, Plcb2, Gna15, Pcsk1, Itpr2 
Regulation of Insulin Secretion 
by Glucagon-like Peptide-1  
2.122 0.0338 Gng2, Kcnb1, Prkar1b, Akap5, Adcy5, Rapgef4, Gng3, Kcng2, 




Gng7, Gnb5, Rapgef3, Gng4, Gngt2 
SHC1 events in EGFR signaling  2.12 0.034 Grb2, Cdk1, Ywhab, Shc1, Mapk3, Sos1, Egfr, Mapk1 
mRNA Splicing  2.117 0.0342 
Hnrnpl, Hnrnpf, Ptbp1, Srsf2, Sf3a3, Ncbp1, Hnrnpm, Eftud2, 
Smc1a, Sf3b2, Pcbp2, Hnrnpul1, Snrnp200, Prpf4, Lsm2, 
Hnrnpa2b1, Sf3b3, Hnrnpu, Snrpa, Dhx38, Sf3a1, Hnrnpa1, 
Pcbp1, Srsf1, Srsf3, Cpsf1, Snrnp70, Prpf8, Cstf1, Magoh, 
Ddx23, Sf3b4, Snrpb, Cd2bp2, U2af1, Gtf2f2, Thoc4, Srsf6, 
Polr2j, Nudt21, Ncbp2 
mRNA Splicing - Major Pathway  2.117 0.0342 
Hnrnpl, Hnrnpf, Ptbp1, Srsf2, Sf3a3, Ncbp1, Hnrnpm, Eftud2, 
Smc1a, Sf3b2, Pcbp2, Hnrnpul1, Snrnp200, Prpf4, Lsm2, 
Hnrnpa2b1, Sf3b3, Hnrnpu, Snrpa, Dhx38, Sf3a1, Hnrnpa1, 
Pcbp1, Srsf1, Srsf3, Cpsf1, Snrnp70, Prpf8, Cstf1, Magoh, 
Ddx23, Sf3b4, Snrpb, Cd2bp2, U2af1, Gtf2f2, Thoc4, Srsf6, 
Polr2j, Nudt21, Ncbp2 
Activation of Kainate Receptors 
upon glutamate binding  
2.116 0.0344 
Gng2, Dlg4, Grik2, Plcb3, Gng3, Gng12, Gnb4, Gng10, Plcb1, 
Plcb2, Dlg3, Gng7, Grik1, Gnb5, Gng4, Gngt2 
CDO in myogenesis  2.112 0.0347 
Ctnna2, Ctnna1, Bnip2, Mef2b, Ctnnb1, Cdh4, Boc, Neo1, 
Tcf3, Mapk12, Cdon, Map2k6, Ntn3 
Myogenesis  2.112 0.0347 
Ctnna2, Ctnna1, Bnip2, Mef2b, Ctnnb1, Cdh4, Boc, Neo1, 
Tcf3, Mapk12, Cdon, Map2k6, Ntn3 
Homologous Recombination 
Repair  
2.108 0.0351 Lig1, Rpa1, Rad51, Brca1, Brip1, Mre11a, Mdc1, Nbn, Brca2 
Homologous recombination 
repair of replication-independent 
double-strand breaks  
2.108 0.0351 Lig1, Rpa1, Rad51, Brca1, Brip1, Mre11a, Mdc1, Nbn, Brca2 
Glutamate Neurotransmitter 
Release Cycle  
2.099 0.0358 
Slc38a2, Stx1a, Gls, Vamp2, Syt1, Slc1a7, Snap25, Cplx1, 
Stxbp1, Slc1a1 
GRB2 events in ERBB2 signaling  2.095 0.0361 
Nrg1, Grb2, Cdk1, Nrg3, Erbb2, Ywhab, Mapk3, Nrg2, Sos1, 
Egfr, Mapk1 
Activation of the pre-replicative 
complex  
2.079 0.0376 
Mcm2, Mcm5, Pole, Mcm6, Rpa1, Mcm4, Cdc7, Dbf4, Prim1, 





Unfolded Protein Response  2.066 0.0388 
Srpr, Atp6v0d1, Pdia6, Hspa5, Hsp90b1, Dnajb11, Mbtps1, 
Tpp1, Herpud1, Asns, Tln1, Atf4, Sec31a, Hdgf, Ddx11, Calr, 
Exosc8, Exosc3, Serp1, Acadvl, Shc1, Dnajc3, Ppp2r5b, 
Hyou1, Cul7, Exosc2, Ssr1, Srprb, Wipi1, Exosc9, Kdelr3, 
Nfyc, Edem1 
ADP signalling through P2Y 
purinoceptor 12 
2.061 0.0393 
Gng2, Gnai1, Gng3, Gnai2, Gng12, Gnb4, Gng10, Gng7, Gnb5, 
Gng4, Gngt2 
Kinesins  2.048 0.0406 
Kif5c, Racgap1, Kif22, Kifap3, Kif11, Kif23, Kif20a, Kif15, 
Kif2c, Kif3c, Kifc1, Kif5a, Kif4, Cenpe, Kif2a, Kif3a, Klc3, 
Kif3b, Klc1 
Export of Viral 
Ribonucleoproteins from Nucleus  
2.046 0.0407 
Nup205, Nup188, Nup107, Ran, Nup93, Nup50, Nup85, 
Nup62, Nup37, Nupl1, Nup133, Nup214, Nup155, Rae1, Xpo1, 
Nup88, Nup43 
GABA receptor activation  2.032 0.0421 
Gnal, Gng2, Gnai1, Gabrg3, Kcnj2, Gabbr2, Gabbr1, Adcy5, 
Kcnj6, Gabrb3, Gng3, Adcy2, Gabrg2, Gabra5, Gnai2, Gng12, 
Gabra3, Arhgef9 
Diabetes pathways  2.021 0.0433 
Pcsk2, Srpr, Igfbp4, Atp6v0d1, Pdia6, Stx1a, Bche, Hspa5, 
Hsp90b1, Mmp2, Dnajb11, Mbtps1, Tpp1, Herpud1, Vamp2, 
Asns, Tln1, Atf4, Sec31a, Hdgf, Myo5a, Ddx11, Calr, Snap25, 
Exosc8, Exosc3, Serp1, Igf2, Igf2bp2, Acadvl, Myc, Shc1, 
Dnajc3, Ppp2r5b, Igf1, Pappa2, Exoc5, Igf2bp1, Hyou1, 
Igfbp5, Cul7, Exosc2, Ssr1, Srprb, Igfbp2, Actb, Exoc6, Wipi1, 
Exosc9, Kdelr3, Slc30a5, Exoc8, Nfyc, Pcsk1, Edem1, Exoc4, 
Slc30a6, Slc30a7, Exosc7, Nfya, Cpe, Exoc2, Dis3, Mboat4, 
Sec11c, Exosc5, Parn, Mbtps2 
Mitotic G1-G1/S phases  2.02 0.0434 
Ccna2, Mcm2, Top2a, Mcm5, Pole, Mcm6, Rpa1, Mcm4, 
Cdk1, E2f2, Dhfr, Pcna, Skp2, Cdk4, Psmc1, Fbxo5, Cdc7, 
Psma1, Dbf4, Prim1, Mcm10, Mcm3, Psmc4, Mnat1, Ccne1, 
Pole2, Rrm2, Cdc45, Ccnd3, Pola2, Rbl1, Cdk2, Mybl2, Cdc6, 
Mcm7, Tyms, Cdt1, Orc2, Psmc2, Myc, Max, Wee1, Hdac1, 
Cdkn1b, Cdc25a, E2f4, Psmd4, Psmd7, Mcm8, Psma4, Psmd5, 
Psmd12, Psmc3, Cdkn2c, Psmc6, Dyrk1a, Psmb2, Cks1b 
Inhibition of Insulin Secretion by 
Adrenaline/Noradrenaline  
2.013 0.0441 
Gng2, Gnai1, Adcy5, Gng3, Adra2a, Gnao1, Cacna1d, Gnai2, 
Gng12, Cacna1c, Gnb4, Cacnb3, Gng10, Gng7, Gnb5, Gng4, 
Gngt2 
Adenylate cyclase inhibitory 





Inhibition of adenylate cyclase 
pathway 
2.007 0.0448 Gnal, Gnai1, Adcy5, Adcy2, Gnai2, Adcy1, Adcy7 
Sema3A PAK dependent Axon 
repulsion  
2.006 0.0449 Nrp1, Plxna2, Plxna4, Sema3a, Hsp90ab1, Pak1, Fyn 
Chromosome Maintenance  1.998 0.0457 
Lmnb1, Lig1, Cenpn, Pole, Rpa1, Pold3, Pold1, Pcna, Cenpa, 
Hjurp, Fen1, Smc1a, Tinf2, Prim1, Dna2, Brca1, Pole2, Rfc1, 
Pola2, Cenpo, H2afz, Cenpq, Rfc4, Terf1, Rfc3, Cenph, Syne1, 
Ruvbl1, Npm1, Cenpk, Rec8, Rfc5, Rad21, Ruvbl2, Pold2, 
Mis18bp1, Rfc2, Mlf1ip, Rbbp7, 2610039C10Rik, Dkc1 
Presynaptic function of Kainate 
receptors 
1.995 0.046 
Gng2, Plcb3, Gng3, Gng12, Gnb4, Gng10, Plcb1, Plcb2, Gng7, 
Gnb5, Gng4, Gngt2 
APC/C-mediated degradation of 
cell cycle proteins  
1.986 0.0471 
Ccna2, Aurkb, Cdk1, Bub1b, Ube2d1, Skp2, Aurka, Psmc1, 
Fbxo5, Psma1, Psmc4, Ube2c, Plk1, Cdk2, Cdc20, Mad2l1, 
Cdc23, Cdc26, Psmc2, Psmd4, Cdc16, Psmd7, Pttg1, Anapc1, 
Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2 
Regulation of mitotic cell cycle  1.986 0.0471 
Ccna2, Aurkb, Cdk1, Bub1b, Ube2d1, Skp2, Aurka, Psmc1, 
Fbxo5, Psma1, Psmc4, Ube2c, Plk1, Cdk2, Cdc20, Mad2l1, 
Cdc23, Cdc26, Psmc2, Psmd4, Cdc16, Psmd7, Pttg1, Anapc1, 
Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2 
Assembly of the pre-replicative 
complex  
1.976 0.0482 
Mcm2, Mcm5, Mcm6, Mcm4, E2f2, Psmc1, Psma1, Mcm3, 
Psmc4, Gmnn, Cdc6, Mcm7, Cdt1, Orc2, Psmc2, Psmd4, 
Psmd7, Mcm8, Psma4, Psmd5, Psmd12, Psmc3, Psmc6, Psmb2 
Metal ion SLC transporters  1.973 0.0485 
Slc41a2, Slc11a2, Slc39a10, Slc31a1, Slc39a7, Slc39a1, 
Slc39a6, Slc40a1, Heph, Slc30a5, Slc41a1, Slc30a6, Slc39a5, 
Slc30a3, Slc30a7, Slc30a8, Slc30a1 
Activation of NMDA receptor 
upon glutamate binding and 
postsynaptic events  
1.968 0.0491 
Grin2a, Camk2g, Gria4, Dlg4, Camk4, Rasgrf2, Grin2b, 
Rps6ka3, Camkk1, Gria2, Grin1, Prkacb, Camk2b, Gria1, 
Mapk1, Rasgrf1 
Reduction of cytosolic Ca++ 
levels  
1.968 0.0491 Slc8a3, Slc8a1, Atp2b2, Slc8a2, Atp2a3, Atp2b1, Atp2b3 
G-protein beta:gamma signalling  1.963 0.0497 




























8.4. The Reactome pathways for the 168 vs. 0 hour signature  
 
Set  NES  p-value  Ledge  
G alpha (z) signalling events  3.449 0.000562 
Rgs4, Prkch, Adcy2, Rgs19, Gng4, Prkcd, Gng3, Gnb1, Gnb5, 
Rgs20, Gng12, Adcy5, Adcy9, Rgs17, Gng2, Gng7, Gnb4, Prkca, 
Gnb3, Adra2c, Gnai1 
Activation of Rac  2.867 0.00414 Slit2, Pak1, Nck2, Pak6, Gpc1, Rac1, Pak3, Pak7 
NOD1/2 Signaling Pathway 2.77 0.00561 
Casp2, Tnfaip3, Map2k6, Mapk11, Tab2, Casp4, Casp8, Map3k7, 
Nod2, Birc2, Cyld, Casp9 
Nucleotide-binding domain, 
leucine rich repeat containing 
receptor (NLR) signaling 
pathways  
2.755 0.00587 
Casp2, Bcl2l1, Txnip, Tnfaip3, Map2k6, Mapk11, P2rx7, Tab2, 
Casp4, Casp8, Map3k7, Nod2, Birc2, Panx1, Cyld, Casp9 
Inactivation of APC/C via 
direct inhibition of the APC/C 
complex  
2.755 0.00587 
Cdc23, Bub1b, Anapc4, Mad2l1, Ube2d1, Cdc26, Cdc20, Bub3, 
Anapc1, Anapc2, Cdc27, Cdc16 
Inhibition of the proteolytic 
activity of APC/C required for 
the onset of anaphase by 
mitotic spindle checkpoint 
components  
2.755 0.00587 
Cdc23, Bub1b, Anapc4, Mad2l1, Ube2d1, Cdc26, Cdc20, Bub3, 
Anapc1, Anapc2, Cdc27, Cdc16 
Other semaphorin interactions  2.717 0.00659 Sema4a, Sema5a, Sema7a, Sema6a, Plxnc1, Plxna4, Plxnd1 
Rho GTPase cycle  2.71 0.00674 
Rhou, Rasgrf2, Arhgap26, Rhoq, Rhob, Syde2, Ralbp1, Arhgap28, 
Trip10, Racgap1, Arhgap5, Arhgap31, Ngef, Rac3, Rhoc, Ect2, 
Mcf2, Arap3, Arhgef4, Mcf2l, Rhoj, Arhgap15, Gdi1, Arhgap11a, 
Bcr, Gmip, Abr, A2m, Arhgef2, Rasgrf1, Stard13, Arhgap19, 
Srgap2, Rhov, Ocrl, Itsn1, Akap13, Plekhg5, Arhgdia, Depdc1b, 
Rac1, Arhgap44, Arhgef18, Rhobtb1, Arhgef11 
Signaling by Rho GTPases  2.71 0.00674 
Rhou, Rasgrf2, Arhgap26, Rhoq, Rhob, Syde2, Ralbp1, Arhgap28, 
Trip10, Racgap1, Arhgap5, Arhgap31, Ngef, Rac3, Rhoc, Ect2, 
Mcf2, Arap3, Arhgef4, Mcf2l, Rhoj, Arhgap15, Gdi1, Arhgap11a, 
Bcr, Gmip, Abr, A2m, Arhgef2, Rasgrf1, Stard13, Arhgap19, 




Rac1, Arhgap44, Arhgef18, Rhobtb1, Arhgef11 
APC-Cdc20 mediated 
degradation of Nek2A  
2.61 0.00906 
Nek2, Cdc23, Bub1b, Anapc4, Mad2l1, Ube2d1, Cdc26, Cdc20, 
Bub3, Anapc1, Anapc2, Cdc27 
GABA synthesis, release, 
reuptake and degradation  
2.537 0.0112 
Gad1, Aldh5a1, Syt1, Slc6a13, Slc6a11, Stxbp1, Slc6a1, Cplx1, 
Stx1a, Slc32a1, Snap25, Abat, Vamp2, Rab3a 
Recycling pathway of L1  2.522 0.0117 
Kif4, Msn, Src, Rps6ka1, Ap2a2, L1cam, Rdx, Dpysl2, 
4930506M07Rik, Dnm1, Ezr, Dnm3, Cltc, Ap2a1, Rps6ka4, 
Rps6ka6, Ap2m1, Ap2b1 
Phosphorylation of the APC/C  2.51 0.0121 
Cdk1, Cdc23, Anapc4, Ube2d1, Cdc26, Anapc1, Anapc2, Plk1, 
Cdc27, Cdc16 
Nuclear signaling by ERBB4  2.407 0.0161 
Stat5a, Stat5b, Hbegf, Cul1, Cxcl12, Tab2, Nrg1, Aph1b, Psenen, 
Pgr, Nrg3, Adam17, Psen1, Gfap, Wwox 
Interleukin-6 signaling  2.376 0.0175 Stat3, Socs3, Jak1, Il6ra 
p38MAPK events  2.323 0.0202 
Src, Ralgds, Mapk11, Ralb, Rala, Hras1, Mapkapk3, Nras, 
Mapkapk2 
activated TAK1 mediates p38 
MAPK activation  
2.291 0.0219 
Map2k6, Mapk11, Tab2, Map3k7, Nod2, Mapkapk3, Mapkapk2, 
Ripk2, Tab1, Tab3 
Cyclin A/B1 associated events 
during G2/M transition  
2.286 0.0222 Xpo1, Ccna2, Ccnb2, Cdc25b, Cdk1 
Interleukin-2 signaling  2.271 0.0231 
Grb2, Stat5a, Stat5b, Pik3r3, Pik3cd, Jak1, Pik3cb, Mapk3, Gab2, 
Cdk1, Jak3, Il2rb, Pik3r1, Hras1, Ptk2b, Ywhab 
Growth hormone receptor 
signaling  
2.237 0.0253 Stat3, Socs3, Cish, Stat5a, Stat5b, Mapk3, Ptpn1 
TAK1 activates NFkB by 
phosphorylation and activation 
of IKKs complex  
2.202 0.0277 Rela, Nfkb2, Nfkbia, Tab2, Nfkbib, Hmg1l1, Map3k7, Nod2 
Mitotic Prometaphase  2.196 0.0281 
Cenpf, Xpo1, Zwilch, Ndel1, Kntc1, Casc5, Cenpp, Sgol1, 
Fam33a, Bub1, Nuf2, Smc1a, Birc5, Cenpa, Cenpi, Cenpe, Incenp, 
Aurkb, Rad21, Spc25, Ppp2r5b, Nsl1, Ckap5, Cenpq, Ndc80, 
Cenpk, Bub1b, Kif18a, Sgol2, Nup160, Mad2l1, Cenpn, Ranbp2, 




Ercc6l, Plk1, Nup85, Ppp2r5e, Pmf1, Smc3, Kif2c, Stag2, Cenpl, 
Seh1l, Ppp2r5d, Ahctf1, Stag1, Zwint, Cenpt, Cdca8, Spc24, 
Taok1 
Signaling by Robo receptor  2.193 0.0283 
Slit2, Pak1, Nck2, Vasp, Pak6, Cap1, Srgap2, Evl, Gpc1, Robo2, 
Rac1, Pak3, Pak7 
Circadian Clock  2.193 0.0283 
Srebf1, Ccrn4l, Arntl2, Csnk1e, Cul1, Fbxl3, Bhlhe41, Serpine1, 
Med1, Cpt1a, Nr3c1, Hif1a, Atf2, Per2, Bhlhe40, Ncoa6, Nr1d1, 
Carm1 
M Phase 2.149 0.0317 
Cenpf, Xpo1, Kif23, Zwilch, Ndel1, Kntc1, Casc5, Cenpp, Sgol1, 
Fam33a, Bub1, Nuf2, Smc1a, Birc5, Cenpa, Kif20a, Cenpi, Cenpe, 
Incenp, Aurkb, Rad21, Spc25, Ppp2r5b, Nsl1, Ckap5, Cenpq, 
Ndc80, Cenpk, Bub1b, Kif18a, Sgol2, Nup160, Mad2l1, Cenpn, 
Ranbp2, Ccdc99, Nup107, Fbxo5, Mlf1ip, Cdc20, Bub3, Itgb3bp, 
Ska1, Cenpm, Ercc6l, Plk1, Nup85, Ppp2r5e, Pmf1, Smc3, Kif2c, 
Stag2 
Mitotic Spindle Checkpoint  2.126 0.0335 
Cdc23, Bub1b, Anapc4, Mad2l1, Ube2d1, Cdc26, Cdc20, Bub3, 
Anapc1, Anapc2, Cdc27, Cdc16 
TRAF6 Mediated Induction of 
proinflammatory cytokines  
2.086 0.0369 
Rela, Nfkb2, Map2k6, Nfkbia, Mapk3, Mapk11, Rps6ka1, Cdk1, 
Tab2, Nfkbib, Hmg1l1, Map3k7, Jun, Nod2, Mapk9, Map2k4, 
Dusp3, Mapk7, Dusp6, Mapkapk3, Mapk10, Atf2 
Regulated proteolysis of 
p75NTR 
2.084 0.0372 Rela, Aph1b, Psenen, Adam17, Psen1 
APC/C:Cdc20 mediated 
degradation of Cyclin B  
2.05 0.0403 
Cdk1, Cdc23, Anapc4, Ube2d1, Cdc26, Cdc20, Anapc1, Anapc2, 
Cdc27, Cdc16 
Dopamine Neurotransmitter 
Release Cycle  
2.05 0.0403 Syn3, Syn1, Syt1, Stxbp1, Cplx1, Stx1a 
Serotonin Neurotransmitter 
Release Cycle  
2.05 0.0403 Syn3, Syn1, Syt1, Stxbp1, Cplx1, Stx1a 
Double-Strand Break Repair  2.05 0.0404 
Brca1, Brca2, Mdc1, Brip1, Xrcc5, Atm, Prkdc, Rad51, Lig1, 
Rpa1, Nbn 
Metal ion SLC transporters  2.044 0.041 
Slc11a2, Slc39a6, Slc41a2, Slc30a3, Cp, Slc31a1, Slc30a1, 




Signalling to RAS  2.018 0.0436 
Grb2, Src, Ralgds, Mapk3, Mapk11, Shc2, Cdk1, Ralb, Rala, Ngf, 
Hras1, Ywhab, Mapkapk3, Nras, Mapkapk2, Sos1, Map2k1 
MAP kinase activation in TLR 
cascade 
1.996 0.046 
Map2k6, Mapk3, Mapk11, Rps6ka1, Cdk1, Tab2, Map3k7, Jun, 
Nod2, Mapk9, Map2k4, Dusp3, Mapk7, Dusp6, Mapkapk3, 
Mapk10, Atf2, Mapkapk2, Ppp2r5d, Map2k1, Ripk2, Tab1, 
Mapk1, Tab3, Ppp2r1a 
Activation of the AP-1 family 
of transcription factors  
1.992 0.0464 Mapk3, Mapk11, Jun, Mapk9, Mapk10, Atf2 
Interleukin-7 signaling  1.984 0.0472 Stat5a, Stat5b, Pik3r3, Jak1, Jak3, Pik3r1, Il7 
Inhibition of replication 
initiation of damaged DNA by 
RB1/E2F1  





8.5. The Reactome pathways for the 72 vs. 24 hour signature  
 
Set  NES  p-value  Ledge  
Neurotransmitter Receptor 
Binding And Downstream 
Transmission In The Postsynaptic 
Cell  
4.022 5.76e-05 
Gnal, Kcnj6, Gabrg3, Gng4, Gria4, Gabrb3, Grin2a, Camk4, 
Grik2, Grip1, Gabbr2, Adcy5, Plcb3, Gng2, Rasgrf1, Rps6ka3, 
Gnai2, Adcy8, Grin2b, Chrna7, Rasgrf2, Grik1, Gabra5, Grip2, 
Adcy2, Camk2d, Kcnj2, Dlg4, Gabrb2, Camk2g, Akap5, 
Chrnb2, Cacng4, Grin1, Gabbr1, Prkca, Gnai1, Cacng2, Plcb1, 
Adcy1, Chrne, Myo6, Gabrg2, Gabra3, Camk2b, Gria3, 
Gabra2, Ap2b1, Grik4, Braf, Cacng3, Kcnj3, Nsf, Gng13, 
Gria2 
G alpha (z) signalling events  3.956 7.64e-05 
Prkce, Gng4, Rgs4, Adcy5, Gng2, Gnai2, Adcy8, Rgs17, 
Rgs20, Adcy2, Prkca, Gnai1, Adcy1 
Interleukin-6 signaling  3.684 0.000229 Stat1, Stat3, Jak2, Il6st, Il6, Tyk2, Socs3 
GABA A receptor activation  3.661 0.000252 Gabrg3, Gabrb3, Gabra5, Gabrb2, Gabrg2, Gabra3, Gabra2 
DSCAM interactions  3.487 0.000488 Dscam, Dcc, Ntn1, Mapk8, Pak1, Dscaml1 
Transmission across Chemical 
Synapses  
3.444 0.000573 
Gnal, Cacna2d3, Kcnj6, Gabrg3, Gad2, Gng4, Syt1, Gria4, 
Slc6a13, Gls, Gabrb3, Grin2a, Camk4, Grik2, Grip1, Gabbr2, 
Adcy5, Plcb3, Gng2, Rasgrf1, Snap25, Rps6ka3, Gnai2, Adcy8, 
Grin2b, Chrna7, Rasgrf2, Gad1, Syn1, Grik1, Gabra5, Stxbp1, 
Vamp2, Grip2, Adcy2, Camk2d, Cacna1a, Cacna1b, Kcnj2, 
Dlg4, Gabrb2, Camk2g, Akap5, Chrnb2, Cacng4, Grin1, 
Gabbr1, Prkca, Dnajc5, Abat, Gnai1, Cacng2, Plcb1, Adcy1, 
Syn2, Slc38a2, Cplx1, Slc1a1, Cacna2d1, Slc38a1, Chrne, 
Myo6, Gabrg2, Comt, Gabra3, Camk2b, Gria3, Gabra2, Ap2b1, 
Grik4, Braf, Cacng3, Kcnj3, Stx1a, Slc1a7, Nsf, Gng13, Gria2, 
Cacnb1, Slc1a3, Rps6ka2, Kcnj9 
Neuronal System 3.255 0.00113 
Gnal, Kcnh8, Cacna2d3, Vamp1, Kcnj6, Gabrg3, Gad2, Hcn4, 
Kcnk10, Kcnq3, Kcnmb1, Gng4, Syt1, Gria4, Slc6a13, Kcnab1, 
Gls, Kcnn2, Gabrb3, Grin2a, Camk4, Grik2, Grip1, Kcnh1, 
Gabbr2, Adcy5, Plcb3, Gng2, Rasgrf1, Snap25, Rps6ka3, 
Gnai2, Stx1b, Kcnh7, Adcy8, Grin2b, Kcnma1, Hcn1, Kcng2, 
Chrna7, Kcnq1, Rasgrf2, Kcnc2, Gad1, Syn1, Stx7, Grik1, 
Gabra5, Stxbp1, Vamp2, Grip2, Adcy2, Camk2d, Cacna1a, 
Cacna1b, Kcnj2, Kcnq2, Dlg4, Kcnv1, Gabrb2, Camk2g, 




Abat, Gnai1, Cacng2, Plcb1, Adcy1, Syn2, Slc38a2, Gjd2, 
Cplx1, Slc1a1, Cacna2d1, Kcna1, Kcnc1, Slc38a1, Chrne, 
Myo6, Gabrg2, Comt, Stx12, Kcnn1, Gabra3, Stx6, Stx2, 
Camk2b, Gria3, Kcnd2, Gabra2, Ap2b1, Syt2, Panx1, Grik4, 
Braf, Cacng3, Kcna5, Kcnj3, Stx1a, Slc1a7, Nsf, Gng13, Gria2, 
Kcnmb2, Cacnb1, Slc1a3, Rps6ka2, Kcnk6, Kcnj9 
Signaling by Robo receptor 3.25 0.00115 
Nck2, Srgap1, Robo2, Pak6, Pak7, Pak1, Clasp2, Pak3, Srgap2, 
Cap1, Clasp1, Evl, Arhgap39, Pfn1, Srgap3, Pak4 
Removal of DNA patch 
containing abasic residue  
3.145 0.00166 
Mutyh, Mpg, Pold4, Pold3, Apex1, Pold2, Pcna, Pold1, Nthl1, 
Lig1, Mbd4, Smug1, Fen1, Polb 




Mutyh, Mpg, Pold4, Pold3, Apex1, Pold2, Pcna, Pold1, Nthl1, 
Lig1, Mbd4, Smug1, Fen1, Polb 
GABA receptor activation  3.015 0.00257 
Gnal, Kcnj6, Gabrg3, Gng4, Gabrb3, Gabbr2, Adcy5, Gng2, 
Gnai2, Adcy8, Gabra5, Adcy2, Kcnj2, Gabrb2, Gabbr1, Gnai1, 
Adcy1, Gabrg2, Gabra3, Gabra2 
DCC mediated attractive 
signaling  
2.975 0.00293 Dcc, Ntn1, Fyn, Ablim3, Trio, Ptk2, Ablim2, Wasl, Ablim1 
Regulation of IFNA signaling  2.926 0.00344 Usp18, Stat1, Stat2, Ptpn6, Tyk2, Ifnar1, Socs3 
Opioid Signalling  2.885 0.00391 
Gnal, Pde4b, Gng4, Ppp3cc, Camk4, Adcy5, Plcb3, Gng2, 
Gnai2, Adcy8, Oprm1, Gnao1, Adcy2, Ppp1r1b, Pde1c, 
Ppp3ca, Prkca, Ppp1ca, Gnai1, Plcb1, Adcy1 
Nephrin interactions  2.872 0.00407 
Magi2, Nck2, Pik3r1, Spnb2, Nphs1, Fyn, Cask, Actn3, Actn4, 
Wasl, Spna2, Kirrel2 
Platelet homeostasis  2.782 0.0054 
Slc8a3, Kcnmb1, Gng4, Slc8a1, Pde10a, Gng2, Gucy1a2, 
Atp2b2, Atp2b1, Kcnma1, Trpc7, Stim1, Pde3a, Ptpn6, Pde11a, 
Ppp2r5e, Gucy1b3, Fgr, Prkg1, Pde1a, Atp2b3, Gng13, Atp2b4, 
Kcnmb2, Ppp2r5d, Ppp2r5b, P2rx1, Mapk14, Ptpn11, Gng8, 
Itpr2, Kcnmb4, Gnb5, Pde3b, Nos1 
GABA synthesis, release, 
reuptake and degradation  
2.706 0.00682 
Gad2, Syt1, Slc6a13, Snap25, Gad1, Stxbp1, Vamp2, Dnajc5, 
Abat, Cplx1 
G beta:gamma signalling through 
2.702 0.00689 




PLC beta  Gng3, Gnb4, Gng7, Gngt2, Gnb3, Gng10, Gnb1, Gng12 
Interaction between L1 and 
Ankyrins  
2.643 0.00822 
Kcnq3, Scn8a, Nfasc, Nrcam, Ank3, Spnb2, Scn3a, Kcnq2, 
Scn1a, Scn3b, Scn2a1, Ank1, Spnb3, Spna2, Scn7a, L1cam, 
Scn1b 
Activation of NMDA receptor 
upon glutamate binding and 
postsynaptic events  
2.637 0.00837 
Gria4, Grin2a, Camk4, Rasgrf1, Rps6ka3, Adcy8, Grin2b, 
Rasgrf2, Camk2d, Dlg4, Camk2g, Grin1, Adcy1, Camk2b, 
Gria3, Braf, Gria2, Rps6ka2 
Base Excision Repair  2.593 0.0095 
Mutyh, Mpg, Pold4, Pold3, Xrcc1, Apex1, Pold2, Pcna, Pold1, 
Nthl1 
Resolution of Abasic Sites (AP 
sites)  
2.593 0.0095 
Mutyh, Mpg, Pold4, Pold3, Xrcc1, Apex1, Pold2, Pcna, Pold1, 
Nthl1 
Adenylate cyclase inhibitory 
pathway 
2.52 0.0117 Gnal, Adcy5, Gnai2, Adcy8, Adcy2, Gnai1, Adcy1 
Inhibition of adenylate cyclase 
pathway 
2.52 0.0117 Gnal, Adcy5, Gnai2, Adcy8, Adcy2, Gnai1, Adcy1 
Activation of GABAB receptors  2.487 0.0129 
Gnal, Kcnj6, Gng4, Gabbr2, Adcy5, Gng2, Gnai2, Adcy8, 
Adcy2, Kcnj2, Gabbr1, Gnai1, Adcy1 
GABA B receptor activation  2.487 0.0129 
Gnal, Kcnj6, Gng4, Gabbr2, Adcy5, Gng2, Gnai2, Adcy8, 
Adcy2, Kcnj2, Gabbr1, Gnai1, Adcy1 
Processive synthesis on the C-
strand of the telomere  
2.459 0.0139 
Rpa1, Pold4, Pold3, Pold2, Pcna, Pold1, Rpa2, Lig1, Dna2, 
Fen1 
L1CAM interactions  2.456 0.014 
Sh3gl2, Kcnq3, Dcx, Cntn1, Dnm3, Scn8a, 4930506M07Rik, 
Nfasc, Rps6ka3, Nrcam, Ank3, Spnb2, Pak1, Scn3a, Csnk2b, 
Kcnq2, Dlg4, Chl1, Scn1a, Kif4, Alcam, Scn3b, Dnm1, Stip1, 
Scn2a1, Cntnap1, Ank1, Ap2b1, Spnb3, Fgfr1, Spna2, 
Rps6ka2, Ncam1, Scn7a, Egfr, Clta, L1cam, Scn1b, Nrp1, 
Csnk2a2, Mapk1, Itga5, Scn9a 
Removal of the Flap Intermediate 
from the C-strand  
2.438 0.0147 Rpa1, Pold4, Pold3, Pold2, Pcna, Pold1 
Disease  2.432 0.015 
Pcsk2, App, Prkce, Vamp1, Eif2ak2, Sh3gl2, Acadvl, Pag1, 
Gtf2e1, Syt1, Cdk1, Grb2, Camk4, Mmp2, Hspa5, Adcy5, 




Adam17, Taf6, Stx1b, Nup205, Actb, Adcy8, Psmc2, Pik3r1, 
Tbp, Pdia6, Cpe, Adam12, Mnat1, Nup50, Stx7, Rps23, Hdgf, 
Vamp2, Srpr, Polr2g, Tpp1, Adcy2, Mbtps1, Rps16, Psmd7, 
Psma1, Ran, Ap1s2, Calr, Elmo1, Cdkn1b, Th1l, Aaas, Ncbp1, 
Srprb, Nup188, Ddx11, Ubc, Ncbp2, Pde1c, Fyn, Prkca, 
Gtf2h4, Psmc4, Rps10, Rps5, Adcy1, Nup107, Nup93, Nup88, 
Mfge8, Sh3kbp1, Gsk3b, Nup37, Wipi1, Cdkn1a, Rnmt, 
Ap1m1, Spry2, Rpl3, Rpsa, Psmd5, Tceb3, Rps3a, Stx12, 
Ssrp1, Rps3, Dnajb11, Rpl19, Rplp0, Kras, Psmd4, Mbtps2, 
Stx6, Psma4, Taf5, Rpl17, Stx2, Psma7, Rps11, Igfbp4, Spcs1, 
Npm1, Gtf2h3, Exosc8, Xrcc5, Eps15, Ap2b1, Rcc1, Nup62, 
Taf9, Rps29, Gtf2f2, Syt2, Igfbp2, Slc25a5, Apcs, Hist1h3c, 
Sec31a, Psmc1, Rps8, Psmb11, Rpl27a, Pde1a, Herpud1, Rps7, 
Igf2, Stx1a, Rps25, H2afz, Gfpt1, Prkar1b, Rpl18a, Trib3, 
Rpl4, Tln1, Rps9, Rpl6, Atp6v0d1, Tatdn2, Hsp90b1, Spcs2, 
Lig1, Eif2s1, Gosr2, Pten, Rpl27, Rpl35, Rpl11, Serp1, Rpl23a, 
Exosc3, Exosc1, Rps4x, Supt16h, Mboat4, Ppp2r5b, Cd28, 
Polr2j, Ywhab, Egfr, Ssr1, Rngtt, Rpl37, Them4, Prkar2a, 
Nup155, Pappa2, Cpsf4, Hmga1, Fkbp14, Hyou1, Psmc3, 
Psmd9, Igf2bp3, Egf, Clta, Akt1, Psme3, Ptpn11, Adcy4, 
Hist1h2bm, Pacs1, Itpr2, Psmc5, Hist1h2bp, Polr2c, Nup43, 
Exosc9, D17Wsu104e, Rpl34, Rplp1, Zbtb17, Cdc37, Rpl7, 
Cd4, Canx, Rpl24, Cxxc1, Psmb2, Rps6, Banf1, Exoc2, Mapk1, 
Psma2, Kdelr3, Fen1, Lmna, Tgfbi, Tspyl2, Phlpp1, Rpl14, 
Rps15a, H2-Q10, Slc30a5, Arhgef7 
Botulinum neurotoxicity  2.425 0.0153 
Vamp1, Syt1, Snap25, Stx1b, Stx7, Vamp2, Stx12, Stx6, Stx2, 
Syt2, Stx1a 
Transport of the SLBP 
independent Mature mRNA  
2.409 0.016 
Nup205, Nup50, Aaas, Nxf1, Ncbp1, Nup188, Ncbp2, Nup107, 
Nup93, Nup88, Nup37 
Netrin mediated repulsion signals  2.406 0.0161 Dcc, Unc5d, Unc5c, Ntn1, Fyn, Ptk2, Ptpn11, Unc5a 
G-protein beta:gamma signalling  2.387 0.017 
Gng4, Plcb3, Gng2, Pik3r5, Plcb1, Pik3cg, Gng13, Akt1, Gng8, 
Plcb2, Gnb5, Gnb2, Pdpk1, Gng3, Gnb4, Gng7, Gngt2, Rhoa, 
Gnb3, Gng10, Gnb1, Gng12 
Activation of Kainate Receptors 
upon glutamate binding  
2.38 0.0173 Gng4, Grik2, Plcb3, Gng2, Grik1, Dlg4, Plcb1 
Signaling by the B Cell Receptor 
(BCR)  
2.348 0.0189 
Nfkbia, Trpc1, Grb2, Casp9, Psmc2, Pik3r1, Stim1, Plcg2, 
Card11, Psmd7, Psma1, Rasgrp1, Cdkn1b, Ikbkg, Ubc, Fyn, 
Psmc4, Bcl10, Btk, Sh3kbp1, Gsk3b, Cdkn1a, Cblb, Rel, 




Psmb11, Trib3, Pten, Them4, Psmc3, Psmd9, Akt1, Psme3, 
Itpr2, Nfkbie, Psmc5, Psmb2, Psma2, Phlpp1, Rela, Nfkb1, 
Cd79a, Dapp1, Shc1, Sos1, Rictor, Prkcb, Pik3cd, Psmd1, 
Psmd12, Psmb1 
Post NMDA receptor activation 
events  
2.343 0.0192 
Grin2a, Camk4, Rasgrf1, Rps6ka3, Adcy8, Grin2b, Rasgrf2, 
Camk2d, Dlg4, Camk2g, Grin1, Adcy1 
Activation of the AP-1 family of 
transcription factors  
2.287 0.0222 Mapk8, Mapk10, Mapk9, Fos, Mapk14, Jun, Mapk1 
Transport of the SLBP Dependant 
Mature mRNA  
2.282 0.0225 
Nup205, Nup50, Aaas, Nxf1, Ncbp1, Nup188, Ncbp2, Nup107, 
Nup93, Nup88, Nup37 
N-glycan trimming in the ER and 
Calnexin/Calreticulin cycle  
2.261 0.0238 Man1b1, Ganab, Calr, Uggt1, Pdia3, Mogs 
Glutamate Neurotransmitter 
Release Cycle  
2.23 0.0257 
Syt1, Gls, Snap25, Stxbp1, Vamp2, Slc38a2, Cplx1, Slc1a1, 
Stx1a, Slc1a7 
ADP signalling through P2Y 
purinoceptor 12 
2.229 0.0258 
Gng4, Gng2, Gnai2, Gnai1, Gng13, Gng8, Gnb5, Gnb2, Gng3, 
Gnb4, Gng7, Gngt2, Gnb3, P2ry12, Gnai3, Gng10, Gnb1, 
Gng12 
Unfolded Protein Response  2.222 0.0263 
Acadvl, Hspa5, Cul7, Pdia6, Hdgf, Srpr, Tpp1, Mbtps1, Calr, 
Srprb, Ddx11, Wipi1, Dnajb11, Mbtps2, Exosc8, Sec31a, 
Herpud1, Gfpt1, Tln1, Atp6v0d1, Tatdn2, Hsp90b1, Eif2s1, 
Gosr2, Serp1, Exosc3, Exosc1, Ppp2r5b, Ssr1, Fkbp14, Hyou1, 
Exosc9, D17Wsu104e, Zbtb17, Cxxc1, Kdelr3, Lmna, Tspyl2, 
Klhdc3, Shc1, Exosc7, Ern1, Atf3 
Ion channel transport  2.214 0.0269 
Atp8a1, Gabrg3, Gabrb3, Atp10b, Atp8a2, Atp2b2, Atp2b1, 
Atp11b, Atp1b1, Gabra5, Gabrb2, Atp9a, Atp11c, Gabrg2, 
Glra3, Gabra3, Atp8b1, Gabra2, Glra4, Atp2b3, Atp2b4, 
Atp8b2, Htr3a, Atp9b, Gabra1, Arhgef9, Atp1a3, Glra2 
Activation of Rac  2.2 0.0278 Nck2, Pak6, Pak7, Pak1, Pak3 
Repair synthesis for gap-filling by 
DNA polymerase in TC-NER  
2.199 0.0278 
Rpa1, Pold4, Pold3, Pold2, Pcna, Pold1, Rfc4, Pole2, Rfc3, 
Pole, Rpa2 
Repair synthesis of patch ~27-30 
bases long by DNA polymerase  
2.199 0.0278 





MAP kinase activation in TLR 
cascade 
2.197 0.028 
Cdk1, Rps6ka3, Map2k4, Mapk8, Mapk10, Ikbkg, Mapkapk3, 
Irak1, Mef2c, Mapk9, Nod2, Rps6ka2, Ppp2r5d, Fos, Map2k3, 
Mapk14, Tab3, Nod1, Mef2a, Atf1, Jun, Mapk1, Dusp6, Tab2, 
Mapkapk2, Dusp3, Dusp4 
Inhibition of Insulin Secretion by 
Adrenaline/Noradrenaline  
2.19 0.0285 Gng4, Adcy5, Gng2, Gnai2, Gnao1, Cacna1c, Gnai1, Cacna1d 
Gap-filling DNA repair synthesis 
and ligation in GG-NER  
2.177 0.0294 
Rpa1, Pold4, Pold3, Pold2, Pcna, Pold1, Rfc4, Pole2, Rfc3, 
Pole, Rpa2, Lig1 
Gap-filling DNA repair synthesis 
and ligation in TC-NER  
2.177 0.0294 
Rpa1, Pold4, Pold3, Pold2, Pcna, Pold1, Rfc4, Pole2, Rfc3, 
Pole, Rpa2, Lig1 
Class C/3 (Metabotropic 
glutamate/pheromone receptors)  
2.175 0.0296 Grm7, Gabbr2, Grm4, Gprc6a, Gabbr1, Grm5, Casr, Tas1r3 
Platelet calcium homeostasis  2.174 0.0297 Slc8a3, Slc8a1, Atp2b2, Atp2b1, Trpc7, Stim1 
Proteolytic cleavage of SNARE 
complex proteins  
2.146 0.0319 Vamp1, Snap25, Stx1b, Stx7, Vamp2, Stx12, Stx6, Stx2, Stx1a 
MAPK targets/ Nuclear events 
mediated by MAP kinases  
2.134 0.0328 
Rps6ka3, Mapk8, Mapk10, Mef2c, Mapk9, Rps6ka2, Ppp2r5d, 
Fos, Mapk14, Mef2a, Atf1, Jun, Mapk1, Dusp6, Mapkapk2, 
Dusp3, Dusp4 
Activation of Chaperones by 
IRE1alpha  
2.133 0.0329 
Acadvl, Hspa5, Cul7, Pdia6, Hdgf, Srpr, Tpp1, Srprb, Ddx11, 
Wipi1, Dnajb11, Sec31a, Gfpt1, Tln1, Atp6v0d1, Tatdn2, 
Gosr2, Serp1, Ppp2r5b, Ssr1, Fkbp14, Hyou1, D17Wsu104e, 
Zbtb17, Cxxc1, Kdelr3, Lmna, Tspyl2, Klhdc3, Shc1 
Interferon alpha/beta signaling  2.1 0.0357 
Usp18, Irf1, Ifitm3, Irf9, Irf7, Stat1, Gm14446, Irf4, Ifi35, 
Stat2, Irf3, Ptpn6, Ifi27l1, Isg15, Oas1a, Tyk2, Ifnar1, Oasl1 
Other semaphorin interactions  2.089 0.0367 Plxnc1, Sema6d, Sema6a, Sema7a, Sema4a, Plxna4 
Activation of Chaperone Genes 
by XBP1(S)  
2.086 0.037 
Acadvl, Cul7, Pdia6, Hdgf, Srpr, Tpp1, Srprb, Ddx11, Wipi1, 
Dnajb11, Sec31a, Gfpt1, Tln1, Atp6v0d1, Tatdn2, Gosr2, 
Serp1, Ppp2r5b, Ssr1, Fkbp14, Hyou1, D17Wsu104e, Zbtb17, 
Cxxc1, Kdelr3, Lmna, Tspyl2, Klhdc3, Shc1 
DARPP-32 events  2.082 0.0374 





Calnexin/calreticulin cycle 2.076 0.0379 Man1b1, Ganab, Calr, Uggt1, Pdia3 
Removal of the Flap Intermediate  2.065 0.0389 
Rpa1, Pold4, Pold3, Pola2, Pold2, Pcna, Pold1, Rpa2, Prim1, 
Prim2, Dna2, Fen1 
Resolution of AP sites via the 
single-nucleotide replacement 
pathway 
2.059 0.0395 Mutyh, Mpg, Xrcc1, Apex1, Nthl1, Mbd4, Smug1, Polb 
Glucose transport  2.058 0.0396 
Slc2a4, Nup205, Nup50, Aaas, Nup188, Nup107, Nup93, 
Nup88, Nup37, Slc2a3, Nup62, Hk3, Slc2a2, Gck, Nup155 
Depolarization of the Presynaptic 
Terminal Triggers the Opening of 
Calcium Channels  
2.058 0.0396 Cacna2d3, Cacna1a, Cacna1b, Cacng4, Cacng2, Cacna2d1 
Antigen Activates B Cell 
Receptor Leading to Generation 
of Second Messengers  
2.053 0.0401 
Trpc1, Grb2, Pik3r1, Stim1, Plcg2, Fyn, Btk, Sh3kbp1, Cblb, 
Sykb 
TRAF6 Mediated Induction of 
proinflammatory cytokines  
2.051 0.0403 
Nfkbia, Nfkb2, App, Cdk1, Rps6ka3, Map2k4, Mapk8, 
Mapk10, Ikbkg, Mapkapk3, Ubc, Irak1, Mef2c, Mapk9, Nod2, 
Rps6ka2, Ppp2r5d, Fos, Map2k3, Mapk14, Tab3, Nod1, Mef2a, 
Atf1, Jun, Mapk1, Dusp6, Rela, Nfkb1, Tab2, Mapkapk2, 
Dusp3, Dusp4 
Processive synthesis on the 
lagging strand  
2.04 0.0413 
Rpa1, Pold4, Pold3, Pola2, Pold2, Pcna, Pold1, Rpa2, Prim1, 
Lig1, Prim2, Dna2, Fen1 
Regulation of Insulin Secretion 
by Acetylcholine  
2.038 0.0416 Chrm3, Gna14, Plcb3, Gna15, Prkca, Plcb1 
Cell Cycle Checkpoints  2.028 0.0426 
Cdc7, Cdk1, Bub1b, Rpa1, Mcm5, Wee1, Mcm2, Cdc23, 
Psmc2, Ccnb2, Trp53, Bub3, Psmd7, Psma1, Cdkn1b, Cdc20, 
Ubc, Cdk2, Psmc4, Ube2c, Cdkn1a, Cdc45, Psmd5, Rfc4, 
Ccne1, Ube2d1, Psmd4, Psma4, Orc6, Psma7, Mcm10, Mcm7, 
Rfc3, Psmc1, Psmb11, Rpa2, Dbf4, Rad9, Psmc3, Psmd9, 
Cdc25c, Mcm3, Psme3, Rad1, Cdc26, Psmc5, Mad2l1, Atrip, 
Psmb2, Psma2, Rfc2, Rad9b, Mcm4, Anapc11, Hus1, Psmd1, 
Psmd12, Orc4, Psmb1, Mcm6, Rpa3 
Nitric oxide stimulates guanylate 
cyclase  
2.026 0.0427 
Kcnmb1, Pde10a, Gucy1a2, Kcnma1, Pde3a, Pde11a, Gucy1b3, 







Man1b1, Man1a, Fut8, Gfpt2, St8sia3, Mcfd2, B4galt5, Ganab, 
B4galt6, Man1c1, Alg3, Calr, Rpn2, Alg8, Mgat4b, Uggt1, 
Mgat3, Pdia3, Man1a2, Sec13, Mogs, Sec31a, Mgat4c, Dpagt1, 
Rpn1, Gfpt1, Ddost, Alg2, Pgm3, Mgat2, Gmppa, Mgat5, 
Dolpp1 
N-glycan antennae elongation in 
the medial/trans-Golgi  
2.018 0.0436 
Fut8, St8sia3, B4galt5, B4galt6, Mgat4b, Mgat3, Mgat4c, 
Mgat2, Mgat5 
Glutamate Binding, Activation of 
AMPA Receptors and Synaptic 
Plasticity 
2.017 0.0437 
Gria4, Grip1, Grip2, Camk2d, Dlg4, Camk2g, Akap5, Cacng4, 
Prkca, Cacng2, Myo6, Camk2b, Gria3, Ap2b1, Cacng3, Nsf, 
Gria2 
Trafficking of AMPA receptors  2.017 0.0437 
Gria4, Grip1, Grip2, Camk2d, Dlg4, Camk2g, Akap5, Cacng4, 
Prkca, Cacng2, Myo6, Camk2b, Gria3, Ap2b1, Cacng3, Nsf, 
Gria2 
JNK (c-Jun kinases) 
phosphorylation and activation 
mediated by activated human 
TAK1  
2.012 0.0443 
Map2k4, Mapk8, Mapk10, Ikbkg, Irak1, Mapk9, Nod2, Tab3, 
Nod1 
Presynaptic function of Kainate 
receptors 
2.005 0.045 
Gng4, Plcb3, Gng2, Plcb1, Gng13, Gng8, Plcb2, Gnb5, Gnb2, 
Gng3, Gnb4, Gng7, Gngt2, Gnb3, Gng10, Gnb1, Gng12 
MyD88-independent cascade 
initiated on plasma membrane  
2.003 0.0452 
Nfkbia, Irf7, Nfkb2, App, Cdk1, Rps6ka3, Map2k4, Mapk8, 
Mapk10, Irf3, Ikbkg, Mapkapk3, Ubc, Irak1, Mef2c, Mapk9, 
Ly96, Nod2, Rps6ka2, Ppp2r5d, Fos, Map2k3, Mapk14, Tab3, 
Nod1, Mef2a, Atf1, Jun, Mapk1, Dusp6, Rela, Nfkb1, Tab2, 
Mapkapk2, Dusp3, Dusp4, Ager, Ticam2 
Adenylate cyclase activating 
pathway 
1.988 0.0468 Gnal, Adcy5, Adcy8, Adcy2, Adcy1 
Facilitative Na+-independent 
glucose transporters  
1.978 0.048 Slc2a4, Slc2a7, Slc2a3, Slc2a12, Slc2a2, Slc2a10, Slc2a5 
Transport of Mature mRNA 
Derived from an Intronless 
Transcript 
1.967 0.0492 
Nup205, Nup50, Aaas, Nxf1, Ncbp1, Nup188, Ncbp2, Nup107, 
Nup93, Nup88, Nup37 
Axon guidance  1.967 0.0492 
Rnd1, Gfra2, Met, Plxnc1, Dcc, Nck2, Trpc1, Sh3gl2, Kcnq3, 
Unc5d, Srgap1, Dcx, Robo2, Cdk1, Grb2, Cntn1, Rhog, Dnm3, 




Sema6a, Rps6ka3, Cacna1i, Ntn1, Nrcam, St8sia4, Trpc7, 
Ank3, Spnb2, Pak1, Siah2, Rgmb, Dpysl3, Scn3a, Csnk2b, 
Kcnq2, Dlg4, Chl1, Gfra1, Scn1a, Crmp1, Clasp2, Fyn, Artn, 
Sema7a, Kif4, Cacna1c, Col2a1, Alcam, Dpysl5, Col1a2, 
Gsk3b, Sema4a, Ablim3, Scn3b, Dnm1, Pak3, Stip1, Scn2a1, 
Srgap2, Cntnap1, Kras, Ank1, Cdk5r1, Cacna1d, Cap1, Clasp1, 
Ap2b1, Plxna4, Spnb3, Col4a5, Fgfr1, Trio, Tln1, Ptk2, 
Cacna1h, Neo1, Ablim2, Cfl1, Wasl, Rhob, Cacnb1, Spna2, 
Rps6ka2, Ablim1, Ncam1, Sema3a, Evl, Scn7a, Ywhab, Egfr, 
Erbb2, Hfe2, Arhgap39, Pitpna, Fes, Plxna2, Pfn1, Srgap3, 
Pak4, Cacna1s, Hsp90ab1, Pip5k1c, Clta, Ptpn11, 





8.6. The Reactome pathways for the 168 vs. 72 hour signature  
 
Set  NES  p-value  Ledge  




Psat1, Asns, Psph, Glul, Aldh18a1, Gpt2, Gls, Got2, Got1, Gpt, 
Phgdh 
Activation of Rac  3.573 0.000352 Nck2, Pak3, Sos1, Slit2, Pak4, Pak7, Pak1, Pak6 
Signaling by Robo receptor  3.278 0.00105 
Nck2, Vasp, Pak3, Cap1, Sos1, Arhgap39, Clasp2, Pfn1, Slit2, Pfn2, 
Pak4, Pak7, Pak1 
Regulation of IFNA 
signaling  
3.207 0.00134 Ifnar2, Stat2, Socs3, Tyk2, Ptpn6, Jak1, Usp18, Stat1 
GABA A receptor activation  2.862 0.00421 





Mars, Cars, Gars, Aars, Nars, Tars, Iars, Farsa, Kars, Yars, Aimp2, 
Lars, Sars, Wars, Vars 
Zinc influx into cells by the 
SLC39 gene family  
2.697 0.007 Slc39a10, Slc39a1, Slc39a6, Slc39a8, Slc39a7 
PPARA Activates Gene 
Expression  
2.608 0.0091 
Srebf1, Havcr2, Hmgcr, Me1, Grhl1, Chd9, Txnrd1, Trib3, Smarcd3, 
Plin2, Tead2, Ncoa1, Ncoa2, Ankrd1, Ncoa6, Nfya, Med31, Esrra, 
Med4, Tead3, Cdk19, Cyp1a1, Fdft1, Cpt1a, Ugt1a10, Angptl4, 
Ppargc1a, Rgl1, Acadm, Med13, Ncor1, Tbl1x, Acsl1, Ccnc, Pparg, 
Abcb4, Arntl, Med21, Abca1, G0s2, Hmgcs2, Yap1, Srebf2, 
Tnfrsf21, Agt, Med11, Apoa2, Med15, Slc27a1, BC006779, Fhl2, 
Wwtr1, Ep300, Med25, Med1, Cpt2, Med30, Med29 
Zinc transporters  2.607 0.00914 Slc39a10, Slc39a1, Slc30a7, Slc39a6, Slc39a8, Slc39a7, Slc30a2 
tRNA Aminoacylation  2.593 0.00951 
Mars, Cars, Gars, Aars, Nars, Tars, Iars, Farsa, Kars, Yars, Yars2, 
Sars2, Tars2, Aimp2, Lars, Sars, Wars, Iars2, Vars, Nars2, Aimp1, 
Hars, Dars, Vars2, Qars 
Interleukin-6 signaling  2.438 0.0148 Il6st, Jak2, Socs3, Stat3, Tyk2, Cbl, Jak1 
Disease  2.407 0.0161 Adcy2, Tgfbi, Atf3, Cdkn1a, Casp9, Hmga1, Pik3r1, Igfbp5, Xpo1, 




Rcc1, Stx6, Lmna, Igf2bp1, Asns, Actb, Sos1, Stam, Trib3, Pcsk2, 
Pappa2, Tcea1, Cul7, Psmf1, Mapk1, Adrbk1, Pag1, Slc30a7, 
Dock2, Vamp1, Srprb, Exoc3, Sec31a, Rnmt, Ap1s2, Igfbp4, 
Edem1, Acadvl, Ccnt1, Psip1, Th1l, Wipi1, Pdia5, Aaas, Nmt1, 
Snca, Rps29, Tln1, Lig1, Exoc6, Syt2, Igf2bp2, Gsn, Ran, Klhdc3, 
Adcy8, Akt3, Igf1, Exoc7, Psme3, Nup62, Psmc4, Mfge8, Cpsf4, 
App, Exoc2, Hgs, Adcy1, Mmp2, Ap1m1, Supt5h, Rdbp, Akt1s1, 
Rpl36a, Nup188, Ranbp2, Akt1, Gm10136, Shc1, Rps18, Gsk3a, 
Nup93, Nfya, Hist3h2bb-ps, Exosc6, Nupl1, Dnajc3, Rps8, Banf1, 
Kpnb1, Rps11, Ssrp1, Grb2, Cltc, Nup50, Dcp2, Tceb3, Kpna1, 
Rpl18a, Prkcd, Exoc5, Psmc1, Psmd4, Stx3, Rps15a, Psmc3, Calr, 
Sh3gl2, Exosc3, Cbl, Rpl27a, Cdc37, Csk, Gsk3b, Nup133, Nup210, 
Atf6, Rplp1, Pten, Dnajb11, Rps2, Ap1s1, Ap2a1, Rictor, Ipo5, 
Exosc5, Rpl26, Mnat1, Vps37c, Grsf1, Rplp0, Rps5, Gtf2h4, Psma1, 
Arfgap1, Egfr, Rps6, Prkaca, Rps3a, Exosc4, Pde1c, Ccnt2, Igfbp2, 
Taf12, Taf6, Psmb1, Stx5a, Rpl28, Exosc2, Mdm2, Taf10, Extl3, 
Hyou1, Ctsg, Zbtb17, Rps4x, Hist3h2ba, Kras, Rpl39, Rplp2, Ercc3, 
Kdelr3, Eif2ak2, Skp1a, Tgfb1, Gtf2e1, Cd4, Cdk9, Elmo1, Polr2b, 
Rpl14, Rbx1, Rps26, Ap1m2, Psmc5, Rpl23, Ctdp1, Rpl34, Hras1, 
Polr2c, Rpl37, Ell, Rpl6, Rps25, Epn1, Foxo4, Camk4, Creb1, Egf, 
Phlpp1, Hsp90b1, Hist1h2ah, Fen1, Nppa, Cd28, Bche, Nr4a1, 
Adcy9, Rac1, Rps23, Taf13, Psmc2, Ercc2, Ssr1, Itpr3, Taf4a, 
Dctn1, Wfs1, H2afz, Rpl35, Taf11, Cxxc1, Ranbp1, Stx4a, Pak2, 
Pcsk1, Tpr, Psmd3, Tatdn2, Vps28, Psme1, Rpl37a, Gfpt1, Ttr, Clta, 
Ubc 
Sulfur amino acid 
metabolism  
2.394 0.0167 Gclc, Cdo1, Ahcy, Mtap, Cth, Csad, Got1, Suox, Tst, Gclm, Ethe1 
Growth hormone receptor 
signaling  
2.351 0.0187 Stat5a, Jak2, Mapk1, Socs3, Stat3, Cish, Lyn, Stat5b 
Signaling by ERBB4  2.321 0.0203 
Cdkn1a, Casp9, Pik3r1, Stat5a, Sos1, Trib3, Jak2, Mapk1, Erbb3, 
Cul1, Stat5b, Nrg2, Akt3, Hbegf, Akt1s1, Akt1, Shc1, Gsk3a, 
Cxcl12, Grb2, Gfap, Gsk3b, Wwp1, Pten, Erbb4, Rictor, Ncor1, 
Egfr, Aph1b, Nrg1, Tab2, Mdm2, Prlr, Kras, Skp1a, Psenen, Rbx1, 
Hras1, Nrg3, Foxo4, Creb1, Yap1, Pgr, Egf, Phlpp1 
Regulation of Lipid 
Metabolism by Peroxisome 
proliferator-activated 
receptor alpha (PPARalpha)  
2.321 0.0203 
Srebf1, Havcr2, Hmgcr, Me1, Grhl1, Chd9, Txnrd1, Trib3, Smarcd3, 
Plin2, Tead2, Ncoa1, Ncoa2, Ankrd1, Ncoa6, Nfya, Med31, Esrra, 
Med4, Tead3, Cdk19, Cyp1a1, Fdft1, Cpt1a, Ugt1a10, Angptl4, 
Ppargc1a, Rgl1, Acadm, Med13, Ncor1, Tbl1x, Acsl1, Ccnc, Pparg, 
Abcb4, Arntl, Med21, Abca1, G0s2, Hmgcs2, Yap1, Srebf2, 




Wwtr1, Sin3b, Ep300, Med25, Med1, Cpt2, Med30, Med29 
G alpha (z) signalling events  2.32 0.0204 
Adcy2, Prkce, Gnb4, Adcy8, Adcy1, Gng2, Rgs4, Gng4, Adra2b, 
Gnai2, Rgs19, Gnb1, Prkcd, Gnai1, Prkch, Gnb2, Rgs17, Adra2a, 
Gnb5, Adcy9, Gng10, Gnai3 
Intrinsic Pathway for 
Apoptosis  
2.317 0.0205 
Trp53, Casp9, Bak1, Ppp3cc, Casp8, Mapk8, Xiap, Nmt1, Bcl2l1, 
Akt1, Dynll2, Bax, Bcl2, Ppp3r1, Bmf, E2f1 
CDO in myogenesis  2.253 0.0243 
Neo1, Cdh4, Ctnna2, Ctnna1, Boc, Mapk12, Tcf3, Spag9, Mapk11, 
Tcf4, Cdh2, Map2k6 
Myogenesis  2.253 0.0243 
Neo1, Cdh4, Ctnna2, Ctnna1, Boc, Mapk12, Tcf3, Spag9, Mapk11, 
Tcf4, Cdh2, Map2k6 
N-glycan antennae 
elongation in the 
medial/trans-Golgi  
2.21 0.0271 Fut8, B4galt3, St8sia2, Mgat3, B4galt2, St6gal1, St8sia6, St8sia3 
Unfolded Protein Response  2.185 0.0289 
Atf3, Hdgf, Atf4, Preb, Herpud1, Lmna, Asns, Cul7, Srprb, Sec31a, 
Edem1, Acadvl, Wipi1, Pdia5, Tln1, Klhdc3, Shc1, Gsk3a, Nfya, 
Exosc6, Dnajc3, Dcp2, Calr, Exosc3, Atf6, Dnajb11, Exosc5, 
Arfgap1, Exosc4, Exosc2, Extl3, Hyou1, Zbtb17, Kdelr3 
Other semaphorin 
interactions  
2.183 0.029 Plxna4, Plxna2, Sema5a 
Iron uptake and transport  2.176 0.0295 
Tfrc, Fth1, Hmox1, Cybrd1, Atp6v0a2, Cp, Abcg2, Trf, Atp6v1d, 
Slc11a2, Steap3, Mcoln1, Atp6v0c, Atp6v1e2, Atp6v1g3, Slc46a1, 
Tcirg1, Atp6v0e, Atp6v0e2, Atp6v1a, Atp6v1c2, Atp6v0b, Heph, 
Atp6v1c1 
Metal ion SLC transporters  2.176 0.0296 
Slc39a10, Slc39a1, Slc41a1, Slc30a7, Slc39a6, Slc39a8, Slc39a7, 
Slc30a2, Cp, Slc11a2, Slc39a5, Slc11a1 
Glycogen breakdown 
(glycogenolysis)  




Pik3r1, Rhob, Pik3r5, Plcg2, Pik3r3, Lyn, Akt3, Akt1, Rhog, Pik3r2, 
Vav3, Vav2, Rhoa, Pik3cb, Pik3cg, Gp6, Rac1, Col1a1, Col1a2, 
Prkcz 
DARPP-32 events  2.088 0.0368 Ppp1r1b, Ppp3cc, Pde4b, Ppp2r5d, Ppp3r1, Prkaca, Ppp3ca, Pde4a, 








Pgm1, Pfkfb3, Pygb, Pck2, Pgd, Eno3, Hk2, Galt, G6pdx, G6pc2, 
Phkb, Aaas, Fbp1, Nup62, Pgam2, Aldoa, Got2, Phkg1, Slc2a1, 
Got1, Prps1, Nup188, Ranbp2, Mgam, Slc2a4, Nup93, Tkt, Galk1, 
Nupl1, Ppp2r5d, Nup50, Pkm2, Pfkfb2, Gpi1, Gapdhs, Pygm, 
Nup133, Nup210, Slc2a5, Ugp2, Mdh2, Khk, Prkaca, Pgam1, Pcx, 
Slc25a12, Gys2, Amy1, Gys1, Pklr, Pygl 
PI3K events in ERBB2 
signaling  
2.013 0.0442 
Cdkn1a, Casp9, Pik3r1, Trib3, Erbb3, Nrg2, Akt3, Hbegf, Akt1s1, 
Akt1, Gsk3a, Grb2, Gsk3b, Pten, Erbb4, Rictor, Egfr, Nrg1, Erbb2, 
Mdm2, Nrg3, Foxo4, Creb1, Egf, Phlpp1, Nr4a1 
AKT phosphorylates targets 
in the cytosol  
2.004 0.045 Cdkn1a, Casp9, Akt3, Akt1s1, Akt1, Gsk3a, Gsk3b 
Transport to the Golgi and 
subsequent modification  
1.996 0.0459 
Preb, Fut8, B4galt3, Lman1, St8sia2, Sec31a, Mgat3, Mgat1, 
Man1a2, B4galt2, Sec23a, St6gal1, St8sia6 




Rela, Nfkb2, Tab3, Dusp3, Mapk1, Nfkbib, Mapk8, Mapkapk2, 
Mapk10, Rps6ka3, Map2k4, App, Nfkbia, Ticam1, Ripk2, Mapk11, 
Ppp2r5d, Ikbkg, Rps6ka1, Map2k6, Tab2, Map3k7, Mapkapk3, 
Rps6ka5 
SHC1 events in ERBB2 
signaling  
1.988 0.0468 
Sos1, Mapk1, Erbb3, Nrg2, Hbegf, Shc1, Grb2, Erbb4, Egfr, Nrg1, 
Erbb2, Kras, Hras1, Nrg3, Egf 
TAK1 activates NFkB by 
phosphorylation and 
activation of IKKs complex  
1.988 0.0468 Rela, Nfkb2, Tab3, Nfkbib, App, Nfkbia, Ripk2, Ikbkg 
 
 
